<SEC-DOCUMENT>0001136261-21-000034.txt : 20210311
<SEC-HEADER>0001136261-21-000034.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311161605
ACCESSION NUMBER:		0001136261-21-000034
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SEELOS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001017491
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870449967
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22245
		FILM NUMBER:		21733491

	BUSINESS ADDRESS:	
		STREET 1:		300 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(646) 998-6475

	MAIL ADDRESS:	
		STREET 1:		300 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APRICUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20100914

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEXMED INC
		DATE OF NAME CHANGE:	19970311
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
<TITLE>2020 10-K DOC</TITLE>
</HEAD>
<FONT FACE="Times New Roman" SIZE="2">
<BODY LINK="#0000ff" VLINK="#800080">

<DIV align=left>
<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">
</DIV>

<B><FONT SIZE=4><P ALIGN="CENTER">UNITED STATES<BR>
                  SECURITIES AND EXCHANGE COMMISSION&nbsp;<BR>
</FONT><FONT SIZE=2>                  Washington, D.C.&nbsp;20549&nbsp;</P>
<P ALIGN="CENTER">____________________________</P>
</FONT><FONT SIZE=4><P ALIGN="CENTER">FORM 10-K</P></B>


</FONT><FONT SIZE=2>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="5%" VALIGN="TOP">
<B><FONT FACE="Wingdings" SIZE=3><P ALIGN="JUSTIFY">x</B></FONT></TD>
<TD WIDTH="95%" VALIGN="TOP">
<B><FONT SIZE=2><P ALIGN="JUSTIFY">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=2>
<P ALIGN="CENTER">For the Fiscal Year Ended December 31, 2020</P>

<P ALIGN="CENTER">or</P></B></FONT>

<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="5%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</FONT><B><FONT FACE="Wingdings" SIZE=3>o</B></FONT></TD>
<TD WIDTH="95%" VALIGN="TOP">
<B><FONT SIZE=2><P ALIGN="JUSTIFY">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=2><P ALIGN="CENTER">For the Transition Period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

</B><P ALIGN="CENTER">Commission File Number&nbsp;000-22245</P>

<B><P ALIGN="CENTER">____________________________</P>
</B><P ALIGN="CENTER">&nbsp;</FONT><B><FONT SIZE=4>SEELOS THERAPEUTICS, INC.<BR>
</B></FONT><FONT SIZE=2>                  (Exact name of registrant as specified in its charter)</P>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="49%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">Nevada</B></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">87-0449967</B></FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">(State or other jurisdiction of incorporation or organization)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">(I.R.S.&nbsp;&nbsp;Employer Identification No.)</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</P>
<B><P ALIGN="CENTER">300 Park Avenue, 12<SUP>th</SUP> Floor, New York, NY 10022<BR>
</B>                  (Address of principal executive offices and zip code)</P>

<FONT SIZE=2><P ALIGN="CENTER">
                       <B>(646) 293-2100<BR>
</B>                  (Registrant's telephone number, including area code)</P>

</FONT><FONT SIZE=1><P ALIGN="CENTER">&nbsp;</P>
</FONT><B><FONT SIZE=2><P ALIGN="CENTER">Securities registered pursuant to Section&nbsp;12(b) of the Act:</P></B>


<TABLE BORDER=0 CELLSPACING=0 WIDTH=99%>
<TR>
<TD WIDTH="33%" VALIGN="BOTTOM">
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;<B>Title of Each Class</B></FONT></TD>
<TD WIDTH="34%" VALIGN="BOTTOM">
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;<B>Trading Symbol</B></FONT></TD>
<TD WIDTH="33%" VALIGN="BOTTOM">
<B><FONT SIZE=2><P ALIGN="CENTER">Name of Each Exchange on Which Registered</B></FONT></TD>
</TR>
<TR>
<TD WIDTH="33%" VALIGN="BOTTOM">
<FONT SIZE=2><P ALIGN="CENTER">Common Stock, par value $0.001 per share</FONT></TD>
<TD WIDTH="34%" VALIGN="BOTTOM">
<FONT SIZE=2><P ALIGN="CENTER">SEEL</FONT></TD>
<TD WIDTH="33%" VALIGN="BOTTOM">
<FONT SIZE=2><P ALIGN="CENTER">The Nasdaq Stock Market LLC</FONT></TD>
</TR>
</TABLE>


<B><FONT SIZE=2>
<P ALIGN="CENTER">Securities registered pursuant to section 12(g) of the Act: None.</P></B>

<P ALIGN="JUSTIFY">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;Yes &nbsp;&nbsp;</FONT>
<FONT FACE="Wingdings" SIZE=3>o</FONT><FONT SIZE=2> &nbsp;&nbsp;No&nbsp;</FONT><FONT FACE="Wingdings" SIZE=3>x</P></FONT><FONT SIZE=2>

<P ALIGN="JUSTIFY">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act. Yes &nbsp;&nbsp;</FONT>
<FONT FACE="Wingdings" SIZE=3>o</FONT><FONT SIZE=2> &nbsp;No&nbsp;&nbsp;</FONT><FONT FACE="Wingdings" SIZE=3>x</P></FONT><FONT SIZE=2>

<P ALIGN="JUSTIFY">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</FONT><FONT FACE="Wingdings" SIZE=3> x</FONT><FONT SIZE=2>  &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT FACE="Wingdings" SIZE=3> o</P></FONT><FONT SIZE=2>

<P ALIGN="JUSTIFY">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (&sect;&nbsp;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</FONT><FONT FACE="Wingdings" SIZE=3>x</FONT><FONT SIZE=2>  No&nbsp;&nbsp;</FONT><FONT FACE="Wingdings" SIZE=3>o</P></FONT><FONT SIZE=2>


<P>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions
of &quot;large accelerated filer,&quot; &quot;accelerated filer,&quot; &quot;smaller reporting company,&quot; and &quot;emerging growth company&quot; in Rule&nbsp;12b-2 of the Exchange Act:</P>

<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=0 ALIGN=CENTER WIDTH=100%>
<TR><TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=2><P>
Large accelerated filer  &nbsp;&nbsp; <FONT FACE="WINGDINGS">&#168; <FONT FACE="Times New Roman">
</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=2><P>
Accelerated filer &nbsp;&nbsp; <FONT FACE="WINGDINGS">&#168; <FONT FACE="Times New Roman">
</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=2><P>
Non-accelerated filer &nbsp;&nbsp; <FONT FACE="WINGDINGS">&#168; <FONT FACE="Times New Roman">
</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=2><P>
Smaller reporting company &nbsp;&nbsp; <FONT FACE="WINGDINGS">&#120; <FONT FACE="Times New Roman"></P>
</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=2><P>
Emerging growth company  &nbsp;&nbsp; <FONT FACE="WINGDINGS">&#168; <FONT FACE="Times New Roman"></P>
</FONT></TD>
</TR>
</TABLE>



<FONT SIZE=2><P>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp; <FONT FACE="Wingdings">&#111;</FONT><FONT FACE="Times New Roman" SIZE=2>
</P>

<P ALIGN="JUSTIFY">
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 &nbsp;&nbsp; <FONT FACE="WINGDINGS">&#168; </FONT><FONT FACE="Times New Roman">  </P>



<P ALIGN="JUSTIFY">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</FONT><FONT
FACE="Wingdings" SIZE=3>o</FONT><FONT SIZE=2> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT FACE="Wingdings" SIZE=3>x</P></FONT><FONT SIZE=2><FONT FACE="Times New Roman">

<P ALIGN="JUSTIFY">As of March 4, 2021, 73,249,554 shares of the common stock, par value $0.001, of the registrant were outstanding.&nbsp;</P>

<P ALIGN="JUSTIFY">The aggregate market value of the voting stock held by non-affiliates of the registrant the last business day of the registrant's most recently completed second fiscal
quarter: $41.5 million based upon the closing sale price of the registrant's common stock of $2.19 on that date. Shares of the registrant's common stock held by each officer and director and by
each person known to own in excess of 10% of outstanding shares of the registrant's common stock have been excluded in that such persons may be
deemed to be affiliates. The determination of affiliate status is not necessarily a conclusive determination for other purposes.</P>


<B><P ALIGN="CENTER">DOCUMENTS INCORPORATED BY REFERENCE</P></B>

<P ALIGN="JUSTIFY">Certain information required to be disclosed in Part III of this report is incorporated by reference from the information contained in the registrant's Definitive Proxy
Statement for the 2021 Annual Meeting of Stockholders, which Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal
year ended December 31, 2020.</P>


<DIV align=left>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">
</DIV>


<B><P ALIGN="CENTER">
                  Table of Contents </P></B>

<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=0 WIDTH=85%>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="BOTTOM">
<FONT SIZE=2><P ALIGN="RIGHT">Page</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">
<B><FONT SIZE=2><P ALIGN="CENTER">PART I.</B></FONT></TD>
<TD WIDTH="6%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item1">ITEM 1.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>BUSINESS</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"> 1</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item1a">ITEM 1A.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>RISK FACTORS</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">19</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item1b">ITEM 1B.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>UNRESOLVED STAFF COMMENTS</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">48</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item2">ITEM 2.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>PROPERTIES</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">48</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item3">ITEM 3.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>LEGAL PROCEEDINGS</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">48</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item4">ITEM 4.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>MINE SAFETY DISCLOSURES</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">48</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">
<B><FONT SIZE=2><P ALIGN="CENTER">PART II.</B></FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item5">ITEM 5.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">49</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item6">ITEM 6.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>SELECTED FINANCIAL DATA</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">49</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item7">ITEM 7.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">49</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item7a">ITEM 7A.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">61</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item8">ITEM 8.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">62</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item9">ITEM 9.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">87</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item9a">ITEM 9A.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>CONTROLS AND PROCEDURES</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">87</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item9b">ITEM 9B.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>OTHER INFORMATION</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">88</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">
<B><FONT SIZE=2><P ALIGN="CENTER">PART III.</B></FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item10">ITEM 10.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">88</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item11">ITEM 11.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>EXECUTIVE COMPENSATION</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">88</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item12">ITEM 12.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">88</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item13">ITEM 13.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">89</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item14">ITEM 14.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>PRINCIPAL ACCOUNTANT FEES AND SERVICES</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">89</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">
<B><FONT SIZE=2><P ALIGN="CENTER">PART IV.</B></FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item15">ITEM 15.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">89</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="83%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="#item16">ITEM 16.</A></FONT></TD>
<TD WIDTH="83%" VALIGN="TOP">
<FONT SIZE=2><P>FORM 10-K SUMMARY</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">97</FONT></TD>
</TR>











</TABLE>


<FONT FACE="Times New Roman" SIZE="2">


<P ALIGN="CENTER">                                                                                                   i
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<B><FONT SIZE=2><P ALIGN="CENTER">PART I</P></B>

<U><P ALIGN="CENTER">Cautionary Note Regarding Forward-Looking Statements</P></U>

<P>This report includes &quot;forward-looking statements&quot; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &quot;Securities
Act&quot;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;). Those statements include statements regarding the intent, belief
or current expectations of Seelos Therapeutics, Inc. and its subsidiaries (&quot;we,&quot; &quot;us,&quot; &quot;our,&quot; the &quot;Company&quot; or &quot;Seelos&quot;) and
our management team. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially
from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to those risks and uncertainties set forth in Item&nbsp;1A of this
Report.&nbsp;In light of the significant risks and uncertainties inherent in the forward-looking statements included in this Report, the inclusion of such statements should not be
regarded as a representation by us or any other person that our objectives and plans will be achieved. Further, these forward-looking statements reflect our view only as of the date
of this report. Except as required by law, we undertake no obligations to update any forward-looking statements and we disclaim any intent to update forward-looking statements
after the date of this report to reflect subsequent developments. Accordingly, you should also carefully consider the factors set forth in other reports or documents that we file from
time to time with the Securities and Exchange Commission (&quot;SEC&quot;).</P>

<P>We have common law trademark rights in the unregistered marks &quot;Seelos Therapeutics, Inc.,&quot; &quot;Seelos&quot; and the Seelos logo in certain jurisdictions.
Vitaros is a registered trademark of Ferring International Center S.A. (&quot;Ferring&quot;) in certain countries outside of the United States. This Annual Report on Form 10-K also
includes trademarks, tradenames and service marks that are the property of other organizations.  Solely for convenience, trademarks and tradenames referred to in this Annual
Report on Form 10-K appear without the<SUP> &reg;</SUP> and <SUP>&trade;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not
assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.</P>

<B><P><A NAME="item1">ITEM 1. BUSINESS</A></P></B>

<P>We are a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous
System (&quot;CNS&quot;) disorders and other rare disorders. </P>

<P>Our business model is to advance multiple late-stage therapeutic candidates as well as earlier stage assets with proven mechanisms of action or with strong scientific rationale
that address large markets with unmet medical needs and for which there is a strong economic and scientific rationale for development.  </P>

<P>Our product development pipeline is as follows:</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=98%>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="19%" VALIGN="TOP" HEIGHT=16><B><FONT SIZE=2><P ALIGN="CENTER">Product</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">Indication</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">Development Phase</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">Development Status</B></FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-002</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Acute Suicidal Ideation and Behavior (ASIB) in </FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase II</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Patients being dosed for Part A</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Intranasal Racemic Ketamine</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Major Depressive Disorder (MDD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-005</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Amyotrophic Lateral Sclerosis (ALS)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase IIb/III</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Startup activities initiated</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">IV Trehalose </FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Sanfilippo Syndrome</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase II</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Collecting Natural History Data</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-004</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Parkinson's Disease (PD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pre-IND</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Preclinical studies to commence soon</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Gene Therapy</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-006</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Parkinson's Disease (PD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase II/III</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Evaluating studies to advance into late stage trials</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Partial Dopamine Agonist</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-007</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Parkinson's Disease (PD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pre-IND</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Preclinical data expected in early 2021</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Peptide Inhibitor</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-008</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pediatric Esophagitis, Asthma, Atopic Dermatitis</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pre-IND</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Formulation work underway</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">CRTh2 Antagonist</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">                                                                                                   1
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<P>Lead Programs</P></B>

<P>Our lead programs are currently SLS-002 for the treatment of acute suicidal ideation and behavior (&quot;ASIB&quot;) in major depressive disorder (&quot;MDD&quot;), and
SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (&quot;ALS&quot;).  SLS-005 for the potential treatment of Sanfilippo Syndromes currently requires additional
natural history data, which is being explored.</P>

<B><P>SLS-002</B> is intranasal racemic ketamine with two investigational new drug applications (&quot;INDs&quot;), the lead program is focused on the treatment of ASIB in MDD.
SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500 subjects. SLS-002 addresses an
unmet need for an efficacious drug to treat suicidality in the United States. Traditionally, anti-depressants have been used in this setting but many of the existing treatments are
known to contribute to an increased risk of suicidal thoughts in some circumstances, and if and when they are effective, it often takes weeks for the full therapeutic effect to be
manifested. We believe there is a large opportunity in the United States and
European markets for products in this space. Based on information gathered from the databases of the Agency for Healthcare Research and Quality, there were more than 500,000
visits to emergency rooms for suicide attempts in 2013 in the United States alone. Experimental studies suggest ketamine has the potential to be a rapid, effective treatment for
refractory depression and suicidality. The clinical development program for SLS-002 includes two parallel healthy volunteer studies (Phase I).
We announced interim data from our Phase I study of SLS-002 during the quarterly period ended March 31, 2020. The study demonstrated that
90mg of SLS-002, when administered as a monotherapy and in combination with an oral antidepressant, was generally safe and well-tolerated. Further, in March 2020, we
completed a Type C meeting with the U.S. Food and Drug Administration (the "FDA") and received guidance to conduct a Phase II proof of concept study of SLS-002 for ASIB in
patients with MDD, to support the further clinical development of this product candidate, together with nonclinical data under development. As a result of the Type C meeting and the
Fast Track designation for SLS-002 for the treatment of ASIB in patients with MDD, we believe we are well positioned to pursue the FDA's expedited programs for drug development
and review.  On June 23, 2020, we announced the final safety data from our Phase I pharmacokinetics/pharmacodynamics study of intranasal racemic ketamine (SLS-002) as well
as the planned design of a Phase II, double blind, placebo-controlled Proof of Concept ("PoC") study for ASIB in patients with MDD. We initiated this PoC study in two parts: Part A
is an open-label study of 16 patients, and will be followed by Part B, which is a double blind, placebo-controlled study of approximately 120 patients. On January 15, 2021, we
announced dosing of the first patients in Part A of the PoC study.</P>

<B><P>SLS-005 </B>is IV Trehalose, a protein stabilizer that crosses the blood-brain-barrier, activates autophagy and lysosomal biogenesis. Based on the
pre-clinical and in-vitro studies, there is a sound scientific rationale for developing Trehalose for the treatment of ALS and other indications such as Sanfilippo syndromes. Trehalose
is a low molecular weight disaccharide (.342 kDa) that protects against pathological processes in cells. It has been shown to penetrate muscle and cross the blood-brain-barrier. In
animal models of several diseases associated with abnormal cellular-protein aggregation, it has been shown to reduce pathological aggregation of misfolded proteins as well as to
activate autophagy pathways through the activation of Transcription Factor EB (&quot;TFEB&quot;), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is
an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.</P>

<P>Trehalose 90 mg/mL IV solution has demonstrated promising clinical potential in prior Phase II clinical development for oculopharyngeal muscular dystrophy
(&quot;OPMD&quot;) and spinocerebellar ataxia type 3 (&quot;SCA3&quot;), also known as Machado Joseph disease, with a good safety profile and encouraging efficacy results.
Pathological accumulation of protein aggregates within cells, whether in the CNS or in muscle, eventually leads to loss of function and ultimately cell death. Prior preclinical studies
indicate that this platform has the potential to prevent mutant protein aggregation in other devastating PolyA/PolyQ diseases.</P>

<P ALIGN="CENTER">                                                                                                   2
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>We own two United States patents for parenteral administration of trehalose for patients with OPMD and SCA3, both of which are expected to expire in 2034. In addition, Orphan
Drug Designation for OPMD and SCA3 has been secured in the United States and in the European Union (&quot;EU&quot;). In February 2019, we assumed a collaborative
agreement, turned subsequently into a research grant, with Team Sanfilippo Foundation (&quot;TSF&quot;), a nonprofit medical research foundation founded by parents of children
with Sanfilippo syndrome. On April 30, 2020, we were granted Orphan Drug Designation ("ODD") for SLS-005 in Sanfilippo syndrome from the FDA. SLS-005 was previously
granted ODD from the FDA and European Medicines Agency for SCA3 and OPMD as well as Fast Track designation for OPMD. On April 22, 2020, we received a Notice of
Allowance from the United States Patent and Trademark Office for our U.S. patent number 10,751,353 (application number 16/263,707) titled "COMPOSITIONS AND METHODS
FOR TREATING AN AGGREGATION DISEASE OR DISORDER" for trehalose (SLS-005). The allowed claims cover the composition of matter and method of use for trehalose
(SLS-005) for treating a disease or disorder selected from any one of the following: Spinal and bulbar muscular atrophy; Dentatombral-pallidoluysian atrophy; Pick's disease;
corticobasal degeneration; progressive supranuclear palsy; frontotemporal dementia; or parkinsonism linked to chromosome 17. On May 15, 2020, we were granted Rare Pediatric
Disease Designation (&quot;RPDD&quot;) for SLS-005 in Sanfilippo syndrome from the FDA. RPDD is an incentive program created under the Federal Food, Drug, and Cosmetic
Act  to encourage the development of new therapies for the prevention and treatment of certain rare pediatric diseases. At present, we are initiating the startup activities for a clinical
study in ALS.  In December 2020, we announced the selection of SLS-005 for the Healey ALS platform trial led by the Harvard Medical School, Massachusetts. The Healey ALS
platform trial is designed to study multiple potential treatments for ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce costs and
shorten development timelines.</P>

<P>Additionally, we are developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, licensed from Duke University, and
SLS-007, licensed from The Regents of the University of California, for the potential treatment of Parkinson's Disease (&quot;PD&quot;), SLS-008, targeted at chronic inflammation
in asthma and orphan indications such as pediatric esophagitis, SLS-010 in narcolepsy and related disorders and SLS-012, an injectable therapy for post-operative pain
management.</P>

<B><P>Strategy and Ongoing Programs</P>
</B>
<B><U><P>SLS-002:</U></B> The clinical development program for SLS-002 includes two parallel healthy volunteer studies (Phase I).  Following these Phase I studies, we
completed a Type C meeting with the FDA in March 2020 and received guidance to conduct a Phase II proof of concept study of SLS-002 for ASIB in patients with MDD. The startup
activities are underway and have enrolled several patients in Part A of our open-label study.</P>

<B><U><P>SLS-005</U></B> is undergoing startup activities for a clinical study in ALS.  In December 2020, we announced the selection of SLS-005 for the Healey ALS platform
trial led by the Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple potential treatments for ALS simultaneously. The platform trial
model aims to greatly accelerate the study access, reduce costs, and shorten development timelines. We are continuing to explore trials in Sanfilippo syndromes and are seeking
more natural history data based on the guidance from regulatory agencies.</P>

<B><U><P>SLS-004</U> </B>is an all-in-one lentiviral vector, targeted for gene editing through DNA methylation within intron 1 of the SNCA gene responsible for
expressing alpha-synuclein protein. SLS-004, when delivered to dopaminergic neurons derived from human induced pluripotent stem cells (hiPSCs) of a PD patient, modified the
expression on alpha-synuclein and exhibited reversal of the disease-related cellular-phenotypes characteristics of the neurons. The role of mutated SNCA in PD pathogenesis and
the need to maintain the normal physiological levels of alpha-synuclein protein emphasize the so-far unmet need to develop new therapeutic strategies, such as SLS-004, targeting
the regulatory mechanism of alpha-synuclein expression. </P>
<P>On May 28, 2020, we announced the initiation of a preclinical study of SLS-004 in PD through an all-in-one lentiviral
vector targeting the synuclein alpha gene. We are constructing a bimodular viral system harboring an endogenous alpha-synuclein (&#945;-synuclein) transgene
and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related pathologies.</P>

<P ALIGN="CENTER">                                                                                                   3
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<U><P>SLS-006</U> </B>is a true partial dopamine agonist, originally developed by Wyeth Pharmaceuticals, Inc., with previous clinical studies on 340 subjects in various Phase I
and Phase II studies. It is a potent D2/D3 agonist/antagonist that has shown promising efficacy with statistical significance in Phase II studies in early stage PD patients and an
attractive safety profile. Moreover, it has also shown synergistic effect with reduced doses of L-DOPA. We are evaluating studies to advance the product candidate into late stage
trials.</P>
<B>
<U><P>SLS-007</U> </B>is a rationally designed peptide-based approach, targeting the NACore (nonamyloid component core)
of alpha-synuclein to inhibit the protein from aggregation. Recent in-vitro and cell culture research have shown SLS-007 has the ability to stop the
propagation and seeding of &#945;-synuclein aggregates. We will evaluate the potential for in-vi</FONT><FONT SIZE=2>vo delivery of SLS-007 in a PD transgenic mice model.
The goal will be to establish in-vivo pharmacokinetics/pharmacodynamics and target engagement parameters of SLS-007, a family of anti-alpha-synuclein peptidic inhibitors. On
June 25, 2020, we announced the initiation of a preclinical study of SLS-007 in PD delivered through an adeno associated
viral ("AAV") vector targeting the non-amyloid component core of &#945;-synuclein. We have initiated an in vivo preclinical study of SLS-007 in rodents to assess the
ability of two specific novel peptides, S62 and S71, delivered via AAV1/2 viral vector, to protect
dopaminergic function in the preformed &#945;-synuclein fibril rodent model of PD. Production of AAV1/2 vectors encoding each of the two novel peptides
incorporatin</FONT><FONT SIZE=2>g hemagglutinin tags has already been completed. This preclinical study is designed to establish the in vivo pharmacokinetic and
pharmacodynamic profiles and target engagement parameters of SLS-007. Top-line data is currently expected in early 2021.</P>
<B>
<U><P>SLS-008</U> </B>is<B> </B>an orally available antagonist for Chemoattractant Receptor-homologous molecules expressed on TH2 cells (&quot;CRTh2&quot;), targeted at
chronic inflammation in asthma and a pediatric orphan indication. We have a &quot;family&quot; of compounds under our SLS-008 program. We intend to file an IND after
completion of IND-enabling studies, which are currently in progress, in an undisclosed pediatric orphan indication where there is a high unmet need for an effective oral therapy.</P>

<P>Additionally, we are developing several preclinical programs, most of which have well-defined mechanisms of action, including:</P>


<UL>
<LI>SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders; and </LI>
<LI>SLS-012, an injectable therapy for post-operative pain management.</LI></UL>

<B>
<P>Impact of COVID-19</P>

</B><P>In March 2020, we began taking precautionary measures to protect the health and safety of our employees and contractors and further assessing the actual and potential
impact of the coronavirus (&quot;COVID-19&quot;) pandemic on our business, financial condition and operations. COVID-19 infections have been reported throughout the United
States, along with other jurisdictions in which our suppliers, partners and collaborators operate. In addition, COVID-19 has caused disruption and volatility in the global capital
markets, and has led to an economic slowdown. Certain national, provincial, state and local governmental authorities have issued proclamations and/or directives aimed at
minimizing the spread of COVID-19 and additional, more restrictive proclamations and/or directives may be issued in the future. Before the recent COVID-19 outbreak, most of our
employees worked remotely. In addition, our clinical trial for SLS-002 in ASIB in MDD completed the clinical testing phase in February 2020. On June 23, 2020, we released the final
pharmacokinetics/pharmacodynamics portion of the data. Also, we did not experience any significant delays with opening our clinical sites for SLS-002 during the fourth quarter of
2020 and have not experienced any such delays during the first quarter of 2021 to date.  Accordingly, the impact of the travel restrictions and shelter-in-place orders have not had a
material impact on our operations to date. Additionally, the pandemic has not materially affected our liquidity as we maintain our resources in the form of cash.</P>

<P>In addition, although we do not currently expect the preventative measures taken to date to have a material adverse impact on our business for the first half of 2021, the ultimate
impact of the COVID-19 pandemic on our business, financial condition and results of operations is unknown and will depend on future developments and risks, which are highly
uncertain and cannot be predicted. These developments and risks include, among others, the duration and severity of the COVID-19 pandemic, the impact on capital markets, the
impact on our partners and the regulatory agencies that oversee our sector and any additional

<P ALIGN="CENTER">                                                                                                   4
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
preventative and protective actions that governmental authorities, or we, may
implement, any of which may result in an extended period of business disruption, including potential delays in commencing future clinical trials, or in completing enrollment for any
clinical trials we may commence or in the FDA or other regulatory agencies conducting in-person inspections or accommodations for alternatives to in-person inspections. Any
resulting financial impact cannot be reasonably estimated at this time, but the COVID-19 pandemic may force us to make adjustments to our business, our plans and our timeline for
developing assets, including our programs. In addition, the pandemic is currently not anticipated to have a material adverse impact on our business, financial condition and results of
operations, including our ability to raise additional capital, although, if the pandemic continues at its current rate into the first quarter of 2021, it could have a material adverse impact
on our business. </P>
<B>
<P>Merger</P>

</B><P>On January 24, 2019, Apricus Biosciences, Inc., a Nevada corporation (&quot;Apricus&quot;), completed a business combination  with Seelos Therapeutics, Inc., a
Delaware corporation (&quot;STI&quot;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &quot;Merger Agreement&quot;) entered into
on July 30, 2018. Pursuant to the Merger Agreement, (i) a subsidiary of Apricus merged with and into STI, with STI (renamed as &quot;Seelos Corporation&quot;) continuing as a
wholly-owned subsidiary of Apricus and the surviving corporation of the merger and (ii) Apricus was renamed as &quot;Seelos Therapeutics, Inc.&quot; (the &quot;Merger&quot;).
Upon completion of the Merger, our business became primarily the business conducted by STI, which was a clinical-stage biopharmaceutical company focused on the development
and commercialization of CNS therapeutics with known mechanisms of action in areas with a highly unmet medical need. Also, on January 23, 2019, in connection with, and prior to
the completion of, the Merger, we effected a reverse stock split of our common stock at a ratio of 1-for-30 (the &quot;Reverse Stock Split&quot;). Our previous ticker symbol was
&quot;APRI&quot;. Shares of our common stock commenced trading on the Nasdaq Capital Market under the ticker symbol &quot;SEEL&quot; as of market open on January 24,
2019. See Note 1 to our consolidated financial statements for more information regarding the Merger.</P>
<B>
<P>Acquisition of Assets from Bioblast Pharma Ltd. (&quot;Bioblast&quot;)</P>
<I>
</I></B><P>On February 15, 2019, we entered into an Asset Purchase Agreement (the "Bioblast Asset Purchase Agreement") with Bioblast. Pursuant to the Bioblast Asset
Purchase Agreement, we acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the "Bioblast Asset Purchase"). At the closing of the Bioblast
Asset Purchase (the "Bioblast Closing"), we paid to Bioblast $1.5 million in cash in February 2019 and an additional $2.0 million in cash in February 2020.  Accordingly, we
recognized a $3.5 million charge to research and development expense during the three months ended March 31, 2019.  Under the terms of the Bioblast Asset Purchase
Agreement, we agreed to pay additional consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (1) within 15 days following the completion of
our or our affiliate's first Phase II(b) clinical trial of Trehalose satisfying certain criteria, we will pay to Bioblast $8.5 million in cash; and (2) within 15 days following the approval for
commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first new drug application (an &quot;NDA&quot;) or New Drug Submission,
respectively, of Trehalose filed by us or our affiliates, we will pay to Bioblast $8.5 million in cash. In addition, we agreed to pay Bioblast a cash royalty equal to 1% of the net sales of
Trehalose.  Under the terms of the Bioblast Asset Purchase, we assumed a collaborative agreement with TSF, a nonprofit medical research foundation founded by parents of
children with Sanfilippo syndrome. TSF, upon approval by the FDA, plans to begin a Phase II(b)/III clinical trial in up to 24 patients with Sanfilippo syndrome, which is now known
under the study name SLS-005. We will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement entitle us to access all clinical data from this
trial.  On July 15, 2019, we amended the agreement whereby we agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5
million towards the funding of the trial.</P>

<P ALIGN="CENTER">                                                                                                   5
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Acquisition of Assets from Vyera Pharmaceuticals, AG (&quot;Vyera&quot;)</P></B>

<P>On March 6, 2018, we entered into an asset purchase agreement with Vyera</FONT><FONT SIZE=1> </FONT><FONT SIZE=2>pursuant to which we acquired the assets (the
&quot;Vyera Assets&quot;) and liabilities (the &quot;Vyera Assumed Liabilities&quot;) of Vyera related to TUR-002 (intranasal ketamine), which is known as SLS-002. We are
obligated to use commercially reasonable efforts to seek regulatory approval in the United States for and commercialize SLS-002. </P>

<P>As consideration for the Vyera Assets, we paid to Vyera a non-refundable cash payment of $150,000 on May 21, 2018. As further consideration for the Vyera Assets, upon
public announcement of the entry by Apricus and STI into the Merger Agreement, we paid to Vyera a non-refundable cash payment of $150,000.  As further consideration for the
Vyera Assets, we issued to Vyera 191,529 shares of common stock and paid Vyera a non-refundable cash payment $1,000,000 on January 29, 2019. </P>

<P>Pursuant to the amendment to the asset purchase agreement entered into with Vyera on October 15, 2019, we issued Vyera 1,809,845 registered shares of our common stock
on January 2, 2020 and made cash payments to Vyera in the amounts of $750,000, $750,000, $1.0 million and $1.0 million in October 2019, January 2020, April 2020 and July
2020, respectively.</P>

<P>Pursuant to the amendment to the asset purchase agreement entered into with Vyera on February 15, 2021, we agreed to make cash payments to Vyera in the amount of $3.0
million in each of February 2021, June 2021 and September 2021 in exchange for a lower royalty percentage on potential net sales of SLS-002.</P>

<P>In the event that we sell, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then we must pay Vyera an amount equal to 4% of
the net proceeds actually received by us as an upfront payment in such sale.</P>

<P>We agreed to pay to Vyera certain one-time, non-refundable milestone payments consisting of (i) $10.0 million upon approval by the FDA of an NDA, with respect to SLS-002,
(ii) $5.0 million upon approval by the European Medicines Agency (the &quot;EMA&quot;) of the foreign equivalent to an NDA with respect to SLS-002 in the EU (either in its entirety
or including at least one of France, Germany or, if at the time the United Kingdom is a member of the EU, the United Kingdom), the United Kingdom, if at the time the United
Kingdom is not a member of the EU, Japan or the People's Republic of China (each, a &quot;Major Market&quot;), (iii) $2.5 million upon approval by the EMA of the foreign
equivalent to an NDA with respect to SLS-002 in a second Major Market, (iv) $5.0 million upon the achievement of $250.0 million in net sales of SLS-002, (v) $10.0 million upon the
achievement of $500.0 million in net sales of SLS-002, (vi) $15.0 million upon the achievement of $1.0 billion in net sales of SLS-002, (vii) $20.0 million upon the achievement of
$1.5 billion in net sales of SLS-002, and (viii) $25.0 million upon the achievement of $2.0 billion in net sales of SLS-002. We will also pay to Vyera a royalty percentage in the mid-single
digits on aggregate annual net sales of SLS-002.</P>

<B><P>Acquisition of License from Stuart Weg, MD</P>

</B><P>On August 29, 2019, we entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &quot;Weg License Agreement&quot;), pursuant
to which we were granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002.  Under the terms of the Weg License
Agreement, we paid an upfront license fee of $75,000 upon execution of the agreement.  We agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January
2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31,
2021, $0.2 million on January 2, 2022.  We paid the required $0.1 million on January 2, 2020 and $0.125 million on January 2, 2021.  As further consideration, we agreed to pay Dr.
Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of our common stock upon the
issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and unblinding the data for the statistically significant readout of a Phase
III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the
United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory from the EMA in the EU, for such product (the &quot;Milestone Product&quot;), (iii) $3.0 million upon FDA approval of an NDA for the

<P ALIGN="CENTER">                                                                                                   6
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
Milestone Product, (iv) $2.0 million upon regulatory approval by the EMA for the Milestone Product, and (v) $1.5 million upon regulatory
approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by us under milestones (i)-(v) will be $6.6 million. We will also pay to Dr. Weg
a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.</P>

<B>
<P>Acquisition of License from The Regents of the University of California</P>
</B>
<P>On March 7, 2019, we entered into an exclusive license agreement (the &quot;UC Regents License Agreement&quot;) with The Regents of the University of California
(&quot;The UC Regents&quot;) pursuant to which we were granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was
created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a famil</FONT><FONT FACE="Times New Roman" SIZE=2>y of rationally-
designed peptide inhibitors that target the aggregation of alpha-synuclein (&#945;-synuclein). We plan to study this initial approach in PD and will further evaluate the potential
clinical approach in other disorders affecting the CNS.  This pr</FONT><FONT SIZE=2>ogram is now known as SLS-007.  Upon entry into the UC Regents License Agreement, we
paid to The UC Regents $0.1 million.  Under the terms of the UC Regents License Agreement, we agreed to pay additional consideration upon the achievement of certain
milestones in the future, as follows: (i) within 90 days following the completion of dosing of the first patient in a Phase I clinical trial, we will pay $50,000; (ii) within 90 days following
dosing of the first patient in a Phase II clinical trial, we will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, we will pay $0.3 million;
(iv) within 90 days following the first commercial sales in the U.S., we will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market, we will pay
$1.0.million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, we will pay $2.5 million. We are also obligated to pay a single digit
royalty on sales of the product, if any.  In addition, if we fail to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce our
license to a nonexclusive license. </P>

<B><P>Acquisition of License from Duke University</P>
</B>
<P>On June 27, 2019, we entered into an exclusive license agreement (the &quot;Duke License Agreement&quot;) with Duke University pursuant to which we were granted an
exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression.  We plan to study this initial approach in PD and
will further evaluate the potential clinical approach in other disorders affecting the CNS.  This program is now known as SLS-004.   Upon entry into the Duke License Agreement, we
paid to Duke University $0.1 million.  We agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30
days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, we will pay $0.1 million; (ii) within 30 days following
dosing of the first patient in a Phase I clinical trial, we will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, we will pay $0.5 million; (iv)
within 30 days following dosing of the first patient in a Phase III clinical trial, we will pay $1.0 million; and (v) within 30 days following an NDA approval, we will pay $2.0 million. We
are also obligated to pay a single digit royalty on sales of the product, if any.  In addition, if we fail to achieve certain milestones within a specified timeframe, Duke University may
terminate the agreement.</P>

<B><P>Acquisition of License from Ligand Pharmaceuticals Incorporated</P>
</B>
<P>On September 21, 2016, we entered into a License Agreement (the &quot;License Agreement&quot;) with Ligand Pharmaceuticals Incorporated (&quot;Ligand&quot;),
Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the &quot;Licensors&quot;), pursuant to which, among other things, the Licensors granted to us an exclusive,
perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006,
acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously,
the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or
both of the Licensors' two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the &quot;Licensed Products&quot;), and (ii) copyrights, trade
secrets, moral rights and all other intellectual and proprietary rights related thereto. We are obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the

<P ALIGN="CENTER">                                                                                                   7
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
Licensed Products in the United States or a Major Market, and (c) commercialize the Licensed Products in each country where regulatory
approval is obtained. We have the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical
trials and non-clinical studies we believe appropriate to obtain regulatory approvals for commercialization of the Licensed Products. We also have the exclusive right and sole
responsibility and decision-making authority to commercialize any of the Licensed Products.</P>

<P>As partial consideration for the grant of the rights and licenses under the License Agreement, we paid to Ligand a nominal option fee. As further partial consideration for the
grant of the rights and licenses to us under the License Agreement, we are obligated to pay to Ligand an aggregate of $1.3 million within 30 days after the closing of the issuance
and sale by us of debt and/or equity securities for gross proceeds to us of at least $7.5 million. In connection with the closing of the Merger, we issued 392,307 shares of common
stock to settle this obligation.  As further partial consideration for the grant of the rights and licenses to us by Ligand under the License Agreement, we agreed to pay to Ligand
certain one-time, non-refundable milestone payments upon the achievement of certain financing milestones, consisting of (i) the lesser of $3.5 million or 10% of the net proceeds to
us in the event of our initial public offering or a financing transaction consummated in connection with a transaction as a result of which our business becomes owned or controlled
by an existing issuer with a class of securities registered under the Exchange Act and immediately after such transaction, the security holders of us as of immediately before such
transaction own, as a result of such transaction, at least 35% of the equity securities or voting power of such issuer, or (ii) the lesser of $3.5 million or 10% of the net proceeds to us
in the event we are acquired.  In connection with the closing of the Merger, we issued 408,946 shares of common stock to settle this obligation.</P>

<P>As further partial consideration for the grant of the rights and licenses under the License Agreement, we agreed to pay to Ligand certain one-time, non-refundable regulatory
milestone payments in connection with the Licensed Products, other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $750,000
upon submission of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA approval of an application for a particular
Licensed Product, (iii) $1.125 million upon regulatory approval in a Major Market for a particular Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major
Market for a particular Licensed Product.</P>

<P>As further partial consideration for the grant of the rights and licenses under the License Agreement, we agreed to pay to Ligand certain one-time, non-refundable regulatory
milestone payments in connection with the Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon
submission of an application with the FDA or equivalent foreign body for such a particular Licensed Product, (ii) $350,000 upon FDA approval of an application for such a particular
Licensed Product, (iii) $125,000 upon regulatory approval in a Major Market for such a particular Licensed Product, and (iv) $125,000 upon regulatory approval in a second Major
Market for such a particular Licensed Product.</P>

<P>As further partial consideration for the grant of the rights and licenses under the License Agreement, we agreed to pay to Ligand certain one-time, non-refundable commercial
milestone payments in connection with the Licensed Products, consisting of (i) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed
Products based upon Aplindore, (ii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor
antagonist, (iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may
be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of
which is acetaminophen), (iv) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists, (v) $20.0
million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (vi) $20.0 million upon the achievement of $2.0 billion of
cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net
sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including,
without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen),

<P ALIGN="CENTER">                                                                                                   8
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
and (viii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists.</P>

<P>We will also pay to Ligand middle single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or
Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty in the upper single digit to lower double
digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed
Products are covered under a licensed patent. Additionally, we will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed Products other than in
connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent and a tiered
incremental royalty in the lower single digit to middle single digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or
Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent.</P>
<B>
<P>Legacy Pre-Merger Programs</P>
</B>
<P>As a result of the Merger, our going-forward operations are primarily those of STI. Pursuant to the Merger, we retained certain assets and technologies that were Apricus' assets
and technologies before the consummation of the Merger. Despite our expectation that our primary operations will be those of STI on a going-forward basis, we may choose to
monetize legacy Apricus assets in the future. We may also seek to monetize such assets pursuant to certain contractual obligations. Prior to the closing of the Merger, in addition to
strategic efforts, we had been historically focused on the development of innovative product candidates in the areas of urology and rheumatology. We have two legacy product
candidates: a product candidate in the United States intended for the topical treatment of erectile dysfunction (&quot;ED&quot;), which we in-licensed from Warner Chilcott
Company, Inc., now a subsidiary of Allergan plc (&quot;Allergan&quot;) (the &quot;CVR Product Candidate&quot;); and a product candidate which has completed a Phase IIa
clinical trial for the treatment of Raynaud's Phenomenon, secondary to scleroderma, for which we own worldwide rights. At the closing of the Merger, we entered into a Contingent
Value Rights Agreement (the &quot;CVR Agreement&quot;) with STI, Richard Pascoe, as representative of holders of the contingent value rights (&quot;CVRs&quot;), and a rights
agent. Pursuant to the CVR Agreement, each of the Apricus pre-Merger stockholders received one CVR for each share of Apricus common stock held of record immediately prior to
the closing of the Merger. Each CVR represents the right to receive payments based on the CVR Product Candidate and certain related assets and technologies. In particular, the
holders of the CVRs will be entitled to receive 90% of any cash payments (or the fair market value of any non-cash payments) exceeding $500,000 received, during a period of ten
years from the closing of the Merger, based on the sale or out-licensing of the CVR Product Candidate or related assets and technologies, including any milestone payments, less
reasonable transaction expenses.</P>
<B>
<P>Patent Portfolio</P>
</B>
<P>As of March 4, 2021, we owned or in-licensed approximately 38 issued patents that relate to our core programs, which will expire from 2021 through 2034, approximately.  Also,
as of that same date, we owned or in-licensed approximately 47 patent applications that relate to our core programs, which if ultimately issued would expire as late as approximately
2041, based upon the potential expiration date of the last to expire of those patent applications. </P>

<P>To further strengthen our global patent position on our proprietary products under development and to expand the patent protection to other markets, we have filed foreign
patent applications, many of which correspond to our issued United States patents and pending United States patent applications. These foreign filings have resulted in numerous
issued patents and currently pending patent applications.</P>

<P>While we have obtained patents and have patent applications pending, the extent of effective patent protection in the United States and other countries is highly
uncertain.&nbsp;No consistent policy addresses the breadth of claims allowed in or the degree of protection afforded under patents of medical and pharmaceutical
companies.&nbsp;Patents we currently own or may obtain might not be sufficiently broad to protect us against competitors with similar technology.&nbsp;Any of our patents could be
invalidated or circumvented.</P>

<P ALIGN="CENTER">                                                                                                   9
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>The holders of competing patents could determine to commence a lawsuit against us and may even prevail in any such lawsuit.&nbsp;Litigation could result in substantial cost to
and diversion of effort by us, which may harm our business. In addition, our efforts to protect or defend our proprietary rights may not be successful or, even if successful, may result
in substantial cost to us.</P>
<B>
<P>Trademark Portfolio</P>
</B>
<P>As of March 4, 2021, we owned approximately 5 registered trademarks and 2 pending trademark applications worldwide. We have common law trademark rights in the
unregistered marks &quot;Seelos Therapeutics, Inc.,&quot; &quot;Seelos&quot; and the Seelos logo in certain jurisdictions. Vitaros is a registered trademark of Ferring in certain
countries outside of the United States. </P>

<P>While we have obtained registered trademarks, have trademark applications pending and may have common law trademark rights where applicable, the extent of effective
trademark protection in the United States and other countries is highly uncertain.&nbsp;Trademarks we currently own or may obtain might not be sufficiently broad to protect us
against competitors.&nbsp;Any of our trademarks could be invalidated or circumvented.</P>

<P>Even where we have registered trademarks, competitors could seek to invalidate these registrations.&nbsp;Any such litigation could result in substantial cost to and diversion of
effort by us, which may harm our business. In addition, our efforts to protect or defend our proprietary rights may not be successful or, even if successful, may result in substantial
cost to us.</P>
<B>
<P>Governmental Regulation</P>
</B>
<P>Government authorities in the United States (including federal, state and local authorities) and in other countries, extensively regulate, among other things, the manufacturing,
research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing and export
and import of pharmaceutical products, such as our products and product candidates. The process of obtaining regulatory approvals and the subsequent compliance with
appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Moreover, failure to comply with applicable
regulatory requirements may result in, among other things, warning letters, clinical holds, civil or criminal penalties, recall or seizure of products, injunction, disbarment, partial or
total suspension of production or withdrawal of the product from the market. Any agency or judicial enforcement action could have a material adverse effect on us.</P>

<B><I><P>United States Government Regulation</P>
</I></B>
<P>In the United States, the FDA regulates drugs and medical devices under the Federal Food, Drug, and Cosmetic Act (&quot;FDCA&quot;), and its implementing regulations.
Drugs and devices are also subject to other federal, state and local statutes and regulations. Our product candidates are subject to regulation as combination products, which means
that they are composed of both a drug product and device product. If marketed individually, each component would be subject to different regulatory pathways and reviewed by
different Centers within the FDA. A combination product, however, is assigned to a Center that will have primary jurisdiction over its regulation based on a determination of the
combination product's primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of our product candidates, we
believe the primary mode of action is attributable to the drug component of the product, which means that the FDA's Center for Drug Evaluation and Research would have primary
jurisdiction over the premarket development, review and approval of our product candidates. Accordingly, we have and plan to continue to investigate our products through the IND
framework and seek approval through the NDA pathway. Based on our discussions with the FDA to date, we do not anticipate that the FDA will require a separate medical device
authorization for the unit-dose dispenser to be marketed together with our product candidates, though the device component will need to comply with certain requirements applicable
to devices. The process required by the FDA before our product candidates may be marketed in the United States generally involves the following:</P>


<P ALIGN="CENTER">                                                                                                   10
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<UL>
<LI>submission to the FDA of an IND which must become effective before human clinical trials may begin and must be updated annually; </LI>
<LI>completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA's Good Laboratory Practice regulations; </LI>
<LI>performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication in accordance with
good clinical practices (&quot;GCPs&quot;);</LI>
<LI>submission to the FDA of an NDA after completion of all pivotal clinical trials; </LI>
<LI>a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review; </LI>
<LI>satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the active pharmaceutical ingredient (&quot;API&quot;), and finished drug
product are produced and tested to assess compliance with good manufacturing Practices (&quot;cGMP&quot;) regulations; and </LI>
<LI>FDA review and approval of an NDA prior to any commercial marketing or sale of the drug in the United States. </LI></UL>


<P>An IND is a request for authorization from the FDA to administer an investigational drug product to humans.  The central focus of an IND submission is on the general
investigational plan and the protocol(s) for human studies. The IND also includes results of animal studies or other human studies, as appropriate, as well as manufacturing
information, analytical data and any available clinical data or literature to support the use of the investigational new drug. An IND must become effective before human clinical trials
may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed
clinical trials. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical trials can
begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence.</P>

<P>Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the
requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the study, the parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical trial and any subsequent
protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site's institutional review board
(&quot;IRB&quot;) before the trials may be initiated, and the IRB must monitor the study until completed. There are also requirements governing the reporting of ongoing clinical
trials and clinical trial results to public registries.</P>

<P>The clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three
phases of an investigation are as follows:</P>


<UL>
<LI>Phase I. Phase I includes the initial introduction of an investigational new drug into humans. Phase I clinical trials are typically closely monitored and may be conducted in
patients with the target disease or condition or in healthy volunteers. These studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of
the investigational drug in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. During Phase I clinical trials, sufficient
information about the investigational drug's pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase II
clinical trials. The total number of participants included in Phase I clinical trials varies, but is generally in the range of 20 to 80. </LI>
<LI>Phase II. Phase II includes controlled clinical trials conducted to preliminarily or further evaluate the effectiveness of the investigational drug for a particular indication(s) in
patients with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with
the drug. Phase II clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population, usually involving no more than several hundred
participants. </LI>
<LI>Phase III. Phase III clinical trials are generally controlled clinical trials conducted in an expanded patient population generally at geographically dispersed clinical trial sites. They
are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety, to
establish the overall benefit-risk relationship of the investigational drug product, and to provide an adequate basis for product approval. Phase III clinical trials usually involve several
hundred to several thousand participants. </LI></UL>

<P ALIGN="CENTER">                                                                                                   11
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>A pivotal study is a clinical study which adequately meets regulatory agency requirements for the evaluation of a drug candidate's efficacy and safety such that it can be used to
justify the approval of the product. Generally, pivotal studies are also Phase III studies but may be Phase II studies if the trial design provides a well-controlled and reliable
assessment of clinical benefit, particularly in situations where there is an unmet medical need.</P>

<P>The FDA, the IRB or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being
exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as
a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain
data from the study. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</P>

<P>Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information is submitted to
the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application includes all relevant data available from pertinent preclinical
and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product's chemistry, manufacturing, controls
and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a
number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the
safety and effectiveness of the investigational drug product to the satisfaction of the FDA.</P>

<P>Once the NDA submission has been accepted for filing, within 60 days following submission, the FDA's goal is to review applications for new molecular entities within ten
months of the filing date or, if the application relates to a serious or life-threatening indication and demonstrates the potential to provide a significant improvement in safety or
effectiveness over currently marketed therapies, six months from the filing date. The review process is often significantly extended by FDA requests for additional information or
clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is
not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</P>

<P>After the FDA evaluates the NDA and conducts inspections of manufacturing facilities where the drug product and/or its active pharmaceutical ingredient will be produced, it may
issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A
complete response letter indicates that the review cycle of the application is complete and the application is not ready for approval. A complete response letter may require additional
clinical data and/or an additional pivotal Phase III clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or
manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could also approve
the NDA with a risk evaluation and mitigation strategy to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such
as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling,
development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase IV
clinical trials and surveillance to further assess and monitor the product's safety and effectiveness after commercialization. Regulatory approval of oncology products often requires
that patients in clinical trials be followed for long periods to determine the overall survival benefit of the drug.</P>

<P>After regulatory approval of a drug product is obtained, manufacturers are required to comply with a number of post-approval requirements. The holder of an approved NDA
must report, among other things, certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements
concerning advertising and promotional labeling for the approved product. Also, quality control and manufacturing procedures must

<P ALIGN="CENTER">                                                                                                   12
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
continue to conform to cGMP after approval to ensure and preserve the long-term stability of the drug product and compliance with relevant manufacturing requirements applicable to the device component. The
FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive and record keeping requirements. In addition, changes to the
manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also
require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may
decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other
aspects of regulatory compliance.</P>

<P>We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our product candidates. Future FDA and state inspections may
identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In
addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or
holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further
marketing. Newly discovered or developed safety or effectiveness data may require changes to a product's approved labeling, including the addition of new warnings and
contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation,
may be established, or the FDA's policies may change, which could delay or prevent regulatory approval of our products under development.</P>
<B><I>
<P>The Hatch-Waxman Amendments</P>
</B>
<P>ANDA Approval Process</P>
</I>
<P>The Hatch-Waxman Act, established abbreviated FDA approval procedures for drugs that are shown to be equivalent to proprietary drugs previously approved by the FDA
through its NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application (&quot;ANDA&quot;) with the FDA. An ANDA is a
comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and
stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. Premarket applications for generic drugs are
termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that
its product is bioequivalent to the innovator drug.</P>

<P>In certain situations, an applicant may obtain ANDA approval of a generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the
filing and approval of an ANDA Suitability Petition. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise
new questions of safety and effectiveness as compared to the innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not equivalent to the
referenced innovator drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition. However, such a product might be approved under an NDA, with
supportive data from clinical trials.</P>
<I>
<P>505(b)(2) NDAs</P>
</I>
<P>As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may submit an NDA under Section
505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required
for approval comes from studies not conducted by, or for, the applicant or for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that
reliance on FDA's previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies of the new
product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference
drug. The FDA may then approve the new product candidate for all, or some, of the label

<P ALIGN="CENTER">                                                                                                   13
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
indications for which the branded reference drug has been approved, as well as for any
new indication sought by the 505(b)(2) applicant. We anticipate filing 505(b)(2) NDAs for our lead product candidates, which would rely, in part, on the FDA's previous findings of
safety and efficacy of the active ingredient.</P>
<I>
<P>Orange Book Listing</P>
</I>
<P>In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant's
product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book. Any applicant who files an ANDA seeking approval
of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent
information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4)
such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a
paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the
approved NDA to which the ANDA or 505(b)(2) application refers. The applicant may also elect to submit a ``section viii'' statement certifying that its proposed label does not contain
(or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the reference NDA holder and patent owners assert a
patent challenge directed to one of the Orange Book listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the
application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit or a decision in the infringement case that
is favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded
reference drug has expired as described in further detail below.</P>
<I>
<P>Non-Patent Exclusivity</P>
</I>
<P>In addition to patent exclusivity, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or
505(b)(2) application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of a new
chemical entity (&quot;NCE&quot;), which is a drug that contains an active moiety that has not been approved by FDA in any other NDA. An ``active moiety'' is defined as the
molecule or ion responsible for the drug substance's physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA
seeking approval of a generic version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA's findings regarding that drug, except that FDA may
accept an application for filing after four years if the follow-on applicant makes a paragraph IV certification. A drug, including one approved under Section 505(b)(2), may obtain a
three-year period of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more
new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. Should this
occur, the FDA would be precluded from approving any ANDA or 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However,
unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period.</P>
<B><I>
<P>Europe/Rest of World Government Regulation</P>
</I></B>
<P>In addition to regulations in the United States, we may be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any
commercial sales and distribution of our product candidates.</P>

<P>Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of
clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial
application much like the IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application (&quot;CTA&quot;) must be

<P ALIGN="CENTER">                                                                                                   14
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
submitted to each country's national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country's
requirements, clinical trial development may proceed.
The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials
are conducted in accordance with cGCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</P>

<P>To obtain regulatory approval of an investigational drug under EU regulatory systems, we must submit a marketing authorization application. The application used to file the NDA
in the United States is similar to that required in Europe, with the exception of, among other things, country-specific document requirements.</P>

<P>For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing,
pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with cGCPs and the applicable regulatory requirements
and the ethical principles that have their origin in the Declaration of Helsinki.</P>

<P>If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product
recalls, seizure of products, operating restrictions and criminal prosecution.</P>
<I>
<P>Authorization Procedures in the European Union</P>
</I>
<P>Medicines can be authorized in the EU by using either the centralized authorization procedure or national authorization procedures.</P>


<UL>
<LI>Centralized Procedure. Under the Centralized Procedure a so-called Community Marketing Authorization is issued by the European Commission, based on the opinion of the
Committee for Medicinal Products for Human Use of the EMA. The Community Marketing Authorization is valid throughout the entire territory of the European Economic Area
(&quot;EEA&quot;) (which includes the 27 Member States of the EU plus Norway, Liechtenstein and Iceland). The Centralized Procedure is mandatory for certain types of products,
such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes,
auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute
a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </LI>
<LI>For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing authorization to the EMA, as long as
the medicine concerned is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health. </LI>
<LI>National Authorization Procedures. There are also two other possible routes to authorize medicinal products in several countries, which are available for investigational drug
products that fall outside the scope of the centralized procedure: </LI>

<UL>
<LI>Decentralized Procedure.  Using the Decentralized Procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that
have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure. Under the Decentralized Procedure the applicant
chooses one country as Reference Member State. The regulatory authority of the Reference Member State will then be in charge of leading the assessment of the marketing
authorization application.</LI>
<LI>Mutual Recognition Procedure. In the Mutual Recognition Procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that
country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the
original, national marketing authorization.</LI></UL>
</UL>

<P ALIGN="CENTER">                                                                                                   15
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>In the EU, upon receiving marketing authorization, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. If
granted, data exclusivity prevents regulatory authorities in the EU from referencing the innovator's data to assess a generic application. During the additional two-year period of
market exclusivity, a generic marketing authorization can be submitted, and the innovator's data may be referenced, but no generic product can be marketed until the expiration of
the market exclusivity. However, there is no guarantee that a product will be considered by the EU's regulatory authorities to be a new chemical entity, and products may not qualify
for data exclusivity.</P>
<B><I>
<P>Other Health Care Laws</P>
</I></B>
<P>We may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we may market our product
candidates, if approved.&nbsp; These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, physician sunshine and privacy and security
laws and regulations.</P>
<P>The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or
indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal
healthcare programs such as the Medicare and Medicaid programs.&nbsp; The Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced
the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does
not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. The majority of
states also have anti-kickback laws which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial
insurers.</P>

<P>Additionally, the civil False Claims Act prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the United States
government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of
the False Claims Act can result in very significant monetary penalties and treble damages. The federal government is using the False Claims Act, and the accompanying threat of
significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the United States, for example, in connection with the promotion
of products for unapproved uses and other sales and marketing practices.&nbsp; The government has obtained multi-million and multi-billion dollar settlements under the False
Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the
government will continue to devote substantial resources to investigating healthcare providers' and manufacturers' compliance with applicable fraud and abuse laws.</P>

<P>The federal Health Insurance Portability and Accountability Act of 1996 (&quot;HIPAA&quot;) also created new federal criminal statutes that prohibit among other actions,
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully
embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a
violation.</P>

<P>There has also been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, (collectively, &quot;the Affordable Care Act&quot;), among other things, imposed new
reporting requirements on drug manufacturers for payments made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians
and their immediate family members.&nbsp; Failure to submit timely, accurately and completely the required information may result in civil monetary penalties of up to an aggregate
of approximately $0.2 million per year (or up to an aggregate of $1.1 million per year for &quot;knowing failures&quot;), for all payments, transfers of value or ownership or
investment interests that are not timely,

<P ALIGN="CENTER">                                                                                                   16
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
accurately and completely reported in an annual submission.&nbsp; Drug manufacturers are required to submit reports to the government by
the 90th day of each calendar year.&nbsp; Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices
and/or require the tracking and reporting of marketing expenditures and pricing information as well as gifts, compensation and other remuneration to physicians.</P>

<P>We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the
Health Information Technology and Clinical Health Act (&quot;HITECH&quot;), and their respective implementing regulations, including the final omnibus rule published on January
25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes
HIPAA's privacy and security standards directly applicable to &quot;business associates,&quot; defined as independent contractors or agents of covered entities that create, receive,
maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties
that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or
injunctions in federal courts to enforce the federal HIPAA laws and seek attorney's fees and costs associated with pursuing federal civil actions. In addition, state laws govern the
privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.</P>
<I>
<P>Coverage and Reimbursement</P>
</I>
<P>Sales of our product candidates, once approved, will depend, in part, on the extent to which the costs of our products will be covered by third-party payors, such as government
health programs, private health insurers and managed care organizations. Third-party payors generally decide which drugs they will cover and establish certain reimbursement
levels for such drugs. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the
level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. Patients who are prescribed treatments for their conditions
and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs.  Patients are unlikely to use our
products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.  Sales of our products and product candidates, if
approved, will therefore depend substantially on the extent to which the costs of products and our product candidates will be paid by third-party payors.  Additionally, the market for
our products and product candidates will depend significantly on access to third-party payors' formularies without prior authorization, step therapy, or other limitations such as
approved lists of treatments for which third-party payors provide coverage and reimbursement.  Additionally, coverage and reimbursement for therapeutic products can differ
significantly from payor to payor. One third-party payor's decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the
medical product or service, or will provide coverage at an adequate reimbursement rate.  As a result, the coverage determination process will require us to provide scientific and
clinical support for the use of our products to each payor separately and will be a time-consuming process.</P>

<P>In addition, the United States government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls,
restrictions on coverage and reimbursement and requirements for substitution of generic products.  Adoption of price controls and cost-containment measures, and adoption of more
restrictive policies in jurisdictions with existing controls and measures, could further limit our future net revenue and results.  Decreases in third-party reimbursement for our products
and product candidates or a decision by a third-party payor to not cover our products or product candidates could reduce physician usage of our products and product candidates, if
approved, and have a material adverse effect on our sales, results of operations and financial condition.</P>
<I>
<P>Health Care Reform</P>
</I>
<P>In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of
operations. There have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs.</P>

<P ALIGN="CENTER">                                                                                                   17
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>In particular, in the United States, the Affordable Care Act has had, and is expected to continue to have, a significant impact on the healthcare industry. The Affordable Care Act
was designed to expand coverage for the uninsured while at the same time containing overall healthcare costs. The Affordable Care Act, among other things, addressed a new
methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected,
increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid
managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and established a new Medicare Part D coverage gap
discount program, in which manufacturers must agree to offer 50% point-of-sale discounts, which, through subsequent legislative amendments, was increased to 70%, off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer's outpatient drugs to be covered under Medicare Part
D.  Substantial new provisions affecting compliance were also enacted, which may require us to modify our business practices with healthcare providers and entities.</P>

<P>Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act. We expect that the current presidential administration
and U.S. Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. Most recently, the Tax Cuts and Jobs Act
was enacted, which, among other things, removes penalties for not complying with Affordable Care Act's individual mandate to carry health insurance. There is still uncertainty with
respect to the impact President Biden's administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold, and could have an impact on
coverage and reimbursement for healthcare items and services covered by plans that were authorized by the Affordable Care Act.</P>

<P>In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare
payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through
2025 unless additional Congressional action is taken. Additionally, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things,
further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three
to five years. Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in
several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United
States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal
and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</P>


<B><P>Employees</P></B>

<P>As of March 4, 2021, we had 10 employees, 9 of which are full-time employees, and all of whom are in the United States. Our organization will rely
primarily on outsourcing research, development and clinical trial activities, and manufacturing operations, as well as other functions critical to our business. We believe this approach
enhances our ability to focus on our core product opportunities, allocate resources efficiently to different projects and allocate internal resources more effectively.  None of our
employees are represented by a collective bargaining agreement.&nbsp;We believe that we have a good relationship with our employees.  </P>

<P ALIGN="CENTER">                                                                                                   18
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<P>Corporate Information</P>

</B><P>We were incorporated under the laws of the State of Nevada in 1987, as NexMed, Inc. On September 10, 2010, we changed our name to "Apricus Biosciences, Inc." On
January 24, 2019, we completed the Merger with STI (formerly known as Seelos Therapeutics, Inc.), a Delaware corporation, and, upon completion of the Merger, we changed our
name to "Seelos Therapeutics, Inc." Shares of our common stock commenced trading on the Nasdaq Capital Market under the ticker symbol "SEEL" as of market open on January 24, 2019.</P>

<B>
<P>Available Information</P>
</B>
<P>We file annual, quarterly and current reports, proxy statements and other information with the SEC, and we have an Internet website address at
<U>http://www.seelostherapeutics.com</U>. We make available free of charge on our Internet website address our annual report on Form 10-K, quarterly reports on Form 10-Q,
current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Sections&nbsp;13(a) or 15(d) of the Exchange Act as well as our proxy statements as
soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.&nbsp;You may also obtain copies of such documents from the SEC's website at <U>http://www.sec.gov</U>.</P>



<B><P><A NAME="item1a">ITEM 1A.  RISK FACTORS </A></P>
</B>

<I><P>We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business,
prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following
discussion of risk factors, in its entirety, in addition to other information contained in this Annual Report on Form 10-K and our other public filings with the SEC. Other events that we
do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.</P></I>

<B><P>Risk Factor Summary</P>

</B><P ALIGN="JUSTIFY">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks
that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together
with all of the other information appearing in or incorporated by reference into this prospectus, the applicable prospectus supplement and any related free writing prospectus before
making investment decisions regarding the offered securities. </P>

<UL>

<LI>We are a clinical-stage company, we have a very limited operating history, are not currently profitable, do not expect to become profitable in the near
future and may never become profitable.</LI>
<LI>We are dependent on the success of one or more of our current product candidates and we cannot be&nbsp;certain that any of them will receive
regulatory approval or be commercialized.</LI>
<LI>If development of our product candidates does not produce favorable results, or encounters challenges, we and our collaborators, if&nbsp;any, may be
unable to commercialize these products.</LI>
<LI>We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability.</LI>
<LI>Given our lack of current cash flow, we will need to raise additional capital; however, it may be unavailable&nbsp;to us or, even if capital is obtained,
may cause dilution or place significant restrictions on our ability to&nbsp;operate our business. If we fail to raise the necessary additional capital, we may be unable to complete the
development and commercialization of our product candidates, or continue our development programs.</LI>
<LI>Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval&nbsp;or commercialization or have
other significant adverse implications on our business, financial condition and&nbsp;results of operations.</LI>
<LI>Delays in the commencement or completion of clinical trials could result in increased costs to us and delay&nbsp;our ability to establish strategic
collaborations.</LI>
<LI>A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and
operations.</LI>
<LI>Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</LI>
<LI>We intend to rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks.&nbsp;If these third parties do not
successfully carry out their contractual duties, meet expected deadlines, or comply with&nbsp;regulatory requirements, we may not be able to obtain regulatory approval for or
commercialize our product&nbsp;candidates and our business, financial condition and results of operations could be substantially harmed.</LI>

</UL>

<P ALIGN="CENTER">                                                                                                   19
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<UL>

<LI>Our product candidates are subject to extensive regulation under the FDA, the EMA or comparable foreign authorities, which can be costly and time
consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</LI>
<LI>If our competitors have product candidates that are approved faster, marketed more effectively, are better&nbsp;tolerated, have a more favorable safety
profile or are demonstrated to be more effective than ours, our&nbsp;commercial opportunity may be reduced or eliminated.</LI>
<LI>We rely completely on third parties to manufacture our preclinical and clinical drug supplies, and our&nbsp;business, financial condition and results of
operations could be harmed if those third parties fail to provide us&nbsp;with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.</LI>
<LI>The commercial success of our product candidates depends upon their market acceptance among physicians,&nbsp;patients, healthcare payors and the
medical community.</LI>
<LI>If we fail to retain current members of our senior management and scientific personnel, or to attract and&nbsp;keep additional key personnel, we may be
unable to successfully develop or commercialize our product&nbsp;candidates.</LI>
<LI>We may not be successful in obtaining or maintaining necessary rights to our product candidates through&nbsp;acquisitions and in-licenses.</LI>
<LI>If we fail to comply with our obligations in the agreements under which we in-license intellectual property and other rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</LI>
<LI>We may not be able to protect our proprietary or licensed technology in the marketplace.</LI>
<LI>The market price of our common stock is expected to be volatile.</LI></UL>

<B>
<P ALIGN="JUSTIFY">Risk Factors</P>

<P>Risks Related to the Company</P>

<I><P>We are a clinical-stage company, the company has a very limited operating history, are not currently profitable, do not expect&nbsp;to become profitable in the near future
and may never become profitable.</P>
</I></B>

<P>We are a clinical-stage biopharmaceutical company. Since our incorporation, we have focused primarily on the development and acquisition of clinical-stage therapeutic
candidates, which has not changed as a result of  the completion of the business combination between Apricus Biosciences, Inc., a Nevada corporation (&quot;Apricus&quot;), and
Seelos Therapeutics, Inc., a Delaware corporation (&quot;STI&quot;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization entered into on July
30, 2018, pursuant to which (i) a subsidiary of Apricus merged with and into STI, with STI (renamed as &quot;Seelos Corporation&quot;) continuing as a wholly owned subsidiary of
Apricus and the surviving corporation of the merger and (ii) Apricus was renamed as &quot;Seelos Therapeutics, Inc.&quot; (the &quot;Merger&quot;). All of our therapeutic
candidates are in the clinical development stage and none of our pipeline therapeutic candidates have been approved for marketing or are being marketed or commercialized.</P>

<P>As a result, we have no meaningful historical operations upon which to evaluate our business and prospects and have not yet demonstrated an ability to obtain marketing
approval for any of our product candidates or successfully overcome the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry. We also
have generated minimal revenues from collaboration and licensing agreements and no revenues from product sales to date and continue to incur significant research and
development and other expenses. As a result, we have not been profitable and have incurred significant operating losses in every reporting period since our inception. We have
incurred an accumulated deficit of $75.2 million from our inception through December 31, 2020.</P>

<P>For the foreseeable future, we expect to continue to incur losses, which will increase significantly from historical levels as we expand our drug development activities, seek
partnering and/or regulatory approvals for our product candidates and begin to commercialize them if they are approved by the U.S. Food and Drug Administration (the
&quot;FDA&quot;) the European Medicines Agency (the &quot;EMA&quot;) or comparable foreign authorities. Even if we succeed in developing and commercializing one or more
product candidates, we may never become profitable.</P>
<B><I>
<P>We are dependent on the success of one or more of our current product candidates and we cannot be&nbsp;certain that any of them will receive regulatory approval or be
commercialized.</P></I></B>

<P>We have spent significant time, money and effort on the licensing and development of our core assets, SLS-002, SLS-005 and SLS-006 and our other earlier-stage assets, SLS-
004, SLS-007, SLS-008, SLS-010 and SLS-012. To date, no pivotal clinical trials designed to provide clinically and statistically significant proof of efficacy, or to provide sufficient
evidence of safety to justify approval, have been completed with any of our pipeline product candidates. All of our product candidates will require

<P ALIGN="CENTER">                                                                                                   20
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
additional development, including clinical trials as well as further preclinical studies to evaluate their toxicology, carcinogenicity and pharmacokinetics and optimize their formulation, and regulatory clearances before
they can be commercialized. Positive results obtained during early development do not necessarily mean later development will succeed or that regulatory clearances will be
obtained. Our drug development efforts may not lead to commercial drugs, either because our product candidates may fail to be safe and effective or because we have inadequate
financial or other resources to advance our product candidates through the clinical development and approval processes. If any of our product candidates fail to demonstrate safety
or efficacy at any time or during any phase of development, we would experience potentially significant delays in, or be required to abandon, development of the product
candidate.</P>

<P>We do not anticipate that any of our current product candidates will be eligible to receive regulatory approval from the FDA, the EMA or comparable foreign authorities and begin
commercialization for a number of years, if ever. Even if we ultimately receive regulatory approval for any of these product candidates, we or our potential future partners, if any, may
be unable to commercialize them successfully for a variety of reasons. These include, for example, the availability of alternative treatments, lack of cost-effectiveness, the cost of
manufacturing the product on a commercial scale and competition with other drugs. The success of our product candidates may also be limited by the prevalence and severity of any
adverse side effects. If we fail to commercialize one or more of our current product candidates, we may be unable to generate sufficient revenues to attain or maintain profitability,
and our financial condition and stock price may decline.</P>
<B><I>
<P>If development of our product candidates does not produce favorable results, or encounters challenges, we and our collaborators, if&nbsp;any, may be unable to commercialize
these products.</P>
</I></B>
<P>To receive regulatory approval for the commercialization of our core assets, SLS-002, SLS-005 and SLS-006 and our earlier-stage assets, SLS-004, SLS-007, SLS-008, SLS-
010 and SLS-012, or any other product candidates that we may develop, adequate and well-controlled clinical trials must be conducted to demonstrate safety and efficacy in humans
to the satisfaction of the FDA, the EMA and comparable foreign authorities. In order to support marketing approval, these agencies typically require successful results in one or more
Phase III clinical trials, which our current product candidates have not yet reached and may never reach. The development process is expensive, can take many years and has an
uncertain outcome. Failure can occur at any stage of the process. We may experience numerous unforeseen events during, or as a result of, the development process that could
delay or prevent commercialization of our current or future product candidates, including the following:</P>

<UL>

<LI>clinical trials may produce negative or inconclusive results;</LI>
<LI>preclinical studies conducted with product candidates during clinical development to, among other things, evaluate their toxicology, carcinogenicity and pharmacokinetics and
optimize their formulation may produce unfavorable results; </LI>
<LI>we our or contract manufacturers may encounter manufacturing challenges or FDA may raise concerns regarding Chemistry, Manufacturing, and Controls (CMC) data or GMP
compliance, or biocompatibility or drug-device interaction concerns for our combination product candidates;</LI>
<LI>patient recruitment and enrollment in clinical trials may be slower than we anticipate;</LI>
<LI>costs of development may be greater than we anticipate;</LI>
<LI>our product candidates may cause undesirable side effects that delay or preclude regulatory approval or limit their commercial use or market acceptance, if approved;</LI>
<LI>collaborators who may be responsible for the development of our product candidates may not devote sufficient resources to these clinical trials or other preclinical studies of
these candidates or conduct them in a timely manner; or</LI>
<LI>we may face delays in obtaining regulatory approvals to commence one or more clinical trials.</LI>
</UL>


<P>Success in early development does not mean that later development will be successful because, for example, product candidates in later-stage clinical trials may fail to
demonstrate sufficient safety and efficacy despite having progressed through initial clinical trials.</P>

<P>We have licensed or acquired all of the intellectual property related to our product candidates from third parties. All clinical trials, preclinical studies and other analyses
performed to date with respect to our product candidates have been conducted by their original owners. Therefore, as a company, we have limited experience in conducting clinical
trials for our product candidates. Since our experience with our product candidates is limited, we will need to train our existing personnel and hire additional personnel in order to
successfully administer and manage our clinical trials and other studies as planned, which may result in delays in completing such planned clinical trials and preclinical studies.
Moreover, to date our product candidates have been tested in less than the number of patients that will likely need to be studied to obtain regulatory approval. The data collected
from clinical trials with larger patient populations may not demonstrate sufficient safety and efficacy to support regulatory approval of these product candidates.</P>

<P ALIGN="CENTER">                                                                                                   21
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>We currently do not have strategic collaborations in place for clinical development of any of our current product candidates, except for our collaborative agreement with Team
Sanfilippo Foundation (&quot;TSF&quot;), which we assumed in connection with the asset purchase agreement with Bioblast Pharma Ltd. for IV Trehalose, which is now known as
SLS-005. Therefore, in the future, we or any potential future collaborative partner will be responsible for establishing the targeted endpoints and goals for development of our product
candidates. These targeted endpoints and goals may be inadequate to demonstrate the safety and efficacy levels required for regulatory approvals. Even if we believe data collected
during the development of our product candidates are promising, such data may not be sufficient to support marketing approval by the FDA, the EMA or comparable foreign
authorities. Further, data generated during development can be interpreted in different ways, and the FDA, the EMA or comparable foreign authorities may interpret such data in
different ways than us or our collaborators. Our failure to adequately demonstrate the safety and efficacy of our product candidates would prevent our receipt of regulatory approval,
and ultimately the potential commercialization of these product candidates.</P>

<P>Since we do not currently possess the resources necessary to independently develop and commercialize our product candidates or any other product candidates that we may
develop, we may seek to enter into collaborative agreements to assist in the development and potential future commercialization of some or all of these assets as a component of
our strategic plan. However, our discussions with potential collaborators may not lead to the establishment of collaborations on acceptable terms, if at all, or it may take longer than
expected to establish new collaborations, leading to development and potential commercialization delays, which would adversely affect our business, financial condition and results
of operations.</P>
<B><I>
<P>We expect to continue to incur significant research and development expenses, which may make it difficult&nbsp;for us to attain profitability.</P>
</I></B>
<P>We expect to expend substantial funds in research and development, including preclinical studies and clinical trials of our product candidates, and to manufacture and market
any product candidates in the event they are approved for commercial sale. We also may need additional funding to develop or acquire complementary companies, technologies and
assets, as well as for working capital requirements and other operating and general corporate purposes. Moreover, our planned increases in staffing will dramatically increase our
costs in the near and long-term.</P>

<P>However, our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable
products. Due to our limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and on specific indications. Our
resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</P>

<P>Because the successful development of our product candidates is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially
commercialize them. In addition, we may not be able to generate sufficient revenue, even if we are able to commercialize any of our product candidates, to become profitable.</P>
<B><I>
<P>Given our lack of current cash flow, we will need to raise additional capital; however, it may be unavailable&nbsp;to us or, even if capital is obtained, may cause dilution or place
significant restrictions on our ability to&nbsp;operate our business. If we fail to raise the necessary additional capital, we may be unable to complete the development and
commercialization of our product candidates, or continue our development programs.</P>
</I></B>
<P>Since we will be unable to generate sufficient, if any, cash flow to fund our operations for the foreseeable future, we will need to seek additional equity or debt financing to
provide the capital required to maintain or expand our operations.</P>

<P>As of December 31, 2020, we had a cash balance of approximately $15.7 million.  On January 28, 2021, we completed an underwritten public offering pursuant to which
we sold 17,530,488 shares of our common stock at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to
2,286,585 additional shares of common stock.  The net proceeds to us from the offering were approximately $33.5 million, after deducting underwriting discounts and commissions
and other estimated offering expenses payable by us.<A NAME="_Hlk35258312"> We used $3.8 million of the net proceeds from the offering for the partial repayment of certain
outstanding convertible promissory notes.</P>
<P></A></P>
<P>As a result of our recurring losses from operations, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises
substantial doubt about our ability to continue as a going concern. If we are unsuccessful in our efforts to raise outside financing, we may be required to significantly reduce or cease
operations. The report of our independent registered public accounting firm on our audited financial statements for the year ended December 31, 2020 included a &quot;going
concern&quot; explanatory paragraph indicating that our recurring losses from operations raise substantial doubt about our ability to continue as a going concern.</P>

<P ALIGN="CENTER">                                                                                                   22
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>We currently have an effective shelf registration statement on Form S-3 filed with the SEC.  We may use the shelf registration statement on Form S-3 of which this prospectus
forms a part to offer from time to time any combination of debt securities, common and preferred stock and warrants, and, as of the date hereof, a total of $168.7 million of securities
remains available for issuance pursuant to the shelf registration statement.</P>

<P>In addition, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively affect our
liquidity and ability to continue as a going concern.</P>

<P>There can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing is not available on satisfactory
terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate the development of business opportunities and our ability to achieve our business
objectives, our competitiveness, and our business, financial condition and results of operations will be materially adversely affected. In addition, we may be required to grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our inability to fund our business could lead to the loss of your
investment.</P>

<P>Our future capital requirements will depend on many factors, including, but not limited to:</P>

<UL>

<LI>the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;</LI>
<LI>our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</LI>
<LI>the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates;</LI>
<LI>the number and characteristics of the product candidates we seek to develop or commercialize;</LI>
<LI>the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates;</LI>
<LI>the cost of commercialization activities if any of our current or future product candidates are approved for sale, including marketing, sales and distribution costs;</LI>
<LI>the expenses needed to attract and retain skilled personnel;</LI>
<LI>the costs associated with being a public company;</LI>
<LI>the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and</LI>
<LI>the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.</LI>

</UL>


<P>If we raise additional capital by issuing equity securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these stockholders may
experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock. Given our need for cash
and that equity issuances are the most common type of fundraising for similarly situated companies, the risk of dilution is particularly significant for our stockholders.  In addition,
debt financing may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends and may be secured by all or a portion of our assets.&nbsp; Our inability to raise capital when needed would harm our business, financial condition and
results of operations, and could cause our stock price to decline or require that we wind down our operations altogether.</P>
<B><I>
<P>Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval&nbsp;or commercialization or have other significant adverse
implications on our business, financial condition and&nbsp;results of operations.</P>
</I></B>
<P>Undesirable side effects observed in clinical trials or in supportive preclinical studies with our product candidates could interrupt, delay or halt their development and could result
in the denial of regulatory approval by the FDA, the EMA or comparable foreign authorities for any or all targeted indications or adversely affect the marketability of any such product
candidates that receive regulatory approval. In turn, this could eliminate or limit our ability to commercialize our product candidates.</P>

<P>Our product candidates may exhibit adverse effects in preclinical toxicology studies and adverse interactions with other drugs. There are also risks associated with additional
requirements the FDA, the EMA or comparable foreign authorities may impose for marketing approval with regard to a particular disease.</P>

<P>Our product candidates may require a risk management program that could include patient and healthcare provider education, usage guidelines, appropriate promotional
activities, a post-marketing observational study, and ongoing safety and reporting mechanisms, among other requirements. Prescribing could be limited to physician specialists or physicians trained in the use of

<P ALIGN="CENTER">                                                                                                   23
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
the drug, or could be limited to a more restricted patient population. Any risk management program required for approval of our product candidates
could potentially have an adverse effect on our business, financial condition and results of operations.</P>

<P>Undesirable side effects involving our product candidates may have other significant adverse implications on our business, financial condition and results of operations. For
example:</P>

<UL>

<LI>we may be unable to obtain additional financing on acceptable terms, if at all;</LI>
<LI>our collaborators may terminate any development agreements covering these product candidates;</LI>
<LI>if any development agreements are terminated, we may determine not to further develop the affected product candidates due to resource constraints and may not be able to
establish additional collaborations for their further development on acceptable terms, if at all;</LI>
<LI>if we were to later continue the development of these product candidates and receive regulatory approval, earlier findings may significantly limit their marketability and thus
significantly lower our potential future revenues from their commercialization;</LI>
<LI>we may be subject to product liability or stockholder litigation; and</LI>
<LI>we may be unable to attract and retain key employees.</LI>

</UL>


<P>In addition, if any of our product candidates receive marketing approval and we or others later identify undesirable side effects caused by the product:</P>

<UL>

<LI>regulatory authorities may withdraw their approval of the product, or we or our partners may decide to cease marketing and sale of the product voluntarily;</LI>
<LI>we may be required to change the way the product is administered, conduct additional clinical trials or preclinical studies regarding the product, change the labeling of the
product, or change the product's manufacturing facilities; and</LI>
<LI>our reputation may suffer.</LI>

</UL>

<P>Any of these events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs and expenses of
commercializing the product, which in turn could delay or prevent us from generating significant revenues from the sale of the product.</P>
<B><I>
<P>Our efforts to discover product candidates beyond our current product candidates may not succeed, and any&nbsp;product candidates we recommend for clinical development
may not actually begin clinical trials.</P>
</I></B>
<P>We intend to use our technology, including our licensed technology, knowledge and expertise to develop novel drugs to address some of the world's most widespread and costly
central nervous system, respiratory and other disorders, including orphan indications. We intend to expand our existing pipeline of core assets by advancing drug compounds from
current ongoing discovery programs into clinical development. However, the process of researching and discovering drug compounds is expensive, time-consuming and
unpredictable. Data from our current preclinical programs may not support the clinical development of our lead compounds or other compounds from these programs, and we may
not identify any additional drug compounds suitable for recommendation for clinical development. Moreover, any drug compounds we recommend for clinical development may not
demonstrate, through preclinical studies, indications of safety and potential efficacy that would support advancement into clinical trials. Such findings would potentially impede our
ability to maintain or expand our clinical development pipeline. Our ability to identify new drug compounds and advance them into clinical development also depends upon our ability
to fund our research and development operations, and we cannot be certain that additional funding will be available on acceptable terms, or at all.</P>
<B><I>
<P>Delays in the commencement or completion of clinical trials could result in increased costs to us and delay&nbsp;our ability to establish strategic collaborations.</P>
</I></B>
<P>Delays in the commencement or completion of clinical trials could significantly impact our drug development costs. We do not know whether planned clinical trials will begin on
time or be completed on schedule, if at all. The commencement of clinical trials can be delayed for a variety of reasons, including, but not limited to, delays related to:</P>


<UL>


<LI>obtaining regulatory approval to commence one or more clinical trials;</LI>
<LI>reaching agreement on acceptable terms with prospective third-party contract research organizations (&quot;CROs&quot;) and clinical trial sites;</LI>
<LI>manufacturing sufficient quantities of a product candidate or other materials necessary to conduct clinical trials;</LI>
<LI>obtaining institutional review board approval to conduct one or more clinical trials at a prospective site;</LI>
<LI>recruiting and enrolling patients to participate in one or more clinical trials; and</LI>

</UL>

<P ALIGN="CENTER">                                                                                                   24
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<UL>

<LI>the failure of our collaborators to adequately resource our product candidates due to their focus on other programs or as a result of general market conditions.</LI>

</UL>

<P>In addition, once a clinical trial has begun, it may be suspended or terminated by us, our collaborators, the institutional review boards or data safety monitoring boards charged
with overseeing our clinical trials, the FDA, the EMA or comparable foreign authorities due to a number of factors, including:</P>

<UL>

<LI>failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;</LI>
<LI>inspection of the clinical trial operations or clinical trial site by the FDA, the EMA or comparable foreign authorities resulting in the imposition of a clinical hold;</LI>
<LI>unforeseen safety issues; or</LI>
<LI>lack of adequate funding to continue the clinical trial.</LI>

</UL>


<P>If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and
our ability to commence product sales and generate product revenues from any of our product candidates will be delayed. In addition, any delays in completing our clinical trials will
increase our costs and slow down our product candidate development and approval process. Delays in completing our clinical trials could also allow our competitors to obtain
marketing approval before we do or shorten the patent protection period during which we may have the exclusive right to commercialize our product candidates. Any of these
occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</P>
<B><I>
<P>A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.</P>
</I></B>
<P>On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may
affect our operations and those of third parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of future clinical trials. In
addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to
our product candidates. Additionally, while the potential economic impact brought by, and the duration of the COVID-19 pandemic is difficult to assess or predict, the impact of the
COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the
loss of any of our employees as a result of COVID-19 or another pandemic, may have a material adverse effect on our operations. The ultimate impact of the COVID-19 pandemic is
highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems
or the global economy as a whole. However, these effects could have a material impact on our liquidity, capital resources, operations and business and those of the third parties on
which we rely.</P>
<B><I>
<P>Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</P>
</I></B>
<P>The results of preclinical studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages
of clinical trials may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Many companies in the
biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier
studies. Similarly, our future clinical trial results may not be successful for these or other reasons.</P>

<P>This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are
developed through preclinical to early to late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as
manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended
to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve these intended objectives. In
addition, nonclinical studies may be requested or required even after clinical trials have been commenced or completed.</P>

<P>Any of these changes could make the results of our planned clinical trials or other future clinical trials we may initiate less predictable and could cause our product candidates to
perform differently, including causing toxicities, which could delay completion of our clinical trials, delay approval of our product candidates, and/or jeopardize our ability to
commence product sales and generate revenues.</P>

<P ALIGN="CENTER">                                                                                                   25
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><I>
<P>If we experience delays in the enrollment of patients in our clinical trials, our receipt of necessary&nbsp;regulatory approvals could be delayed or prevented.</P>
</I></B>
<P>We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in
these trials as required by the FDA or other regulatory authorities. In addition, the COVID-19 pandemic may result in a reduction of patient enrollment, a loss of patient enrollment
and other delays affecting our clinical trials.&nbsp; Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of
the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients'
perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are
investigating.</P>

<P>If we fail to enroll and maintain the number of patients for which the clinical trial was designed, the statistical power of that clinical trial may be reduced, which would make it
harder to demonstrate that the product candidate being tested in such clinical trial is safe and effective. Additionally, enrollment delays in our clinical trials may result in increased
development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Our inability to enroll a
sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</P>
<B><I>
<P>We intend to rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks.&nbsp;If these third parties do not successfully carry out their
contractual duties, meet expected deadlines, or comply with&nbsp;regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our
product&nbsp;candidates and our business, financial condition and results of operations could be substantially harmed.</P>
</I></B>
<P>We intend to rely upon third-party CROs, medical institutions, clinical investigators and contract laboratories to monitor and manage data for our ongoing preclinical and clinical
programs. Nevertheless, we maintain responsibility for ensuring that each of our clinical trials and preclinical studies is conducted in accordance with the applicable protocol, legal,
regulatory, and scientific standards and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to
comply with current requirements on good manufacturing practices (&quot;cGMP&quot;) good clinical practices (&quot;GCP&quot;) and good laboratory practice (&quot;GLP&quot;),
which are a collection of laws and regulations enforced by the FDA, the EMA and comparable foreign authorities for all of our product candidates in clinical development. Regulatory
authorities enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators, preclinical study and clinical trial sites, and
other contractors. If we or any of our CROs or vendors fails to comply with applicable regulations, the data generated in our preclinical studies and clinical trials may be deemed
unreliable and the FDA, the EMA or comparable foreign authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing
applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP
regulations. In addition, our clinical trials must be conducted with products produced consistent with cGMP regulations. Our failure to comply with these regulations may require us to
repeat clinical trials, which would delay the development and regulatory approval processes.</P>

<P>We may not be able to enter into arrangements with CROs on commercially reasonable terms, or at all. In addition, our CROs will not be our employees, and except for
remedies available to us under our agreements with such CROs, we will not be able to control whether or not they devote sufficient time and resources to our ongoing preclinical and
clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of
the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or
terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated.
As a result, our business, financial condition and results of operations and the commercial prospects for our product candidates could be materially and adversely affected, our costs
could increase, and our ability to generate revenue could be delayed.</P>

<P>Switching or adding additional CROs, medical institutions, clinical investigators or contract laboratories involves additional cost and requires management time and focus. In
addition, there is a natural transition period when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability to meet
our desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not
have a material adverse effect on our business, financial condition or results of operations.</P>

<B><I>
<P>Our product candidates are subject to extensive regulation under the FDA, the EMA or comparable foreign&nbsp;authorities, which can be costly and time consuming, cause
unanticipated delays or prevent the receipt of the&nbsp;required approvals to commercialize our product candidates.</P>
</I></B>

<P ALIGN="CENTER">                                                                                                   26
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of our product candidates are subject to
extensive regulation by the FDA and other U.S. regulatory agencies, the EMA or comparable authorities in foreign markets. In the U.S., neither we nor our collaborators are
permitted to market our product candidates until we or our collaborators receive approval of a new drug application (&quot;NDA&quot;) from the FDA or receive similar approvals
abroad. The process of obtaining these approvals is expensive, often takes many years, and can vary substantially based upon the type, complexity and novelty of the product
candidates involved. Approval policies or regulations may change and may be influenced by the results of other similar or competitive products, making it more difficult for us to
achieve such approval in a timely manner or at all. Any guidance that may result from recent FDA advisory panel discussions may make it more expensive to develop and
commercialize such product candidates. In addition, as a company, we have not previously filed NDAs with the FDA or filed similar applications with other foreign regulatory
agencies. This lack of experience may impede our ability to obtain FDA or other foreign regulatory agency approval in a timely manner, if at all, for our product candidates for which
development and commercialization is our responsibility.</P>

<P>Despite the time and expense invested, regulatory approval is never guaranteed. The FDA, the EMA or comparable foreign authorities can delay, limit or deny approval of a
product candidate for many reasons, including:</P>

<UL>

<LI>a product candidate may not be deemed safe or effective;</LI>
<LI>agency officials of the FDA, the EMA or comparable foreign authorities may not find the data from non-clinical or preclinical studies and clinical trials generated during
development to be sufficient;</LI>
<LI>the FDA, the EMA or comparable foreign authorities may not approve our third-party manufacturers' processes or facilities; or</LI>
<LI>the FDA, the EMA or a comparable foreign authority may change its approval policies or adopt new regulations.</LI>
<LI>Our inability to obtain these approvals would prevent us from commercializing our product candidates.</LI>

</UL>

<B><I>
<P ALIGN="JUSTIFY">We are pursuing the FDA 505(b)(2) NDA pathway for our lead product candidate, SLS-002, which presents certain additional development and
commercialization risks as compared to a conventional 505(b)(1) NDA for an innovator product candidate. We may pursue this pathway for other product candidates as well. </P>

</I></B><P>For our lead product candidate (SLS-002) we are pursuing development in order to seek potential U.S. Food and Drug Administration (the &quot;FDA&quot;) approval
under an abbreviated regulatory pathway called a 505(b)(2) NDA, which permits the filing of an NDA where at least some of the information required for approval comes from studies
that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. We may also pursue this pathway for other of our product
candidates. Section 505(b)(2), if applicable to us for a particular product candidate, would allow an NDA we submit to the FDA to rely, in part, on data in the public domain or the
FDA's prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for a product candidate by potentially
decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. </P>

<P ALIGN="JUSTIFY">Even if the FDA allows us to rely on the 505(b)(2) regulatory pathway, there is no assurance that such marketing approval will be obtained in a timely
manner, or at all. The FDA may require us to perform additional nonclinical studies and clinical trials, and conduct other development work, to support any change from the reference
listed drug (including with respect to the route of administration and drug delivery method and device), which presents uncertainty about the data that may ultimately be necessary
and could be time-consuming and substantially delay our application for or potential receipt of marketing approval. </P>
<P>Even if we are able to utilize the 505(b)(2) regulatory pathway, a drug approved via this pathway may be subject to the same post-approval limitations, conditions and
requirements as any other drug, including, for example a Risk Evaluation and Mitigation Strategy (&quot;REMS&quot;), which we anticipate will be required for our lead product
candidate.</P>

<P>Also, as has been the experience of others in our industry, our competitors may file citizens' petitions with the FDA to contest approval of our NDA, which may delay or even
prevent the FDA from approving any NDA that we submit under the 505(b)(2) regulatory pathway. If an FDA decision or action relative to our product candidate, or the FDA's
interpretation of Section 505(b)(2) more generally, is successfully challenged, it could result in delays or even prevent the FDA from approving a 505(b)(2) application for such
product candidate. </P>

<P>In addition, we may face Hatch-Waxman litigation in relation to our NDAs submitted under the 505(b)(2) regulatory pathway, which may further delay or prevent the approval of
our product candidate. The pharmaceutical industry is highly competitive, and 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors
of previously approved drugs that are referenced in a 505(b)(2) NDA. If the previously approved drugs referenced in an applicant's 505(b)(2) NDA are protected by patent(s) listed in
the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations publication, or the Orange Book, the 505(b)(2) applicant is required to make a claim after filing its NDA
that each such patent is invalid, unenforceable or will not be infringed. The patent holder may thereafter bring suit for patent infringement, which will

<P ALIGN="CENTER">                                                                                                   27
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
trigger a mandatory 30-month delay (or the shorter of dismissal of the lawsuit or expiration of the patent(s)) in approval of the 505(b)(2) NDA application. </P>

<P>If the FDA determines that our 505(b)(2) regulatory pathway is not viable for SLS-002 or any other applicable product candidate for any reason, we would need to reconsider our
plans and might not be able to commercialize any such product candidate in a cost-efficient manner, or at all. If we were to pursue approval under the 505(b)(1) NDA pathway, we
would be subject to more extensive requirements and risks such as conducting additional clinical trials, providing additional data and information or meeting additional standards for
marketing approval. As a result, the time and financial resources required to obtain marketing approval for our product candidates would likely increase substantially and further
complications and risks associated with our product candidates may arise. Also, new competing products may reach the market faster than ours, which may materially and adversely
affect our competitive position, business and prospects.</P>
<B><I>
<P>Even if our product candidates receive regulatory approval in the U.S., we may never receive approval or&nbsp;commercialize our products outside of the U.S.</P>
</I></B>
<P>In order to market any products outside of the U.S., we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and
efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in
other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA
approval in the U.S. as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval
in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay seeking or obtaining such
approval would impair our ability to develop foreign markets for our product candidates.</P>
<B><I>
<P>Even if any of our product candidates receive regulatory approval, our product candidates may still face future&nbsp;development and regulatory difficulties.</P>
</I></B>
<P>If any of our product candidates receive regulatory approval, the FDA, the EMA or comparable foreign authorities may still impose significant restrictions on the indicated uses or
marketing of the product candidates or impose ongoing requirements for potentially costly post-approval studies and trials. In addition, regulatory agencies subject a product, our
manufacturer and the manufacturer's facilities to continual review and periodic inspections. If a regulatory agency discovers previously unknown problems with a product, including
adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product,
our collaborators or us, including requiring withdrawal of the product from the market. Our product candidates will also be subject to ongoing FDA, the EMA or comparable foreign
authorities' requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information on the drug. If our
product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:</P>

<UL>

<LI>issue warning letters or other notices of possible violations;</LI>
<LI>impose civil or criminal penalties or fines or seek disgorgement of revenue or profits;</LI>
<LI>suspend any ongoing clinical trials;</LI>
<LI>refuse to approve pending applications or supplements to approved applications filed by us or our collaborators;</LI>
<LI>withdraw any regulatory approvals;</LI>
<LI>impose restrictions on operations, including costly new manufacturing requirements, or shut down our manufacturing operations; or</LI>
<LI>seize or detain products or require a product recall.</LI>

</UL>

<B><I>
<P>The FDA, the EMA and comparable foreign authorities actively enforce the laws and regulations prohibiting the&nbsp;promotion of off-label uses.</P>
</I></B>
<P>The FDA, the EMA and comparable foreign authorities strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if
approved. In particular, a product may not be promoted for uses that are not approved by the FDA, the EMA or comparable foreign authorities as reflected in the product's approved
labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our products for their patients in a manner that is
inconsistent with the approved label, if the physicians personally believe in their professional medical judgment that our products could be used in such manner. However, if we are
found to have promoted our products for any off-label uses, the federal government could levy civil, criminal or administrative penalties, and seek fines against us. Such enforcement
has become more common in the industry. The FDA, the EMA or comparable foreign authorities could also request that we enter into a consent decree or a corporate integrity
agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the

<P ALIGN="CENTER">                                                                                                   28
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations.</P>

<B><I>
<P>If our competitors have product candidates that are approved faster, marketed more effectively, are better&nbsp;tolerated, have a more favorable safety profile or are
demonstrated to be more effective than ours, our&nbsp;commercial opportunity may be reduced or eliminated.</P>
</I></B>
<P>The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that
our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including
commercial biopharmaceutical enterprises, academic institutions, government agencies and private and public research institutions. Any product candidates that we successfully
develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</P>

<P>Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, clinical trials, regulatory
approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. Our competitors may succeed in developing technologies and therapies that are more effective, better tolerated or less costly
than any which we are developing, or that would render our product candidates obsolete and noncompetitive. Even if we obtain regulatory approval for any of our product
candidates, our competitors may succeed in obtaining regulatory approvals for their products earlier than we do. We will also face competition from these third parties in recruiting
and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring and in-licensing technologies
and products complementary to our programs or advantageous to our business.</P>

<P>The key competitive factors affecting the success of each of our product candidates, if approved, are likely to be its efficacy, safety, tolerability, frequency and route of
administration, convenience and price, the level of branded and generic competition and the availability of coverage and reimbursement from government and other third-party
payors.</P>

<P>The pharmaceutical market for the treatment of major depressive disorder includes selective serotonin reuptake inhibitors (&quot;SSRIs&quot;), serotonin and norepinephrine
reuptake inhibitors (&quot;SNRIs&quot;) and atypical antipsychotics.  A number of these marketed antidepressants will be generic, and would be key competitors to SLS-002. These
products include Forest Laboratory's Lexapro/Cipralex (escitalopram) and Viibryd (vilazodone), Pfizer, Inc.'s Zoloft (sertraline), Effexor (venlafaxine) and Pristiq (desvenlafaxine),
GlaxoSmithKline plc's Paxil/Seroxat (paroxetine), Eli Lilly and Company's Prozac (fluoxetine) and Cymbalta (duloxetine), AstraZeneca plc's Seroquel (quetiapine) and Bristol-Myers
Squibb Company's Abilify (aripiprazole), among others.</P>

<P>Patients with treatment-resistant depression often require treatment with several antidepressants, such as an SSRI or SNRI, combined with an &quot;adjunct&quot; therapy
such as an antipsychotic compound, such as AstraZeneca plc's Seroquel (quetiapine) and Bristol-Myers Squibb Company's Abilify (aripiprazole), or mood stabilizers, such as
Janssen Pharmaceutica's Topamax (topiramate). In addition, Janssen's Spravato (intranasal esketamine), which has been approved for treatment-resistant depression and for
depressive systems in adults with major depressive disorder with suicidal thoughts or actions, targets the NMDA receptor and is expected to have a faster onset of therapeutic effect
as compared to currently available therapies.</P>

<P>Current treatments for Parkinson's Disease (&quot;PD&quot;) are intended to improve the symptoms of patients. The cornerstone of PD therapy is levodopa, as it is the most
effective therapy for reducing symptoms of PD. There are other drug therapies in development that will target the disease, such as gene and stem cell therapy and A2A receptor
agonists. </P>
<B><I>
<P>We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity&nbsp;for our product candidates.</P>
</I></B>
<P>Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the
Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population
of fewer than 200,000 individuals annually in the United States. In the United States and Europe, obtaining orphan drug approval may allow us to obtain financial incentives, such as
an extended period of exclusivity during which only we are allowed to market the orphan drug. While we plan to seek orphan drug designation from the FDA for SLS-008 for the
treatment of a pediatric indication, we, or any future collaborators, may not be granted orphan drug designations for our product candidates in the U.S. or in other jurisdictions.</P>

<P ALIGN="CENTER">                                                                                                   29
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product
candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it
has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable
exclusivity period. The applicable exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a
drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be
lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the
needs of patients with the rare disease or condition.</P>

<P>Even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because FDA has
taken the position that, under certain circumstances, another drug with the same active chemical and pharmacological characteristics, or moiety, can be approved for the same
condition. Specifically, the FDA's regulations provide that it can approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is
clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</P>
<B><I>
<P>The active ingredient of our lead product candidate, SLS-002, ketamine hydrochloride, is recognized as having the potential for abuse, misuse and diversion and, as a result, is
and will be subject to extensive federal and state laws and regulations governing controlled substances and the entities involved in their research, manufacturing, sale and
distribution, and possession. In addition, we anticipate that if we obtain marketing approval for SLS-002 it will be the subject of an FDA Risk Evaluation and Mitigation Strategy
(REMS).</P>

</I></B><P>Ketamine is listed by the Drug Enforcement Administration (&quot;DEA&quot;) as a Schedule&nbsp;III controlled substance under the Controlled Substances Act. The
DEA classifies substances as Schedule&nbsp;I, II, III, IV or V controlled substances, with Schedule&nbsp;I controlled substances considered to present the highest risk of substance
abuse and Schedule&nbsp;V controlled substances the lowest risk. Scheduled controlled substances are subject to DEA regulations relating to supply, procurement, manufacturing,
storage, distribution and physician prescription procedures. In addition to federal scheduling, some drugs may be subject to state-level controlled substance laws and regulations
and in some cases more broadly applicable or more extensive requirements than those determined by the DEA and FDA. Federal and state-level controlled substance laws impose
a broad range of registration and licensure requirements along with requirements for systems and controls intended to provide security and reduce the risk of diversion and misuse,
and to identify suspicious activities. </P>

<P>Compliance with these laws can be expensive and time consuming. Failure to follow these requirements can lead to significant civil and/or criminal penalties and possibly even
lead to a revocation of a DEA registration and state-level licenses.</P>

<P>If SLS-002 receives marketing approval from the FDA or other regulatory authority, we may be required to implement REMS to address the potential for abuse and misuse of our
product candidate. As a result, our product candidate may only be available through a restricted or limited distribution system to which only certain prescribing healthcare
professionals may have access for their patients or healthcare professionals may be limited in their prescribing. </P>

<P>Furthermore, product candidates containing controlled substances may generate public controversy. As a result, these products may be at risk of having their sale and
distribution and marketing approvals further restricted or in extreme cases withdrawn in the event that regulators were to assess that the benefits of a product no longer outweigh
emerging risks. Political pressures or adverse publicity could lead to delays in, and increased expenses for, and limit or restrict, the commercialization of our product or product
candidates.</P>
<B><I>
<P>We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and&nbsp;limit supply of our product candidates.</P>
</I></B>
<P>The process of manufacturing our product candidates is complex, highly regulated, and subject to several risks. For example, the process of manufacturing our product
candidates is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even
minor deviations from normal manufacturing processes for any of our product candidates could result in reduced production yields, product defects and other supply disruptions. If
microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing
facilities may need to be closed for an extended period of time to investigate and remedy the contamination. In addition, the manufacturing facilities in which our product candidates
are made could be adversely affected by equipment failures, labor shortages, natural disasters, public health crises, pandemics and epidemics, such as the recent coronavirus
disease 2019 (COVID-19), power failures and numerous other factors.</P>

<P ALIGN="CENTER">                                                                                                   30
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>In addition, any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures,
withdrawals or recalls or other interruptions in the supply of our product candidates. We also may need to take inventory write-offs and incur other charges and expenses for product
candidates that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives.</P>
<B><I>
<P>We rely completely on third parties to manufacture our preclinical and clinical drug supplies, and our&nbsp;business, financial condition and results of operations could be
harmed if those third parties fail to provide us&nbsp;with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.</P>
</I></B>
<P>We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our preclinical and clinical drug supplies for use in our clinical trials,
and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on our manufacturers to purchase from third-party
suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw materials that we use to manufacture
our product candidates, and there may be a need to identify alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product
candidates for our clinical trials, and, if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by
our manufacturers. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete such clinical trial, any
significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party
manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates, which could harm our business,
financial condition and results of operations.</P>
<B><I>
<P ALIGN="JUSTIFY">Product candidates that are considered combination products for FDA purposes, such as the SLS-002 drug-device combination product consisting of
ketamine hydrocholoride and a USP aqueous spray solution in a bi-dose nasal delivery device, may face additional challenges, risks and delays in the product development and
regulatory approval process.</P>

</I></B><P>SLS-002 is delivered by an intranasal delivery device and considered a drug-device combination product (the device having been developed by a third party is subject
to a pending license agreement). When evaluating products that utilize a specific drug delivery system or device, the FDA will evaluate the characteristics of that delivery system and
its functionality, as well as the potential for undesirable interactions between the drug and the delivery system, including the potential to negatively impact the safety or effectiveness
of the drug. The FDA review process can be more complicated for combination products, and may result in delays, particularly if novel delivery systems are involved. Additionally,
quality or design concerns with the delivery system could delay or prevent regulatory approval and commercialization of our product candidates.</P>

<B><I><P>We and our contract manufacturers are subject to significant regulation with respect to manufacturing our&nbsp;product candidates. The manufacturing facilities on
which we rely may not continue to meet regulatory&nbsp;requirements.</P>
</I></B>
<P>All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our contract manufacturers for our product candidates, are subject to
extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with
cGMP. These regulations govern manufacturing processes and procedures and the implementation and operation of quality systems to control and assure the quality of
investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties
or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an
NDA or marketing authorization application (&quot;MAA&quot;) on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA, the EMA or comparable
foreign authorities through their facilities inspection program. Some of our contract manufacturers may not have produced a commercially approved pharmaceutical product and
therefore may not have obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a
pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition,
the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or any of our other potential products or
the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we plan to oversee the contract manufacturers, we cannot
control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do
not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction
of the regulatory authority, if ever.</P>

<P ALIGN="CENTER">                                                                                                   31
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or
audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit,
we or the relevant regulatory authority may require remedial measures that may be costly or time consuming for us or a third party to implement, and that may include the temporary
or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with
whom we contract could materially harm our business, financial condition and results of operations.</P>

<P>If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA, the EMA or comparable foreign authorities can impose regulatory sanctions
including, among other things, refusal to approve a pending application for a product candidate, withdrawal of an approval or suspension of production. As a result, our business,
financial condition and results of operations may be materially and adversely affected.</P>

<P>Additionally, if supply from one manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent
foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies or trials if a new manufacturer is relied upon for commercial
production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</P>

<P>These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of
our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at
a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</P>
<B><I>
<P>Any collaboration arrangement that we may enter into in the future may not be successful, which could&nbsp;adversely affect our ability to develop and commercialize our
current and potential future product&nbsp;candidates.</P>
</I></B>
<P>We may seek collaboration arrangements with biopharmaceutical companies for the development or commercialization of our current and potential future product candidates. To
the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are
complex and time consuming to negotiate, execute and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative
arrangements should we choose to enter into such arrangements, and the terms of the arrangements may not be favorable to us. If and when we collaborate with a third party for
development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party.
The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining
the efforts and resources that they will apply to these collaborations.</P>

<P>Disagreements between parties to a collaboration arrangement can lead to delays in developing or commercializing the applicable product candidate and can be difficult to
resolve in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical companies and other third parties are terminated or allowed to expire by the other
party. Any such termination or expiration would adversely affect our business, financial condition and results of operations.</P>
<B><I>
<P>If we are unable to develop our own commercial organization or enter into agreements with third parties to sell&nbsp;and market our product candidates, we may be unable to
generate significant revenues.</P>
</I></B>
<P>We do not have a sales and marketing organization, and we have no experience as a company in the sales, marketing and distribution of pharmaceutical products. If any of our
product candidates are approved for commercialization, we may be required to develop our sales, marketing and distribution capabilities, or make arrangements with a third party to
perform sales and marketing services. Developing a sales force for any resulting product or any product resulting from any of our other product candidates is expensive and time
consuming and could delay any product launch. We may be unable to establish and manage an effective sales force in a timely or cost-effective manner, if at all, and any sales force
we do establish may not be capable of generating sufficient demand for our product candidates. To the extent that we enter into arrangements with collaborators or other third
parties to perform sales and marketing services, our product revenues are likely to be lower than if we marketed and sold our product candidates independently. If we are unable to
establish adequate sales and marketing capabilities, independently or with others, we may not be able to generate significant revenues and may not become profitable.</P>

<P ALIGN="CENTER">                                                                                                   32
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><I>
<P>The commercial success of our product candidates depends upon their market acceptance among physicians,&nbsp;patients, healthcare payors and the medical
community.</P></I></B>

<P>Even if our product candidates obtain regulatory approval, our products, if any, may not gain market acceptance among physicians, patients, healthcare payors and the medical
community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</P>

<UL>

<LI>the effectiveness of our approved product candidates as compared to currently available products;</LI>
<LI>patient willingness to adopt our approved product candidates in place of current therapies;</LI>
<LI>our ability to provide acceptable evidence of safety and efficacy;</LI>
<LI>relative convenience and ease of administration;</LI>
<LI>the prevalence and severity of any adverse side effects;</LI>
<LI>restrictions on use in combination with other products;</LI>
<LI>availability of alternative treatments;</LI>
<LI>pricing and cost-effectiveness assuming either competitive or potential premium pricing requirements, based on the profile of our product candidates and target markets;</LI>
<LI>effectiveness of us or our partners' sales and marketing strategy;</LI>
<LI>our ability to obtain sufficient third-party coverage or reimbursement; and</LI>
<LI>potential product liability claims.</LI>

</UL>


<P>In addition, the potential market opportunity for our product candidates is difficult to precisely estimate. Our estimates of the potential market opportunity for our product
candidates include several key assumptions based on our industry knowledge, industry publications, third-party research reports and other surveys. Independent sources have not
verified all of our assumptions. If any of these assumptions proves to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of the
potential market opportunity. If the actual market for our product candidates is smaller than we expect, our product revenue may be limited, it may be harder than expected to raise
funds and it may be more difficult for us to achieve or maintain profitability. If we fail to achieve market acceptance of our product candidates in the U.S. and abroad, our revenue will
be limited and it will be more difficult to achieve profitability.</P>
<B><I>
<P>If we fail to obtain and sustain an adequate level of reimbursement for our potential products by third-party&nbsp;payors, potential future sales would be materially adversely
affected.</P>
</I></B>
<P>There will be no viable commercial market for our product candidates, if approved, without reimbursement from third-party payors. Reimbursement policies may be affected by
future healthcare reform measures. We cannot be certain that reimbursement will be available for our current product candidates or any other product candidate we may develop.
Additionally, even if there is a viable commercial market, if the level of reimbursement is below our expectations, our anticipated revenue and gross margins will be adversely
affected.</P>

<P>Third-party payors, such as government or private healthcare insurers, carefully review and increasingly question and challenge the coverage of and the prices charged for
drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors. Reimbursement rates may be based on
reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. There is a current trend in the U.S. healthcare industry
toward cost containment.</P>

<P>Large public and private payors, managed care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding
the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, may question the coverage of, and challenge the prices charged for,
medical products and services, and many third-party payors limit coverage of or reimbursement for newly approved healthcare products. In particular, third-party payors may limit the
covered indications. Cost-control initiatives could decrease the price we might establish for products, which could result in product revenues being lower than anticipated. We believe
our drugs will be priced significantly higher than existing generic drugs and consistent with current branded drugs. If we are unable to show a significant benefit relative to existing
generic drugs, Medicare, Medicaid and private payors may not be willing to provide reimbursement for our drugs, which would significantly reduce the likelihood of our products
gaining market acceptance.</P>

<P>We expect that private insurers will consider the efficacy, cost-effectiveness, safety and tolerability of our potential products in determining whether to approve reimbursement for
such products and at what level. Obtaining these approvals can be a time consuming and expensive process. Our business, financial condition and results of operations would be
materially adversely affected if we do not receive approval for reimbursement of our potential products from private insurers on a timely or satisfactory basis. Limitations on coverage
could also be imposed at the local Medicare carrier level or by fiscal intermediaries. Medicare Part D, which provides a pharmacy benefit to Medicare patients as discussed below, does not require

<P ALIGN="CENTER">                                                                                                   33
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
participating prescription drug plans to cover all drugs within a class of products. Our business, financial condition and results of operations could be materially
adversely affected if Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our product candidates or other potential products.</P>

<P>Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. In
many countries, the product cannot be commercially launched until reimbursement is approved. In some foreign markets, prescription pharmaceutical pricing remains subject to
continuing governmental control even after initial approval is granted. The negotiation process in some countries can exceed 12 months. To obtain reimbursement or pricing
approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products to other available therapies.</P>

<P>If the prices for our potential products are reduced or if governmental and other third-party payors do not provide adequate coverage and reimbursement of our drugs, our future
revenue, cash flows and prospects for profitability will suffer.</P>
<B><I>
<P>Current and future legislation may increase the difficulty and cost of commercializing our product candidates&nbsp;and may affect the prices we may obtain if our product
candidates are approved for commercialization.</P>
</I></B>
<P>In the U.S. and some foreign jurisdictions, there have been a number of adopted and proposed legislative and regulatory changes regarding the healthcare system that could
prevent or delay regulatory approval of our product candidates, restrict or regulate post-marketing activities and affect our ability to profitably sell any of our product candidates for
which we obtain regulatory approval.</P>

<P>In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&quot;MMA&quot;) changed the way Medicare covers and pays for pharmaceutical
products. Cost reduction initiatives and other provisions of this legislation could limit the coverage and reimbursement rate that we receive for any of our approved products. While
the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement
rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</P>

<P>In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the &quot;PPACA&quot;),
was enacted. The PPACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud
and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health
policy reforms. The PPACA increased manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate amount for both branded and
generic drugs and revised the definition of &quot;average manufacturer price&quot;, which may also increase the amount of Medicaid drug rebates manufacturers are required to
pay to states. The legislation also expanded Medicaid drug rebates and created an alternative rebate formula for certain new formulations of certain existing products that is intended
to increase the rebates due on those drugs. The Centers for Medicare &amp; Medicaid Services, which administers the Medicaid Drug Rebate Program, also has proposed to
expand Medicaid rebates to the utilization that occurs in the territories of the U.S., such as Puerto Rico and the Virgin Islands. Further, beginning in 2011, the PPACA imposed a
significant annual fee on companies that manufacture or import branded prescription drug products and required manufacturers to provide a 50% discount off the negotiated price of
prescriptions filled by beneficiaries in the Medicare Part D coverage gap, referred to as the &quot;donut hole.&quot; Legislative and regulatory proposals have been introduced at
both the state and federal level to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.</P>

<P>There have been public announcements by members of the U.S. Congress regarding plans to repeal and replace the PPACA and Medicare. For example, on December 22,
2017 the Tax Cuts and Jobs Act of 2017 was signed into law, which, among other things, eliminated the individual mandate requiring most Americans (other than those who qualify
for a hardship exemption) to carry a minimum level of health coverage, effective January 1, 2019. We are not sure whether additional legislative changes will be enacted, or whether
the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In
addition, increased scrutiny by the U.S. Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent
product labeling and post-marketing approval testing and other requirements.</P>


<P>In addition to the PPACA, there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payers to reduce costs while
expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our current and future solutions or
the amounts of reimbursement available for our current and future solutions from governmental agencies or third-party payers. While in general it is difficult to predict specifically
what effects the PPACA or any future healthcare reform legislation or policies will

<P ALIGN="CENTER">                                                                                                   34
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition.</P>

<P>In Europe, the United Kingdom withdrew from the European Union on January 31, 2020 and began a transition period that ended on December 31, 2020. Although the effects of
Brexit have yet to be seen, and the UK is in the process of negotiating trade deals with other countries, Brexit has created additional uncertainties that may ultimately result in new
regulatory costs and challenges for companies and increased restrictions on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand
our operations in Europe and which may have an adverse effect on our business, financial condition and results of operations. Additionally, Brexit may increase the possibility that
other countries may decide to leave the EU in the future.</P>
<B><I>
<P>Changes in government funding for the FDA and other government agencies could hinder their ability to hire and&nbsp;retain key leadership and other personnel, properly
administer drug innovation, or prevent our product&nbsp;candidates from being developed or commercialized, which could negatively impact our business, financial&nbsp;condition
and results of operations.</P>
</I></B>
<P>The ability of the FDA to review and approve new products can be affected by a variety of factors, including budget and funding levels, ability to hire and retain key personnel,
and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies that
fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</P>

<P>In December 2016, the 21<SUP>st</SUP>&nbsp;Century Cures Act was signed into law. This new legislation is designed to advance medical innovation and empower the FDA
with the authority to directly hire positions related to drug and device development and review. However, government proposals to reduce or eliminate budgetary deficits may include
reduced allocations to the FDA and other related government agencies. These budgetary pressures may result in a reduced ability by the FDA to perform their respective roles;
including the related impact to academic institutions and research laboratories whose funding is fully or partially dependent on both the level and timing of funding from government
sources.</P>

<P>Disruptions at the FDA and other agencies may also slow the time necessary for our product candidates to be reviewed or approved by necessary government agencies, which
could adversely affect our business, financial condition and results of operations.</P>
<B><I>
<P>We are subject to &quot;fraud and abuse&quot; and similar laws and regulations, and a failure to comply with such&nbsp;regulations or prevail in any litigation related to
noncompliance could harm our business, financial condition&nbsp;and results of operations.</P>
</I></B>
<P>In the U.S., we are subject to various federal and state healthcare &quot;fraud and abuse&quot; laws, including anti-kickback laws, false claims laws and other laws intended,
among other things, to reduce fraud and abuse in federal and state healthcare programs. The federal Anti-Kickback Statute makes it illegal for any person, including a prescription
drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including
the purchase, order or prescription of a particular drug, or other good or service for which payment in whole or in part may be made under a federal healthcare program, such as
Medicare or Medicaid. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often difficult
to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged under the federal Anti-Kickback
Statute.</P>

<P>The federal False Claims Act prohibits anyone from, among other things, knowingly presenting or causing to be presented for payment to the government, including the federal
healthcare programs, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically
unnecessary items or services. Under the Health Insurance Portability and Accountability Act of 1996, we are prohibited from knowingly and willfully executing a scheme to defraud
any healthcare benefit program, including private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or
fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services to obtain money or property of any healthcare benefit program. Violations
of fraud and abuse laws may be punishable by criminal or civil sanctions, including penalties, fines or exclusion or suspension from federal and state healthcare programs such as
Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the government under
the federal False Claims Act as well as under the false claims laws of several states.</P>

<P>Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not
just governmental payors. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance
Program Guidance for Pharmaceutical Manufacturers or the Pharmaceutical Research and Manufacturers of America's Code on Interactions with Healthcare Professionals. Several
states also impose other marketing restrictions or require pharmaceutical companies to make

<P ALIGN="CENTER">                                                                                                   35
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
marketing or price disclosures to the state. There are ambiguities as to what is required
to comply with these state requirements and if we fail to comply with an applicable state law requirement, we could be subject to penalties.</P>

<P>Neither the government nor the courts have provided definitive guidance on the application of fraud and abuse laws to our business. Law enforcement authorities are
increasingly focused on enforcing these laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found in violation of one of these laws, we could be subject to
significant civil, criminal and administrative penalties, damages, fines, exclusion from governmental funded federal or state healthcare programs and the curtailment or restructuring
of our operations. If this occurs, our business, financial condition and results of operations may be materially adversely affected.</P>
<B><I>
<P>If we face allegations of noncompliance with the law and encounter sanctions, our reputation, revenues and&nbsp;liquidity may suffer, and any of our product candidates that
are ultimately approved for commercialization&nbsp;could be subject to restrictions or withdrawal from the market.</P>
</I></B>
<P>Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any
failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to generate revenues from any of our product candidates that are ultimately
approved for commercialization. If regulatory sanctions are applied or if regulatory approval is withdrawn, our business, financial condition and results of operations will be adversely
affected. Additionally, if we are unable to generate revenues from product sales, our potential for achieving profitability will be diminished and our need to raise capital to fund our
operations will increase.</P>
<B><I>
<P>If we fail to retain current members of our senior management and scientific personnel, or to attract and&nbsp;keep additional key personnel, we may be unable to successfully
develop or commercialize our product&nbsp;candidates.</P>
</I></B>
<P>Our success depends on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. As of March 4, 2021, we have 11 employees.
Our organization will rely primarily on outsourcing research, development and clinical trial activities, and manufacturing operations, as well as other functions critical to our business.
We believe this approach enhances our ability to focus on our core product opportunities, allocate resources efficiently to different projects and allocate internal resources more
effectively.  We have filled several key open positions and are currently recruiting for a few remaining positions. However, competition for qualified personnel is intense. We may not
be successful in attracting qualified personnel to fulfill our current or future needs and there is no guarantee that any of these individuals will join us on a full-time employment basis,
or at all. In the event we are unable to fill critical open employment positions, we may need to delay our operational activities and goals, including the development of our product
candidates, and may have difficulty in meeting our obligations as a public company. We do not maintain &quot;key person&quot; insurance on any of our employees.</P>

<P>In addition, competitors and others are likely in the future to attempt to recruit our employees. The loss of the services of any of our key personnel, the inability to attract or retain
highly qualified personnel in the future or delays in hiring such personnel, particularly senior management and other technical personnel, could materially and adversely affect our
business, financial condition and results of operations. In addition, the replacement of key personnel likely would involve significant time and costs, and may significantly delay or
prevent the achievement of our business objectives.</P>

<P>From time to time, our management seeks the advice and guidance of certain scientific advisors and consultants regarding clinical and regulatory development programs and
other customary matters. These scientific advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that
may limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies in developing products or technologies
that may compete with us.</P>
<B><I>
<P>We will need to increase the size of our organization and may not successfully manage our growth.</P>
</I></B>
<P>We are a clinical-stage biopharmaceutical company with a small number of planned employees, and our management system currently in place is not likely to be adequate to
support our future growth plans. Our ability to grow and to manage our growth effectively will require us to hire, train, retain, manage and motivate additional employees and to
implement and improve our operational, financial and management systems. These demands also may require the hiring of additional senior management personnel or the
development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level, would
increase our expenses significantly. Moreover, if we fail to expand and enhance our operational, financial and management systems in conjunction with our potential future growth, it
could have a material adverse effect on our business, financial condition and results of operations.</P>

<P ALIGN="CENTER">                                                                                                   36
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><I>
<P>Our management's lack of public company experience could put us at greater risk of incurring fines or&nbsp;regulatory actions for failure to comply with federal securities laws
and could put us at a competitive&nbsp;disadvantage, and could require our management to devote additional time and resources to ensure&nbsp;compliance with applicable
corporate governance requirements.</P>
</I></B>
<P>Our executive officer does not have prior experience in managing and operating a public company, which could have an adverse effect on his ability to quickly respond to
problems or adequately address issues and matters applicable to public companies. Any failure to comply with federal securities laws, rules or regulations could subject us to fines
or regulatory actions, which may materially adversely affect our business, financial condition and results of operations. Further, since our executive officer does not have prior
experience managing and operating a public company, we may need to dedicate additional time and resources to comply with legally mandated corporate governance policies
relative to our competitors whose management teams have more public company experience.</P>
<B><I>
<P>We are exposed to product liability, non-clinical and clinical liability risks which could place a substantial&nbsp;financial burden upon us, should lawsuits be filed against us.</P>
</I></B>
<P>Our business exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical formulations and
products. In addition, the use in our clinical trials of pharmaceutical products and the subsequent sale of these products by us or our potential collaborators may cause us to bear a
portion of or all product liability risks. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial condition and
results of operations.</P>

<P>We currently carry product liability insurance for our clinical development activities. On occasion, large judgments have been awarded in class action lawsuits based on drugs
that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our
insurance coverage, could adversely affect our results of operations and business.</P>
<B><I>
<P>Our research and development activities involve the use of hazardous materials, which subject us to&nbsp;regulation, related costs and delays and potential liabilities.</P>
</I></B>
<P>Our research and development activities involve the controlled use of hazardous materials and chemicals, and we will need to develop additional safety procedures for the
handling and disposing of hazardous materials. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous
environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of
biohazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with,
and substantial fines or penalties if we violate any of these laws or regulations.</P>
<B><I>
<P>We rely significantly on information technology and any failure, inadequacy, interruption or security lapse&nbsp;of that technology, including any cybersecurity incidents, could
harm our ability to operate our business&nbsp;effectively.</P>
</I></B>
<P>Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks,
computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause
interruptions in our operations, and could result in a material disruption of our drug development and clinical activities and business operations, in addition to possibly requiring
substantial expenditures of resources to remedy. The loss of drug development or clinical trial data could result in delays in our regulatory approval efforts and significantly increase
our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and our development programs and the development of our product candidates could be delayed.</P>
<B><I>
<P>Our employees and consultants may engage in misconduct or other improper activities, including&nbsp;noncompliance with regulatory standards and requirements.</P>
</I></B>
<P>We are exposed to the risk of employee or consultant fraud or other misconduct. Misconduct by our employees or consultants could include intentional failures to comply with
FDA regulations, provide accurate information to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations,
report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are
subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide
range of pricing, discounting, marketing and promotion, sales commissions, customer incentive programs and other business arrangements. Employee and

<P ALIGN="CENTER">                                                                                                   37
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
consultant misconduct also could involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not
always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such
actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business,
financial condition and results of operations, and result in the imposition of significant fines or other sanctions against us.</P>
<B><I>
<P>Business disruptions such as natural disasters could seriously harm our future revenues and financial&nbsp;condition and increase our costs and expenses.</P>
</I></B>
<P>We and our suppliers may experience a disruption in our and their business as a result of natural disasters. A significant natural disaster, such as an earthquake, hurricane,
flood or fire, could severely damage or destroy our headquarters or facilities or the facilities of our manufacturers or suppliers, which could have a material and adverse effect on our
business, financial condition and results of operations. In addition, terrorist acts or acts of war targeted at the U.S., and specifically the greater New York, New York region, could
cause damage or disruption to us, our employees, facilities, partners and suppliers, which could have a material adverse effect on our business, financial condition and results of
operations.</P>
<B><I>
<P>We may engage in strategic transactions that could impact our liquidity, increase our expenses and present&nbsp;significant distractions to our management.</P>
</I></B>
<P>From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of products, product candidates
or technologies. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures,
restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term
expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our business, financial condition and results
of operations. For example, these transactions may entail numerous operational and financial risks, including:</P>

<UL>

<LI>exposure to unknown liabilities;</LI>
<LI>disruption of our business and diversion of our management's time and attention in order to develop acquired products, product candidates or technologies;</LI>
<LI>incurrence of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;</LI>
<LI>higher-than-expected transaction and integration costs;</LI>
<LI>write-downs of assets or goodwill or impairment charges;</LI>
<LI>increased amortization expenses;</LI>
<LI>difficulty and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and personnel;</LI>
<LI>impairment of relationships with key suppliers or customers of any acquired businesses or product lines due to changes in management and ownership; and</LI>
<LI>inability to retain key employees of any acquired businesses.</LI>

</UL>

<P>Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do
complete may be subject to the foregoing or other risks, and could have a material adverse effect on our business, financial condition and results of operations.</P>
<B>
<P>Risks Related to Our Intellectual Property</P>
<I>
<P>We may not be successful in obtaining or maintaining necessary rights to our product candidates through&nbsp;acquisitions and in-licenses.</P>
</I></B>
<P>Because several of our programs require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain and
exploit these proprietary rights. In addition, we may need to acquire or in-license additional intellectual property in the future. We may be unable to acquire or in-license any
compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our product candidates. We face competition with
regard to acquiring and in-licensing third-party intellectual property rights, including from a number of more established companies. These established companies may have a
competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a
competitor may be unwilling to assign or license intellectual property rights to us. We also may be unable to acquire or in-license third-party intellectual property rights on terms that
would allow us to make an appropriate return on our investment.</P>

<P ALIGN="CENTER">                                                                                                   38
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>We may enter into collaboration agreements with U.S. and foreign academic institutions to accelerate development of our current or future preclinical product candidates.
Typically, these agreements include an option for the company to negotiate a license to the institution's intellectual property rights resulting from the collaboration. Even with such an
option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to license rights from a collaborating
institution, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our desired program.</P>

<P>If we are unable to successfully obtain required third-party intellectual property rights or maintain our existing intellectual property rights, we may need to abandon development
of the related program and our business, financial condition and results of operations could be materially and adversely affected.</P>
<B><I>
<P>If we fail to comply with our obligations in the agreements under which we in-license intellectual property&nbsp;and other rights from third parties or otherwise experience
disruptions to our business relationships with&nbsp;our licensors, we could lose intellectual property rights that are important to our business.</P>
</I></B>
<P>Our license agreement with Ligand Pharmaceuticals Incorporated, Neurogen Corporation and CyDex Pharmaceuticals, Inc. (the &quot;Ligand License Agreement&quot;), our
license agreement with the Regents of the University of California (the &quot;UC Regents License Agreement&quot;) and our license agreement with Duke University (the
&quot;Duke License Agreement&quot;, together with the Ligand License Agreement and the UC Regents License Agreement, the &quot;License Agreements&quot;) are important
to our business and we expect to enter into additional license agreements in the future. The License Agreements impose, and we expect that future license agreements will impose,
various milestone payments, royalties and other obligations on us. If we fail to comply with our obligations under these agreements, or if we file for bankruptcy, we may be required
to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we would not be able
to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses could materially and adversely affect our
business, financial condition and results of operations.</P>

<P>Pursuant to the terms of the Ligand License Agreement, the licensors each have the right to terminate the Ligand License Agreement with respect to the programs licensed by
such licensor under certain circumstances, including, but not limited to: (i) if we do not pay an amount that is not disputed in good faith, (ii) if we willfully breach the Ligand License
Agreement in a manner for which legal remedies would not be expected to make such licensor whole, or (iii) if we file or have filed against us a petition in bankruptcy or make an
assignment for the benefit of creditors. In the event the Ligand License Agreement is terminated by a licensor, all licenses granted to us by such licensor will terminate immediately.
Further, pursuant to the terms of the UC Regents License Agreement, the licensor has the right to terminate the UC Regents License Agreement or reduce our license to a
nonexclusive license if we fail to achieve certain milestones within a specified timeframe. Similarly, pursuant to the terms of the Duke License Agreement, the licensor has the right
to terminate the Duke License Agreement if we fail to achieve certain milestones within a specified timeframe.</P>

<P>In some cases, patent prosecution of our licensed technology may be controlled solely by the licensor. If our licensor fails to obtain and maintain patent or other protection for the
proprietary intellectual property we in-license, then we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could
market competing products using the intellectual property. In certain cases, we may control the prosecution of patents resulting from licensed technology. In the event we breach any
of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and
involves complex legal, business and scientific issues. Disputes may arise regarding intellectual property subject to a licensing agreement, including, but not limited to:</P>

<UL>

<LI>the scope of rights granted under the license agreement and other interpretation-related issues;</LI>
<LI>the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</LI>
<LI>the sublicensing of patent and other rights;</LI>
<LI>our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</LI>
<LI>the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us, our licensors and our collaborators; and</LI>
<LI>the priority of invention of patented technology.</LI>

</UL>


<P ALIGN="CENTER">                                                                                                   39
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>If disputes over intellectual property and other rights that we have in-licensed prevents or impairs our ability to maintain our current licensing arrangements on acceptable terms,
we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with any such obligations to our licensor, such licensor may
terminate their licenses to us, in which case we would not be able to market products covered by these licenses. The loss of our licenses would have a material adverse effect on
our business.</P>
<B><I>
<P>We are required to make certain cash payments and may be required to pay milestones and royalties pursuant to certain commercial agreements, which could adversely affect
the overall profitability for us of any products that we may seek to commercialize.</P>
</I></B>
<P>Under the terms of the Ligand License Agreement, we may be obligated to pay the licensors under the License Agreement up to an aggregate of approximately $135 million in
development, regulatory and sales milestones. We will also be required to pay royalties on future worldwide net product sales. In addition pursuant to the asset purchase agreement,
as amended, with Vyera Pharmaceuticals AG ("Vyera") we may be obligated to pay an aggregate of approximately $92.5 million in development, regulatory and sales milestones
and we will be required to pay royalties to Vyera on any net sales of SLS-002. We will also be required to pay up to an aggregate of approximately $17 million in development and
regulatory milestones and royalties on any net sales of SLS-005 pursuant to our asset purchase agreement with Bioblast Pharma Ltd. These cash, milestone and royalty payments
could adversely affect the overall profitability for us of any products that we may seek to commercialize. Pursuant to the amended and restated license agreement with Stuart Weg,
M.D., we will be required to make a $0.2 million cash payment to Dr. Weg in January 2022 if certain conditions are not met.</P>
<B><I>
<P>We may not be able to protect our proprietary or licensed technology in the marketplace.</P>
</I></B>
<P>We depend on our ability to protect our proprietary or licensed technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other
agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability and any licensor's or licensee's ability to
obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary or licensed technology and products. We currently in-license some of our
intellectual property rights to develop our product candidates and may in-license additional intellectual property rights in the future. We cannot be certain that patent enforcement
activities by our current or future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other
intellectual property rights. We also cannot be certain that our current or future licensors will allocate sufficient resources or prioritize their or our enforcement of such patents. Even if
we are not a party to these legal actions, an adverse outcome could prevent us from continuing to license intellectual property that we may need to operate our business, which
would have a material adverse effect on our business, financial condition and results of operations.</P>

<P>We believe we will be able to obtain, through prosecution of patent applications covering our owned technology and technology licensed from others, adequate patent protection
for our proprietary drug technology, including those related to our in-licensed intellectual property. If we are compelled to spend significant time and money protecting or enforcing
our licensed patents and future patents we may own, designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other proprietary rights
held by others, our business, financial condition and results of operations may be materially and adversely affected. If we are unable to effectively protect the intellectual property
that we own or in-license, other companies may be able to offer the same or similar products for sale, which could materially adversely affect our business, financial condition and
results of operations. The patents of others from whom we may license technology, and any future patents we may own, may be challenged, narrowed, invalidated or circumvented,
which could limit our ability to stop competitors from marketing the same or similar products or limit the length of term of patent protection that we may have for our products.</P>
<B><I>
<P>Obtaining and maintaining patent protection depends on compliance with various procedural, document&nbsp;submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent&nbsp;protection for licensed patents, pending patent applications and potential future patent applications and patents&nbsp;could be
reduced or eliminated for non-compliance with these requirements.</P>
</I></B>
<P>Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to be paid to the U.S. Patent and
Trademark Office (&quot;USPTO&quot;) and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the applicable patent and/or patent
application. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable
rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. If this occurs with respect to our in-licensed patents or patent applications we may file in the future, our competitors might be able to use our
technologies, which would have a material adverse effect on our business, financial condition and results of operations.</P>

<P ALIGN="CENTER">                                                                                                   40
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>The patent positions of pharmaceutical products are often complex and uncertain. The breadth of claims allowed in pharmaceutical patents in the U.S. and many jurisdictions
outside of the U.S. is not consistent. For example, in many jurisdictions, the support standards for pharmaceutical patents are becoming increasingly strict. Some countries prohibit
method of treatment claims in patents. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our licensed or
owned intellectual property or create uncertainty. In addition, publication of information related to our current product candidates and potential products may prevent us from
obtaining or enforcing patents relating to these product candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to
offer the strongest patent protection.</P>

<P>Patents that we currently license and patents that we may own or license in the future do not necessarily ensure the protection of our licensed or owned intellectual property for
a number of reasons, including, without limitation, the following:</P>

<UL>

<LI>the patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product candidates;</LI>
<LI>there can be no assurance that the term of a patent can be extended under the provisions of patent term extensions afforded by U.S. law or similar provisions in foreign
countries, where available;</LI>
<LI>the issued patents and patents that we may obtain or license in the future may not prevent generic entry into the market for our product candidates;</LI>
<LI>we, or third parties from whom we in-license or may license patents, may be required to disclaim part of the term of one or more patents;</LI>
<LI>there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;</LI>
<LI>there may be prior art of which we are aware, which we do not believe affects the validity or enforceability of a patent claim, but which, nonetheless, ultimately may be found to
affect the validity or enforceability of a patent claim;</LI>
<LI>there may be other patents issued to others that will affect our freedom to operate;</LI>
<LI>if the patents are challenged, a court could determine that they are invalid or unenforceable;</LI>
<LI>there might be a significant change in the law that governs patentability, validity and infringement of our licensed patents or any future patents we may own that adversely
affects the scope of our patent rights;</LI>
<LI>a court could determine that a competitor's technology or product does not infringe our licensed patents or any future patents we may own; and</LI>
<LI>the patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory licensing.</LI>

</UL>

<P>If we encounter delays in our development or clinical trials, the period of time during which we could market our potential products under patent protection would be
reduced.</P>

<P>Our competitors may be able to circumvent our licensed patents or future patents we may own by developing similar or alternative technologies or products in a non-infringing
manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which our competitors claim
that our licensed patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval to market their own products
similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our licensed patents or any future patents we may own, including by
filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we may
own invalid or unenforceable. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if we own or in-
license valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</P>

<P>The issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In this regard, third parties may challenge our licensed
patents or any future patents we may own in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent
claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology
and products, or limit the duration of the patent protection of our technology and potential products. In addition, given the amount of time required for the development, testing and
regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized.</P>

<P ALIGN="CENTER">                                                                                                   41
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><I>
<P>We may infringe the intellectual property rights of others, which may prevent or delay our drug development&nbsp;efforts and prevent us from commercializing or increase the
costs of commercializing our products.</P>
</I></B>
<P>Our commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights of third parties. For example, there
could be issued patents of which we are not aware that our current or potential future product candidates infringe. There also could be patents that we believe we do not infringe, but
that we may ultimately be found to infringe.</P>

<P>Moreover, patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently
occurs substantially later than the date on which the underlying discoveries were made and patent applications were filed. Because patents can take many years to issue, there may
be currently pending applications of which we are unaware that may later result in issued patents that our product candidates or potential products infringe. For example, pending
applications may exist that claim or can be amended to claim subject matter that our product candidates or potential products infringe. Competitors may file continuing patent
applications claiming priority to already issued patents in the form of continuation, divisional, or continuation-in-part applications, in order to maintain the pendency of a patent family
and attempt to cover our product candidates.</P>

<P>Third parties may assert that we are employing their proprietary technology without authorization and may sue us for patent or other intellectual property infringement. These
lawsuits are costly and could adversely affect our business, financial condition and results of operations and divert the attention of managerial and scientific personnel. If we are
sued for patent infringement, we would need to demonstrate that our product candidates, potential products or methods either do not infringe the claims of the relevant patent or that
the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing
evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and
attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not
have sufficient resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and cover our products or their use, the
holders of any of these patents may be able to block our ability to commercialize our products unless we acquire or obtain a license under the applicable patents or until the patents
expire.</P>

<P>We may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative
technology could result in delays in the introduction of our products or lead to prohibition of the manufacture or sale of products by us. Even if we are able to obtain a license, it may
be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the
infringing technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys' fees, if we
are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business
operations, which could materially and adversely affect our business, financial condition and results of operations. Any claims by third parties that we have misappropriated their
confidential information or trade secrets could have a similar material and adverse effect on our business, financial condition and results of operations. In addition, any uncertainties
resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</P>
<B><I>
<P>Any claims or lawsuits relating to infringement of intellectual property rights brought by or against us will be&nbsp;costly and time consuming and may adversely affect our
business, financial condition and results of operations.</P>
</I></B>
<P>We may be required to initiate litigation to enforce or defend our licensed and owned intellectual property. Lawsuits to protect our intellectual property rights can be very time
consuming and costly. There is a substantial amount of litigation involving patent and other intellectual property rights in the biopharmaceutical industry generally. Such litigation or
proceedings could substantially increase our operating expenses and reduce the resources available for development activities or any future sales, marketing or distribution
activities.</P>

<P>In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover,
there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are resolved.
Further, any claims we assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their patents. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from
the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</P>

<P ALIGN="CENTER">                                                                                                   42
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>In addition, our licensed patents and patent applications, and patents and patent applications that we may apply for, own or license in the future, could face other challenges,
such as interference proceedings, opposition proceedings, re-examination proceedings and other forms of post-grant review. Any of these challenges, if successful, could result in
the invalidation of, or in a narrowing of the scope of, any of our licensed patents and patent applications and patents and patent applications that we may apply for, own or license in
the future subject to challenge. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve and would divert our
management and scientific personnel's time and attention.</P>
<B><I>
<P>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to&nbsp;protect our products.</P>
</I></B>
<P>As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the
biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, the U.S. previously enacted and is
currently implementing wide-ranging patent reform legislation. Specifically, on September 16, 2011, the Leahy-Smith America Invents Act (the &quot;Leahy-Smith Act&quot;) was
signed into law and included a number of significant changes to U.S. patent law, and many of the provisions became effective in March 2013. However, it may take the courts years
to interpret the provisions of the Leahy-Smith Act, and the implementation of the statute could increase the uncertainties and costs surrounding the prosecution of our licensed and
future patent applications and the enforcement or defense of our licensed and future patents, all of which could have a material adverse effect on our business, financial condition
and results of operations.</P>

<P>In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or
weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events
has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and
regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future.</P>
<B><I>
<P>We may not be able to protect our intellectual property rights throughout the world.</P>
</I></B>
<P>Filing, prosecuting and defending patents on product candidates throughout the world would be prohibitively expensive. Competitors may use our licensed and owned
technologies in jurisdictions where we have not licensed or obtained patent protection to develop their own products and, further, may export otherwise infringing products to
territories where we may obtain or license patent protection, but where patent enforcement is not as strong as that in the U.S. These products may compete with our products in
jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them
from so competing.</P>

<P>Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which
could make it difficult for us to stop the infringement of our licensed patents and future patents we may own, or marketing of competing products in violation of our proprietary rights
generally. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may
encounter significant problems in protecting and defending our licensed and owned intellectual property both in the U.S. and abroad. For example, China currently affords less
protection to a company's intellectual property than some other jurisdictions. As such, the lack of strong patent and other intellectual property protection in China may significantly
increase our vulnerability regarding unauthorized disclosure or use of our intellectual property and undermine our competitive position. Proceedings to enforce our future patent
rights, if any, in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</P>
<B><I>
<P>We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</P>
</I></B>
<P>In order to protect our proprietary and licensed technology and processes, we rely in part on confidentiality agreements with our corporate partners, employees, consultants,
manufacturers, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of our confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade
secrets and proprietary information. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</P>

<P ALIGN="CENTER">                                                                                                   43
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><I>
<P>We may be subject to claims that our employees, consultants or independent contractors have wrongfully&nbsp;used or disclosed confidential information of third parties.</P>
</I></B>
<P>We expect to employ individuals who were previously employed at other biopharmaceutical companies. Although we have no knowledge of any such claims against us, we may
be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees'
former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are
successful, litigation could result in substantial cost and be a distraction to our management and other employees. To date, none of our employees have been subject to such
claims.</P>
<B><I>
<P>We may be subject to claims challenging the inventorship of our licensed patents, any future patents we may&nbsp;own and other intellectual property.</P>
</I></B>
<P>Although we are not currently experiencing any claims challenging the inventorship of our licensed patents or our licensed or owned intellectual property, we may in the future be
subject to claims that former employees, collaborators or other third parties have an interest in our licensed patents or other licensed or owned intellectual property as an inventor or
co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates.
Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on
our business, financial condition and results of operations. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</P>
<B><I>
<P>If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign&nbsp;legislation extending the terms of our licensed patents and any future
patents we may own, our&nbsp;business, financial condition and results of operations may be materially and adversely affected.</P>
</I></B>
<P>Depending upon the timing, duration and specifics of FDA regulatory approval for our product candidates, one or more of our licensed U.S. patents or future U.S. patents that we
may license or own may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during drug development and the FDA
regulatory review process. This period is generally one-half the time between the effective date of an investigational new drug application (&quot;IND&quot;) (falling after issuance of
the patent), and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Patent term restorations, however,
cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval by the FDA.</P>

<P>The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. It takes at least six months to obtain approval of the application for
patent term extension. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant
patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we
are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, the period during which we will have the right to exclusively
market our product will be shortened and our competitors may obtain earlier approval of competing products, and our ability to generate revenues could be materially adversely
affected.</P>
<B>
<P>Risks Related to Owning Our Common Stock</P>
<I>
<P>The market price of our common stock is expected to be volatile.</P>
</I></B>

<P>The trading price of our common stock is likely to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</P>

<UL>

<LI>results from, and any delays in, planned clinical trials for our product candidates, or any other future product candidates, and the results of trials of competitors or those of other
companies in our market sector;</LI>
<LI>any delay in filing an NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA's review of that
NDA;</LI>
<LI>significant lawsuits, including patent or stockholder litigation;</LI>
<LI>inability to obtain additional funding;</LI>
<LI>failure to successfully develop and commercialize our product candidates;</LI>
<LI>changes in laws or regulations applicable to our product candidates;</LI>

</UL>

<P ALIGN="CENTER">                                                                                                   44
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<UL>

<LI>inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable prices;</LI>
<LI>unanticipated serious safety concerns related to any of our product candidates;</LI>
<LI>adverse regulatory decisions;</LI>
<LI>introduction of new products or technologies by our competitors;</LI>
<LI>failure to meet or exceed drug development or financial projections we provide to the public;</LI>
<LI>failure to meet or exceed the estimates and projections of the investment community;</LI>
<LI>the perception of the biopharmaceutical industry by the public, legislatures, regulators and the investment community;</LI>
<LI>announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</LI>
<LI>disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our licensed and owned
technologies;</LI>
<LI>additions or departures of key scientific or management personnel;</LI>
<LI>changes in the market valuations of similar companies;</LI>
<LI>general economic and market conditions and overall fluctuations in the U.S. equity market; </LI>
<LI>public health crises, pandemics and epidemics, such as the COVID-19 pandemic;</LI>
<LI>sales of our common stock by us or our stockholders in the future; and</LI>
<LI>trading volume of our common stock.</LI>

</UL>

<P>In addition, the stock market in general, and small biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been
unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock,
regardless of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may cause our stock price to decline rapidly and
unexpectedly.</P>
<B><I>
<P>If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to
access the capital markets could be negatively impacted.</P>
</I></B>
<P>We must continue to satisfy the Nasdaq Capital Market's continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per
share for 30 consecutive business days. If a company fails for 30 consecutive business days to meet the $1.00 minimum closing bid price requirement, The Nasdaq Stock Market
LLC (&quot;Nasdaq&quot;) will send a deficiency notice to the company, advising that it has been afforded a &quot;compliance period&quot; of 180 calendar days to regain
compliance with the applicable requirements.</P>

<P>A delisting of our common stock from the Nasdaq Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the
price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the
potential loss of confidence by investors and employees.</P>

<P ALIGN="JUSTIFY">On November 11, 2020, we received written notice from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for our common
stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with
Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until May 10, 2021, to regain compliance. We regained compliance after the closing
bid price of our common stock had been at $1.00 per share or greater for twenty consecutive business days, from December 10, 2020 through January 8, 2021.</P>

<P>In addition, we have previously received similar notices from Nasdaq that our bid price of our common stock had closed below the minimum $1.00 per share requirement for
continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Even though we regained compliance with the Nasdaq Capital Market's minimum market
value of listed securities requirement and minimum closing bid price requirement, there is no guarantee that we will remain in compliance with such listing requirements or other
listing requirements in the future. Any failure to maintain compliance with continued listing requirements of the Nasdaq Capital Market could result in delisting of our common stock
from the Nasdaq Capital Market and negatively impact our company and holders of our common stock, including by reducing the willingness of investors to hold our common stock
because of the resulting decreased price, liquidity and trading of our common stock, limited availability of price quotations and reduced news and analyst coverage. Delisting may
adversely impact the perception of our financial condition, cause reputational harm with investors, our employees and parties conducting business with us and limit our access to
debt and equity financing.</P>

<P ALIGN="CENTER">                                                                                                   45
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><I>
<P>Our management owns a significant percentage of our stock&nbsp;and will be able to exert significant control over matters subject to stockholder approval.</P>
</I></B>
<P>As of March 4, 2021, Dr. Mehra, our sole executive officer and a director, owns approximately 4.4% of our outstanding common stock. Therefore, Dr. Mehra will have the ability
to influence us through this ownership position.</P>

<P>This significant concentration of stock ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in
companies that have stockholders with substantial ownership positions. As a result, Dr. Mehra could significantly influence or determine all matters requiring approval by our
stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of these stockholders may not always coincide
with our interests or the interests of other stockholders. This may also prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in
your best interests as one of our stockholders and he may act in a manner that advances his best interests and not necessarily those of other stockholders, including seeking a
premium value for his common stock, and might affect the prevailing market price for our common stock.</P>

<B><I><P>We will incur significant costs as a result of operating as a public company, our management has limited experience managing a public company, and our management
will be required to devote substantial time to new compliance initiatives.</P>
</I></B>
<P>The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &quot;Dodd-Frank Act&quot;) as well as rules subsequently
implemented by the SEC and Nasdaq have imposed various requirements on public companies. There are significant corporate governance and executive compensation related
provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political environment and the current
high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and
impact (in ways we cannot currently anticipate) the manner in which we operate our business. Our management and other personnel will need to devote a substantial amount of time
to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and
costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be
required to incur substantial costs to maintain our current levels of such insurance coverage.</P>

<P>As a publicly traded company, we will incur legal, accounting and other expenses associated with the SEC reporting requirements applicable to a company whose securities are
registered under the Exchange Act, as well as corporate governance requirements, including those under the Sarbanes-Oxley Act, the Dodd-Frank Act and other rules implemented
by the SEC and Nasdaq. The expenses incurred by public companies generally to meet SEC reporting, finance and accounting and corporate governance requirements have been
increasing in recent years as a result of changes in rules and regulations and the adoption of new rules and regulations applicable to public companies.</P>

<B><I><P>Sales of a substantial number of shares of our common stock in the public market by our existing stockholders, future issuances of our common stock or&nbsp;rights to
purchase our common stock, could cause our stock&nbsp;price to fall.</P>
</I></B>
<P>Sales of a substantial number of shares of our common stock by our existing stockholders in the public market, or the perception that these sales might occur, could depress the
market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may
have on the prevailing market price of our common stock. As of March 4, 2021, we have outstanding warrants to purchase an aggregate of approximately 9.0 million shares of our
common stock, which, if exercised, would further increase the number of shares of our common stock outstanding and the number of shares eligible for resale in the public
market.</P>
<B><I>
<P>The Financing Warrants contain price-based adjustment provisions which, if triggered, may cause substantial&nbsp;additional dilution to our stockholders.</P>
</I></B>
<P>On October 16, 2018, we entered into a Securities Purchase Agreement with the investors listed on the Schedule of Buyers attached thereto, as amended, pursuant to which,
among other things, we issued warrants to purchase shares of our common stock (the &quot;Financing Warrants&quot;).</P>

<P>The outstanding Financing Warrants contain price-based adjustment provisions, pursuant to which the exercise price of the Financing Warrants may be adjusted downward in
the event of certain dilutive issuances by us. </P>

<P>If the Financing Warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to our then-existing stockholders and increase the
number of shares eligible for resale in the public market. As of March 4, 2021, the Financing Warrants were exercisable for approximately 0.3 million shares of our common stock at an exercise price of

<P ALIGN="CENTER">                                                                                                   46
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
$0.2957 per share of common stock.  Sales of substantial numbers of such shares in the public market could depress the market price of our common stock.
</P>
<B><I>
<P>Anti-takeover provisions in our governing documents and under Nevada law could make an&nbsp;acquisition of us</I></B> <B><I>more difficult and may prevent attempts by
our stockholders to replace or remove our management.</P>
</I></B>
<P>Provisions in our articles of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors
and the ability of the board of directors to issue preferred stock without stockholder approval. Although we believe these provisions collectively will provide for an opportunity to
receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In
addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to
replace members of the board of directors, which is responsible for appointing the members of management.</P>

<P>Certain provisions of Nevada corporate law deter hostile takeovers. Specifically, Nevada Revised Statutes (&quot;NRS&quot;) 78.411 through 78.444 prohibit a publicly held
Nevada corporation from engaging in a &quot;combination&quot; with an &quot;interested stockholder&quot; for a period of two years following the date the person first became an
interested stockholder, unless (with certain exceptions) the &quot;combination&quot; or the transaction by which the person became an interested stockholder is approved in a
prescribed manner. Generally, a &quot;combination&quot; includes a merger, asset or stock sale, or certain other transactions resulting in a financial benefit to the interested
stockholder. Generally, an &quot;interested stockholder&quot; is a person who, together with affiliates and associates, beneficially owns or within two years prior to becoming an
&quot;interested stockholder&quot; did own, 10% or more of a corporation's voting power. While these statutes permit a corporation to opt out of these protective provisions in its
articles of incorporation, our articles of incorporation do not include any such opt-out provision.</P>

<P>Nevada's &quot;acquisition of controlling interest&quot; statutes, NRS 78.378 through 78.3793, contain provisions governing the acquisition of a controlling interest in certain
Nevada corporations. These &quot;control share&quot; laws provide generally that any person that acquires a &quot;controlling interest&quot; in certain Nevada corporations may
be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These statutes provide that a person acquires a
&quot;controlling interest&quot; whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to
exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the
election of directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction taking it over the threshold and within the 90 days immediately
preceding the date when the acquiring person acquired or offered to acquire a controlling interest become &quot;control shares&quot; to which the voting restrictions described
above apply. While these statutes permit a corporation to opt out of these protective provisions in its articles of incorporation or bylaws, our articles of incorporation and bylaws do
not include any such opt-out provision.</P>

<P>Further, NRS 78.139 also provides that directors may resist a change or potential change in control of the corporation if the board of directors determines that the change or
potential change is opposed to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies pursuant to NRS
78.138(4).</P>
<B><I>
<P>Our pre-Merger net operating loss carryforwards and certain other tax attributes may be subject to limitations.&nbsp;The pre-Merger net operating loss carryforwards and certain
other tax attributes of us&nbsp;may also be subject to limitations as a result of ownership changes resulting from the Merger.</P>
</I></B>
<P>In general, a corporation that undergoes an &quot;ownership change&quot; as defined in Section 382 of the United States Internal Revenue Code of 1986, as amended, is
subject to limitations on its ability to utilize its pre-change net operating loss carryforwards to offset future taxable income. In general, an ownership change occurs if the aggregate
stock ownership of certain stockholders, generally stockholders beneficially owning five percent or more of a corporation's common stock, applying certain look-through and
aggregation rules, increases by more than 50 percentage points over such stockholders' lowest percentage ownership during the testing period, generally three years. We may have
experienced ownership changes in the past and may experience ownership changes in the future. It is possible that our net operating loss carryforwards and certain other tax
attributes may also be subject to limitation as a result of ownership changes in the past and/or the closing of the Merger. Consequently, even if we achieve profitability, we may not
be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of
operations.</P>
<B><I>
<P>We may never pay dividends on our common stock so any returns&nbsp;would be limited to the appreciation of our stock.</P>
</I></B>
<P>We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and does not anticipate it will declare or pay any cash
dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</P>

<P ALIGN="CENTER">                                                                                                   47
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<P>General Risk Factors</P>
<I>
<P>An active trading market for our common stock may not be sustained, and you may not&nbsp;be able to resell your common stock at a desired market price.</P>
</I></B>
<P>If no active trading market for our common stock is sustained, you may be unable to sell your shares when you wish to sell them or at a price that you consider attractive or
satisfactory. The lack of an active market may also adversely affect our ability to raise capital by selling securities in the future or impair our ability to acquire or in-license other
product candidates, businesses or technologies using our shares as consideration.</P>

<B><I><P>Our internal control over financial reporting may not meet the standards required by&nbsp;Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain
effective internal control over&nbsp;financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, could have a material adverse effect&nbsp;on our business and
share price.</P>

</I></B><P>Our management is required to report on the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our
management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation.</P>

<P>In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies or material
weaknesses that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. In addition,
we may encounter problems or delays in completing the implementation of any requested improvements and, when required, receiving a favorable attestation in connection with the
attestation provided by our independent registered public accounting firm. Failure to achieve and maintain an effective internal control environment could have a material adverse
effect on our business, financial condition and results of operations and could limit our ability to report our financial results accurately and in a timely manner.</P>
<B><I>
<P>If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could
decline.</P>
</I></B>

<P>The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the
analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results
fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for
our common stock could decrease, which might cause our stock price and trading volume to decline.</P>


<B><P><A NAME="item1b">ITEM 1B.   UNRESOLVED STAFF COMMENTS</A></P></B>

<P>None.</P>

<B><P><A NAME="item2">ITEM 2.   PROPERTIES</A></P></B>

<P>We currently lease one corporate office property in New York, New York, as our corporate office space for approximately 300 square feet. We believe that our leased facility is
generally well maintained and in good operating condition and that the space is suitable and sufficient for our operational needs.</P>



<B><P><A NAME="item2">ITEM 3.  LEGAL PROCEEDINGS</A></P></B>

<P>We may be a party to certain other litigation that is either judged to be not material or that arises in the ordinary course of business from time to time. We intend to vigorously defend our
interests in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business, financial condition or results of operations. However, due to
the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.</P>

<B><P><A NAME="item4">ITEM 4. </B> <B>MINE SAFETY DISCLOSURES</A>?</P></B>

<P>Not applicable.</P>

<P ALIGN="CENTER">                                                                                                   48
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P ALIGN="CENTER">PART II.</P></B>

<B><P><A NAME="item5">ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</A></P></B>

<P>Our common stock is traded on the Nasdaq Capital Market under the symbol &quot;SEEL.&quot;  Before January 24, 2019, our common stock was trading under the ticker
symbol &quot;APRI&quot;.  The daily market activity and closing prices of our common stock can be found at www.nasdaq.com.</P>

<P>On March 4, 2021, the last reported sales price for our common stock on the Nasdaq Capital Market was $2.66 per share, and we had approximately 104 holders of
record of our common stock. One of our shareholders is Cede&nbsp;&amp;&nbsp;Co., a nominee for Depository Trust Company (&quot;DTC&quot;). Shares of common stock that
are held by financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC, and are considered to be held of record by
Cede&nbsp;&amp;&nbsp;Co. as one stockholder. </P>

<B><P>Dividend Policy</P>
</B>
<P>We have never declared or paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment
of dividends on our capital stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may
consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the common stock price
appreciates.</P>

<B><P>Unregistered Sales of Equity Securities and Use of Proceeds</P>
</B>
<P>None.</P>



<B><P><A NAME="item6">ITEM 6.  SELECTED FINANCIAL DATA</A></P></B>

<P>Not applicable.</P>


<B><P><A NAME="item7">ITEM 7.&#9;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></P></B>

<B><P>Overview</P></B>

<P>We are a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System
(&quot;CNS&quot;) disorders, and other rare disorders. </P>

<B><P>Impact of COVID-19</P>

</B><P>In March 2020, we began taking precautionary measures to protect the health and safety of our employees and contractors and further assessing the actual and potential
impact of the coronavirus (&quot;COVID-19&quot;) pandemic on our business, financial condition and operations. COVID-19 infections have been reported throughout the United
States, along with other jurisdictions in which our suppliers, partners and collaborators operate. In addition, COVID-19 has caused disruption and volatility in the global capital
markets, and has led to an economic slowdown. Certain national, provincial, state and local governmental authorities have issued proclamations and/or directives aimed at
minimizing the spread of COVID-19 and additional, more restrictive proclamations and/or directives may be issued in the future. Before the recent COVID-19 outbreak, most of our
employees worked remotely. In addition, our clinical trial for SLS-002 in ASIB in MDD completed the clinical testing phase in February 2020. On June 23, 2020, we released the final
pharmacokinetics/pharmacodynamics portion of the data. Also, we did

<P ALIGN="CENTER">                                                                                                   49
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
not experience any significant delays with opening our clinical sites for SLS-002 during the fourth quarter of
2020 and have not experienced any such delays during the first quarter of 2021 to date.  Accordingly, the impact of the travel restrictions and shelter-in-place orders have not had a
material impact on our operations to date. Additionally, the pandemic has not materially affected our liquidity as we maintain our resources in the form of cash.</P>

<P>In addition, although we do not currently expect the preventative measures taken to date to have a material adverse impact on our business for the first half of 2021, the ultimate
impact of the COVID-19 pandemic on our business, financial condition and results of operations is unknown and will depend on future developments and risks, which are highly
uncertain and cannot be predicted. These developments and risks include, among others, the duration and severity of the COVID-19 pandemic, the impact on capital markets, the
impact on our partners and the regulatory agencies that oversee our sector and any additional preventative and protective actions that governmental authorities, or we, may
implement, any of which may result in an extended period of business disruption, including potential delays in commencing future clinical trials, or in completing enrollment for any
clinical trials we may commence or in the FDA or other regulatory agencies conducting in-person inspections or accommodations for alternatives to in-person inspections. Any
resulting financial impact cannot be reasonably estimated at this time, but the COVID-19 pandemic may force us to make adjustments to our business, our plans and our timeline for
developing assets, including our programs. In addition, the pandemic is currently not anticipated to have a material adverse impact on our business, financial condition and results of
operations, including our ability to raise additional capital. However, if the pandemic continues at its current rate into the second quarter of 2021, it could have a material adverse
impact on our business.</P>

<B><P>Merger</P>

</B><P>On January 24, 2019, Apricus completed the Merger with STI. Upon completion of the Merger, we changed our name to Seelos Therapeutics, Inc. and focused on the
development and commercialization of CNS therapeutics with known mechanisms of action in areas with a highly unmet medical need. Also, on January 23, 2019, in connection
with, and prior to the completion of, the Merger, we effected the Reverse Stock Split. Shares of our common stock commenced trading on the Nasdaq Capital Market under the
ticker symbol "SEEL" as of market open on January 24, 2019. Our previous ticker symbol was "APRI". See Note 1 to our consolidated financial statements for more information
regarding the Merger.</P>

<P>Our business model is to advance multiple late-stage therapeutic candidates with proven mechanisms of action that address large markets with unmet medical needs and
for which there is a strong economic and scientific rationale for development.  </P>

<P>Our product development pipeline is as follows:</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=98%>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="19%" VALIGN="TOP" HEIGHT=16><B><FONT SIZE=2><P ALIGN="CENTER">Product</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">Indication</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">Development Phase</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<B><FONT SIZE=2><P ALIGN="CENTER">Development Status</B></FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-002</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Acute Suicidal Ideation and Behavior (ASIB) in </FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase II</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Patients being dosed for Part A</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Intranasal Racemic Ketamine</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Major Depressive Disorder (MDD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-005</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Amyotrophic Lateral Sclerosis (ALS)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase IIb/III</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Startup activities initiated</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">IV Trehalose </FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Sanfilippo Syndrome</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase II</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Collecting Natural History Data</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-004</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Parkinson's Disease (PD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pre-IND</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Preclinical studies to commence soon</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Gene Therapy</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-006</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Parkinson's Disease (PD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Phase II/III</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Evaluating studies to advance into late stage trials</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Partial Dopamine Agonist</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-007</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Parkinson's Disease (PD)</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pre-IND</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Preclinical data expected in early 2021</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Peptide Inhibitor</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">SLS-008</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pediatric Esophagitis, Asthma, Atopic Dermatitis</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Pre-IND</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">Formulation work underway</FONT></TD>
</TR>
<TR><TD WIDTH="19%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P ALIGN="CENTER">CRTh2 Antagonist</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="31%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="1%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" HEIGHT=16><P></P></TD>
</TR>
</TABLE>


<P ALIGN="CENTER">                                                                                                   50
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<P>Lead Programs</P>
</B>
<P>Our lead programs are currently SLS-002 for the treatment of acute suicidal ideation and behavior (&quot;ASIB&quot;) in major depressive disorder (&quot;MDD&quot;), and
SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (&quot;ALS&quot;).  SLS-005 for the potential treatment of Sanfilippo Syndromes currently requires additional
natural history data, which is being explored.</P>

<B><U><P>SLS-002</U></B>&nbsp;is intranasal racemic ketamine with two investigational new drug applications (&quot;INDs&quot;), the lead program is focused on the
treatment of ASIB in MDD. SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500 subjects.
SLS-002 addresses an unmet need for an efficacious drug to treat suicidality in the United States. Traditionally, anti-depressants have been used in this setting but many of the
existing treatments are known to contribute to an increased risk of suicidal thoughts in some circumstances, and if and when they are effective, it often takes weeks for the full
therapeutic effect to be manifested. We believe there is a large opportunity
in the United States and European markets for products in this space. Based on information gathered from the databases of the Agency for Healthcare Research and Quality, there
were more than 500,000 visits to emergency rooms for suicide attempts in 2013 in the United States alone. Experimental studies suggest ketamine has the potential to be a rapid,
effective treatment for refractory depression and suicidality. </P>

<P>The clinical development program for SLS-002 includes two parallel healthy volunteer studies (Phase I).
We announced interim data from our Phase I study of SLS-002 during the quarterly period ended March 31, 2020. The study demonstrated that
90mg of SLS-002, when administered as a monotherapy and in combination with an oral antidepressant, was generally safe and well-tolerated. Further, in March 2020, we
completed a Type C meeting with the FDA and received guidance to conduct a Phase II proof of concept study of SLS-002 for ASIB in patients with MDD, to support the further
clinical development of this product candidate, together with nonclinical data under development.</P>

<P>As a result of the Type C meeting and the Fast Track designation for SLS-002 for the treatment of ASIB in patients with MDD, we believe we are well positioned to pursue the
FDA's expedited programs for drug development and review. </P>

<P>On June 23, 2020, we announced the final safety data from our Phase I pharmacokinetics/pharmacodynamics study of intranasal racemic ketamine (SLS-002) as well as the
planned design of a Phase II double blind, placebo-controlled Proof of Concept ("PoC") study for ASIB in patients with MDD. We initiated this PoC study in two parts: Part A is an
open-label study of 16 patients, and will be followed by Part B, which is a double blind, placebo-controlled study of approximately 120 patients.  On January 15, 2021, we announced
dosing of the first patients in Part A of the PoC study.</P>
<B>
<U><P>SLS-005</U> </B>is IV Trehalose, a protein stabilizer that crosses the blood-brain-barrier, activates autophagy and lysosomal biogenesis. Based on the pre-clinical and in-vitro studies,
there is a sound scientific rationale for developing Trehalose for the treatment of ALS and other indications such as Sanfilippo syndromes.  Trehalose is a low molecular
weight disaccharide (.342 kDa) that protects against pathological processes in cells. It has been shown to penetrate muscle and cross the blood-brain-barrier. In animal models of
several diseases associated with abnormal cellular-protein aggregation, it has been shown to reduce pathological aggregation of misfolded proteins as well as to activate autophagy
pathways through the activation of Transcription Factor EB (&quot;TFEB&quot;), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging
therapeutic target for a number of diseases with pathologic accumulation of storage material.</P>

<P>Trehalose 90 mg/mL IV solution has demonstrated promising clinical potential in prior Phase II clinical development for oculopharyngeal muscular dystrophy
(&quot;OPMD&quot;) and spinocerebellar ataxia type 3 (&quot;SCA3&quot;), also known as Machado Joseph disease, with a good safety profile and encouraging efficacy results.
Pathological accumulation of protein aggregates within

<P ALIGN="CENTER">                                                                                                   51
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
cells, whether in the CNS or in muscle, eventually leads to loss of function and ultimately cell death. Prior preclinical studies
indicate that this platform has the potential to prevent mutant protein aggregation in other devastating PolyA/PolyQ diseases.</P>

<P>We own two United States patents for parenteral administration of trehalose for patients with OPMD and SCA3, both of which are expected to expire in 2034. In addition, Orphan
Drug Designation for OPMD and SCA3 has been secured in the United States and in the European Union (&quot;EU&quot;). In February 2019, we assumed a collaborative
agreement, turned subsequently into a research grant, with Team Sanfilippo Foundation (&quot;TSF&quot;), a nonprofit medical research foundation founded by parents of children
with Sanfilippo syndrome. On April 30, 2020, we were granted Orphan Drug Designation ("ODD") for SLS-005 in Sanfilippo syndrome from the FDA. SLS-005 was previously
granted ODD from the FDA and European Medicines Agency for SCA3 and OPMD as well as Fast Track designation for OPMD. On April 22, 2020, we received a Notice of
Allowance from the United States Patent and Trademark Office for our U.S. patent number 10,751,353 (application number 16/263,707) titled "COMPOSITIONS AND METHODS
FOR TREATING AN AGGREGATION DISEASE OR DISORDER" for trehalose (SLS-005). The allowed claims cover the composition of matter and method of use for trehalose
(SLS-005) for treating a disease or disorder selected from any one of the following: Spinal and bulbar muscular atrophy; Dentatombral-pallidoluysian atrophy; Pick's disease;
corticobasal degeneration; progressive supranuclear palsy; frontotemporal dementia; or parkinsonism linked to chromosome 17. On May 15, 2020, we were granted Rare Pediatric
Disease Designation (&quot;RPDD&quot;) for SLS-005 in Sanfilippo syndrome from the FDA. RPDD is an incentive program created under the Federal Food, Drug, and Cosmetic
Act to encourage the development of new therapies for the prevention and treatment of certain rare pediatric diseases. At present, we are initiating the startup activities for a clinical
study in ALS.  In December 2020, we announced the selection of SLS-005 for the Healey ALS platform trial led by the Harvard Medical School, Massachusetts. The Healey ALS
platform trial is designed to study multiple potential treatments for ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce costs and
shorten development timelines.</P>

<P>Additionally, we are developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, licensed from Duke
University, and SLS-007, licensed from The Regents of the University of California, for the potential treatment of Parkinson's Disease (&quot;PD&quot;), SLS-008, targeted at
chronic inflammation in asthma and orphan indications such as pediatric esophagitis, SLS-010 in narcolepsy and related disorders and SLS-012, an injectable therapy
for post-operative pain management.</P>

<B><P>Strategy and Ongoing Programs</P>
</B>
<B><U><P>SLS-002:</U></B> The clinical development program for SLS-002 includes two parallel healthy volunteer studies (Phase I). Following these Phase I studies, we
completed a Type C meeting with the FDA in March 2020 and received guidance to conduct a Phase II proof of concept study of SLS-002 for ASIB in patients with MDD. The startup
activities are underway and have enrolled several patients in Part A of our open-label study.</P>

<B><U><P>SLS-005</U></B> is undergoing startup activities for a clinical study in ALS.  In December 2020, we announced the selection of SLS-005 for the Healey ALS platform
trial led by the Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple potential treatments for ALS simultaneously. The platform trial
model aims to greatly accelerate the study access, reduce costs, and shorten development timelines. We are continuing to explore trials in Sanfilippo syndromes and are seeking
more natural history data based on the guidance from regulatory agencies.</P>

<B><U><P>SLS-004</U> </B>is<B> </B>an all-in-one lentiviral vector, targeted for gene editing through DNA methylation within intron 1 of the SNCA gene responsible for
expressing alpha-synuclein protein. SLS-004, when delivered to dopaminergic neurons derived from human induced pluripotent stem cells (hiPSCs) of a PD patient, modified the
expression on alpha-synuclein and exhibited reversal of the disease-related cellular-phenotypes characteristics of the neurons.  The role of mutated SNCA in PD pathogenesis and
the need to maintain the normal physiological levels of alpha-synuclein protein emphasize the so-far unmet need to develop new therapeutic strategies, such as SLS-004, targeting
the regulatory mechanism of alpha-synuclein expression.  On May 28, 2020, we announced the initiation of a preclinical study
of SLS-004 in PD through an all-in-one lentiviral vector targeting the synuclein alpha gene. We are constructing a bimodular viral system harboring an endogenous

<P ALIGN="CENTER">                                                                                                   52
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
alpha-synuclein (&#945;-synuclein) transgene and inducible regulated repressive CRISPR/Cas9-u</FONT><FONT SIZE=2>nit to achieve constitutive activation and inducible suppression of
PD-related pathologies. </P>

<B>
<U><P>SLS-006</U></B> is a true partial dopamine agonist, originally developed by Wyeth Pharmaceuticals, Inc., with previous clinical studies on 340 subjects in various
Phase I and Phase II studies. It is a potent D2/D3 agonist/antagonist that has shown promising efficacy with statistical significance in Phase II studies in early stage PD patients and
an attractive safety profile. Moreover, it has also shown synergistic effect with reduced doses of L-DOPA. We are evaluating studies to advance the product candidate into late stage
trials. </P>

<B><U><P>SLS-007</U></B> is<B> </B>a rationally designed peptide-based approach, targeting the NACore (nonamyloid component core) of alpha-synuclein to inhibit the
protein from aggregation. Recent in-vitro and cell culture research have shown SLS-007 has the ability to stop the
propagation and seeding of &#945;-synuclein aggregates. We will evaluate the potential for in-vivo delivery of SLS-007 in a PD transgenic mice model.
The goal will be to establish in-vivo pharmacokinetics/pharmacodynamics and target engagement parameters of SLS-007, a family of anti-alpha-synuclein peptidic inhibitors.  On
June 25, 2020, we announced the initiation of a preclinical study of SLS-007 in PD delivered through an adeno associated
viral ("AAV") vector targeting the non-amyloid component core of &#945;-synuclein. We have initiated an in vivo preclinical study of SLS-007 in rodents to assess the ability of two
specific novel peptides, S62 and S71, delivered via AAV1/2 viral vector, to protect dopaminergic function in the preformed &#945;-synuclein fibril rodent model of PD. Production of
AAV1/2 vectors encoding each of the two novel peptides incorporating hemagglutinin tags has already been completed. Th</FONT><FONT SIZE=2>is preclinical study is designed
to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement parameters of SLS-007. Top-line data is currently expected in early 2021.</P>
<B>
<U><P>SLS-008</U> </B>is<B> </B>an orally available antagonist for Chemoattractant Receptor-homologous molecules expressed on TH2 cells (&quot;CRTh2&quot;), targeted at
chronic inflammation in asthma and a pediatric orphan indication. We have a &quot;family&quot; of compounds under our SLS-008 program. We intend to file an IND after
completion of IND-enabling studies, which are currently in progress, in an undisclosed pediatric orphan indication where there is a high unmet need for an effective oral therapy.</P>
<B>
</B><P>Additionally, we are developing several preclinical programs, most of which have well-defined mechanisms of action, including:</P>


<UL>
<LI>SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders; and </LI>
<LI>SLS-012, an injectable therapy for post-operative pain management.</LI></UL>


<B><P>Acquisition of Assets from Bioblast</P></B>

<P>On February 15, 2019, we entered into the Bioblast Asset Purchase Agreement with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, we acquired all of
the assets of Bioblast relating to a therapeutic platform known as Trehalose. We paid to Bioblast $1.5 million in cash in February 2019, and an additional $2.0 million in cash in
February 2020.  Under the terms of the Bioblast Asset Purchase Agreement, we agreed to pay additional consideration to Bioblast upon the achievement of certain milestones in the
future, as follows: (1) within 15 days following the completion of our or our affiliate's first Phase II(b) clinical trial of Trehalose satisfying certain criteria, we will pay to Bioblast $8.5
million in cash; and (2) within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New
Drug Submission, respectively, of Trehalose filed by us or our affiliates, we will pay to Bioblast $8.5 million in cash. In addition, we agreed to pay Bioblast a cash royalty equal to 1%
of the net sales of Trehalose.  Under the terms of the Bioblast Asset Purchase, we assumed a collaborative agreement with TSF, a nonprofit medical research foundation founded
by parents of children with Sanfilippo syndrome. TSF, upon approval by the FDA, plans to begin a Phase II(b)/III clinical trial in up to 24 patients with Sanfilippo syndrome, which is
now known under the study name SLS-005. We will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement entitle us to access all clinical
data from this trial.  On July 15, 2019, we amended the agreement whereby we agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant
of up to $1.5 million towards the funding of the trial.</P>

<P ALIGN="CENTER">                                                                                                   53
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Acquisition of License from The Regents of the University of California</P>
</B>
<P>On March 7, 2019, we entered into the UC Regents License Agreement pursuant to which we were granted an exclusive license to intellectual property owned by The UC
Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of r</FONT><FONT
FACE="Times New Roman" SIZE=2>ationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (&#945;-synuclein). We plan to study this initial approach in
PD and will further evaluate the potential clinical approach in other disorders affecting the CNS.  This program </FONT><FONT SIZE=2>is now known as SLS-007.   Upon entry into
the UC Regents License Agreement, we paid to The UC Regents $0.1 million.  Under the terms of the UC Regents License Agreement, we agreed to pay additional consideration
upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the completion of dosing of the first patient in a Phase I clinical trial, we will pay
$50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, we will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III
clinical trial, we will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., we will pay $1.0 million; (v) within 90 days following the first commercial sales
in any European market, we will pay $1.0.million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, we will pay $2.5 million. We
are also obligated to pay a single digit royalty on sales of the product, if any.  In addition, if we fail to achieve certain milestones within a specified timeframe, The UC Regents may
terminate the agreement or reduce our license to a nonexclusive license. </P>

<B><P>Acquisition of License from Duke University</P>
</B>
<P>On June 27, 2019, we entered into the Duke License Agreement pursuant to which we were granted an exclusive license to a gene therapy program targeting the regulation of
the SNCA gene, which encodes alpha-synuclein expression.  We plan to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders
affecting the CNS.  This program is now known as SLS-004.   Upon entry into the Duke License Agreement, we paid to Duke University $0.1 million.  Under the terms of the Duke
License Agreement, we agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following
filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, we will pay $0.1 million; (ii) within 30 days following dosing of the
first patient in a Phase I clinical trial, we will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, we will pay $0.5 million; (iv) within 30
days following dosing of the first patient in a Phase III clinical trial, we will pay $1.0 million; and (v) within 30 days following an NDA approval, we will pay $2.0 million. We are also
obligated to pay a single digit royalty on sales of the product, if any.  In addition, if we fail to achieve certain milestones within a specified timeframe, Duke University may terminate
the agreement.</P>

<P>We intend to become a leading biopharmaceutical company focused on neurological and psychiatric disorders, including orphan indications. Our business strategy
includes:</P>


<UL>
<LI>Advancing SLS-002 in ASIB in MDD and PTSD; </LI>
<LI>Advancing SLS-004 in PD;</LI>
<LI>Advancing SLS-005 in ALS and Sanfilippo syndrome;</LI>
<LI>Advancing SLS-007 in PD as a monotherapy;</LI>
<LI>Filing an IND for SLS-008 in an undisclosed indication;</LI>
<LI>Forming strategic collaborations in the EU and Asian markets; and</LI>
<LI>Acquiring synergistic assets in the central nervous system therapy space through licensing and partnerships.</LI></UL>


<P>We also have two legacy product candidates: a product candidate in the United States for the treatment of ED, which we in-licensed from Warner Chilcott Company, Inc., now a
subsidiary of Allergan; and a product candidate which has completed a Phase IIa clinical trial for the treatment of Raynaud's Phenomenon, secondary to scleroderma, for which we
own worldwide rights.</P>

<P ALIGN="CENTER">                                                                                                   54
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Results of Operations</P>
<I>
<P>Revenues</P>

</I></B><P>We recorded $0 and $375,000 in grant revenue during the year ended December 31, 2020 and 2019, respectively.  The $375,000 in revenue in 2019 was related to our
amended agreement with TSF, pursuant to which we agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5 million
towards the funding of the trial.   </P>
<B><I>
<P>Operating Expense</P></I></B>

<P>Operating expense was as follows (in thousands, except percentages):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF COLSPAN=4 ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" BGCOLOR=#FFFFFF COLSPAN=3 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2020 vs 2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" BGCOLOR=#FFFFFF ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
$   Change</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" BGCOLOR=#FFFFFF ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
% Change</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" WIDTH="41%" ><FONT FACE="Times New Roman" SIZE=-1>
Operating expense</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="13%"  ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF WIDTH="13%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF WIDTH="1%"  ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF WIDTH="13%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Research and development</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                    10,984&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                    22,563&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     (11,579)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
-51%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      General and administrative</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                      7,775&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                      7,559&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                           216&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
3%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Total operating expense</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                    18,759&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                    30,122&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                     (11,363)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
-38%</FONT></TD>
</TR>
</TABLE>


<B><I><P>Research and Development Expenses</P>

</I></B><P>Research and development (&quot;R&amp;D&quot;) costs are expensed as they are incurred and include the cost of compensation and related expenses, as well as
expenses for third parties who conduct R&amp;D on our behalf. The $11.6 million decrease in R&amp;D expense during the year ended December 31, 2020, as compared to the
same period in 2019, are as follows (in thousands, except percentages):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF COLSPAN=4 ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" BGCOLOR=#FFFFFF COLSPAN=3 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2020 vs 2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" BGCOLOR=#FFFFFF ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
$   Change</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" BGCOLOR=#FFFFFF ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
% Change</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" WIDTH="41%" ><FONT FACE="Times New Roman" SIZE=-1>
Research and development expenses</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="13%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="13%"  ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF WIDTH="13%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF WIDTH="1%"  ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF WIDTH="13%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Cash payments for licenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      8,733&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                       (8,733)</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
-100%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Non-cash payments licenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         193&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      5,250&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                       (5,057)</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
-96%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Clinical trial expenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      4,868&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      2,821&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                        2,047&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
73%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Manufacturing expenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      1,792&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      2,706&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          (914)</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
-34%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Employee compensation</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      1,828&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      1,718&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                           110&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
6%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Contract consulting expenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      1,837&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      1,132&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                           705&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
62%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Other research and development expenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         466&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         203&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                           263&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
130%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
          Total research and development expenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    10,984&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    22,563&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     (11,579)</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
-51%</FONT></TD>
</TR>
</TABLE>

<P>The $11.6 million decrease in R&amp;D expense during the year ended December 31, 2020, as compared to the same period in 2019, resulted primarily from a decrease in
license fees of approximately $13.8 million and manufacturing costs of approximately $914,000.  These decreases were partially offset by increases in clinical trial costs of
approximately $2.0 million and external consulting costs of approximately $705,000.</P>
<B><I>
<P>General and Administrative Expenses</P>
</I></B>
<P>General and administrative (&quot;G&amp;A&quot;) costs include expenses for personnel, finance, legal, business development and investor relations. G&amp;A expenses
increased by $216,000 during the year ended December 31, 2020, as compared to the same period in 2019. This increase was primarily due to non-cash stock-based compensation
of approximately $1.3 million and costs including, but not limited to, investor relations costs of approximately $401,000 and patent maintenance and external legal costs of
approximately $319,000 during the year ended December 31, 2020.  This increase was partially offset by decreases in legal and administrative costs associated with the Merger
incurred during the year ended December 31, 2019 of $2.0 million. </P>

<P ALIGN="CENTER">                                                                                                   55
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><I>
<P>Other Income and Expense</P>
</I></B>
<P>Other income and expense was as follows (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=75%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="68%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="14%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="14%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Other income (expense)</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Interest income</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                           45&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         151&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Interest expense</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                       (164)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         (29)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Loss on warrant issuance</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    (5,020)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Change in fair value of warrant liabilities</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                       (223)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (16,501)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Change in fair value of convertible notes payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                       (109)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Total other expense</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    (342)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (21,508)</FONT></TD>
</TR>
</TABLE>

<B><I><P>Interest Income</P>

</I></B><P>Interest income was $45,000 and $151,000 for the year ended December 31, 2020 and 2019, respectively.  The decrease in interest income primarily related to the
lower average cash balances along with lower interest rates earned during the year ended December 31, 2020 compared to the year ended December 31, 2019.</P>

<B><I><P>Interest Expense</P>
</I></B>
<P>Interest expense was $164,000 and $29,000 for the year ended December 31, 2020 and 2019, respectively.  The increase is due to the issuance of certain convertible notes in
December 2020 (see below).</P>

<B><I><P>Loss on warrant issuance</P>
</I></B>
<P>Loss on warrant issuance was $0 and $5.0 million for the year ended December 31, 2020 and 2019, respectively.  The loss was due to the fair value of the warrants exceeding
the net cash proceeds from the Merger.     </P>

<B><I><P>Change in Fair Value of Warrant Liability</P>
</I></B>
<P>The fair value of warrant liability was $1.1 million and $963,000 at December 31, 2020 and 2019, respectively.  The change in fair value of warrant liabilities of $223,000 and
$16.5 million during the year ended December 31, 2020 and 2019, respectively, is due to revaluation of the two series of warrants to purchase shares of common stock issued on
January 24, 2019 (the &quot;Series A Warrants&quot; and the &quot;Series B Warrants&quot; and, together, the &quot;Pre-Merger Warrants&quot;) pursuant to that certain
Securities Purchase Agreement, dated October 16, 2018, by and among Apricus, STI and the investors listed on the Schedule of Buyers attached thereto (the &quot;Pre-Merger
SPA&quot;).</P>

<B><I><P>Change in Fair Value of Convertible Notes Payable</P>
</I></B>
<P>The convertible notes were converted into common stock pursuant to the Merger on January 24, 2019.  The change in fair value of convertible notes was an expense of $0 and
$109,000 during the year ended December 31, 2020 and 2019, respectively.</P>

<B><P>Liquidity, Capital Resources and Financial Condition</P>
</B>
<P>We have generated limited revenues, incurred operating losses since inception, and we expect to continue to incur significant operating losses for the foreseeable future and
may never become profitable. As of December 31, 2020, we had $15.7 million in cash and an accumulated deficit of $75.2 million. We have historically funded our operations
through the issuance of convertible notes (the &quot;Notes&quot;) (see Note 7 to our consolidated financial statements), the sale of common stock (see Note 4 to our consolidated
financial statements) and the exercise of warrants (see Note 8 to our consolidated financial statements).  </P>

<P ALIGN="CENTER">                                                                                                   56
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>On January 28, 2021, we completed an underwritten public offering pursuant to which we sold 17,530,488 shares of our common stock at a price to the public of $2.05 per
share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to us from the offering
were approximately $33.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. We used $3.8 million of the net
proceeds from the offering for the partial repayment of the Notes (as defined below).</P>

<P>On December 11, 2020, we entered into a Securities Purchase Agreement (the &quot;Lind Securities Purchase Agreement&quot;) with Lind Global Asset Management II, LLC
(the "Investor") pursuant to which, among other things, on December 11, 2020, we issued and sold to the Investor, in a private placement transaction, in exchange for the payment
by the Investor of $10,000,000, (1) a convertible promissory note (the "Note") in an aggregate principal amount of $12,000,000 (the "Principal Amount"), which will bear no interest
and mature on December 11, 2022 (the "Maturity Date"), and (2) 975,000 shares (the "Closing Shares") of our common stock.  At any time following June 11, 2021, and from time to
time before the Maturity Date, the Investor shall have the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price
per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the "Conversion Price"). Prior to June 11, 2021, we will have
the right to prepay up to sixty-six and two-thirds percent (66<SUP>2/3</SUP>%) of the then-outstanding Principal Amount of the Note with no penalty. On or after July 11, 2021, we
will have the right to prepay up to the then-outstanding Principal Amount of the Note with no penalty; however, if we exercise such prepayment right, the Investor will have the option
to convert up to thirty-three and one-third percent (33<SUP>1/3</SUP>%) of the amount that we elect to prepay at the Conversion Price. Subject to certain exceptions, we will be
required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase
money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the Note, unless waived by the Investor in advance.  Beginning
on June 9, 2021, the Note will amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the Note, divided by (ii) the number of
months remaining until the Maturity Date. All amortization payments shall be payable solely in cash, plus a 2% premium. </P>

<P>On December 17, 2020, we entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities
Purchase Agreement (the "December 17 SPAs"), pursuant to which we sold, in private placement transactions, in exchange for the payment by the accredited investors of an
aggregate of $1,138,023.16, (1) convertible promissory notes (the "December 17 Notes") in an aggregate principal amount of $1,365,627.80, which will bear no interest and mature
on December 17, 2022, and (2) an aggregate of 110,956 shares of our common stock. On December 18, 2020, we entered into an additional securities purchase agreement with an
accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the "December 18 SPA" and, together with the December 17 SPAs, the
"Subsequent Securities Purchase Agreements"), pursuant to which we sold, in a private placement transaction, in exchange for the payment by the accredited investor of
$269,372.50, (1) a convertible promissory note (the "December 18 Note" and, together with the December 17 Notes, the "Subsequent Notes," and, together with the Note, the
"Notes") in an aggregate principal amount of $323,247, which will bear no interest and mature on December 18, 2022, and (2) 26,263 shares of our common stock. The Subsequent
Securities Purchase Agreements were entered into with certain accredited investors pursuant to the right to participate in future offerings provided to the accredited investors in
connection with the registered direct offering we completed in September 2020. The Subsequent Securities Purchase Agreements have substantially the same terms as the Lind
Securities Purchase Agreement, and the Subsequent Notes have substantially the same terms as the Note. In connection with the Subsequent Securities Purchase Agreements, we
repaid $1.4 million of principal amount of the Note on January 8, 2021.</P>

<P>On September 4, 2020, we entered into a Securities Purchase Agreement with certain institutional investors (the &quot;September 2020 Securities Purchase Agreement&quot;),
pursuant to which we issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately $6.4
million, after deducting the placement agent's fees and offering expenses (see Note 4 to our consolidated financial statements).  We also agreed to issue to the investors
unregistered warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the &quot;September 2020 Warrants&quot;). The September 2020
Warrants have an exercise price of $0.84 per share of common stock, will be exercisable six months from the date of issuance and will expire on March 9, 2026.  The combined
purchase price for one share and one warrant to purchase half of a share of common stock in the offerings was $0.79.</P>

<P>On May 4, 2020, we qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under
the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the "PPP Lender"), for an aggregate principal amount of approximately $147,000 (the "PPP Loan").
The PPP Loan bears interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, has a term of two years and is unsecured and guaranteed by the U.S.
Small Business Administration. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program upon our request to the extent that the PPP Loan proceeds are used to pay

<P ALIGN="CENTER">                                                                                                   57
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
expenses permitted by the Paycheck Protection Program, including payroll costs, covered rent and mortgage obligations and covered utility
payments incurred by us. We intend to apply for forgiveness of the PPP Loan with respect to these covered expenses. To the extent that all or part of the PPP Loan is not forgiven,
we will be required to pay interest on the PPP Loan at a rate of 1.0% per annum, and commencing in the fourth quarter of 2020, principal and interest payments will be required
through the maturity date in May 2022. The terms of the PPP Loan provide for customary events of default including, among other things, payment defaults, breach of
representations and warranties and insolvency events. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.</P>

<P>On March 16, 2020, we completed an underwritten public offering pursuant to which we sold 7,500,000 shares of our common stock at a price to the public of $0.60 per share.
The net proceeds to us from this offering were approximately $4.0 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</P>

<P>On February 13, 2020, we completed an underwritten public offering, pursuant to which we sold 6,666,667 shares of our common stock at a price to the public of $0.75 per
share. On February 19, 2020, we sold an additional 999,999 shares of our common stock at a price to the public of $0.75 per share pursuant to the full exercise of the underwriters'
option to cover over-allotments. The net proceeds to us from this offering were approximately $5.0 million, after deducting underwriting discounts and commissions and other
estimated offering expenses payable by us.   </P>

<P>On August 23, 2019, we entered into a Securities Purchase Agreement with certain institutional investors (the &quot;August 2019 Securities Purchase Agreement&quot;),
pursuant to which we issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately $6.7
million, before deducting the placement agents' fees and other estimated offering expenses (see Note 4 to our consolidated financial statements).  We also agreed to issue to the
investors unregistered warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the &quot;August 2019 Warrants&quot;). The August 2019
Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of
issuance.  The combined purchase price for one share and one warrant to purchase half of a share of common stock in the offerings was $1.50.</P>

<P>On June 17, 2019, we entered into an Equity Distribution Agreement (the &quot;Equity Distribution Agreement&quot;) with Piper Jaffray &amp; Co., as sales agent (&quot;Piper
Jaffray&quot;), pursuant to we may offer and sell, from time to time, through Piper Jaffray up to $50,000,000 in shares of our common stock. During the year ended December 31,
2019, we sold 1,197,676 shares for net proceeds of approximately $2.6 million pursuant to the Equity Distribution Agreement (see Note 4 to our consolidated financial statements).
On August 23, 2019, we suspended our continuous offering under the Equity Distribution Agreement and the Equity Distribution Agreement terminated in accordance with its terms
on December 7, 2020.</P>

<P>During the year ended December 31, 2020 and 2019, we received approximately $45 thousand and $4.5 million, respectively, in proceeds from the exercise of approximately
154 thousand and 14.3 million Series A Warrants and Series B Warrants, respectively. </P>

<P>We expect to use the net proceeds from the above transactions primarily for general corporate purposes, which may include financing our normal business operations,
developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. In addition, pursuant to the amended and restated license agreement
with Stuart Weg, M.D., if certain conditions are not met, make an additional cash payment of $0.2 million in January 2022.   We believe that in order for us to meet our obligations
arising from normal business operations for the next twelve months, we require additional capital in the form of equity, debt or both.  Without additional capital, our ability to continue
to operate will be limited.  These financial statements do not include any adjustments to the recoverability and classification of recorded assets amounts and classification of
liabilities that might be necessary should we not be able to continue as a going concern.</P>

<P>We currently have an effective shelf registration statement on Form S-3 filed with the SEC.  We may use the shelf registration statement on Form S-3 of which this prospectus
forms a part to offer from time to time any combination of debt securities, common and preferred stock and warrants, and, as of the date hereof, a total of $168.7 million of securities
remains available for issuance pursuant to the shelf registration statement.  </P>

<P ALIGN="CENTER">                                                                                                   58
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>The accompanying audited consolidated financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the realization
of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification
of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern.</P>

<P>Our future liquidity and capital funding requirements will depend on numerous factors, including:</P>

<UL>

<LI>our ability to raise additional funds to finance our operations;</LI>
<LI>our ability to maintain compliance with the listing requirements of The Nasdaq Capital Market;</LI>
<LI>the outcome, costs and timing of any clinical trial results for our current or future product candidates;</LI>
<LI>potential litigation expenses;</LI>
<LI>the emergence and effect of competing or complementary products or product candidates;</LI>
<LI>our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or
that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</LI>
<LI>our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;</LI>
<LI>the terms and timing of any collaborative, licensing or other arrangements that we have or may establish;</LI>
<LI>the trading price of our common stock; </LI>
<LI>our ability to secure a development partner for our product candidate in the United States for the treatment of ED; and</LI>
<LI>our ability to increase the number of authorized shares outstanding to facilitate future financing events.</LI>

</UL>

<P>We will need to raise substantial additional funds through one or more of the following: issuance of additional debt, equity, or both and/or the completion of a licensing or other
commercial transaction for one or more of our product candidates. If we are unable to maintain sufficient financial resources, our business, financial condition and results of
operations will be materially and adversely affected. This could adversely affect future development and business activities, operations and business plans, such as future clinical
studies and/or other future ventures. There can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible
debt financings may have a dilutive effect on the holdings of our existing stockholders.  No assurances can be given that we will be able to obtain additional financing.</P>

<P>On November 11, 2020, we received written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty consecutive business days, the
bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule
5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until May 10, 2021, to regain compliance. We regained
compliance after the closing bid price of our common stock had been at $1.00 per share or greater for twenty consecutive business days, from December 10, 2020 through January 8, 2021. </P>

<B>
<P>Cash Flow Summary</P></B>

<P>The following table summarizes selected items in our consolidated statements of cash flows&nbsp;(in thousands):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0">
<TR VALIGN="TOP">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="68%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="14%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="14%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Net cash provided by (used in) operations</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
                 &nbsp;&nbsp;&nbsp;&nbsp;      Net cash used in operating activities</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
            (20,913)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
            (19,305)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
                 &nbsp;&nbsp;&nbsp;&nbsp;      Net cash provided by financing activities</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    26,314&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    29,524&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Net increase in cash</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     5,401&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    10,219&nbsp;</FONT></TD>
</TR>
</TABLE>

<P> &nbsp; </P>

<P ALIGN="CENTER">                                                                                                   59
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<I>
<P>Operating Activities</P></I>

<P>Cash used in operating activities of $20.9 million in the year ended December 31, 2020 was primarily due to the net loss of $19.1 million and changes in operating assets
and liabilities of $4.5 million, which was partially offset by $2.0 million in stock compensation expense.  </P>

<P>Cash used in operating activities of $19.3 million in the year ended December 31, 2019 was primarily due to the net loss of $51.3 million, which was partially offset by changes in
the fair value of the warrant liabilities of $16.5 million, changes in operating assets and liabilities of $6.9 million, $3.0 million in non-cash expense for the acquisition of licenses for
research and development, and the loss on warrant issuance of $5.0 million.  </P>

<I><P>Investing Activities</P>
</I>
<P>No cash was used in investing activities during the years ended December 31, 2020 or 2019.</P>

<I><P>Financing Activities</P>
</I>
<P>Cash provided by financing activities of $26.3 million in the year ended December 31, 2020 was primarily due to the proceeds from the exercise of warrants, the proceeds from
the issuance and sale of the Note and the Closing Shares, the issuance and sale of common stock pursuant to the September 2020 Securities Purchase Agreement, the PPP Loan,
and proceeds from our February 2020 and March 2020 public offerings.</P>

<P>Cash provided by financing activities of $29.5 million in the year ended December 31, 2019 was primarily due to the proceeds from the exercise of warrants, the proceeds from
the issuance and sale of common stock pursuant to the August 2019 Securities Purchase Agreement, the proceeds from the issuance and sale of common stock and warrants
pursuant to the Pre-Merger SPA and proceeds from the issuance and sale of common stock pursuant to the Equity Distribution Agreement.</P>

<I><P>Contractual Obligations</P>
</I>
<P>We have entered into long-term agreements with certain manufacturers and suppliers that require us to make contractual payment to these organizations. We expect to enter
into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term commitments of cash.</P>


<P>The following represents our contractual obligations as of December 31, 2020 (in thousands):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0">
<TR VALIGN="TOP">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Less than</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
More than</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Contractual Obligations</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Total</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
1 year</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2-3 years</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
4-5 years</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
5 years</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Cash payments for license fees</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             325&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             125&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
               200&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    -  &nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Purchase obligations (1)</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  15,828&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  9,922&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  5,906&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    -  &nbsp;</FONT></TD>
</TR>
</TABLE>


<P>(1) &nbsp; Purchase obligations primarily represent commitments for agreements with external service providers, under which we will incur expenses relating to clinical trials of SLS-002
and SLS-005 and other clinical candidates. These agreements are cancellable on notice of up to three months.</P>

<B><P>Off-Balance Sheet Arrangements</P>

</B><P>As of December 31, 2020, we did not have any off-balance sheet arrangements as defined in Item&nbsp;303(a)(4)(ii) of Regulation S-K.</P>

<B><P>Recent Accounting Pronouncements</P>
</B>
<P>See Note 1 to our consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any, on us.</P>

<P ALIGN="CENTER">                                                                                                   60
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<P>Critical Accounting Estimates and Policies<A NAME="Critical_accounting_estimates"></A></P>
</B>
<P>The preparation of financial statements in accordance with United States generally accepted accounting principles (&quot;GAAP&quot;) requires management to make
estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical
experience, market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management's best knowledge of
current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have
control. If market and other conditions change from those that we anticipate, our consolidated financial statements may be materially affected. In addition, if our assumptions change,
we may need to revise our estimates, or take other corrective actions, either of which may also have a material effect in our consolidated financial statements.  We review our
estimates, judgments, and assumptions used in our accounting practices periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We
believe that these estimates are reasonable; however, our actual results may differ from these estimates.</P>

<P>We believe that the following critical accounting policies and estimates have a higher degree of inherent uncertainty and require our most significant judgments:</P>
<B><I>
<P>Accrual of Research and Development Expenses. </P>

</I></B><P>Research and development costs are expensed as incurred and include salaries and benefits; costs paid to third-party contractors to perform research, conduct clinical
trials, develop and manufacture pre-approval drug materials and delivery devices. Clinical trial costs are a significant component of research and development expenses and include
costs associated with third-party contractors. Invoicing from third-party contractors for services performed can lag several months. We accrue the costs of services rendered in
connection with third-party contractor activities based on our estimate of management fees, site management and monitoring costs and data management costs. Differences
between actual clinical trial costs from estimated clinical trial costs have not been material and are adjusted for in the period in which they become known.</P>

<B><I><P>Stock Based Compensation</P></I></B>

<P>Stock based compensation expense includes charges related to options awards to employees and directors. The estimated grant date fair value of stock options granted to
employees and directors is calculated based upon the closing stock price of our common stock on the date of the grant and recognized as stock-based compensation expense over
the expected service period, which is typically approximated by the vesting period.</P>

<P>We estimate the fair value of each option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires us to
estimate our dividend yield rate, expected volatility and risk-free interest rate over the life of the option.&nbsp;The use of estimates on these factors may cause the fair value of the
option to be under or overestimated (see Note 9 to our consolidated financial statements for the current estimates used in the Black-Scholes option pricing model).</P>

<B><I><P>Valuation of Warrant Liability</P>

</I></B><P>Our outstanding Series A Warrants are classified as liabilities in the accompanying consolidated balance sheets as they contain provisions that are considered outside
of our control, such as requiring us to maintain active registration of the shares underlying such warrants. The warrants were recorded at fair value using the Black-Scholes option
pricing model. The fair value of these warrants is re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income
(expense) in the accompanying consolidated statements of operations.</P>

<B><P><A NAME="item7a">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></P></B>

<P>Not applicable.</P>


<P ALIGN="CENTER">                                                                                                   61
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<B><P><A NAME="item8">ITEM 8. FINANCIAL STATEMENTS </A></P>


<P>INDEX TO FINANCIAL STATEMENTS</P></B>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR><TD WIDTH="83%" VALIGN="BOTTOM" HEIGHT=16><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" HEIGHT=16>
<B><FONT SIZE=1><P ALIGN="CENTER">PAGE
</B></FONT></TD>
</TR>
<TR><TD WIDTH="83%" VALIGN="top" BGCOLOR="#FFFFFF">
<FONT SIZE=2><P>Report of Independent Registered Public Accounting Firm</FONT></TD>
<TD WIDTH="17%" VALIGN="top" BGCOLOR="#FFFFFF"><FONT SIZE=2><P ALIGN="CENTER">63</P></TD>
</TR>
<TR><TD WIDTH="83%" VALIGN="top">
<FONT SIZE=2><P>Financial Statements:</FONT></TD>
<TD WIDTH="17%" VALIGN="top"><P></P></TD>
</TR>
<TR><TD WIDTH="83%" VALIGN="top" BGCOLOR="#FFFFFF">
<FONT SIZE=2><P>Consolidated Balance Sheets as of December 31, 2020 and 2019</FONT></TD>
<TD WIDTH="17%" VALIGN="top" BGCOLOR="#FFFFFF"><FONT SIZE=2><P ALIGN="CENTER">64</P></TD>
</TR>
<TR><TD WIDTH="83%" VALIGN="top">
<FONT SIZE=2><P>Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2020 and 2019</FONT></TD>
<TD WIDTH="17%" VALIGN="top"><FONT SIZE=2><P ALIGN="CENTER">65</P></TD>
</TR>
<TR><TD WIDTH="83%" VALIGN="top">
<FONT SIZE=2><P>Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the years ended December 31, 2020 and 2019</FONT></TD>
<TD WIDTH="17%" VALIGN="top"><FONT SIZE=2><P ALIGN="CENTER">66</P></TD>
</TR>
<TR><TD WIDTH="83%" VALIGN="top" BGCOLOR="#FFFFFF">
<FONT SIZE=2><P>Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019</FONT></TD>
<TD WIDTH="17%" VALIGN="top" BGCOLOR="#FFFFFF"><FONT SIZE=2><P ALIGN="CENTER">67</P></TD>
</TR>
<TR><TD WIDTH="83%" VALIGN="top" BGCOLOR="#FFFFFF">
<FONT SIZE=2><P>Notes to the Consolidated Financial Statements</FONT></TD>
<TD WIDTH="17%" VALIGN="top" BGCOLOR="#FFFFFF"><FONT SIZE=2><P ALIGN="CENTER">68</P></TD>
</TR>
</TABLE>

<P> &nbsp; </P>
<P> &nbsp; </P>
<P> &nbsp; </P>


<P ALIGN="CENTER">                                                                                                   62
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>



<B><P ALIGN="JUSTIFY">Report of Independent Registered Public Accounting Firm</P></B>

<P>To the Stockholders and Board of Directors<BR>
Seelos Therapeutics, Inc.:</P>

<I><P>Opinion on the Consolidated Financial Statements</P>
</I><P>We have audited the accompanying consolidated balance sheets of Seelos Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019,
the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and cash flows for each of the years in the two-year period ended
December 31, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the
two-year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</P>

<I><P>Going Concern </P></I>

<P>The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the
consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to
continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</P>
<I>
<P>Basis for Opinion</P>
</I><P>These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</P>
<P>We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to
perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for
the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P>Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>

<I><P>Critical Audit Matters</P></I>

<P>Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the
audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or
complex judgments. We determined that there are no critical audit matters.</P>


<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P>/s/ KPMG LLP</P>

</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P>We have served as the Company's auditor since 2017</P>

<P>Short Hills, New Jersey<BR>
March 11, 2021</P>




<FONT FACE="Times New Roman" SIZE="2">

<P ALIGN="CENTER">                                                                                                   63
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>



<B><P ALIGN="CENTER">Seelos Therapeutics, Inc. and Subsidiaries<BR>
                  Consolidated Balance Sheets<BR>
                  (In thousands, except share and per share data)</P></B>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="72%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Assets</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Current assets</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Cash</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           15,662&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           10,261&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Prepaid expenses and other current assets</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             1,832&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                835&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Total current assets</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           17,494&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           11,096&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Total assets</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           17,494&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           11,096&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Liabilities and stockholders' equity (deficit)</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Current liabilities</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Accounts payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             1,887&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                796&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Accrued expenses</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             1,924&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             1,919&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Licenses payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                125&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             7,100&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Convertible debt</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              2,431&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Warrant liabilities, at fair value</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             1,062&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                963&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Total current liabilities</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
              7,429&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
           10,778&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
     Licenses payables, long-term</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                200&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                325&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
     Note payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                147&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
     Convertible debt, long-term</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             7,146&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Total liabilities</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           14,922&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           11,103&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Commitments and contingencies (note 11)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Stockholders' equity (deficit)</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           issued or outstanding as of December 31, 2020 and December 31, 2019</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Common stock, $0.001 par value, 120,000,000 shares authorized,&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;            54,535,891 and 27,028,533 issued and outstanding as of &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;            December 31, 2020 and December 31, 2019, respectively</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  54&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  27&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Additional paid-in-capital</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
           77,680&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
           56,027&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Accumulated deficit</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
         (75,162)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
         (56,061)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Total stockholders' equity (deficit)</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             2,572&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (7)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Total liabilities and stockholders' equity (deficit)</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           17,494&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
           11,096&nbsp;</FONT></TD>
</TR>
</TABLE>



<P ALIGN="CENTER">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P> &nbsp; </P>


<P ALIGN="CENTER">                                                                                                   64
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<B><P ALIGN="CENTER">Seelos Therapeutics, Inc. and Subsidiaries<BR>
                  Consolidated Statements of Operations and Comprehensive Loss<BR>
                  (In thousands, except per share data)</P></B>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="72%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Revenues</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Grant revenue</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                          -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     375&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Total revenues</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                          -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     375&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Operating expense</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Research and development</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                10,984&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                22,563&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      General and administrative</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  7,775&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  7,559&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Total operating expense</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                18,759&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                30,122&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Loss from operations</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              (18,759)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              (29,747)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Other income (expense)</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Interest income</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                       45&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     151&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Interest expense</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   (164)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     (29)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Loss on warrant issuance</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                (5,020)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Change in fair value of warrant liabilities</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   (223)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              (16,501)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Change in fair value of convertible notes payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                          -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                   (109)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Total other income (expense)</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                   (342)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
              (21,508)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Net loss and comprehensive loss</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
              (19,101)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
              (51,255)</FONT></TD>
</TR>
<TR>
<TD ALIGN="right" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Net loss per share basic and diluted</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (0.43)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (2.52)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Weighted-average common shares outstanding basic and diluted</FONT></TD>
<TD ALIGN="right" VALIGN="bottom" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
         44,766,640&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="bottom" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
         20,308,818&nbsp;</FONT></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P> &nbsp; </P>

<P ALIGN="CENTER">                                                                                                   65
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<B><P ALIGN="CENTER">Seelos Therapeutics, Inc. and Subsidiaries<A NAME="Consolidated_Statements_of_Stockholders_"></A><BR>
                  Consolidated Statements of Changes in Stockholders' Equity (Deficit)<BR>
                  (In thousands)</P></B>


<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=99%>
<TR VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Common </B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Common </B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Additional </B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Total </B></FONT></TD>
</TR>
<TR VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Stock </B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Stock </B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Paid-In </B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Accumulated </B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
 Stockholders' </B></FONT></TD>
</TR>
<TR STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)">
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Shares) </B></FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Amount) </B></FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
 Capital </B></FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
 Deficit </B></FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Equity (Deficit)</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1><B>
 Balance as of December 31, 2018 </B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               3,081,546&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 3&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                97&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
            (4,806)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  (4,706)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Stock-based compensation expense&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              459&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      459&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock and warrants in a private &nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;    offering, net of $16.5 million warrant liability&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               1,829,407&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 2&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          2&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Effect of reverse merger&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  947,218&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 1&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
            (300)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     (299)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Warrants exercised for cash&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             14,332,620&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               14&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           4,503&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   4,517&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock for license acquired&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  992,782&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 1&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           2,999&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   3,000&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Reclass of warrant liabilities related to Series A&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;    warrants exercised for cash&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           5,600&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   5,600&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Reclass of Series B warrants from warrant liability&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;    to stockholders' equity&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
         31,473&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 31,473&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock for conversion of debt and&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;    accrued interest&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  172,284&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           2,715&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   2,715&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock and warrants, pursuant to &nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;     Securities Purchase Agreement, net of issuance&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               4,475,000&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 5&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           5,915&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   5,920&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock in at-the-market offering,&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;     net of issuance costs&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               1,197,676&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 1&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           2,566&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   2,567&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Net loss&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
          (51,255)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                (51,255)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1><B>
 Balance as of December 31, 2019 </B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             27,028,533&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               27&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
         56,027&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
          (56,061)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         (7)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Stock-based compensation expense&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           2,044&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   2,044&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock for prepaid services&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  400,000&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              330&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      330&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock for license acquired&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               1,809,845&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 2&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           2,441&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   2,443&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock,&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;     net of issuance costs&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             15,166,666&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               15&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           8,835&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   8,850&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Warrants exercised for cash&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  153,628&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              169&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      169&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock, pursuant to&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;     Securities Purchase Agreements, net of issuance costs&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               1,112,219&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 1&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           1,378&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   1,379&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Beneficial conversion feature of convertible debt&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              100&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      100&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Issuance of common stock and warrants, pursuant to&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;     September 2020 Securities Purchase Agreement,&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;     net of issuance costs&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               8,865,000&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                 9&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           6,356&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   6,365&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 Net loss&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                              -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                 -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
          (19,101)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
          (19,101)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1><B>
 Balance as of December 31, 2020 </B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             54,535,891&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
               54&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
         77,680&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
          (75,162)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                   2,572&nbsp;</FONT></TD>
</TR>
</TABLE>

<P> &nbsp; </P>
<P> &nbsp; </P>


<P ALIGN="CENTER">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P> &nbsp; </P>

<P ALIGN="CENTER">                                                                                                   66
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P ALIGN="CENTER">Seelos Therapeutics, Inc. and Subsidiaries<A NAME="Consolidated_Statements_of_Cash_Flows__U"></A><BR>
                  Consolidated Statements of Cash Flows<BR>
                  (In thousands)</P></B>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Cash flows from operating activities:</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Net loss</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
              (19,101)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
              (51,255)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;      Adjustments to reconcile net loss to net cash used in operating activities</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Stock-based compensation expense</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  2,044&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     459&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Shares issued for services</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     124&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Research and development expenses - license acquired</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     192&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  3,000&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Change in fair value of convertible notes payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     109&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Change in fair value of warrant liability</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     223&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                16,501&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Loss on warrant issuance</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  5,020&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Amortization of debt discount</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                       150&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;      Changes in operating assets and liabilities</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Prepaid expenses and other current assets</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   (791)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   (686)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Accounts payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  1,091&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                (1,424)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Accrued expenses</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         5&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  1,533&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Accrued interest</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                       13&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Licenses payable</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                (4,850)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  7,425&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;                Net cash used in operating activities</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
              (20,913)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
              (19,305)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Cash flows provided by financing activities</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Proceeds from issuance of common stock and warrants in a private offering</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                16,520&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Proceeds from issuance of common stock, net of issuance costs</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  8,850&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Proceeds from issuance of common stock and warrants, pursuant to</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           Securities Purchase Agreement, net of issuance costs</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  6,365&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  5,920&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Proceeds from issuance of common stock and convertible notes payable,</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;           net of issuance costs</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                10,907&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Proceeds from note payable</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     147&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Proceeds from issuance of common stock in at-the-market offering</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  2,567&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Proceeds from exercise of warrants</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                       45&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  4,517&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
 &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;                Net cash provided by financing activities</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                26,314&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                29,524&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Net increase in cash</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  5,401&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                10,219&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Cash, beginning of period</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                10,261&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                       42&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1><B>
Cash, end of period</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                15,662&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double"ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                10,261&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Supplemental disclosure of cash flow information:</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Cash paid for interest</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                       11&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                       16&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Cash paid for income taxes</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Non-cash investing and financing activities:</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Issuance of common stock for license payable</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  2,443&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Issuance of common stock for conversion of debt</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  2,551&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Issuance of common stock for conversion of accrued interest</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     164&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Issuance of common stock for license acquired</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  3,000&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Effect of reverse merger</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     299&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Reclass of warrant liabilities related to Series A warrants exercised for cash</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     124&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  5,600&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Reclass of Series B warrants from warrant liability to stockholders' equity</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                         -&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                31,473&nbsp;</FONT></TD>
</TR>
</TABLE>



<P ALIGN="CENTER">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P> &nbsp; </P>

<P ALIGN="CENTER">                                                                                                   67
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>



<B><P ALIGN="CENTER">Seelos Therapeutics, Inc. and Subsidiaries</P></B>

<B><P>Notes to Consolidated Financial Statements</P></B>

<B><P>1. Organization and Summary of Significant Accounting Policies</P></B>

<B><P>Organization</P></B>

<P>Seelos Therapeutics, Inc. and Subsidiaries (&quot;Seelos&quot; or the &quot;Company&quot;) is a Nevada corporation that was initially formed in 1987. The Company is a
clinical-stage biopharmaceutical company focused on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory and other disorders.
</P>

<B><P>Merger with Apricus Biosciences, Inc.</P>

</B><P>On January 24, 2019, Apricus Biosciences, Inc., a Nevada corporation (&quot;Apricus&quot;), completed a business combination with Seelos Therapeutics, Inc., a
Delaware corporation (&quot;STI&quot;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &quot;Merger Agreement&quot;) entered into
on July 30, 2018. Pursuant to the Merger Agreement, (i) a subsidiary of Apricus merged with and into STI, with STI (renamed as &quot;Seelos Corporation&quot;) continuing as a
wholly owned subsidiary of Apricus and the surviving corporation of the merger and (ii) Apricus was renamed as &quot;Seelos Therapeutics, Inc.&quot; (the &quot;Merger&quot;).
</P>

<P>The Merger was accounted for as a reverse recapitalization under United States generally accepted accounting principles (&quot;U.S. GAAP&quot;) because the primary assets
of Apricus were nominal following the close of the Merger. STI was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i)
STI's stockholders and other persons holding securities convertible, exercisable or exchangeable directly or indirectly for STI common stock owned the majority of Apricus
immediately following the effective time of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company and (iii) STI's management holds all key
positions in the management of the combined company. Accordingly, the historical financial statements of STI became the Company's historical financial statements, including the
comparative prior periods.  </P>
<B>
<P>Basis of Presentation and Principles of Consolidation</P>
</B>
<P>The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.&nbsp;All significant intercompany accounts and transactions
have been eliminated in consolidation.</P>

<B><P>Use of Estimates</P></B>

<P>The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting
period. The most significant estimates in the Company's financial statements relate to the valuation of warrants, valuation of convertible notes payable, valuation of common stock
and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily
apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual
results, the Company's future results of operations will be affected.</P>

<P ALIGN="CENTER">                                                                                                   68
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Fair Value of Financial Instruments</P>
</B>
<P>The carrying amounts of financial instruments such as accounts receivable, accounts payable and accrued expenses approximate their related fair values due to the short-term
nature of these instruments.</P>
<B>
<P>Leases</P>
</B>
<P>The Company records a right-of use (&quot;ROU&quot;) asset and a lease liability on its balance sheet for all leases with terms of 12 months or longer. Leases are classified as
either finance or operating, with classification affecting the pattern of expense recognition in the income statement.  Historically, the Company recorded rent expense associated with
its operating lease on a straight-line basis over the term of the lease. The difference between rent payments and straight-line rent expense was recorded as deferred rent in accrued
liabilities. </P>
<B>
</B><P>As of December 31, 2020, the Company's leases had original terms of 12 months or less. The Company does not recognize ROU assets and lease liabilities that arise from
leases with an original term of 12 months or less. Rather the Company recognizes the lease payments on a straight-line basis over the term of the lease.</P>
<B>
<P>Fair Value Measurements</P>
</B>
<P>The Company follows the accounting guidance in the Financial Accounting Standards Board (&quot;FASB&quot;) Accounting Standards Codification (&quot;ASC&quot;) Topic
820, Fair Value Measurements and Disclosures (&quot;ASC 820&quot;), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis.
Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.</P>

<P>The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</P>

<P>Level 1: Quoted prices in active markets for identical assets or liabilities. </P>

<P>Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</P>

<P>Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models,
discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</P>

<P>The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets
and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</P>

<P>The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair
value hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during the years ended December 31, 2020 and 2019 (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)">
<TD WIDTH="40%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="58%" COLSPAN=10 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Fair Value Measurements as of December 31, 2020</B></FONT></TD>
</TR>
<TR VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)">
<TD WIDTH="40%" STYLE="border-bottom: black 1.5pt solid" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Level 1) </B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Level 2) </B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Level 3) </B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 Total </B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1><B>
Assets</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  Cash</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  15,662&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  15,662&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1><B>
Liabilities</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  Warrant liabilities, at fair value</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                    1,062&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                    1,062&nbsp;</FONT></TD>
</TR>
</TABLE>


<P ALIGN="CENTER">                                                                                                   69
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)">
<TD WIDTH="40%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="58%" COLSPAN=10 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Fair Value Measurements as of December 31, 2019</B></FONT></TD>
</TR>
<TR VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)">
<TD WIDTH="40%" STYLE="border-bottom: black 1.5pt solid" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Level 1) </B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Level 2) </B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 (Level 3) </B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
 Total </B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1><B>
Assets</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  Cash</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  10,261&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  10,261&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1><B>
Liabilities</B></FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  Warrant liabilities, at fair value</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                    963&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                    963&nbsp;</FONT></TD>
</TR>
</TABLE>


<P>The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the
fair value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2020 and 2019:</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=75%>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended</B></FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="66%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
December 31, 2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
December 31, 2019</B></FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Risk-free interest rate</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
0.18%</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
1.66%</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Volatility</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
116.77%</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
110.80%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Dividend yield</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
  - %</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
  - %</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Expected term</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
3.07</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
4.07</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Weighted-average fair value</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00"><FONT FACE="Times New Roman" SIZE=-1>
1.40</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00"><FONT FACE="Times New Roman" SIZE=-1>
1.06</FONT></TD>
</TR>
</TABLE>

<P>The following table is a reconciliation for the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=60%>
<TR>
<TD WIDTH="75%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="23%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
Warrant liabilities</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Balance as of December 31, 2018</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                               -  &nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp; Warrant issued in connection with financing</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                               21,535&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp; Warrant liability reclassified to stockholders' equity</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                           (37,073)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp; Change in fair value measurement of warrant liability</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                               16,501&nbsp;</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Balance as of December 31, 2019</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                               963&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp; Warrant liability reclassified to stockholders' equity</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                           (124)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp; Change in fair value measurement of warrant liability</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                                  223&nbsp;</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Balance as of December 31, 2020</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                               1,062&nbsp;</FONT></TD>
</TR>
</TABLE>


<P>Of the inputs used to value the outstanding common stock warrant liabilities as of December 31, 2020 and 2019, the most subjective input is the Company's estimate of
expected volatility of its common stock.</P>

<B><P>Fair Value Option</P>

</B><P>As permitted under ASC Topic 825, Financial Instruments (&quot;ASC 825&quot;), the Company had elected the fair value option to account for its convertible notes. In
accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Statement of Operations. As a result of applying the
fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.  </P>



<P ALIGN="CENTER">                                                                                                   70
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Grant Revenue</P>

</B><P>The Company determined that its grant agreement with Team Sanfilippo Foundation (&quot;TSF&quot;), a nonprofit medical research foundation founded by parents of
children with Sanfilippo syndrome, is within the scope of ASC Topic 606 &quot;Revenue from Contracts with Customers&quot;. Under the TSF agreement, TSF makes certain
milestone payments to the Company as certain milestones related to a specified Phase II/III clinical trial, defined in the agreement, are met. The Company determined that there is
one performance obligation under the TSF agreement. The variable consideration, in the form of milestone payments, is attributed to the completed portion of the performance
obligation that triggers or results in the payments.  During the year ended December 31, 2020 and 2019, the Company recognized $0 and $375,000 of revenue, respectively, from a
milestone payment received as the milestone payment represents the Company's completed portion of its performance obligation.</P>
<B>
<P>Research and Development</P>
</B>
<P>Research and development costs are expensed as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and
related expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development and consulting agreements in
place.</P>
<B>
<P>Income Taxes</P>
</B>
<P>Income taxes are accounted for under the asset and liability method.&nbsp;Deferred income taxes are recorded for temporary differences between financial statement carrying
amounts and the tax basis of assets and liabilities.&nbsp;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are
expected to reverse.&nbsp;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.</P>

<P>The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or
expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.</P>
<B>
<P>Income (Loss) Per Common Share</P>
</B>
<P>Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each
period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result
in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of
shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</P>

<P>The following potentially dilutive securities outstanding for the year ended December 31, 2020 and 2019 have been excluded from the computation of diluted weighted average
shares outstanding, as they would be anti-dilutive (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=75%>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="66%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Outstanding stock options</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
               5,120&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
               522&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Outstanding warrants</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
            10,066&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
            3,584&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Convertible notes</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             8,556&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             - &nbsp;</FONT></TD>
</TR>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
          23,742&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
          4,106&nbsp;</FONT></TD>
</TR>
</TABLE>


<P ALIGN="CENTER">                                                                                                   71
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Stock-Based Compensation</P>

</B><P>The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date
fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line
basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes
option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and
the application of management's judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of
operations based upon the underlying individual's role at the Company.</P>
<B>
<P>Segment Information</P>
</B>
<P>The Company operates under one segment which develops pharmaceutical products. </P>
<B>
<P>Recent Accounting Pronouncements</P>
</B>
<P>In August 2018, the FASB issued Accounting Standards Update (&quot;ASU&quot;) No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the
Disclosure Requirements for Fair Value Measurement (&quot;ASU 2018-13&quot;). The amendments in this ASU require certain existing disclosure requirements in Topic 820 to be
modified or removed, and certain new disclosure requirements to be added to the Topic. In addition, this ASU allows entities to exercise more discretion when considering fair value
measurement disclosures. The Company adopted ASU 2018-13 effective January 1, 2020.  The adoption of ASU 2018-13 did not have a material effect on the Company's financial
statements.</P>

<P>In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&quot;ASU 2019-12&quot;), which is intended
to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends
existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with
early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</P>

<P>In August 2020, the FASB issued ASU 2020-06: Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This standard simplifies the accounting for convertible debt instruments by
removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will
account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities
that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted
method for calculating diluted earnings per share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are
applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020, and an entity should
adopt the provisions at the beginning of its annual fiscal year. The Company is evaluating the impact of ASU 2020-06 on its consolidated financial statements and related
disclosures.</P>

<B><FONT SIZE=2><P>2.  Liquidity and Going Concern</P></B>

<P>The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the
realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and
classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.</P>

<P>The Company has limited revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and
may never become profitable. As of December 31, 2020, the Company had $15.7 million in cash and an accumulated deficit of $75.2 million. The Company has historically funded
its operations through the issuance of convertible notes (see Note 7), the sale of common stock (see Note 4) and the exercise of warrants (see Note 8).</P>







<P ALIGN="CENTER">                                                                                                   72
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year beyond the release date of this Annual Report on Form 10-K.  Based on such evaluation and the Company's current plans, which are subject to change,
management believes that the Company's existing cash and cash equivalents as of December 31, 2020 are not sufficient to satisfy its operating cash needs for at least one
year.</P>

<P>The Company believes it will need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity and/or the completion of a
licensing or other commercial transaction for one or more of the Company's product candidates. If the Company is unable to maintain sufficient financial resources, its business,
financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies
and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company's business operations. There can be no
assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive
effect on the holdings of the Company's existing stockholders.</P>


<B>
<P>3.  Business Combination</P>

</B><P>On January 24, 2019, Apricus completed the business combination with STI in accordance with the terms of the Merger Agreement. </P>

<P>The Merger was accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Apricus were nominal at the close of the Merger. STI was
determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) STI stockholders and other persons holding securities convertible,
exercisable or exchangeable directly or indirectly for STI common stock owned the majority of the Company immediately following the effective time of the Merger, (ii) STI holds the
majority (four of five) of board seats of the combined company, and (iii) STI's management holds all key positions in the management of the combined company.</P>

<P>STI acquired no tangible assets and assumed no employees or operation from Apricus.  Additionally, Apricus' intellectual property was considered to have no value.  The
remaining Apricus liabilities had a fair value of approximately $300 thousand.</P>

<P>In connection with the Merger, STI entered into a Contingent Value Rights Agreement (the &quot;CVR Agreement&quot;). Pursuant to the CVR Agreement, Apricus
stockholders received one contingent value right (&quot;CVR&quot;) for each share of Apricus common stock held of record immediately prior to the closing of the Merger. Each
CVR represents the right to receive payments based on Apricus' U.S. assets related to products in development, intended for the topical treatment of erectile dysfunction, which are
known as Vitaros in certain countries outside of the United States (the &quot;CVR Product Candidate&quot;). In particular, CVR holders will be entitled to receive 90% of any cash
payments (or the fair market value of any non-cash payments) exceeding $500,000 received, during a period of ten years from the closing of the Merger, based on the sale or out-licensing
of Apricus' CVR Product Candidate intangible asset, including any milestone payments (the &quot;Contingent Payments&quot;), less reasonable transaction expenses. STI
is entitled to retain the first $500,000 and 10% of any Contingent Payments. STI assigned no value to the CVR Product Candidate intangible asset as of December 31, 2020 or the
CVR in the acquisition accounting.</P>



<P ALIGN="CENTER">                                                                                                   73
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>4. Common Stock Offerings</P>

<P>Securities Purchase Agreements</P>

</B><I><P>December 2020 Convertible Note and Private Placement</P></I>

<P>In December 2020, the Company issued an aggregate of 1,112,219 shares of common stock in conjunction with the issuance of convertible notes at a discount for aggregate net proceeds
of $10.9 million (see Note 7).</P>
<I>
<P>2020 Registered Direct Offering and Concurrent Private Placement</P>

</I><P>On September 4, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors (the &quot;September 2020 Securities Purchase
Agreement&quot;) pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering, resulting in total net proceeds
of $6.4 million, after deducting the placement agent's fees and other offering expenses. The shares were offered by the Company pursuant to the Company's shelf registration
statement on Form S-3 filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on November 2, 2017, as amended.  The Company also issued to the investors
warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the "September 2020 Warrants"). The September 2020 Warrants have an exercise
price of $0.84 per share of common stock, will be exercisable beginning on March 9, 2021 and will expire on March 9, 2026.</P>

<P>The combined purchase price for one share and one warrant to purchase 0.75 of a share of common stock in the offerings was $0.79. The closing of the offerings occurred on
September 9, 2020.</P>

<I><P>2019 Registered Direct Offering and Concurrent Private Placement</P></I>

<P>On August 23, 2019, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company issued and sold an
aggregate of 4,475,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million, before deducting the placement
agents' fees and other estimated offering expenses. The shares were offered by the Company pursuant to the Company's shelf registration statement on Form S-3 filed with the
SEC on November 2, 2017, as amended.  The Company issued to the investors warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement
(the &quot;August 2019 Warrants&quot;). The August 2019 Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of
issuance and will expire four years following the date of issuance.  The combined purchase price for one share and one warrant to purchase half of a share of common stock in the
offerings was $1.50. Roth Capital Partners, LLC (&quot;Roth&quot;) served as the placement agent for the issuance and sale of the shares and the warrants, and the Company paid
Roth an aggregate fee equal to 7.0% of the gross proceeds received by the Company in the offerings. </P>

<B><P>Public Offerings</P>
</B>
<P>On March 16, 2020, the Company completed an underwritten public offering pursuant to which it sold 7,500,000 shares of its common stock at a price to the public of $0.60 per
share. The net proceeds to the Company from this offering were approximately $4.0 million, after deducting underwriting discounts and commissions and other offering expenses
payable by the Company. </P>

<P>On February 13, 2020, the Company completed an underwritten public offering, pursuant to which it sold 6,666,667 shares of its common stock at a price to the public of $0.75
per share. On February 19, 2020, the Company sold an additional 999,999 shares of its common stock at a price to the public of $0.75 per share pursuant to the full exercise of the
underwriters' option to cover over-allotments. The net proceeds to the Company from this offering were approximately $4.8 million, after deducting underwriting discounts and
commissions and other offering expenses payable by the Company. </P>




<P ALIGN="CENTER">                                                                                                   74
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>Stock Purchase Agreement with Vyera</P></B>

<P>On January 2, 2020, the Company entered into a stock purchase agreement (the &quot;Stock Purchase Agreement&quot;) with Phoenixus AG f/k/a Vyera Pharmaceuticals,
AG and Turing Pharmaceuticals AG (&quot;Vyera&quot;), pursuant to which the Company issued to Vyera 1,809,845 registered shares of the Company's common stock (the
&quot;Shares&quot;). The Company entered into the Stock Purchase Agreement in accordance with an asset purchase agreement with Vyera, as amended by the amendment
entered into with Vyera on October 15, 2019 (see Note 5). As partial consideration for the assets of Vyera, the Company agreed to issue the Shares pursuant to the Stock Purchase
Agreement. </P>

<B><P>Consulting Agreement</P></B>

<P>On May 11, 2020, the Company entered into a consulting agreement (the &quot;Consulting Agreement&quot;) with an advisory firm, pursuant to which the advisory firm agreed
to provide the Company with certain management consulting, business and advisory services. The Company agreed to issue the advisory firm 300,000 unregistered shares of the
Company's common stock, which shares were issued on May 11, 2020, plus $80,000 in cash. On June 9, 2020, the Company and the advisory firm entered into an amendment to
the Consulting Agreement (the &quot;Amendment&quot;). Pursuant to the Amendment, the advisory firm agreed to provide the Company with additional services and, in
consideration, the Company agreed to issue the advisory firm an additional 200,000 unregistered shares of the Company's common stock (the &quot;Additional Shares&quot;), plus
$20,000 in cash. The Additional Shares were issued to the advisory firm on June 9, 2020 and are subject to certain vesting restrictions.  </P>

<P>Through December 31, 2020, the Company has recognized approximately $431,000 of consulting expense under this Consulting Agreement.  On July 9, 2020, the Company
cancelled the Consulting Agreement with an effective date of August 9, 2020.  The Company also canceled 100,000 shares that will not vest due to the cancellation of the Consulting
Agreement.</P>

<B><P>Equity Distribution Agreement</P>
</B>
<P>On June 17, 2019, the Company entered into an Equity Distribution Agreement (the &quot;Equity Distribution Agreement&quot;) with Piper Jaffray &amp; Co., as sales agent
(&quot;Piper Jaffray&quot;), pursuant to which the Company could offer and sell, from time to time, through Piper Jaffray (the &quot;Offering&quot;) up to $50,000,000 in shares.
Under the terms of the Equity Distribution Agreement, Piper Jaffray was entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares under the
Equity Distribution Agreement. During the year ended December 31, 2019, the Company sold 1,197,676 shares for net proceeds of approximately $2.6 million pursuant to the Equity
Distribution Agreement.  On August 23, 2019, the Company suspended its continuous offering under the Equity Distribution Agreement and the Equity Distribution Agreement
terminated in accordance with its terms on December 7, 2020.</P>

<B><P>Pre-Merger Financing</P>
</B>
<P>On January 24, 2019, STI and Apricus closed a private placement transaction with certain accredited investors (the &quot;Investors&quot;), whereby, among other things, STI
issued to investors shares of STI's common stock immediately prior to the Merger in a private placement transaction (the &quot;Financing&quot;), pursuant to a Securities Purchase
Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors, as amended (the &quot;Purchase Agreement&quot;).</P>

<P>Pursuant to the Purchase Agreement, STI (i) issued and sold to the Investors an aggregate of 2,374,672 shares of STIs common stock which converted pursuant to the
exchange ratio in the Merger into the right to receive 1,829,407 shares of the Company's common stock and (ii) issued warrants representing the right to acquire 1,463,519 shares
of common stock at a price per share of $4.15, subject to adjustment as provided therein (the &quot;Series A Warrants&quot;), most recently adjusted to a price per share of
$0.2957 per share, and additional warrants initially representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided
therein (the &quot;Series B Warrants&quot; together with the Series A Warrants, the &quot;Investor Warrants&quot;), for aggregate gross proceeds of $18.0 million, or $16.5 million
net of financing fees.  The terms of the Investor Warrants included certain provisions that could result in adjustments to both the number of warrants issued and the exercise price of
each warrant, which resulted in the warrants being classified as a liability upon issuance (see Note 8). The Investor Warrants were recorded at fair value of $21.5 million upon
issuance and given the liability exceed the proceeds received, a loss of $5.0 million was recognized.</P>


<P ALIGN="CENTER">                                                                                                   75
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>On March 7, 2019, the Company entered into Amendment Agreements (collectively, the &quot;Amendment Agreements&quot;) with each Investor amending: (i) the Purchase
Agreement, (ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate number of shares of common stock
issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised as of March 7, 2019). The terms of the Investor Warrants continue to include
certain provisions that could result in a future adjustment to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the
Amendment Agreements.</P>

<P>At December 31, 2020, 0.8 million Series A Warrants remain unexercised.  All Series B Warrants were exercised during the year ended December 31, 2019.</P>

<B>
<P>5. License Agreements</P>

<P>Acquisition of License from Ligand Pharmaceuticals Incorporated</P>

</B><P>On September 21, 2016, the Company entered into a License Agreement (the &quot;License Agreement&quot;) with Ligand Pharmaceuticals Incorporated
(&quot;Ligand&quot;), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the &quot;Licensors&quot;), pursuant to which, among other things, the Licensors
granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore,
which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without
limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is
now known as SLS-010, and either or both of the Licensors' two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the &quot;Licensed
Products&quot;), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially
reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one
of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a
member of the European Union, Japan or the People's Republic of China (each, a &quot;Major Market&quot;) or the United States, and (c) commercialize the Licensed Products in
each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any
Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed
Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.</P>

<P>In connection with the closing of the Merger, the Company issued 801,253 shares of common stock to Ligand and recognized research and development expense totaling
approximately $2.2 million during the three months ended March 31, 2019 for the License Agreement.  </P>


<P ALIGN="CENTER">                                                                                                   76
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<P>The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection
with Aplindore for the indication of Parkinson's Disease (&quot;PD&quot;) or Restless Leg Syndrome, consisting of (i) $750,000 upon submission of an application with the FDA or
equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA approval of an application for a particular Licensed Product, (iii) $1.125 million upon regulatory
approval in a Major Market for a particular Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major Market for a particular Licensed Product.</P>

<P>The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products in connection with
Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon submission of an application with the FDA or equivalent foreign body for such a
particular Licensed Product, (ii) $350,000 upon FDA approval of an application for such a particular Licensed Product, (iii) $125,000 upon regulatory approval in a Major Market for
such a particular Licensed Product, and (iv) $125,000 upon regulatory approval in a second Major Market for such a particular Licensed Product.</P>

<P>The Company agreed to pay to Ligand certain one-time, non-refundable commercial milestone payments in connection with the Licensed Products, consisting of (i) $10.0 million
upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (ii) $10.0 million upon the achievement of $1.0 billion of
cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales
of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without
limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), (iv) $10.0 million upon the achievement of $1.0 billion of cumulative
worldwide net sales of Licensed Products based upon CRTh2 antagonists, (v) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed
Products based upon Aplindore, (vi) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor
antagonist, (vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may
be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of
which is acetaminophen), and (viii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists.</P>

<P>The Company will also pay to Ligand middle single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication
of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty in the upper single digit to lower
double digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such
Licensed Products are covered under a licensed patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed Products
other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent and a
tiered incremental royalty in the lower single digit to middle single digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of
PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent.</P>

<P>The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</P>

<P ALIGN="CENTER">                                                                                                   77
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<P>Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (&quot;Vyera&quot;)</P>
</B>
<P>On March 6, 2018, the Company entered into an asset purchase agreement with Vyera, pursuant to which the Company acquired the assets (the &quot;Vyera Assets&quot;)
and liabilities (the &quot;Vyera Assumed Liabilities&quot;) of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The Company is obligated to use
commercially reasonable efforts to seek regulatory approval in the United States for and commercialize SLS-002. </P>

<P>As consideration for the Vyera Assets, the Company paid to Vyera a non-refundable cash payment of $150,000 on May 21, 2018. As further consideration for the Vyera Assets,
upon public announcement of the entry by Apricus and STI into the Merger Agreement, the Company paid to Vyera a non-refundable cash payment of $150,000.  As further
consideration for the Vyera Assets, the Company issued to Vyera 191,529 shares of common stock and paid Vyera a non-refundable cash payment of $1,000,000 on January 29,
2019.  </P>

<P>Pursuant to the amendment to the asset purchase agreement entered into by the Company and Vyera on October 15, 2019, the Company issued Vyera 1,809,845 registered
shares of the Company's common stock on January 2, 2020 and made cash payments to Vyera in the amounts of $750,000, $750,000, $1.0 million and $1.0 million in October
2019, January 2020, April 2020 and July 2020, respectively.</P>

<P>In the event that the Company sells, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company must pay Vyera an amount equal to 4% of
the net proceeds actually received by the Company as an upfront payment in such sale.</P>

<P>The Company agreed to pay to Vyera certain one-time, non-refundable milestone payments consisting of (i) $10.0 million upon approval by the FDA of a new drug application
(an &quot;NDA&quot;), with respect to SLS-002, (ii) $5.0 million upon approval by the European Medicines Agency (the &quot;EMA&quot;) of the foreign equivalent to an NDA with
respect to SLS-002 in a Major Market, (iii) $2.5 million upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002 in a second Major Market, (iv) $5.0
million upon the achievement of $250.0 million in net sales of SLS-002, (v) $10.0 million upon the achievement of $500.0 million in net sales of SLS-002, (vi) $15.0 million upon the
achievement of $1.0 billion in net sales of SLS-002, (vii) $20.0 million upon the achievement of $1.5 billion in net sales of SLS-002, and (viii) $25.0 million upon the achievement of
$2.0 billion in net sales of SLS-002. The Company will also pay to Vyera a royalty percentage in the mid-single digits on aggregate annual net sales of SLS-002.</P>

<P>The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</P>

<B><P>Acquisition of License from Stuart Weg, MD</P>
</B>
<P>On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &quot;Weg License Agreement&quot;),
pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002.  Under the terms of the Weg
License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement.  The Company agreed to pay additional consideration to Dr. Weg as
follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any
dosage on or before December 31, 2021, $0.2 million on January 2, 2022.  The Company paid the required $0.1 million on January 2, 2020 and $0.125 million on January 2, 2021.
As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by
the closing sales price of the Company's common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and
unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or
equivalent seeking regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the
EU, for such product (the &quot;Milestone Product&quot;), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0

<P ALIGN="CENTER">                                                                                                   78
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
million upon regulatory approval by the
EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the
Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr. Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in
any dosage.</P>

<P>The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</P>

<B><P>Acquisition of Assets from Bioblast Pharma Ltd. (&quot;Bioblast&quot;)</P>
</B>
<P>On February 15, 2019, the Company entered into an Asset Purchase Agreement (the &quot;Bioblast Asset Purchase Agreement&quot;) with Bioblast. Pursuant to the Bioblast
Asset Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the &quot;Bioblast Asset Purchase&quot;).
The Company paid to Bioblast $1.5 million in cash, and the Company paid to Bioblast an additional $2.0 million in February 2020. Accordingly, the Company recognized a $3.5
million charge to research and development expense during the year ended December 31, 2019.  Under the terms of the Bioblast Asset Purchase Agreement, the Company agreed
to pay additional consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (i) within 15 days following the completion of the Company's first
Phase II(b) clinical trial of Trehalose satisfying certain criteria, the Company will pay to Bioblast $8.5 million; and (ii) within 15 days following the approval for commercialization by
the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates, the
Company will pay to Bioblast $8.5 million. In addition, the Company agreed to pay Bioblast a cash royalty equal to 1% of the net sales of Trehalose. Under the terms of the Bioblast
Asset Purchase, the Company assumed a collaborative agreement with TSF, a nonprofit medical research foundation founded by parents of children with Sanfilippo syndrome. TSF,
upon approval by the FDA, planned to begin an open label, Phase II(b) clinical trial in up to 20 patients with Sanfilippo syndrome, which is now known under the study name SLS-005.
The Company will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement entitle the Company access to all clinical data from this trial.
On July 15, 2019, TSF and the Company amended the agreement whereby the Company agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to
provide a grant of up to $1.5 million towards the funding of the trial.</P>

<P>The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</P>

<B><P>Acquisition of License from The Regents of the University of California</P>
</B>
<P>On March 7, 2019, the Company entered into an exclusive license agreement (the &quot;UC Regents License Agreement&quot;) with The Regents of the University of California
(&quot;The UC Regents&quot;) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that
was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed
peptide inhibitors that target the aggregation of alpha-synuclein (&#945;-synuclein). The Company plans to study this initial approach in PD and will further
evaluate the potential clinical approach in other disorders affecting the central nervous</FONT><FONT SIZE=2> system (&quot;CNS&quot;).  This program is now known as SLS-007.
Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development
expense during the year ended December 31, 2019.  Under the terms of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the
achievement of certain milestones in the future, as follows: (i) within 90 days following the completion of dosing of the first patient in a Phase I clinical trial, the Company will pay
$50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a
Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., the Company will pay $1.0 million; (v) within 90 days
following the first commercial sales in any European market, the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a
licensed product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any.  In addition, if the Company fails to
achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce the Company's license to a nonexclusive license. </P>

<P ALIGN="CENTER">                                                                                                   79
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</P>

<B><P>Acquisition of License from Duke University</P>
</B>
<P>On June 27, 2019, the Company entered into an exclusive license agreement (the &quot;Duke License Agreement&quot;) with Duke University pursuant to which the Company
was granted an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression.  The Company plans to study
this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS.  This program is now known as SLS-004.   Upon entry into the
Duke License Agreement, the Company paid to Duke University $0.1 million and recognized $0.1 million charge to research and development expense during the year ended
December 31, 2019.  The Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days
following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company will pay $0.1 million; (ii) within 30 days
following dosing of the first patient in a Phase I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the
Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $1.0 million; and (v) within 30 days following an
NDA approval, the Company will pay $2.0 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any.  In addition, if the Company fails to
achieve certain milestones within a specified timeframe, Duke University may terminate the agreement. </P>

<P>The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</P>

<B><P>6. Accrued Expenses</P></B>

<P>Accrued expenses are comprised of the following (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=75%>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="72%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Professional fees</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  292&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  151&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Personnel related</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  756&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  683&nbsp;</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Outside research and development services</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      764&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                      853&nbsp;</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Other</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                     112&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                     232&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses, net</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  1,924&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  1,919&nbsp;</FONT></TD>
</TR>
</TABLE>

<B><P>7. Debt</P>

<P>Convertible Notes</P>

</B><I><P>December 2020 Convertible Note and Private Placement</P></I>

<P>On December 11, 2020, the Company entered into a Securities Purchase Agreement (the &quot;Lind Securities Purchase Agreement&quot;) with Lind Global Asset
Management II, LLC (the &quot;Investor&quot;) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement
transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the &quot;Note&quot;) in an aggregate principal amount of $12,000,000
(the &quot;Principal Amount&quot;), which will bear no interest and mature on December 11, 2022 (the &quot;Maturity Date&quot;), and (2) 975,000 shares of the Company's
common stock.  At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor shall have the option to convert any portion of the then-outstanding
Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar
transactions (the &quot;Conversion Price&quot;). Prior to June 11, 2021, the Company will have the right to prepay up to sixty-six and two-thirds percent (66<SUP>2/3</SUP>%) of
the then-outstanding Principal Amount of the Note with no penalty. On or after July 11, 2021, the Company will have the right to prepay up to the then-outstanding Principal Amount
of the Note with no penalty; however, if the Company exercises such prepayment right, the Investor will have the option to convert up to thirty-three and one-third percent
(33<SUP>1/3</SUP>%) of the amount that the Company elects to prepay at the Conversion Price. Subject to certain exceptions, the Company will be required to direct proceeds
from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease

<P ALIGN="CENTER">                                                                                                   80
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
obligations or other indebtedness incurred in the ordinary course of business) to repay the Note, unless waived by the Investor in advance.  Beginning on June 9, 2021, the Note will
amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the Note, divided by (ii) the number of months remaining until the
Maturity Date. All amortization payments shall be payable solely in cash, plus a 2% premium.</P>

<P>On December 17, 2020, the Company entered into three separate securities purchase agreements
with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the &quot;December 17 SPAs&quot;),
pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of
an aggregate of $1,138,023, (1)convertible promissory notes (the &quot;December 17 Notes&quot;) in an aggregate principal amount of $1,365,628, which will bear no interest and
mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase
agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the &quot;December 18 SPA&quot;) and, together with the
December 17 SPAs, (the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by
the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which will bear no interest and mature on December 18, 2022
(the &quot;December 18 Note&quot; and, together with the December 17 Notes, the &quot;Subsequent Notes&quot;),
and (2)
26,263 shares of the Company's common stock. The Subsequent Securities Purchase Agreements have substantially the same terms as the Lind Securities Purchase Agreement,
and the Subsequent Notes have substantially the same terms as the Note. </P>

<P>The Company received aggregate net proceeds of $10.9 million from the convertible note offerings, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the
convertible notes and common stock issued under the agreements based on their relative fair values. The Company recognized a beneficial conversion feature discount on the convertible notes of
approximately $0.1 million.</P>

<P>The discount on the convertible notes is being amortized to interest expense, using the effective interest method over the term of the convertible notes. As of December 31,
2020, the principal balance of the convertible notes outstanding and the unamortized discount on the convertible notes is approximately $13.7 million and $4.1 million, respectively.
Interest expense recognized related to the discount was approximately $0.2 million for the year ended December 31, 2020.  </P>

<I><P>Convertible Notes</P></I>

<P>From May 2017 to October 2018, the Company issued convertible notes (the &quot;Convertible Notes&quot;). The aggregate principal amount of the Convertible Notes was
$2.3 million, and the Convertible Notes were due no later than April 30, 2019 with simple interest at the rate of 8% per annum.  The Convertible Notes provided that they were to
convert at a discount of 10% or 20% depending on the terms for each note, or $9.70 to $10.91 per share, respectively.</P>

<P>The Convertible Notes were carried at fair value.  The Company recognized an adjustment relating to changes in the Convertible Notes fair value of $0 and $109 thousand
during the year ended December 31, 2020 and 2019, respectively.</P>

<P>In connection with the closing of the Merger, the Convertible Notes plus unpaid interest were converted into 172,284 shares of common stock at a price of $9.70 or $10.91 per
share.</P>

<I><P>PPP Loan</P></I>

<P>On May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business
Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the &quot;PPP Lender&quot;), for an aggregate principal amount of
approximately $147,000 (the &quot;PPP Loan&quot;). The PPP Loan bears interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, has a term of two
years, and is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection
Program upon the Company's request to the extent that the PPP Loan proceeds are used to pay expenses permitted by the Paycheck Protection Program, including payroll costs,
covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company intends to apply for forgiveness of the PPP Loan with respect to these
covered expenses. To the extent that all or part of the PPP Loan is not forgiven, the Company will be required to pay interest on the PPP Loan at a rate of 1.0% per annum, and
commencing in the fourth quarter of 2020, principal
and interest payments will be required through the maturity date in May 2022. The terms of the PPP Loan provide for customary
events of default including, among other things, payment defaults, breach of representations and warranties and insolvency events. The obligation to repay the PPP Loan may be
accelerated upon the occurrence of an event of default.</P>


<P ALIGN="CENTER">                                                                                                   81
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P>8. Stockholders' Equity</P>

<P>Preferred Stock</P>
</B>
<P>The Company is authorized to issue 10,000,000 shares of preferred stock, par value $0.001.  No shares of preferred stock were outstanding as of December 31, 2020 or
2019.</P>

<B><P>Common Stock</P>
</B>
<P>The Company has authorized 120,000,000 shares of common stock as of December 31, 2020 and 2019.  Each share of common stock is entitled to one voting right.  Common
stock owners are entitled to dividends when funds are legally available and declared by the Board of Directors.</P>

<B><P>Warrants</P>
</B>
<I><P>September 2020 Warrants</P>
</I>
<P>The September 2020 Warrants are exercisable for 6,648,750 shares of common stock at an exercise price per share equal to $0.84.  The September 2020 Warrants are
exercisable beginning six months after the date of issuance and have a term of five and a half years from the date of issuance.</P>

<P>As of December 31, 2020, 6.6 million September 2020 Warrants remain outstanding at an exercise price of $0.84 per share.</P>

<I><P>August 2019 Warrants</P>
</I>
<P>The August 2019 Warrants are exercisable for 2,237,500 shares of common stock at an exercise price per share equal to $1.78.  The August 2019 Warrants are exercisable
beginning six months after the date of issuance and have a term of four years from the date of issuance.</P>

<P>As of December 31, 2020, 2.2 million August 2019 Warrants remain outstanding at an exercise price of $1.78 per share.</P>

<I><P>Series A Warrants</P>
</I>
<P>The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant
to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to
$0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the offerings pursuant to the September 2020 Securities
Purchase Agreement. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024.</P>

<P>During the year ended December 31, 2020 and 2019, 0.2 million and 2.7 million Series A Warrants were exercised for approximately $45 thousand and $4.5 million,
respectively.  As of December 31, 2020, 0.8 million Series A Warrants remain outstanding at an exercise price of $0.2957 per share.</P>

<P ALIGN="CENTER">                                                                                                   82
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<I>
<P>Series B Warrants</P>
</I>
<P>The Series B Warrants were initially exercisable for no shares of common stock, which was adjusted to 7,951,090 shares of common stock on February 27, 2019 and which was
further adjusted to 11,614,483 shares of common stock on March 7, 2019, in each case essentially due to trading at a lower price, pursuant to the terms thereof. The Series B
Warrants had an exercise price of $0.001, were immediately exercisable upon issuance and provided for an expiration date of the day following the later to occur of (i) the
Reservation Date (as defined therein), and (ii) the date on which the Series B Warrants have been exercised in full (without giving effect to any limitation on exercise contained
therein) and no shares remain issuable thereunder.</P>

<P>During the year ended December 31, 2019, 11.6 million Series B Warrants were exercised for approximately $11,614.  As of December 31, 2019, no Series B Warrants remain
outstanding and the Series B Warrants are therefore no longer subject to any further changes in warrants or exercise price.</P>

<P>A summary of warrant activity during the year ended December 31, 2020 is as follows (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=85%>
<TR VALIGN="TOP">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Weighted</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Weighted</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Average</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Average</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Remaining</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Exercise</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Contractual Life</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="right" WIDTH="50%" VALIGN="TOP"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
Warrants</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="TOP"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="13%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
Price</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="19%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
(in years)
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Outstanding at December 31, 2018</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                  -  &nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                       -  &nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Assumed in Merger</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                437&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
             20.59&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     3.5&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Issued</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
           17,481&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               0.42&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     4.1&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Exercised</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
         (14,334)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               0.31&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Outstanding as of December 31, 2019</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             3,584&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               3.86&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     3.3&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Issued</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
              6,648&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               0.84&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     &nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Exercised</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
         (154)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               0.30&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Cancelled</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
         (12)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               18.00&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Outstanding as of December 31, 2020</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             10,066&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               1.84&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     4.4&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Exercisable as of December 31, 2020</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
             3,417&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
               3.79&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                     2.7&nbsp;</FONT></TD>
</TR>
</TABLE>


<P>The Series A Warrants and the Series B Warrants were each recognized as a liability at their fair value upon issuance.  The warrant liability is remeasured to the then fair value
prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the period.  </P>

<B><P>9.  Stock-Based Compensation</P>

</B><P>The Company has the Amended and Restated Apricus 2012 Stock Long Term Incentive Plan (the &quot;2012 Plan&quot;), which provides for the issuance of incentive and
non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over
a period of one to four years and have a maximum term of ten years from the date of grant. As of December 31, 2020, an aggregate of 8,038,582 shares of common stock were
authorized under the Apricus 2012 Plan, of which 3.2 million shares of common stock were available for future grants. Upon completion of the Merger, the Company assumed the
Seelos Therapeutics, Inc. 2016 Equity Incentive Plan (the &quot;2016 Plan&quot;) and awards outstanding under the 2016 Plan became awards for common stock. Effective as of
the Merger, no further awards may be issued under the 2016 Plan. </P>

<P>On May 15, 2020, the Company's stockholders approved the Company's 2020 Employee Stock Purchase Plan (the &quot;ESPP&quot;), whereby qualified employees are
allowed to purchase limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have
authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added
annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which
amount shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31, and (ii) a
number of shares of common stock set by the Company's Board of Directors or the Compensation Committee of the Board of Directors (the &quot;Compensation Committee&quot;)
of the Company on or prior to each such January 1.  The Company did not sell any shares under the ESPP during the year ended December 31, 2020. The compensation costs are
calculated as the fair value of the 15% discount from market price and were approximately $13,000 for the year ended December 31, 2020.</P>

<P ALIGN="CENTER">                                                                                                   83
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>On July 28, 2019, the Compensation Committee adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &quot;2019 Inducement Plan&quot;), which became effective
on August 12, 2019. The 2019 Inducement Plan is substantially similar to the 2016 Plan.  The 2019 Inducement Plan provides for the grant of equity-based awards in the form of
stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective
employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a
material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired
following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the
Company's common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.</P>

<I><P>Stock options</P>
</I>
<P>During the year ended December 31, 2020, the Company granted 4,444,895 stock options to employees with a weighted average exercise price per share of $1.16 and a 10-year term,
subject to the terms and conditions of the 2012 Plan above.  The stock options are subject to time vesting requirements. The stock options granted to employees vest
25% on the first anniversary of the grant and monthly thereafter over the next three years.</P>

<P>During the year ended December 31, 2020, the Company also granted 179,000 non-qualified stock options to non-employee directors and a consultant with a weighted average
exercise price per share of $1.15 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. 24,000 of the stock options granted to non-employee directors vest
1/3rd on the first anniversary of the grant and monthly thereafter over the next two years. 80,000 of the stock options granted to non-employee directors vest monthly over the 12
months following the grant.  75,000 of the stock options granted to a consultant vest 25% on the first anniversary of the grant and monthly thereafter over the next 3 years.</P>

<P>The fair value of stock option grants are estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically
a private company and lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical
volatility of a publicly traded set of peer companies. Additionally, due to an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term
assumption for employee grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free
interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is
zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</P>

<P>During the year ended December 31, 2020, no stock options were exercised and 26,001 options were forfeited.</P>

<P>The following assumptions were used in determining the fair value of the stock options granted during the years ended December 31, 2020 and 2019:</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=75%>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended</B></FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="66%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
December 31, 2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="15%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
December 31, 2019</B></FONT></TD>
</TR>
<TR>
<TD BGCOLOR=#FFFFFF ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Risk-free interest rate</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
0.3%-1.7%</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
1.6%-2.6%</FONT></TD>
</TR>
<TR>
<TD BGCOLOR=#FFFFFF ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Volatility</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
109%-119%</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
109%-113%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Dividend yield</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
  - %</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00%"><FONT FACE="Times New Roman" SIZE=-1>
  - %</FONT></TD>
</TR>
<TR>
<TD BGCOLOR=#FFFFFF ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
Expected term (years)</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:d-mmm"><FONT FACE="Times New Roman" SIZE=-1>
5-7</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman">
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:d-mmm"><FONT FACE="Times New Roman" SIZE=-1>
5-7</FONT></TD>
</TR>
<TR VALIGN="top">
<TD BGCOLOR=#FFFFFF ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Weighted-average fair value</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00"><FONT FACE="Times New Roman" SIZE=-1>
0.97</FONT></TD>
<TD BGCOLOR=#FFFFFF ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:0.00"><FONT FACE="Times New Roman" SIZE=-1>
1.76</FONT></TD>
</TR>
</TABLE>


<P ALIGN="CENTER">                                                                                                   84
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>A summary of stock option activity during the year ended December 31, 2020 is as follows (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=98%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Weighted</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Weighted</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Total</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Average</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Average Remaining</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Aggregate</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Stock</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Exercise</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Contractual</B></FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Intrinsic</B></FONT></TD>
</TR>
<TR>
<TD WIDTH="42%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="11%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
Options</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="11%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
Price</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="19%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
Life (in years)</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="11%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
Value</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Outstanding as of December 31, 2019</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                522&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                     9.18&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          9.0&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                      21&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Granted</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                4,624&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                   1.16&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          9.3&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Exercised</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                 -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                    -  &nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Cancelled</FONT></TD>
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      (26)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.00_)[semicolon]_(* (#,##0.00)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                    1.96&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                            -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    &nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Outstanding as of December 31, 2020</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                5,120&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     1.97&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          9.2&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      1,969&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Vested and expected to vest as of December 31, 2020</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                 353&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    12.45&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          7.4&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      42&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Exercisable as of December 31, 2020</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                 353&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    12.45&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:_(* #,##0.0_)[semicolon]_(* (#,##0.0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
                          7.4&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      42&nbsp;</FONT></TD>
</TR>
</TABLE>


<P>The Company recorded $2.0 million and $459,000 in stock-based compensation expense for the years ended December 31, 2020 and 2019, respectively.</P>

<P>The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company's consolidated statements of
operations (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=90%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="72%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Research and development</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  394&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  118&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
General and administrative</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  1,650&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  341&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  2,044&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                   459&nbsp;</FONT></TD>
</TR>
</TABLE>

<B><P>10.  Income Taxes</P></B>

<P>The Company has incurred net operating losses since inception. At December 31, 2020, the Company has available net operating loss carryforwards
of approximately $46.9 million for federal income tax reporting purposes and approximately $90.6 million for state income tax reporting purposes.</P>

<P>Deferred tax assets consist of the following (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=90%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="72%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Net operating tax loss carryforwards</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                15,223&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                5,632&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Accrued expenses</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    66&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  348&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Stock-based compensation</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    521&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    84&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Start up cost</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  12,320&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                  4,806&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Total deferred tax asset</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
               28,130&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
               10,870&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Less valuation allowance</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
            (28,130)</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
            (10,870)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Net deferred tax asset</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     -  &nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                       -  &nbsp;</FONT></TD>
</TR>
</TABLE>

<P>The federal and state net operating loss carryforwards, not subject to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset
as of December 31, 2020 and 2019 of approximately $15.2 million and $5.6 million, respectively.&nbsp;In consideration of the Company's accumulated losses and the
uncertainty of its ability to utilize this deferred tax asset in the future, the Company has recorded a full valuation allowance as of such dates.</P>

<P>The Company follows&nbsp;the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or
expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is
more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a
probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company's federal income
tax returns for 2017 to 2020 are still open and subject to audit.&nbsp;In addition, net operating losses arising from prior years are also subject to examination at the time they are
utilized in future years.&nbsp;Unrecognized tax benefits, if recognized, would have no effect on the Company's effective tax rate. The Company's policy is to recognize interest and
penalties related to income tax matters in income tax expense. For the years ended December 31, 2020 and 2019, the Company has not recorded any interest or penalties
related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months.</P>


<P ALIGN="CENTER">                                                                                                   85
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>A reconciliation of the Company's unrecognized tax benefits for the years ended December 31, 2020 and 2019, are as follows (in thousands):</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=90%>
<TR VALIGN="top">
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD WIDTH="72%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Beginning balance</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  718&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Change in current period positions</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;      Change in prior period positions</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                     -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
                     (718)</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Ending balance</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    -&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1>
$</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                    -&nbsp;</FONT></TD>
</TR>
</TABLE>

<P>The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended
December 31, 2020 and 2019, are as follows:</P>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=90%>
<TR>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top" STYLE="vnd.ms-excel.numberformat:_(* #,##0_)[semicolon]_(* (#,##0)[semicolon]_(* [dquote]-[dquote]??_)[semicolon]_(@_)"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" COLSPAN=4 ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
Year Ended December 31,</B></FONT></TD>
<TD ALIGN="center" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1><B>
&nbsp;</B></FONT></TD>
</TR>
<TR>
<TD WIDTH="71%" ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2020</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="12%" ALIGN="center" STYLE="vnd.ms-excel.numberformat:@"><FONT FACE="Times New Roman" SIZE=-1><B>
2019</B></FONT></TD>
<TD WIDTH="1%" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Federal statutory tax rate</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      21.0&nbsp;</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      21.0&nbsp;</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
State and local taxes, net of federal benefit</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      11.2&nbsp;</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                      6.7&nbsp;</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Permanent items</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (1.0)</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (9.0)</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Deferred rate changes</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     0.1&nbsp;</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     -  &nbsp;</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Other</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     59.3&nbsp;</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                  (0.3)</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
</TR>
<TR VALIGN="top">
<TD ALIGN="left"><FONT FACE="Times New Roman" SIZE=-1>
Change in valuation allowance</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     (90.6)</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
<TD ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" ALIGN="right"><FONT FACE="Times New Roman" SIZE=-1>
                     (18.4)</FONT></TD>
<TD ALIGN="left" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
</TR>
<TR>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
 &nbsp;&nbsp;&nbsp;&nbsp;  Income tax provision (benefit)</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
                     -  &nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
<TD ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 2.25pt double" ALIGN="right" VALIGN="top"><FONT FACE="Times New Roman" SIZE=-1>
                       -  &nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top" STYLE="vnd.ms-excel.numberformat:0%"><FONT FACE="Times New Roman" SIZE=-1>
%</FONT></TD>
</TR>
</TABLE>

<B><P>11.</B> <B>Commitments and Contingencies</P></B>

<I><P>Leases</P>
</I>
<P>In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019
the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this
rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month.</P>

<P>For the years ended December 31, 2020 and 2019, rent expense totaled $0.1 million and $0.1 million, respectively.</P>

<P>Future minimum rental payments under operating lease as of December 31, 2020 are approximately $42,000 for 2021.</P>

<I><P>Contractual Commitments</P>
</I>
<P>The Company has entered into long-term agreements with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company
expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term
commitments of cash.</P>

<B><P>Litigation</P>
</B>
<P>As of December 31, 2020, there was no material litigation against the Company.</P>

<B><P>12. Subsequent Events</P></B>

<B><P>Public Offering</P>
</B>
<P>On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the
public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the
Company from the offering were approximately $33.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the
Company.  The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.  </P>

<P ALIGN="CENTER">                                                                                                   86
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B>
<P>Amendment of Asset Purchase Agreement with Vyera</P>
</B>
<P>On February 15, 2021 the Company entered into an amendment to the asset purchase agreement with Vyera.  Pursuant to the amendment, the Company agreed to make cash
payments to Vyera in the amount of $3.0 million in each of February 2021, June 2021 and September 2021 in exchange for a lower royalty percentage on potential net sales of SLS-002.</P>


<B><P><A NAME="item9">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</A></P></B>

<P>None.</P>

<B><P><A NAME="item9a">ITEM 9A.</B> <B>CONTROLS AND PROCEDURES</P></A></B>

<B><I><P>Evaluation of Disclosure Controls and Procedures</P></I></B>

<P>Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is
recorded, communicated to our management to allow timely decisions regarding required disclosure, summarized and reported within the time periods specified in the SEC's rules
and forms.</P>

<P>Under the supervision and with the participation of our management, including the Chief Executive Officer (&quot;CEO&quot;), who serves as the principal executive officer and
the principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-
15(e) under the Exchange Act, as of December 31, 2020. Based on this evaluation, our CEO concluded that our disclosure controls and procedures were effective as of
December 31, 2020. </P>

<B><I><P>Management's Report on Internal Control Over Financial Reporting</P>
</I></B>
<P>Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a 15(f). Our
internal control over financial reporting is a process designed, under the supervision and, with the participation of our CEO who serves as our principal executive officer and principal
financial officer, overseen by our Board of Directors and implemented by our management and other personnel, to provide reasonable assurance regarding the reliability of our
financial reporting and the preparation of our financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over
financial reporting includes policies and procedures that:</P>


<UL>
<LI>Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</LI>
<LI>Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</LI>
<LI>Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our
financial statements.</LI></UL>


<P>Because of our inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to
future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate. Management performed an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2020 using criteria established in
the&nbsp;<I>Internal Control-Integrated Framework (2013)</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission (&quot;COSO&quot;).
Based on this assessment, management determined that, as of December 31, 2020, our internal control over financial reporting was effective. Because we are a smaller reporting company,

<P ALIGN="CENTER">                                                                                                   87
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>
KPMG, an independent registered public accounting firm, is not required to attest to or issue a report on the effectiveness of our internal control over financial
reporting.</P>

<B><I><P>Inherent Limitations on Effectiveness of Controls</P>

</I></B><P>A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&nbsp;Accordingly, our disclosure controls and procedures are
designed to provide reasonable, not absolute, assurance that the objectives of our disclosure system are met. Also, projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</P>

<B><I>
<P>Changes in Internal Control over Financial Reporting</P>
</I></B>
<P>Effective September 1, 2020, we implemented a new accounting software which enhanced our internal control structure over financial reporting during the year ended December 31, 2020.  </P>

<B><P><A NAME="item9b">ITEM 9B.&#9;OTHER INFORMATION </A></P></B>

<P>None</P>

<B><P>PART III. </P>
</B>

<B><P><A NAME="item10">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></P></B>

<P>The information required by this item is incorporated by reference from the information contained in our Definitive Proxy Statement to be filed with the SEC within 120 days
after the end of the fiscal year ended December 31, 2020 in connection with the  Annual Meeting of Stockholders to be held in 2021 (the &quot;2021 Proxy Statement&quot;).  To
the extent that we do not file the 2021 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this
Item 10.</P>

<P>We have adopted a Code of Ethics for Officers (the &quot;Code of Ethics&quot;) that is available at the Investors/Media/Corporate Governance Documents section of our
website at www.seelostherapeutics.com.  </P>

<B><P><A NAME="item11">ITEM 11. EXECUTIVE COMPENSATION</A></P></B>

<P>The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement. The 2021 Proxy Statement will be filed within
120 days after the end of the fiscal year ended December 31, 2020. To the extent that we do not file the 2021 Proxy Statement by such date, we will file an amendment to this
Annual Report on Form 10-K that includes the information required by this Item 11.  </P>

<B><P><A NAME="item12">ITEM 12.&nbsp;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</A></P></B>

<P>The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement. The 2021 Proxy Statement will be filed within 120
days after the end of the fiscal year ended December 31, 2020. To the extent that we do not file the 2021 Proxy Statement by such date, we will file an amendment to this Annual
Report on Form 10-K that includes the information required by this Item 12. </P>


<P ALIGN="CENTER">                                                                                                   88
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<B><P><A NAME="item13">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</P></B>

<P>The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement. The 2021 Proxy Statement will be filed within
120 days after the end of the fiscal year ended December 31, 2020. To the extent that we do not file the 2021 Proxy Statement by such date, we will file an amendment to this
Annual Report on Form 10-K that includes the information required by this Item 13.</P>


<B><P><A NAME="item14">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</A></P></B>

<P>The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement. The 2021 Proxy Statement will be filed within 120
days after the end of the fiscal year ended December 31, 2020. To the extent that we do not file the 2021 Proxy Statement by such date, we will file an amendment to this Annual
Report on Form 10-K that includes the information required by this Item 14.</P>

<B><P>PART IV. </P></B>


<B><P><A NAME="item15">ITEM 15.  EXHIBITS</A></P> </B>

<P>(a) 1. <U>Financial Statements:</P></U>

<DIR>

<P>The information required by this item is included in Item 8 of Part II of this Form 10-K.</P>

</DIR>

<P>&nbsp;&nbsp;&nbsp;&nbsp; 2. Financial Statement Schedules</P>

<DIR>

<P>The information required by this item is included in Item 8 of Part II of this Form 10-K.</P>

</DIR>

<P><P>&nbsp;&nbsp;&nbsp;&nbsp; 3. Exhibits</P>

<DIR>

<P>The following exhibits are incorporated by reference or filed as part of this report:</P>

</DIR>

<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="6%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P>EXHIBITS<BR>
NO.</B></FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="94%" VALIGN="BOTTOM">
<B><FONT SIZE=1><P>&nbsp; DESCRIPTION</B></FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000069/exhibit21agreementandplano.htm">2.1</A>+</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Agreement and Plan of Merger and Reorganization, dated July 30, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc.
(incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex21to8-kon10x16x18.htm">2.2</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment No. 1 Agreement and Plan of Merger and Reorganization, dated October 16, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos
Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17,
2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312518349990/d602430dex21.htm">2.3</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment No. 2 Agreement and Plan of Merger and Reorganization, dated December 14, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos
Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 14,
2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001204/ex2_1.htm">2.4</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment No. 3 Agreement and Plan of Merger and Reorganization, dated January 16, 2019, by and among the Company, Arch Merger Sub, Inc. and Seelos
Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16,
2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000068/exh2-1.htm">2.5</A>+</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Asset Purchase Agreement, dated February 15, 2019, by and between the Company and Bioblast Pharma Ltd. (incorporated herein by reference to Exhibit 2.1 to the
Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 19, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/0001005477-97-000778.txt">3.1</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amended and Restated Articles of Incorporation of the Company (incorporated herein by reference to Exhibit 2.1 to the Company's Registration Statement on Form 10-
SB filed with the Securities and Exchange Commission on March 14, 1997).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">                                                                                                   89
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000095013603000741/file002.txt">3.2</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment to Articles of Incorporation of the Company, dated June 22, 2000 (incorporated herein by reference to Exhibit 3.2 to the Company's Annual
Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420406010273/v037542_ex3-4.htm">3.3</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment to Articles of Incorporation of the Company, dated June 14, 2005 (incorporated herein by reference to Exhibit 3.4 to the Company's Annual
Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2006).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-6.htm">3.4</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.6 to
the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-7.htm">3.5</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Correction to Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by
reference to Exhibit 3.7 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420411016743/v215636_ex3-1.htm">3.6</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Designation for Series D Junior-Participating Cumulative Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report
on Form 8-A filed with the Securities and Exchange Commission on March 24, 2011).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420410034002/v188471_ex3-1.htm">3.7</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with
the Securities and Exchange Commission on June 17, 2010).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420410048909/v196361_ex3-1.htm">3.8</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated September 10, 2010 (incorporated herein by reference to Exhibit 3.1
to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2010).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312513224446/d539505dex31.htm">3.9</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Withdrawal of Series D Junior Participating Cumulative Preferred Stock, dated May&nbsp;15, 2013 (incorporated herein by reference to Exhibit 3.1 to the
Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May&nbsp;16, 2013).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749116000227/exhibit31to8-konreversesto.htm">3.10</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with
the Securities and Exchange Commission on October 25, 2016).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000091/apri63017ex310.htm">3.11</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.10 to the Company's Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on August 2, 2017).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000075/apri63018ex312.htm">3.12</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.12 to the Company's Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on August 9, 2018).</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_1.htm">3.13</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment related to the Share Increase Amendment, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.1 to the Company's Current
Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_2.htm">3.14</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certificate of Amendment related to the Name Change, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form
8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">                                                                                                   90
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_3.htm">3.15</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amended and Restated Bylaws, dated January 24, 2019 (incorporated herein by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed with the
Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2>
<P></FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000114/exh3-16.htm"><FONT SIZE=2>3.16</FONT></A></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2>
<P>Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, dated March 25, 2020 (incorporated herein by reference to Exhibit
3.16 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2020)</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2>
<P></FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000124/exh3-1.htm"><FONT SIZE=2>3.17</FONT></A></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2>
<P>Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 18, 2020 (incorporated herein by reference to Exhibit 3.1
to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2020).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="BOTTOM">
<FONT SIZE=2><P></FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000131/exh3-1.htm"><FONT SIZE=2>3.18</FONT></A></TD>
<TD WIDTH="94%" VALIGN="BOTTOM">
<FONT SIZE=2><P>Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, filed May 20, 2020 (incorporated herein by reference
to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2020).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420411016740/v215638_ex4-1.htm">4.1</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on March 24, 2011).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312514375645/d806711dex42.htm">4.2</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant issued to the lenders under the Loan and Security Agreement, dated as of October 17, 2014, by and among the Company, NexMed (U.S.A.), Inc.,
NexMed Holdings, Inc. and Apricus Pharmaceuticals USA, Inc., as borrowers, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time including Oxford
Finance LLC and Silicon Valley Bank (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
October 20, 2014).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312515044589/d871082dex41.htm">4.3</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
February 12, 2015).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex41.htm">4.4</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant issued to Sarissa Capital Domestic Fund LP and Sarissa Capital Offshore Master Fund LP (incorporated herein by reference to Exhibit 4.1 to the
Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex42.htm">4.5</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant issued to other purchasers (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and
Exchange Commission on January 13, 2016).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex43.htm">4.6</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on January 13, 2016).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312516722474/d444660dex41.htm">4.7</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
September 28, 2016).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000048/exhibit49formofwarrant.htm">4.8</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant (incorporated herein by reference to Exhibit 4.9 of Amendment No. 1 to Company's Registration Statement on Form S-1 (File No. 333-217036) filed with
the Securities and Exchange Commission on April 17, 2017).</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">                                                                                                   91
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000063/exhibit41formofwarrantamen.htm">4.9</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on April 21, 2017).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000034/ex412amendmenttowarranttop.htm">4.10</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment to Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.12 of Amendment No. 1 to the Company's Registration Statement on Form
S-3 (File No. 333-2223353) filed with the Securities and Exchange Commission on March 22, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit41to8-kon3x29x18.htm">4.11</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment to Warrant to Purchase Common Stock, dated as of March 27, 2018 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K
filed with the Securities and Exchange Commission on March 29, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit42to8-kon3x29x18.htm">4.12</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March
29, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit43to8-kon3x29x18.htm">4.13</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on March 29, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000065/exhibit41to8-kjune2018warr.htm">4.14</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment to Warrant to Purchase Common Stock, dated as of June 22, 2018, by and between the Company and Sarissa Offshore (incorporated by reference to
Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000085/ex41to8-konsept2018pipe.htm">4.15</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
September 21, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000085/ex42to8-konsept2018pipe.htm">4.16</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Wainwright Warrant (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission
on September 21, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000085/ex43to8-konsept2018pipe.htm">4.17</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Registration Rights Agreement (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on September 21, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex41to8-kon10x16x18.htm">4.18</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Investor Warrants (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on October 17, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex42to8-kon10x16x18.htm">4.19</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Registration Rights Agreement, dated October 16, 2018, by and among the Company and certain investors named therein (incorporated herein by reference to Exhibit
4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000038/exh4-1.htm">4.20</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Series A Warrant, issued to investors on January 31, 2019 (incorporated by reference to Exhibit 4.1 of the Company's Current Report on Form 8-K filed with the
Securities and Exchange Commission on February 6, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000232/exh4-1.htm">4.21</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant, issued to investors on August 27, 2019 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the
Securities and Exchange Commission on August 27, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000167/exh4-1.htm">4.22</FONT></A></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Warrant, issued to investors on September 9, 2020 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed
with the Securities and Exchange Commission on September 9, 2020).</FONT></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">                                                                                                   92
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000212/exh4-1.htm">4.23</FONT></A></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Convertible Promissory Note due December 11, 2022 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K
filed with the Securities and Exchange Commission on December 17, 2020).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000092/exh4-25.htm">4.24</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Description of Securities of Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 4.25 to the Company's Annual Report on Form 10-K
filed with the Securities and Exchange Commission on March 17, 2020). </FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420406014190/v039876_pre14a.htm">10.1</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>2006 Stock Incentive Plan (incorporated herein by reference to Annex A of the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission
on April 6, 2006).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114420408023213/v110197_def14a.htm">10.2</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment to 2006 Stock Incentive Plan (incorporated herein by reference to Appendix A of the Company's Definitive Proxy Statement filed with the Securities and
Exchange Commission on April 18, 2008).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749114000079/apri-2014630xex101.htm">10.3</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Stock Option Grant Notice and Stock Option Agreement under the Company's 2012 Stock Long Term Incentive Plan (incorporated herein by reference to Exhibit
10.1 to the Company's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2014).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749115000083/apri93015ex101.htm">10.4</A>&dagger;</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>License Agreement and Amendment, by and between NexMed (U.S.A.), Inc. and Warner Chilcott Company, LLC, dated September 9, 2015 (incorporated herein by
reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2015).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex101.htm">10.5</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Subscription Agreement dated January 12, 2016, among the Company, Sarissa Capital Domestic Fund LP and Sarissa Capital Offshore Master Fund LP (incorporated
herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749116000164/apri33116ex106.htm">10.6</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Restricted Stock Unit Award Agreement (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on May 9, 2016).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000025/exhibit101-assetpurchaseag.htm">10.7</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Asset Purchase Agreement, dated March 8, 2017, by and between Ferring International Center S.A. and the Company, NexMed (U.S.A.), Inc., NexMed Holdings, Inc.
and NexMed International Limited (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
March 8, 2017).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000025/exhibit102-licenseagreement.htm">10.8</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>License Agreement, dated March 8, 2017, by and between the Company and Ferring International Center S.A. (incorporated herein by reference to Exhibit 10.2 to the
Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2017).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000104/ex42formofregistrationrigh.htm">10.9</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Registration Rights Agreement (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and
Exchange Commission on September 11, 2017).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000065/exhibit101to8-kjune2018war.htm">10.10</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment No. 1 to Subscription Agreement, dated as of June 22, 2018, by and between the Investors and the Company (incorporated by reference to Exhibit 10.1 to
the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000069/exhibit101formofcvragreeme.htm">10.11</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of CVR Agreement (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
July 30, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">                                                                                                   93
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1032toapris-4.htm">10.12</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Indemnification Agreement for the Company's Directors and Officers (incorporated by reference to Exhibit 10.32 of the Company's Registration Statement on
Form S-4 filed on August 31, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1033toapris-4.htm">10.13</A>&dagger;</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>License Agreement, dated September 21, 2016, by and among Seelos Therapeutics, Inc., Ligand Pharmaceuticals Incorporated, Neurogen Corporation and CyDex
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.33 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1034toapris-4.htm">10.14</A>+&dagger;</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Asset Purchase Agreement, dated as of March 6, 2018, by and between Seelos Therapeutics, Inc. and Vyera Pharmaceuticals AG f/k/a Turing Pharmaceuticals AG
(incorporated by reference to Exhibit 10.34 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1035toapris-4.htm">10.15</A>&dagger;</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment to Asset Purchase Agreement, dated as of May 18, 2018, by and between Seelos Therapeutics, Inc. and Vyera Pharmaceuticals AG f/k/a Turing
Pharmaceuticals AG (incorporated by reference to Exhibit 10.35 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1036toapris-4.htm">10.16</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Indemnity Agreement, dated July 8, 2016, by and between Seelos Therapeutics, Inc. and Raj Mehra, Ph.D. (incorporated by reference to Exhibit 10.36 of the Company's
Registration Statement on Form S-4 filed on August 31, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1039toapris-4.htm">10.17</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Seelos Therapeutics, Inc. 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.39 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1040toapris-4.htm">10.18</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Option Agreement under the Seelos Therapeutics, Inc. 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.40 of the Company's Registration
Statement on Form S-4 filed on August 31, 2018).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036119000397/ex10_1.htm">10.19</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Second Amendment Agreement, dated as of January 4, 2019, by and among Seelos Therapeutics, Inc., the Company and the investors party thereto
(incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001204/ex10_1.htm">10.20</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Third Amendment Agreement, dated as of January 16, 2019, by and among Seelos Therapeutics, Inc., the Company and the investors party thereto
(incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000116/exh10-1.htm">10.21</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities
and Exchange Commission on March 26, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000116/exh10-2.htm">10.22</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Employment Agreement by and between the Company and Raj Mehra, Ph.D., dated March 20, 2019 (incorporated herein by reference to Exhibit 10.2 to the Company's
Current Report on Form 8-K filed with the Securities and Exchange Commission on March 26, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000215/exh10-1.htm">10.23</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Seelos Therapeutics, Inc. 2019 Inducement Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities
and Exchange Commission on August 14, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000264/exh10-1.htm">10.24</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment No. 2 to Asset Purchase Agreement, dated as of December 31, 2018, by and between Seelos Therapeutics, Inc. and Phoenixus AG f/k/a Vyera
Pharmaceuticals AG and Turing Pharmaceuticals AG. (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 7, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000220/exh4-3.htm">10.25</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Form of Stock Option Agreement under the Seelos Therapeutics, Inc. 2019 Inducement Plan (incorporated herein by reference to Exhibit 4.3 to the Company's
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August 15, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
</TABLE>


<P ALIGN="CENTER">                                                                                                   94
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000264/exh10-7.htm">10.26^</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amended and Restated Exclusive License Agreement, dated August 29, 2019, by and between Seelos Therapeutics, Inc. and Stuart Weg, MD. (incorporated herein by
reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000239/exh10-1.htm">10.27</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment No. 3 to Asset Purchase Agreement, dated October 15, 2019, by and between Seelos Therapeutics, Inc. and Phoenixus AG (incorporated herein by
reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 21, 2019).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000092/exh10-30.htm">10.28</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment to License Agreement, dated as of February 8, 2019, by and among Ligand Pharmaceuticals Incorporated, Neurogen Corporation, CyDex
Pharmaceuticals, Inc., and Seelos Corporation (incorporated herein by reference to Exhibit 10.30 to the Company's Annual Report on Form 10-K
filed with the Securities and Exchange Commission on March 17, 2020).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000007/exh10-1.htm">10.29</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Stock Purchase Agreement, dated as of January 2, 2020, by and between Seelos Therapeutics, Inc. and Phoenixus AG (incorporated herein by reference to
Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 3, 2020).</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPB">10.30</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan, effective May 15, 2020 (incorporated herein by reference to Appendix
B to the Registrant's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 13, 2020).</P>
</FONT></TD>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPA">10.31</A>#</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Seelos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (incorporated herein by reference to Appendix A to the Registrant's Definitive Proxy Statement
filed with the Securities and Exchange Commission on April 13, 2020).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000167/exh10-1.htm">10.32</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Securities Purchase Agreement, dated September 4, 2020 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed
with the Securities and Exchange Commission on September 9, 2020).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000167/exh10-2.htm">10.33</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Placement Agency Agreement, dated September 4, 2020 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed
with the Securities and Exchange Commission on September 9, 2020).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000212/exh10-1.htm">10.34</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Securities Purchase Agreement, dated as of December 11, 2020, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC
(incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 17, 2020).<BR>
</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000212/exh10-2.htm">10.35</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Security Agreement, dated as of December 11, 2020, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC (incorporated
herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 17, 2020)</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000027/exh10-1.htm">10.36**</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Amendment No. 4 to Asset Purchase Agreement, dated February 15, 2021, by and between Seelos Corporation and Phoenixus AG (incorporated herein by
reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2021).</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000121/exh21-1.htm">21.1</A></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March 28, 2019). </FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="exh23-1.htm">23.1</A>*</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Consent of KPMG, LLP, independent registered public accounting firm.</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="exh31-1.htm">31.1</A>*</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certification of Principal Executive Officer and Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
</TABLE>


<P ALIGN="CENTER">                                                                                                   95
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=95%>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P><A HREF="exh32-1.htm">32.1</A>*</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P>101.INS</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>XBRL Instance Document. (1)</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P>101.SCH</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>XBRL Taxonomy Extension Schema. (1)</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P>101.CAL</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>XBRL Taxonomy Extension Calculation Linkbase. (1)</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P>101.DEF</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>XBRL Taxonomy Extension Definition Linkbase. (1)</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P>101.LAB</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>XBRL Taxonomy Extension Label Linkbase. (1)</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="94%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=2><P>101.PRE</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=2><P>XBRL Taxonomy Extension Presentation Linkbase. (1)</FONT></TD>
</TR>
</TABLE>



<DIR>
<DIR>

<P>(1) Furnished, not filed.</P>

<P>+ &nbsp;&nbsp; All schedules and exhibits to the agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the
Securities Exchange Commission upon request.<BR>
   &dagger;  &nbsp;&nbsp; Confidential treatment has been granted for portions of this exhibit.  Those portions have been omitted and filed  &nbsp;&nbsp; separately with the Securities and Exchange
Commission.<BR>
   * &nbsp;&nbsp; Filed herewith.<BR>
   # &nbsp;&nbsp; Management compensatory plan or arrangement<BR>
   ^      &nbsp;&nbsp; Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of
the omitted schedules and exhibits upon request by the Securities and Exchange Commission.<BR>
    **   &nbsp;&nbsp; Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) would likely cause
competitive harm to the Company if publicly disclosed. The Company hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the Securities and
Exchange Commission.</P>


</DIR>
</DIR>

<P> &nbsp; </P>
<P> &nbsp; </P>





<P ALIGN="CENTER">                                                                                                   96
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>

<P>







<B><P><A NAME="item16">ITEM 16.</B> <B>FORM 10-K SUMMARY</A></P></B>

<P>Not applicable.</P>

<P> &nbsp; </P>
<P> &nbsp; </P>
<P> &nbsp; </P>
<P> &nbsp; </P>


<P ALIGN="CENTER">                                                                                                   97
<HR WIDTH="100%">
<P style="PAGE-BREAK-BEFORE: always" align=left>


<B><P>SIGNATURES</P>
</B><P>Pursuant to&nbsp;the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </P>

<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=85%>
<TR><TD WIDTH="61%" VALIGN="TOP"><P></P></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=2><P>Seelos Therapeutics, Inc.</FONT></TD>
</TR>
<TR><TD WIDTH="61%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="39%" VALIGN="TOP" HEIGHT=5><P></P></TD>
</TR>
<TR><TD WIDTH="61%" VALIGN="TOP">
<FONT SIZE=2><P>Date: March 11, 2021</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="39%" VALIGN="TOP">
<FONT SIZE=2><P>/s/ Raj Mehra, Ph.D.</FONT></TD>
</TR>
<TR><TD WIDTH="61%" VALIGN="TOP"><P></P></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=2><P>Raj Mehra, Ph.D.</FONT></TD>
</TR>
<TR><TD WIDTH="61%" VALIGN="TOP"><P></P></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=2><P>President and Chief Executive Officer</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=2>
<P ALIGN="CENTER">POWER OF ATTORNEY</P>

<B><P>K<SMALL>NOW</SMALL> A<SMALL>LL</SMALL> P<SMALL>ERSONS</SMALL> B<SMALL>Y</SMALL> T<SMALL>HESE</SMALL> P<SMALL>RESENTS</SMALL></B>, that each person whose signature appears
below constitutes and appoints Raj Mehra, Ph.D. his or her true and lawful attorneys-in-fact,
each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other
documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may
do or cause to be done by virtue hereof.</P>

<P>Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons, on behalf of the registrant on the dates and the
capacities indicated.</P>


<TABLE BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH=85%>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>Signature</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Title</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="20%" VALIGN="TOP">
<FONT SIZE=2><P>Date</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>/s/ Raj Mehra, Ph.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>President, Chief Executive Officer, Chairman of the Board and Interim Chief Financial Officer</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=2><P>March 11, 2021</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>Raj Mehra, Ph.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP">
<I><FONT SIZE=2><P>(Principal Executive Officer, Principal Financial and Accounting Officer)</I></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>/s/ Judith Dunn, Ph.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Director</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=2><P>March 11, 2021</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>Judith Dunn, Ph.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>/s/ Brian Lian, Ph.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Director</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=2><P>March 11, 2021</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>Brian Lian, Ph.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>/s/ Daniel J. O'Connor, J.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Director</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=2><P>March 11, 2021</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>Daniel J. O'Connor, J.D.</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>/s/ Richard W. Pascoe</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Director</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=2><P>March 11, 2021</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=2><P>Richard W. Pascoe</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="48%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
<TD WIDTH="20%" VALIGN="TOP"><FONT SIZE=2><P> &nbsp; </P></TD>
</TR>
</TABLE>


<P> &nbsp; </P>
<FONT SIZE=2>

<P ALIGN="CENTER">                                                                                                   98
<HR WIDTH="100%">

<P> &nbsp; </P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exh23-1.htm
<DESCRIPTION>CONSENT
<TEXT>
<HTML>
<HEAD>
<TITLE>2020 10-K Exhibit 23.1</TITLE>
</HEAD>
<body bgcolor=white>
<FONT FACE="Arial" SIZE="2">

<DIV style="width: 85%">

<p align="right">
                                                                    EXHIBIT 23.1  </P>


<B><P ALIGN="CENTER">Consent of Independent Registered Public Accounting Firm</P></B>




<P>The Board of Directors<BR>
Seelos Therapeutics, Inc.:</P>


<P>We consent to the incorporation by reference in the registration statement (Nos. 333-250810, 333-234812, and 333-217036) on Form S-1, registration statement (Nos. 333-169132,
333-251356, 333-229491, 333-229490, 333-223353, 333-221285, 333-220624, 333-200799, 333-198066, 333-191679, 333-182703, 333-178832, 333-178592, 333-165958,
333-152591, 333-148060, 333-140110, 333-132611, 333-125565, 333-122114, 333-117717, 333-111894, 333-107137, 333-105509, 333-96813, 333-46976, and 333-91957) on
Form S-3 and registration statement (Nos. 333-238562, 333-233305, 333-229846, 333-218368, 333-215419, 333-210040, 333-204748, 333-191680, 333-182704, 333-152284,
333-138598, 333-174392, 333-167365, and 333-93435) on Form S-8 of Seelos Therapeutics, Inc. of our report dated March 11, 2021, with respect to the consolidated
balance sheets of Seelos Therapeutics, Inc. as of December 31, 2020 and 2019, and the related statements of operations and comprehensive loss, stockholders' equity (deficit), and
cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes, which report appears in the December&nbsp;31, 2020 annual report on
Form 10-K of Seelos Therapeutics, Inc.</P>

<P>Our report dated March 11, 2021 contains an explanatory paragraph that states that Seelos Therapeutics, Inc. has suffered recurring losses from operations and has a net
capital deficiency, which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might
result from the outcome of that uncertainty.</P>


<P> &nbsp; </P>

<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P>/s/ KPMG LLP </P>

</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P> &nbsp; </P>

<P>Short Hills, New Jersey<BR>
March 11, 2021</P>



<P> &nbsp; </P>


<HR WIDTH="100%">

<P> &nbsp; </P>

</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh31-1.htm
<DESCRIPTION>302 CERTIFICATE
<TEXT>
<HTML>
<HEAD>
<TITLE>2020 10-K Exhibit 31.1</TITLE>
</HEAD>
<BODY LINK="#0000ff" VLINK="#800080">
<FONT FACE="Times New Roman" SIZE="2">


<B><FONT SIZE=2><P ALIGN="RIGHT">EXHIBIT 31.1</P></B>


<B><P ALIGN="CENTER">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND INTERIM CHIEF FINANCIAL OFFICER</P></B>

<P ALIGN="JUSTIFY">I, Raj Mehra, Ph.D., certify that:</P>

<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="4%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>1.</FONT></TD>
<TD WIDTH="96%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">I have reviewed this Annual Report on Form 10-K of Seelos Therapeutics, Inc.;&nbsp;</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="4%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>2.</FONT></TD>
<TD WIDTH="96%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="4%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>3.</FONT></TD>
<TD WIDTH="96%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="4%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>4.</FONT></TD>
<TD WIDTH="96%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="8%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P><P ALIGN="RIGHT">(a) &nbsp; &nbsp;</FONT></TD>
<TD WIDTH="92%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;&nbsp;</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="8%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P><P ALIGN="RIGHT">(b) &nbsp; &nbsp;</FONT></TD>
<TD WIDTH="92%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;&nbsp;</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="8%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P><P ALIGN="RIGHT">(c) &nbsp; &nbsp;</FONT></TD>
<TD WIDTH="92%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="8%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P><P ALIGN="RIGHT">(d) &nbsp; &nbsp;</FONT></TD>
<TD WIDTH="92%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during
the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="4%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>5.</FONT></TD>
<TD WIDTH="96%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="8%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P><P ALIGN="RIGHT">(a) &nbsp; &nbsp;</FONT></TD>
<TD WIDTH="92%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=99%>
<TR><TD WIDTH="8%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P><P ALIGN="RIGHT">(b) &nbsp; &nbsp;</FONT></TD>
<TD WIDTH="92%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="JUSTIFY">Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant's internal control over financial reporting.</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=2>
<TABLE BORDER=0 CELLSPACING=1 BORDERCOLOR="#000000" WIDTH=45%>
<TR><TD VALIGN="top">&nbsp;</TD>
</TR>
<TR><TD VALIGN="top">&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Date: March 11, 2021</FONT></TD>
</TR>
<TR><TD VALIGN="top">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
<TD STYLE="border-bottom: black 1.5pt solid" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>/S/ Raj Mehra, Ph.D.</FONT></TD>
</TR>
<TR><TD VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Raj Mehra, Ph.D.</FONT></TD>
</TR>
<TR><TD VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Chief Executive Officer, President and Interim Chief Financial Officer</FONT></TD>
</TR>
</TABLE>



<P> &nbsp; </P>


<HR WIDTH="100%">


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exh32-1.htm
<DESCRIPTION>906 CERTIFICATE
<TEXT>
<HTML>
<HEAD>


<TITLE>2020 10-K Exhibit 32.1</TITLE>
</HEAD>
<BODY LINK="#0000ff" VLINK="#800080">
<FONT FACE="Times New Roman" SIZE="2">


<B><P ALIGN="RIGHT">EXHIBIT 32.1</P></B>

<B><FONT FACE="inherit,Times New Roman" SIZE=2><P ALIGN="CENTER">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND INTERIM CHIEF FINANCIAL OFFICER<BR>
                   PURSUANT TO<BR>
                   18 U.S.C. SECTION 1350,<BR>
                   AS ADOPTED PURSUANT TO<BR>
                   SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P></B>

<P ALIGN="JUSTIFY">I, Raj Mehra, Ph.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual
Report on Form 10-K of Seelos Therapeutics, Inc. for the year ended December 31, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Seelos Therapeutics, Inc.</P>


<TABLE BORDER=0 CELLSPACING=2 BORDERCOLOR="#000000" WIDTH=85%>
<TR><TD VALIGN="top" COLSPAN=3>&nbsp;</TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="top">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top">&nbsp;</TD>
<TD WIDTH="39%" VALIGN="top">&nbsp;</TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Date: March 11, 2021</FONT></TD>
<TD WIDTH="7%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>By:</FONT></TD>
<TD STYLE="border-bottom: black 1.5pt solid" WIDTH="39%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>/S/ Raj Mehra, Ph.D.</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="top">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Name:</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Raj Mehra, Ph.D.&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="top">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="TOP">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Title:</FONT></TD>
<TD WIDTH="39%" VALIGN="top">
<FONT FACE="inherit,Times New Roman" SIZE=2><P>Chief Executive Officer, President and Interim Chief Financial Officer</FONT></TD>
</TR>
</TABLE>





<P> &nbsp; </P>

<HR WIDTH="100%">


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>seel-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: SEEL%2D12%2D31%2D2020.xfr; Date: 2021%2D03%2D10T17:52:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:SEEL="http://SEEL/20201231">
    <link:schemaRef xlink:href="seel-20201231.xsd" xlink:type="simple" />
    <xbrli:context id="FI2018Q3">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2018Q3YTD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2017Q4">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2016Q4">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2017Q4YTD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_apri_TwoThousandTwelveIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:TwoThousandTwelveIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_apri_TwoThousandTwelveIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:TwoThousandTwelveIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_apri_TwoThousandTwelveIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:TwoThousandTwelveIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-01to2021-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_August232019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August232019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_June172019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:June172019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_January242019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January242019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_March72019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:March72019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-30_custom_LicensefromLigandPharmaceuticalsIncorporatedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:LicensefromLigandPharmaceuticalsIncorporatedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_custom_AssetsfromVyeraPharmaceuticalsAGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsAGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-01to2019-02-28_custom_AssetsfromBioblastPharmaLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromBioblastPharmaLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-01to2019-03-31_custom_UCRegentsLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:UCRegentsLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-01to2019-06-30_custom_DukeLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:DukeLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_December2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:December2020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_September42020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September42020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_March162020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:March162020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_February132020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:February132020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_January22020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January22020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_May112020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May112020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="trading_price">
      <xbrli:measure>SEEL:trading_price</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="clinical_trial">
      <xbrli:measure>SEEL:clinical_trial</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="usd">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="segment">
      <xbrli:measure>SEEL:segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="closing_price">
      <xbrli:measure>SEEL:closing_price</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="warrant">
      <xbrli:measure>SEEL:warrant</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="payment">
      <xbrli:measure>SEEL:payment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="day">
      <xbrli:measure>SEEL:day</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="number">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="usdPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="director">
      <xbrli:measure>SEEL:director</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="FI2017Q4" unitRef="shares" decimals="INF">3.417000</SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice contextRef="FI2017Q4" unitRef="usdPerShare" decimals="INF">3.79</SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2">.30</SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2">.84</SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q3" unitRef="usdPerShare" decimals="2">3.86</SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" unitRef="usdPerShare" decimals="2">1.84</SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2">18.00</SEEL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice>
    <dei:AmendmentFlag contextRef="FD2018Q3YTD">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="FD2018Q3YTD">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="FD2018Q3YTD">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="FD2018Q3YTD">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentPeriodEndDate contextRef="FD2018Q3YTD">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentType contextRef="FD2018Q3YTD">10-K</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="FD2018Q3YTD">0001017491</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="FD2018Q3YTD">Seelos Therapeutics, Inc.</dei:EntityRegistrantName>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">2044000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">2044000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">2044000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">1650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">341000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q3" unitRef="usdPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" unitRef="usdPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">223000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">16501000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">37073000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" unitRef="usd" decimals="-3">124000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">-16501000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" unitRef="usd" decimals="-3">-223000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4" unitRef="usd" decimals="-3">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3">1062000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="usd" decimals="-3">963000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">-19101000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">-51255000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-19101000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-51255000</us-gaap:NetIncomeLoss>
    <us-gaap:NumberOfOperatingSegments contextRef="FD2018Q3YTD" unitRef="segment" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q3" unitRef="usdPerShare" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" unitRef="usdPerShare" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q3" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="FI2018Q3" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q3" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">6365000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">5920000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3">154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF">14334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3">6648000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF">17481000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="FI2018Q3" unitRef="shares" decimals="-3">3584000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="FI2017Q4" unitRef="shares" decimals="INF">10066000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="FI2016Q4" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">54535891</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">27028533</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">3081546</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">153628</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">14332620</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">169000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">169000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">4517000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">14000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">4503000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockholdersEquity contextRef="FI2018Q3" unitRef="usd" decimals="-3">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2017Q4" unitRef="usd" decimals="-3">2572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2016Q4" unitRef="usd" decimals="-3">-4706000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">77680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-75162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">56027000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-56061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">97000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-4806000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;1. Organization and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"&gt;&lt;b&gt;Organization&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Seelos Therapeutics, Inc. and Subsidiaries&#13;(&amp;#34;Seelos&amp;#34; or the &amp;#34;Company&amp;#34;) is a Nevada corporation that was initially formed in 1987. The Company is a clinical-stage&#13;biopharmaceutical company focused on developing novel technologies and therapeutics for the treatment of central nervous system,&#13;respiratory and other disorders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Merger with Apricus Biosciences, Inc.&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On January 24, 2019, Apricus Biosciences,&#13;Inc., a Nevada corporation (&amp;#34;Apricus&amp;#34;), completed a business combination with Seelos Therapeutics, Inc., a Delaware corporation&#13;(&amp;#34;STI&amp;#34;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &amp;#34;Merger Agreement&amp;#34;)&#13;entered into on July 30, 2018. Pursuant to the Merger Agreement, (i) a subsidiary of Apricus merged with and into STI, with STI&#13;(renamed as &amp;#34;Seelos Corporation&amp;#34;) continuing as a wholly owned subsidiary of Apricus and the surviving corporation of the&#13;merger and (ii) Apricus was renamed as &amp;#34;Seelos Therapeutics, Inc.&amp;#34; (the &amp;#34;Merger&amp;#34;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Merger was accounted for as a reverse&#13;recapitalization under United States generally accepted accounting principles (&amp;#34;U.S. GAAP&amp;#34;) because the primary assets&#13;of Apricus were nominal following the close of the Merger. STI was determined to be the accounting acquirer based upon the terms&#13;of the Merger and other factors, including: (i) STI's stockholders and other persons holding securities convertible, exercisable&#13;or exchangeable directly or indirectly for STI common stock owned the majority of Apricus immediately following the effective time&#13;of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company and (iii) STI's management holds&#13;all key positions in the management of the combined company. Accordingly, the historical financial statements of STI became the&#13;Company's historical financial statements, including the comparative prior periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Basis of Presentation and Principles of&#13;Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The consolidated financial statements include&#13;the accounts of the Company and its wholly-owned subsidiaries.&amp;#160;All significant intercompany accounts and transactions have&#13;been eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The preparation of these consolidated financial&#13;statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts&#13;of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported&#13;amounts of expenses during the reporting period. The most significant estimates in the Company's financial statements relate to&#13;the valuation of warrants, valuation of convertible notes payable, valuation of common stock and the valuation of stock options.&#13;These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable&#13;under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities&#13;and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely&#13;from these estimates. To the extent there are material differences between the estimates and actual results, the Company's future&#13;results of operations will be affected.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The carrying amounts of financial instruments&#13;such as accounts receivable, accounts payable and accrued expenses approximate their related fair values due to the short-term&#13;nature of these instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company records a right-of use (&amp;#34;ROU&amp;#34;)&#13;asset and a lease liability on its balance sheet for all leases with terms of 12 months or longer. Leases are classified as either&#13;finance or operating, with classification affecting the pattern of expense recognition in the income statement. Historically, the&#13;Company recorded rent expense associated with its operating lease on a straight-line basis over the term of the lease. The difference&#13;between rent payments and straight-line rent expense was recorded as deferred rent in accrued liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020, the Company's leases&#13;had original terms of 12 months or less. The Company does not recognize ROU assets and lease liabilities that arise from leases&#13;with an original term of 12 months or less. Rather the Company recognizes the lease payments on a straight-line basis over the&#13;term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company follows the accounting guidance&#13;in the Financial Accounting Standards Board (&amp;#34;FASB&amp;#34;) Accounting Standards Codification (&amp;#34;ASC&amp;#34;) Topic 820, Fair&#13;Value Measurements and Disclosures (&amp;#34;ASC 820&amp;#34;), for its fair value measurements of financial assets and liabilities measured&#13;at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount&#13;that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at&#13;the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market&#13;participants would use in pricing an asset or a liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The accounting guidance requires fair value&#13;measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Level 1: Quoted prices in active markets for&#13;identical assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Level 2: Observable inputs other than Level&#13;1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Level 3: Unobservable inputs which are supported&#13;by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted&#13;cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant&#13;judgment or estimation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The fair value hierarchy also requires an&#13;entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and&#13;liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the&#13;fair value measurement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following tables present information about&#13;the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value&#13;hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during the years&#13;ended December 31, 2020 and 2019 (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 40%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 1) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 2) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 3) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,662&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,662&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liabilities, at fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 40%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 1) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 2) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 3) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,261&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,261&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liabilities, at fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The common stock warrant liabilities were&#13;recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the fair&#13;value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2020 and 2019:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.18%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.66%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;116.77%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;110.80%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.07&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted-average fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.06&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following table is a reconciliation for&#13;the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 75%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 23%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrant liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant issued in connection with financing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21,535&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liability reclassified to stockholders' equity&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(37,073)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in fair value measurement of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;16,501&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liability reclassified to stockholders' equity&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(124)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in fair value measurement of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;223&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Of the inputs used to value the outstanding&#13;common stock warrant liabilities as of December 31, 2020 and 2019, the most subjective input is the Company's estimate of expected&#13;volatility of its common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Fair Value Option&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As permitted under ASC Topic 825, Financial&#13;Instruments (&amp;#34;ASC 825&amp;#34;), the Company had elected the fair value option to account for its convertible notes. In accordance&#13;with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Statement of&#13;Operations. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed&#13;as incurred and were not deferred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company determined that its grant agreement&#13;with Team Sanfilippo Foundation (&amp;#34;TSF&amp;#34;), a nonprofit medical research foundation founded by parents of children with Sanfilippo&#13;syndrome, is within the scope of ASC Topic 606 &amp;#34;Revenue from Contracts with Customers&amp;#34;. Under the TSF agreement, TSF makes&#13;certain milestone payments to the Company as certain milestones related to a specified Phase II/III clinical trial, defined in&#13;the agreement, are met. The Company determined that there is one performance obligation under the TSF agreement. The variable consideration,&#13;in the form of milestone payments, is attributed to the completed portion of the performance obligation that triggers or results&#13;in the payments. During the year ended December 31, 2020 and 2019, the Company recognized $0 and $375,000 of revenue, respectively,&#13;from a milestone payment received as the milestone payment represents the Company's completed portion of its performance obligation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Research and development costs are expensed&#13;as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related&#13;expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development&#13;and consulting agreements in place.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Income taxes are accounted for under the asset&#13;and liability method.&amp;#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts&#13;and the tax basis of assets and liabilities.&amp;#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect&#13;for the years in which the differences are expected to reverse.&amp;#160;A valuation allowance is provided if it is more likely than&#13;not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company also follows the provisions of&#13;accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken&#13;or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure&#13;and transition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Income (Loss) Per Common Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Basic loss per share is computed by dividing&#13;net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period.&#13;Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible&#13;debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic&#13;and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both&#13;calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is&#13;anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following potentially dilutive securities&#13;outstanding for the year ended December 31, 2020 and 2019 have been excluded from the computation of diluted weighted average shares&#13;outstanding, as they would be anti-dilutive (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,120&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;522&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,066&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,584&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,556&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;23,742&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,106&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company expenses stock-based compensation&#13;to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of&#13;the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules&#13;are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The&#13;Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used&#13;in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and&#13;the application of management's judgment. All stock-based compensation costs are recorded in general and administrative or research&#13;and development costs in the statements of operations based upon the underlying individual's role at the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Segment Information&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company operates under one segment which&#13;develops pharmaceutical products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In August 2018, the FASB issued Accounting&#13;Standards Update (&amp;#34;ASU&amp;#34;) No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure&#13;Requirements for Fair Value Measurement (&amp;#34;ASU 2018-13&amp;#34;). The amendments in this ASU require certain existing disclosure&#13;requirements in Topic 820 to be modified or removed, and certain new disclosure requirements to be added to the Topic. In addition,&#13;this ASU allows entities to exercise more discretion when considering fair value measurement disclosures. The Company adopted ASU&#13;2018-13 effective January 1, 2020. The adoption of ASU 2018-13 did not have a material effect on the Company's financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In December 2019, the FASB issued ASU No.&#13;2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&amp;#34;ASU 2019-12&amp;#34;), which is intended to simplify&#13;various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic&#13;740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years,&#13;and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is&#13;currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In August 2020, the FASB issued ASU 2020-06:&#13;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity&#13;(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This standard simplifies the&#13;accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature,&#13;as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt&#13;instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest&#13;expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of&#13;ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per&#13;share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable&#13;for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after&#13;December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company is evaluating&#13;the impact of ASU 2020-06 on its consolidated financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntitySmallBusiness contextRef="FD2018Q3YTD">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="FD2018Q3YTD">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory contextRef="FD2018Q3YTD">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityCurrentReportingStatus contextRef="FD2018Q3YTD">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityPublicFloat contextRef="AsOf2020-06-30" unitRef="usd" decimals="-5">41500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-03-04" unitRef="shares" decimals="INF">73249554</dei:EntityCommonStockSharesOutstanding>
    <dei:TradingSymbol contextRef="FD2018Q3YTD">SEEL</dei:TradingSymbol>
    <dei:EntityVoluntaryFilers contextRef="FD2018Q3YTD">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer contextRef="FD2018Q3YTD">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityShellCompany contextRef="FD2018Q3YTD">false</dei:EntityShellCompany>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;10. Income Taxes &lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company has incurred net operating losses&#13;since inception. At December 31, 2020, the Company has available net operating loss carryforwards of approximately $46.9 million&#13;for federal income tax reporting purposes and approximately $90.6 million for state income tax reporting purposes.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Deferred tax assets consist of the following&#13;(in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Net operating tax loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,223&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,632&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;66&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;348&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;521&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Start up cost&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,320&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,806&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Total deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28,130&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,870&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Less valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(28,130)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(10,870)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The federal and state net operating loss carryforwards,&#13;not subject to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset as of&#13;December 31, 2020 and 2019 of approximately $15.2 million and $5.6 million, respectively.&amp;#160;In consideration of the Company's&#13;accumulated losses and the uncertainty of its ability to utilize this deferred tax asset in the future, the Company has recorded&#13;a full valuation allowance as of such dates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company follows&amp;#160;the provisions of&#13;income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected&#13;to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized&#13;in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.&#13;Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing&#13;the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company's federal&#13;income tax returns for 2017 to 2020 are still open and subject to audit.&amp;#160;In addition, net operating losses arising from prior&#13;years are also subject to examination at the time they are utilized in future years.&amp;#160;Unrecognized tax benefits, if recognized,&#13;would have no effect on the Company's effective tax rate. The Company's policy is to recognize interest and penalties related to&#13;income tax matters in income tax expense. For the years ended December 31, 2020 and 2019, the Company has not recorded any interest&#13;or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within&#13;the next twelve months.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;A reconciliation of the Company's unrecognized&#13;tax benefits for the years ended December 31, 2020 and 2019, are as follows (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;718&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in current period positions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in prior period positions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(718)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The reconciliation of income taxes computed&#13;using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31,&#13;2020 and 2019, are as follows:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 73%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Federal statutory tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21.0&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21.0&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;State and local taxes, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11.2&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.7&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Permanent items&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1.0)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(9.0)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Deferred rate changes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.1&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;59.3&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(90.6)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(18.4)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Income tax provision (benefit)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">100000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">100000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q3" unitRef="usd" decimals="-3">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" unitRef="usd" decimals="-3">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" unitRef="usd" decimals="-3">718000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">718000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <SEEL:DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards contextRef="FI2018Q3" unitRef="usd" decimals="-3">5632000</SEEL:DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards>
    <SEEL:DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards contextRef="FI2017Q4" unitRef="usd" decimals="-3">15223000</SEEL:DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q3" unitRef="usd" decimals="-3">10870000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" unitRef="usd" decimals="-3">28130000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q3" unitRef="usd" decimals="-3">10870000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" unitRef="usd" decimals="-3">28130000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q3" unitRef="usd" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" unitRef="usd" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q3" unitRef="shares" decimals="INF">522000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" unitRef="shares" decimals="INF">5120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF">4624000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF">26000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2017Q4" unitRef="shares" decimals="INF">353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q4" unitRef="shares" decimals="INF">353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q3" unitRef="usdPerShare" decimals="INF">84.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" unitRef="usdPerShare" decimals="INF">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="INF">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="INF">1.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" unitRef="usdPerShare" decimals="INF">12.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q4" unitRef="usdPerShare" decimals="INF">12.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q3YTD">P9Y72D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD">P9Y0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q3YTD">P7Y144D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q3" unitRef="usd" decimals="-2">2100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" unitRef="usd" decimals="-2">196900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q4" unitRef="usd" decimals="-2">4200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2017Q4" unitRef="usd" decimals="-2">4200</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">151000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">292000</us-gaap:AccruedProfessionalFeesCurrent>
    <SEEL:ResearchAndDevelopmentAccruedExpense contextRef="FI2018Q3" unitRef="usd" decimals="-3">853000</SEEL:ResearchAndDevelopmentAccruedExpense>
    <SEEL:ResearchAndDevelopmentAccruedExpense contextRef="FI2017Q4" unitRef="usd" decimals="-3">764000</SEEL:ResearchAndDevelopmentAccruedExpense>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">232000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">112000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:SubsequentEventsDate contextRef="From2021-01-01to2021-01-31">2021-01-28</us-gaap:SubsequentEventsDate>
    <us-gaap:SubsequentEventsDate contextRef="From2021-02-01to2021-02-28">2021-02-15</us-gaap:SubsequentEventsDate>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3">23742000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3">5120000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="shares" decimals="-3">10066000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF">4106000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF">522000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="shares" decimals="INF">3584000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="INF">8556000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">963000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">963000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">1062000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">1062000</us-gaap:DerivativeLiabilities>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;3. Business Combination&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On January 24, 2019, Apricus completed the&#13;business combination with STI in accordance with the terms of the Merger Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Merger was accounted for as a reverse&#13;recapitalization under U.S. GAAP because the primary assets of Apricus were nominal at the close of the Merger. STI was determined&#13;to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) STI stockholders and other persons&#13;holding securities convertible, exercisable or exchangeable directly or indirectly for STI common stock owned the majority of the&#13;Company immediately following the effective time of the Merger, (ii) STI holds the majority (four of five) of board seats of the&#13;combined company, and (iii) STI's management holds all key positions in the management of the combined company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;STI acquired no tangible assets and assumed&#13;no employees or operation from Apricus. Additionally, Apricus' intellectual property was considered to have no value. The remaining&#13;Apricus liabilities had a fair value of approximately $300 thousand.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In connection with the Merger, STI entered&#13;into a Contingent Value Rights Agreement (the &amp;#34;CVR Agreement&amp;#34;). Pursuant to the CVR Agreement, Apricus stockholders received&#13;one contingent value right (&amp;#34;CVR&amp;#34;) for each share of Apricus common stock held of record immediately prior to the closing&#13;of the Merger. Each CVR represents the right to receive payments based on Apricus' U.S. assets related to products in development,&#13;intended for the topical treatment of erectile dysfunction, which are known as Vitaros in certain countries outside of the United&#13;States (the &amp;#34;CVR Product Candidate&amp;#34;). In particular, CVR holders will be entitled to receive 90% of any cash payments (or&#13;the fair market value of any non-cash payments) exceeding $500,000 received, during a period of ten years from the closing of the&#13;Merger, based on the sale or out-licensing of Apricus' CVR Product Candidate intangible asset, including any milestone payments&#13;(the &amp;#34;Contingent Payments&amp;#34;), less reasonable transaction expenses. STI is entitled to retain the first $500,000 and 10%&#13;of any Contingent Payments. STI assigned no value to the CVR Product Candidate intangible asset as of December 31, 2020 or the&#13;CVR in the acquisition accounting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;5. License Agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Acquisition of License from Ligand Pharmaceuticals&#13;Incorporated&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On September 21, 2016, the Company entered&#13;into a License Agreement (the &amp;#34;License Agreement&amp;#34;) with Ligand Pharmaceuticals Incorporated (&amp;#34;Ligand&amp;#34;), Neurogen&#13;Corporation and CyDex Pharmaceuticals, Inc. (collectively, the &amp;#34;Licensors&amp;#34;), pursuant to which, among other things, the&#13;Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license&#13;under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or&#13;may be modified for use in a product to be administered by any method in any form including, without limitation injection and&#13;intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor&#13;antagonist, which is now known as SLS-010, and either or both of the Licensors' two proprietary CRTh2 antagonists, which are now&#13;known collectively as SLS-008 (collectively, the &amp;#34;Licensed Products&amp;#34;), and (ii) copyrights, trade secrets, moral rights&#13;and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts&#13;to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in&#13;its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union,&#13;the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the&#13;People's Republic of China (each, a &amp;#34;Major Market&amp;#34;) or the United States, and (c) commercialize the Licensed Products&#13;in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making&#13;authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company&#13;believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive&#13;right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In connection with the closing of the Merger,&#13;the Company issued 801,253 shares of common stock to Ligand and recognized research and development expense totaling approximately&#13;$2.2 million during the three months ended March 31, 2019 for the License Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company also agreed to pay to Ligand certain&#13;one-time, non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection with&#13;Aplindore for the indication of Parkinson's Disease (&amp;#34;PD&amp;#34;) or Restless Leg Syndrome, consisting of (i) $750,000 upon submission&#13;of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA approval&#13;of an application for a particular Licensed Product, (iii) $1.125 million upon regulatory approval in a Major Market for a particular&#13;Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major Market for a particular Licensed Product.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company also agreed to pay to Ligand certain&#13;one-time, non-refundable regulatory milestone payments in connection with the Licensed Products in connection with Aplindore for&#13;the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon submission of an application with the FDA or equivalent&#13;foreign body for such a particular Licensed Product, (ii) $350,000 upon FDA approval of an application for such a particular Licensed&#13;Product, (iii) $125,000 upon regulatory approval in a Major Market for such a particular Licensed Product, and (iv) $125,000 upon&#13;regulatory approval in a second Major Market for such a particular Licensed Product.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company agreed to pay to Ligand certain&#13;one-time, non-refundable commercial milestone payments in connection with the Licensed Products, consisting of (i) $10.0 million&#13;upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (ii) $10.0 million&#13;upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist,&#13;(iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen&#13;(as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation&#13;injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), (iv) $10.0 million upon the&#13;achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists, (v) $20.0 million&#13;upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (vi) $20.0 million&#13;upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist,&#13;(vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen&#13;(as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation&#13;injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), and (viii) $20.0 million upon&#13;the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company will also pay to Ligand middle&#13;single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication&#13;of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental&#13;royalty in the upper single digit to lower double digit range on aggregate annual net sales of Licensed Products in connection&#13;with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a&#13;licensed patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed&#13;Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed&#13;Products are not covered under a licensed patent and a tiered incremental royalty in the lower single digit to middle single digit&#13;range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg&#13;Syndrome in a country where such Licensed Products are not covered under a licensed patent.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The potential regulatory and commercial milestones&#13;are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Acquisition of Assets from Phoenixus AG&#13;f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (&amp;#34;Vyera&amp;#34;)&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On March 6, 2018, the Company entered into&#13;an asset purchase agreement with Vyera, pursuant to which the Company acquired the assets (the &amp;#34;Vyera Assets&amp;#34;) and liabilities&#13;(the &amp;#34;Vyera Assumed Liabilities&amp;#34;) of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The&#13;Company is obligated to use commercially reasonable efforts to seek regulatory approval in the United States for and commercialize&#13;SLS-002.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As consideration for the Vyera Assets, the&#13;Company paid to Vyera a non-refundable cash payment of $150,000 on May 21, 2018. As further consideration for the Vyera Assets,&#13;upon public announcement of the entry by Apricus and STI into the Merger Agreement, the Company paid to Vyera a non-refundable&#13;cash payment of $150,000. As further consideration for the Vyera Assets, the Company issued to Vyera 191,529 shares of common stock&#13;and paid Vyera a non-refundable cash payment of $1,000,000 on January 29, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Pursuant to the amendment to the asset purchase&#13;agreement entered into by the Company and Vyera on October 15, 2019, the Company issued Vyera 1,809,845 registered shares of the&#13;Company's common stock on January 2, 2020 and made cash payments to Vyera in the amounts of $750,000, $750,000, $1.0 million and&#13;$1.0 million in October 2019, January 2020, April 2020 and July 2020, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In the event that the Company sells, directly&#13;or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company must pay Vyera an amount equal to&#13;4% of the net proceeds actually received by the Company as an upfront payment in such sale.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company agreed to pay to Vyera certain&#13;one-time, non-refundable milestone payments consisting of (i) $10.0 million upon approval by the FDA of a new drug application&#13;(an &amp;#34;NDA&amp;#34;), with respect to SLS-002, (ii) $5.0 million upon approval by the European Medicines Agency (the &amp;#34;EMA&amp;#34;)&#13;of the foreign equivalent to an NDA with respect to SLS-002 in a Major Market, (iii) $2.5 million upon approval by the EMA of the&#13;foreign equivalent to an NDA with respect to SLS-002 in a second Major Market, (iv) $5.0 million upon the achievement of $250.0&#13;million in net sales of SLS-002, (v) $10.0 million upon the achievement of $500.0 million in net sales of SLS-002, (vi) $15.0 million&#13;upon the achievement of $1.0 billion in net sales of SLS-002, (vii) $20.0 million upon the achievement of $1.5 billion in net sales&#13;of SLS-002, and (viii) $25.0 million upon the achievement of $2.0 billion in net sales of SLS-002. The Company will also pay to&#13;Vyera a royalty percentage in the mid-single digits on aggregate annual net sales of SLS-002.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The potential regulatory and commercial milestones&#13;are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Acquisition of License from Stuart Weg,&#13;MD&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On August 29, 2019, the Company entered into&#13;an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &amp;#34;Weg License Agreement&amp;#34;), pursuant to which&#13;the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002.&#13;Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement.&#13;The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million&#13;on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or&#13;before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020 and $0.125&#13;million on January 2, 2021. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of&#13;(i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company's common stock&#13;upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and&#13;unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that&#13;has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom,&#13;France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the &amp;#34;Milestone&#13;Product&amp;#34;), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval&#13;by the EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however,&#13;that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr.&#13;Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The potential regulatory and commercial milestones&#13;are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Acquisition of Assets from Bioblast Pharma&#13;Ltd. (&amp;#34;Bioblast&amp;#34;)&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On February 15, 2019, the Company entered&#13;into an Asset Purchase Agreement (the &amp;#34;Bioblast Asset Purchase Agreement&amp;#34;) with Bioblast. Pursuant to the Bioblast Asset&#13;Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the&#13;&amp;#34;Bioblast Asset Purchase&amp;#34;). The Company paid to Bioblast $1.5 million in cash, and the Company paid to Bioblast an additional&#13;$2.0 million in February 2020. Accordingly, the Company recognized a $3.5 million charge to research and development expense during&#13;the year ended December 31, 2019. Under the terms of the Bioblast Asset Purchase Agreement, the Company agreed to pay additional&#13;consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (i) within 15 days following the&#13;completion of the Company's first Phase II(b) clinical trial of Trehalose satisfying certain criteria, the Company will pay to&#13;Bioblast $8.5 million; and (ii) within 15 days following the approval for commercialization by the FDA or the Health Products and&#13;Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates,&#13;the Company will pay to Bioblast $8.5 million. In addition, the Company agreed to pay Bioblast a cash royalty equal to 1% of the&#13;net sales of Trehalose. Under the terms of the Bioblast Asset Purchase, the Company assumed a collaborative agreement with TSF,&#13;a nonprofit medical research foundation founded by parents of children with Sanfilippo syndrome. TSF, upon approval by the FDA,&#13;planned to begin an open label, Phase II(b) clinical trial in up to 20 patients with Sanfilippo syndrome, which is now known under&#13;the study name SLS-005. The Company will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement&#13;entitle the Company access to all clinical data from this trial. On July 15, 2019, TSF and the Company amended the agreement whereby&#13;the Company agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5&#13;million towards the funding of the trial.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The potential regulatory and commercial milestones&#13;are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Acquisition of License from The Regents&#13;of the University of California&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On March 7, 2019, the Company entered into&#13;an exclusive license agreement (the &amp;#34;UC Regents License Agreement&amp;#34;) with The Regents of the University of California (&amp;#34;The&#13;UC Regents&amp;#34;) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents&#13;pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology&#13;relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (&amp;#945;-synuclein).&#13;The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders&#13;affecting the central nervous system (&amp;#34;CNS&amp;#34;). This program is now known as SLS-007. Upon entry into the UC Regents License&#13;Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense&#13;during the year ended December 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional&#13;consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the completion&#13;of dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing&#13;of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of&#13;the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial&#13;sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market,&#13;the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed&#13;product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product,&#13;if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate&#13;the agreement or reduce the Company's license to a nonexclusive license.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The potential regulatory and commercial milestones&#13;are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Acquisition of License from Duke University&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On June 27, 2019, the Company entered into&#13;an exclusive license agreement (the &amp;#34;Duke License Agreement&amp;#34;) with Duke University pursuant to which the Company was granted&#13;an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression.&#13;The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders&#13;affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University&#13;$0.1 million and recognized $0.1 million charge to research and development expense during the year ended December 31, 2019. The&#13;Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as&#13;follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive&#13;validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase&#13;I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical&#13;trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial,&#13;the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company&#13;is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain&#13;milestones within a specified timeframe, Duke University may terminate the agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The potential regulatory and commercial milestones&#13;are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;8. Stockholders' Equity&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company is authorized to issue 10,000,000&#13;shares of preferred stock, par value $0.001. No shares of preferred stock were outstanding as of December 31, 2020 or 2019.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company has authorized 120,000,000 shares&#13;of common stock as of December 31, 2020 and 2019. Each share of common stock is entitled to one voting right. Common stock owners&#13;are entitled to dividends when funds are legally available and declared by the Board of Directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;September 2020 Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The September 2020 Warrants are exercisable&#13;for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants are exercisable&#13;beginning six months after the date of issuance and have a term of five and a half years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020, 6.6 million September&#13;2020 Warrants remain outstanding at an exercise price of $0.84 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;August 2019 Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The August 2019 Warrants are exercisable for&#13;2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants are exercisable beginning&#13;six months after the date of issuance and have a term of four years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020, 2.2 million August&#13;2019 Warrants remain outstanding at an exercise price of $1.78 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;Series A Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Series A Warrants were initially exercisable&#13;for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to&#13;the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent&#13;adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as&#13;a result of the announcement of the offerings pursuant to the September 2020 Securities Purchase Agreement. The Series A Warrants&#13;were immediately exercisable upon issuance and will expire on January 31, 2024.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;During the year ended December 31, 2020 and&#13;2019, 0.2 million and 2.7 million Series A Warrants were exercised for approximately $45 thousand and $4.5 million, respectively.&#13;As of December 31, 2020, 0.8 million Series A Warrants remain outstanding at an exercise price of $0.2957 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;Series B Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Series B Warrants were initially exercisable&#13;for no shares of common stock, which was adjusted to 7,951,090 shares of common stock on February 27, 2019 and which was further&#13;adjusted to 11,614,483 shares of common stock on March 7, 2019, in each case essentially due to trading at a lower price, pursuant&#13;to the terms thereof. The Series B Warrants had an exercise price of $0.001, were immediately exercisable upon issuance and provided&#13;for an expiration date of the day following the later to occur of (i) the Reservation Date (as defined therein), and (ii) the date&#13;on which the Series B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein)&#13;and no shares remain issuable thereunder.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;During the year ended December 31, 2019, 11.6&#13;million Series B Warrants were exercised for approximately $11,614. As of December 31, 2019, no Series B Warrants remain outstanding&#13;and the Series B Warrants are therefore no longer subject to any further changes in warrants or exercise price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;A summary of warrant activity during the&#13;year ended December 31, 2020 is as follows (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 50%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in years) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Assumed in Merger&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;437&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20.59&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.5&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;17,481&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.42&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.1&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(14,334)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.31&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,584&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.86&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.3&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,648&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.84&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(154)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.30&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(12)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18.00&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,066&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.84&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.4&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercisable as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,417&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.79&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.7&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Series A Warrants and the Series B Warrants&#13;were each recognized as a liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value&#13;prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the&#13;period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;9. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company has the Amended and Restated&#13;Apricus 2012 Stock Long Term Incentive Plan (the &amp;#34;2012 Plan&amp;#34;), which provides for the issuance of incentive and non-incentive&#13;stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted&#13;stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant.&#13;As of December 31, 2020, an aggregate of 8,038,582 shares of common stock were authorized under the Apricus 2012 Plan, of which&#13;3.2 million shares of common stock were available for future grants. Upon completion of the Merger, the Company assumed the Seelos&#13;Therapeutics, Inc. 2016 Equity Incentive Plan (the &amp;#34;2016 Plan&amp;#34;) and awards outstanding under the 2016 Plan became awards&#13;for common stock. Effective as of the Merger, no further awards may be issued under the 2016 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On May 15, 2020, the Company's stockholders&#13;approved the Company's 2020 Employee Stock Purchase Plan (the &amp;#34;ESPP&amp;#34;), whereby qualified employees are allowed to purchase&#13;limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering&#13;period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The&#13;ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under&#13;the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount&#13;shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately&#13;preceding December 31, and (ii) a number of shares of common stock set by the Company's Board of Directors or the Compensation&#13;Committee of the Board of Directors (the &amp;#34;Compensation Committee&amp;#34;) of the Company on or prior to each such January 1. The&#13;Company did not sell any shares under the ESPP during the year ended December 31, 2020. The compensation costs are calculated as&#13;the fair value of the 15% discount from market price and were approximately $13,000 for the year ended December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On July 28, 2019, the Compensation Committee&#13;adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &amp;#34;2019 Inducement Plan&amp;#34;), which became effective on August&#13;12, 2019. The 2019 Inducement Plan is substantially similar to the 2016 Plan. The 2019 Inducement Plan provides for the grant of&#13;equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units,&#13;including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate&#13;of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual,&#13;as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee&#13;or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number&#13;of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company's common stock. The 2019 Inducement&#13;Plan is administered by the Compensation Committee and expires on August 12, 2029.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;Stock options&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;During the year ended December 31, 2020, the&#13;Company granted 4,444,895 stock options to employees with a weighted average exercise price per share of $1.16 and a 10-year term,&#13;subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting requirements. The stock&#13;options granted to employees vest 25% on the first anniversary of the grant and monthly thereafter over the next three years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;During the year ended December 31, 2020, the&#13;Company also granted 179,000 non-qualified stock options to non-employee directors and a consultant with a weighted average exercise&#13;price per share of $1.15 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. 24,000 of the stock options&#13;granted to non-employee directors vest 1/3rd on the first anniversary of the grant and monthly thereafter over the next two years.&#13;80,000 of the stock options granted to non-employee directors vest monthly over the 12 months following the grant. 75,000 of the&#13;stock options granted to a consultant vest 25% on the first anniversary of the grant and monthly thereafter over the next 3 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The fair value of stock option grants are&#13;estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and&#13;lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility&#13;based on the historical volatility of a publicly traded set of peer companies. Additionally, due to an insufficient history with&#13;respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a&#13;permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free&#13;interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the&#13;expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and&#13;does not expect to pay any cash dividends in the foreseeable future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;During the year ended December 31, 2020, no&#13;stock options were exercised and 26,001 options were forfeited.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following assumptions were used in determining&#13;the fair value of the stock options granted during the years ended December 31, 2020 and 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 59%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.3%-1.7%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.6%-2.6%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;109%-119%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;109%-113%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Expected term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Weighted-average fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.76&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;A summary of stock option activity during&#13;the year ended December 31, 2020 is as follows (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average Remaining&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Stock&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 42%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Life (in years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;522&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.18&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.0&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,624&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.16&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.3&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(26)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.96&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,120&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.97&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.2&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,969&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested and expected to vest as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;353&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12.45&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.4&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercisable as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;353&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12.45&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.4&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company recorded $2.0 million and $459,000&#13;in stock-based compensation expense for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following table summarizes the total stock-based&#13;compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;394&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;118&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,650&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;341&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,044&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;459&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;11. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In March 2019, the Company entered into a&#13;nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019 the&#13;Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November&#13;2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;For the years ended December 31, 2020 and&#13;2019, rent expense totaled $0.1 million and $0.1 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Future minimum rental payments under operating&#13;lease as of December 31, 2020 are approximately $42,000 for 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;Contractual Commitments&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company has entered into long-term agreements&#13;with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects&#13;to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which&#13;may require up-front payments and long-term commitments of cash.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020, there was no material&#13;litigation against the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;12. Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Public Offering&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On January 28, 2021, the Company completed&#13;an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public&#13;of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional&#13;shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting&#13;discounts and commissions and other estimated offering expenses payable by the Company. The Company used $3.8 million of the net&#13;proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Amendment of Asset Purchase Agreement with&#13;Vyera&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On February 15, 2021 the Company entered into&#13;an amendment to the asset purchase agreement with Vyera. Pursuant to the amendment, the Company agreed to make cash payments to&#13;Vyera in the amount of $3.0 million in each of February 2021, June 2021 and September 2021 in exchange for a lower royalty percentage&#13;on potential net sales of SLS-002.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following tables present information&#13;about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the&#13;fair value hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during&#13;the years ended December 31, 2020 and 2019 (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 40%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 1) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 2) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 3) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,662&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,662&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liabilities, at fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 40%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 1) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 2) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 3) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,261&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,261&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liabilities, at fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following assumptions were used in determining&#13;the fair value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2020 and 2019:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 55%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.18%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.66%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;116.77%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;110.80%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.07&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted-average fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.06&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following table is a reconciliation for&#13;the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 65%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 33%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrant liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant issued in connection with financing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21,535&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liability reclassified to stockholders' equity&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(37,073)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in fair value measurement of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;16,501&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liability reclassified to stockholders' equity&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(124)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in fair value measurement of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;223&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following potentially dilutive securities&#13;outstanding for the year ended December 31, 2020 and 2019 have been excluded from the computation of diluted weighted average&#13;shares outstanding, as they would be anti-dilutive (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,120&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;522&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,066&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,584&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,556&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;23,742&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,106&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Accrued expenses are comprised of the following&#13;(in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;292&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;151&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Personnel related&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;756&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;683&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outside research and development services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;764&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;853&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;112&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;232&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Accrued expenses, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,924&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,919&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;A summary of warrant activity during the&#13;year ended December 31, 2020 is as follows (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 50%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in years) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Assumed in Merger&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;437&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20.59&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.5&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;17,481&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.42&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.1&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(14,334)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.31&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,584&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.86&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.3&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,648&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.84&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(154)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.30&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(12)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18.00&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,066&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.84&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.4&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercisable as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,417&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.79&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.7&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following table summarizes the total&#13;stock-based compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations&#13;(in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;394&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;118&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,650&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;341&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,044&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;459&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following assumptions were used in determining&#13;the fair value of the stock options granted during the years ended December 31, 2020 and 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 59%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.3%-1.7%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.6%-2.6%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;109%-119%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;109%-113%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Expected term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="background-color: white"&gt;&lt;font style="font-size: 10pt"&gt;Weighted-average fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.76&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;A summary of stock option activity during&#13;the year ended December 31, 2020 is as follows (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average Remaining&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Stock&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 42%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Life (in years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;522&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.18&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.0&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,624&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.16&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.3&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(26)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.96&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of December 31, 20120&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,120&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.97&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.2&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,969&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested and expected to vest as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;353&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12.45&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.4&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercisable as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;353&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12.45&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.4&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The reconciliation of income taxes computed&#13;using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31,&#13;2020 and 2019, are as follows:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 73%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Federal statutory tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21.0&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21.0&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;State and local taxes, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11.2&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.7&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Permanent items&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1.0)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(9.0)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Deferred rate changes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.1&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;59.3&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(90.6)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(18.4)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Income tax provision (benefit)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;A reconciliation of the Company's unrecognized&#13;tax benefits for the years ended December 31, 2020 and 2019, are as follows (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;718&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in current period positions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in prior period positions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(718)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Deferred tax assets consist of the following&#13;(in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Net operating tax loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,223&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,632&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;66&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;348&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;521&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Start up cost&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,320&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,806&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Total deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28,130&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,870&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Less valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(28,130)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(10,870)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="INF">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="INF">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" unitRef="usdPerShare" decimals="INF">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="usdPerShare" decimals="INF">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P3Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-12-31_srt_MaximumMember">P7Y0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-12-31_srt_MinimumMember">P5Y0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">P7Y0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-01to2019-12-31_srt_MinimumMember">P5Y0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">P4Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" unitRef="number" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="number" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" unitRef="number" decimals="INF">1.1677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="number" decimals="INF">1.1080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:UseOfEstimates contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The preparation of these consolidated financial&#13;statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts&#13;of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the&#13;reported amounts of expenses during the reporting period. The most significant estimates in the Company's financial statements&#13;relate to the valuation of warrants, valuation of convertible notes payable, valuation of common stock and the valuation of stock&#13;options. These estimates and assumptions are based on current facts, historical experience and various other factors believed&#13;to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of&#13;assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ&#13;materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results,&#13;the Company's future results of operations will be affected.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Merger with Apricus Biosciences, Inc.&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On January 24, 2019, Apricus Biosciences,&#13;Inc., a Nevada corporation (&amp;#34;Apricus&amp;#34;), completed a business combination with Seelos Therapeutics, Inc., a Delaware corporation&#13;(&amp;#34;STI&amp;#34;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &amp;#34;Merger Agreement&amp;#34;)&#13;entered into on July 30, 2018. Pursuant to the Merger Agreement, (i) a subsidiary of Apricus merged with and into STI, with STI&#13;(renamed as &amp;#34;Seelos Corporation&amp;#34;) continuing as a wholly owned subsidiary of Apricus and the surviving corporation of&#13;the merger and (ii) Apricus was renamed as &amp;#34;Seelos Therapeutics, Inc.&amp;#34; (the &amp;#34;Merger&amp;#34;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Merger was accounted for as a reverse&#13;recapitalization under United States generally accepted accounting principles (&amp;#34;U.S. GAAP&amp;#34;) because the primary assets&#13;of Apricus were nominal following the close of the Merger. STI was determined to be the accounting acquirer based upon the terms&#13;of the Merger and other factors, including: (i) STI's stockholders and other persons holding securities convertible, exercisable&#13;or exchangeable directly or indirectly for STI common stock owned the majority of Apricus immediately following the effective time&#13;of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company and (iii) STI's management holds&#13;all key positions in the management of the combined company. Accordingly, the historical financial statements of STI became the&#13;Company's historical financial statements, including the comparative prior periods.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Research and development costs are expensed&#13;as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related&#13;expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development&#13;and consulting agreements in place.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Income taxes are accounted for under the&#13;asset and liability method.&amp;#160;Deferred income taxes are recorded for temporary differences between financial statement carrying&#13;amounts and the tax basis of assets and liabilities.&amp;#160;Deferred tax assets and liabilities reflect the tax rates expected to&#13;be in effect for the years in which the differences are expected to reverse.&amp;#160;A valuation allowance is provided if it is more&#13;likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company also follows the provisions of&#13;accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken&#13;or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure&#13;and transition.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Income (Loss) Per Common Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Basic loss per share is computed by dividing&#13;net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period.&#13;Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible&#13;debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic&#13;and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both&#13;calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is&#13;anti-dilutive.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company expenses stock-based compensation&#13;to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of&#13;the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules&#13;are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The&#13;Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used&#13;in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and&#13;the application of management's judgment. All stock-based compensation costs are recorded in general and administrative or research&#13;and development costs in the statements of operations based upon the underlying individual's role at the Company.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In August 2018, the FASB issued Accounting&#13;Standards Update (&amp;#34;ASU&amp;#34;) No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure&#13;Requirements for Fair Value Measurement (&amp;#34;ASU 2018-13&amp;#34;). The amendments in this ASU require certain existing disclosure&#13;requirements in Topic 820 to be modified or removed, and certain new disclosure requirements to be added to the Topic. In addition,&#13;this ASU allows entities to exercise more discretion when considering fair value measurement disclosures. The Company adopted&#13;ASU 2018-13 effective January 1, 2020. The adoption of ASU 2018-13 did not have a material effect on the Company's financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In December 2019, the FASB issued ASU No.&#13;2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&amp;#34;ASU 2019-12&amp;#34;), which is intended to simplify&#13;various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic&#13;740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years,&#13;and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is&#13;currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In August 2020, the FASB issued ASU 2020-06:&#13;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity&#13;(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This standard simplifies the&#13;accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature,&#13;as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt&#13;instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest&#13;expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of&#13;ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per&#13;share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable&#13;for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after&#13;December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company is evaluating&#13;the impact of ASU 2020-06 on its consolidated financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company records a right-of use (&amp;#34;ROU&amp;#34;)&#13;asset and a lease liability on its balance sheet for all leases with terms of 12 months or longer. Leases are classified as either&#13;finance or operating, with classification affecting the pattern of expense recognition in the income statement. Historically,&#13;the Company recorded rent expense associated with its operating lease on a straight-line basis over the term of the lease. The&#13;difference between rent payments and straight-line rent expense was recorded as deferred rent in accrued liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020, the Company's leases&#13;had original terms of 12 months or less. The Company does not recognize ROU assets and lease liabilities that arise from leases&#13;with an original term of 12 months or less. Rather the Company recognizes the lease payments on a straight-line basis over the&#13;term of the lease.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_apri_TwoThousandTwelveIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_apri_TwoThousandTwelveIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_apri_TwoThousandTwelveIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q4_us-gaap_PlanNameAxis_apri_TwoThousandTwelveIncentivePlanMember" unitRef="shares" decimals="INF">67731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;4. Common Stock Offerings&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Securities Purchase Agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;December 2020 Convertible Note and Private&#13;Placement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In December 2020, the Company issued an aggregate&#13;of 1,112,219 shares of common stock in conjunction with the issuance of convertible notes at a discount for aggregate net proceeds&#13;of $10.9 million (see Note 7).&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;2020 Registered Direct Offering and Concurrent&#13;Private Placement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On September 4, 2020, the Company entered&#13;into a Securities Purchase Agreement with certain institutional investors (the &amp;#34;September 2020 Securities Purchase Agreement&amp;#34;)&#13;pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering,&#13;resulting in total net proceeds of $6.4 million, after deducting the placement agent's fees and other offering expenses. The shares&#13;were offered by the Company pursuant to the Company's shelf registration statement on Form S-3 filed with the Securities and Exchange&#13;Commission (the &amp;#34;SEC&amp;#34;) on November 2, 2017, as amended. The Company also issued to the investors warrants to purchase up&#13;to 6,648,750 shares of common stock in a concurrent private placement (the &amp;#34;September 2020 Warrants&amp;#34;). The September 2020&#13;Warrants have an exercise price of $0.84 per share of common stock, will be exercisable beginning on March 9, 2021 and will expire&#13;on March 9, 2026.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The combined purchase price for one share&#13;and one warrant to purchase 0.75 of a share of common stock in the offerings was $0.79. The closing of the offerings occurred on&#13;September 9, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;2019 Registered Direct Offering and Concurrent&#13;Private Placement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On August 23, 2019, the Company entered into&#13;a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company issued and sold an aggregate&#13;of 4,475,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million,&#13;before deducting the placement agents' fees and other estimated offering expenses. The shares were offered by the Company pursuant&#13;to the Company's shelf registration statement on Form S-3 filed with the SEC on November 2, 2017, as amended. The Company issued&#13;to the investors warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the &amp;#34;August&#13;2019 Warrants&amp;#34;). The August 2019 Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six&#13;months from the date of issuance and will expire four years following the date of issuance. The combined purchase price for one&#13;share and one warrant to purchase half of a share of common stock in the offerings was $1.50. Roth Capital Partners, LLC (&amp;#34;Roth&amp;#34;)&#13;served as the placement agent for the issuance and sale of the shares and the warrants, and the Company paid Roth an aggregate&#13;fee equal to 7.0% of the gross proceeds received by the Company in the offerings.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Public Offerings&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On March 16, 2020, the Company completed an&#13;underwritten public offering pursuant to which it sold 7,500,000 shares of its common stock at a price to the public of $0.60 per&#13;share. The net proceeds to the Company from this offering were approximately $4.0 million, after deducting underwriting discounts&#13;and commissions and other offering expenses payable by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On February 13, 2020, the Company completed&#13;an underwritten public offering, pursuant to which it sold 6,666,667 shares of its common stock at a price to the public of $0.75&#13;per share. On February 19, 2020, the Company sold an additional 999,999 shares of its common stock at a price to the public of&#13;$0.75 per share pursuant to the full exercise of the underwriters' option to cover over-allotments. The net proceeds to the Company&#13;from this offering were approximately $4.8 million, after deducting underwriting discounts and commissions and other offering expenses&#13;payable by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Stock Purchase Agreement with Vyera&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On January 2, 2020, the Company entered into&#13;a stock purchase agreement (the &amp;#34;Stock Purchase Agreement&amp;#34;) with Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing&#13;Pharmaceuticals AG (&amp;#34;Vyera&amp;#34;), pursuant to which the Company issued to Vyera 1,809,845 registered shares of the Company's&#13;common stock (the &amp;#34;Shares&amp;#34;). The Company entered into the Stock Purchase Agreement in accordance with an asset purchase&#13;agreement with Vyera, as amended by the amendment entered into with Vyera on October 15, 2019 (see Note 5). As partial consideration&#13;for the assets of Vyera, the Company agreed to issue the Shares pursuant to the Stock Purchase Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Consulting Agreement&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On May 11, 2020, the Company entered&#13;into a consulting agreement (the &amp;#34;Consulting Agreement&amp;#34;) with an advisory firm, pursuant to which the advisory firm&#13;agreed to provide the Company with certain management consulting, business and advisory services. The Company agreed to issue&#13;the advisory firm 300,000 unregistered shares of the Company's common stock, which shares were issued on May 11, 2020, plus&#13;$80,000 in cash. On June 9, 2020, the Company and the advisory firm entered into an amendment to the Consulting Agreement&#13;(the &amp;#34;Amendment&amp;#34;). Pursuant to the Amendment, the advisory firm agreed to provide the Company with additional&#13;services and, in consideration, the Company agreed to issue the advisory firm an additional 200,000 unregistered shares of&#13;the Company's common stock (the &amp;#34;Additional Shares&amp;#34;), plus $20,000 in cash. The Additional Shares were issued to the&#13;advisory firm on June 9, 2020 and are subject to certain vesting restrictions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Through December 31, 2020, the Company has&#13;recognized approximately $431,000 of consulting expense under this Consulting Agreement. On July 9, 2020, the Company cancelled&#13;the Consulting Agreement with an effective date of August 9, 2020. The Company also canceled 100,000 shares that will not vest&#13;due to the cancellation of the Consulting Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Equity Distribution Agreement&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On June 17, 2019, the Company entered into&#13;an Equity Distribution Agreement (the &amp;#34;Equity Distribution Agreement&amp;#34;) with Piper Jaffray &amp;#38; Co., as sales agent (&amp;#34;Piper&#13;Jaffray&amp;#34;), pursuant to which the Company could offer and sell, from time to time, through Piper Jaffray (the &amp;#34;Offering&amp;#34;)&#13;up to $50,000,000 in shares. Under the terms of the Equity Distribution Agreement, Piper Jaffray was entitled to a commission at&#13;a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Equity Distribution Agreement. During the year ended&#13;December 31, 2019, the Company sold 1,197,676 shares for net proceeds of approximately $2.6 million pursuant to the Equity Distribution&#13;Agreement. On August 23, 2019, the Company suspended its continuous offering under the Equity Distribution Agreement and the Equity&#13;Distribution Agreement terminated in accordance with its terms on December 7, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Pre-Merger Financing&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On January 24, 2019, STI and Apricus closed&#13;a private placement transaction with certain accredited investors (the &amp;#34;Investors&amp;#34;), whereby, among other things, STI issued&#13;to investors shares of STI's common stock immediately prior to the Merger in a private placement transaction (the &amp;#34;Financing&amp;#34;),&#13;pursuant to a Securities Purchase Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors,&#13;as amended (the &amp;#34;Purchase Agreement&amp;#34;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Pursuant to the Purchase Agreement, STI (i)&#13;issued and sold to the Investors an aggregate of 2,374,672 shares of STIs common stock which converted pursuant to the exchange&#13;ratio in the Merger into the right to receive 1,829,407 shares of the Company's common stock and (ii) issued warrants representing&#13;the right to acquire 1,463,519 shares of common stock at a price per share of $4.15, subject to adjustment as provided therein&#13;(the &amp;#34;Series A Warrants&amp;#34;), most recently adjusted to a price per share of $0.2957 per share, and additional warrants initially&#13;representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided therein&#13;(the &amp;#34;Series B Warrants&amp;#34; together with the Series A Warrants, the &amp;#34;Investor Warrants&amp;#34;), for aggregate gross proceeds&#13;of $18.0 million, or $16.5 million net of financing fees. The terms of the Investor Warrants included certain provisions that could&#13;result in adjustments to both the number of warrants issued and the exercise price of each warrant, which resulted in the warrants&#13;being classified as a liability upon issuance (see Note 8). The Investor Warrants were recorded at fair value of $21.5 million&#13;upon issuance and given the liability exceed the proceeds received, a loss of $5.0 million was recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On March 7, 2019, the Company entered into&#13;Amendment Agreements (collectively, the &amp;#34;Amendment Agreements&amp;#34;) with each Investor amending: (i) the Purchase Agreement,&#13;(ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate&#13;number of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised&#13;as of March 7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment&#13;to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment&#13;Agreements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;At December 31, 2020, 0.8 million Series A&#13;Warrants remain unexercised. All Series B Warrants were exercised during the year ended December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;6. Accrued Expenses&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Accrued expenses are comprised of the following&#13;(in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 74%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;292&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;151&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Personnel related&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;756&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;683&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outside research and development services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;764&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;853&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;112&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;232&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Accrued expenses, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,924&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,919&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="FD2018Q3YTD">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityListingSecurityTradingCurrency contextRef="FD2018Q3YTD">USD</dei:EntityListingSecurityTradingCurrency>
    <dei:EntityListingParValuePerShare contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="INF">0.001</dei:EntityListingParValuePerShare>
    <dei:Security12bTitle contextRef="FD2018Q3YTD">Common Stock</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="FD2018Q3YTD">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFileNumber contextRef="FD2018Q3YTD">000-22245</dei:EntityFileNumber>
    <us-gaap:AssetsCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">11096000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">17494000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">835000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">1832000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets contextRef="FI2018Q3" unitRef="usd" decimals="-3">11096000</us-gaap:Assets>
    <us-gaap:Assets contextRef="FI2017Q4" unitRef="usd" decimals="-3">17494000</us-gaap:Assets>
    <us-gaap:PreferredStockValue contextRef="FI2018Q3" unitRef="usd" decimals="-3">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="FI2017Q4" unitRef="usd" decimals="-3">0</us-gaap:PreferredStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q3" unitRef="usd" decimals="-3">11096000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" unitRef="usd" decimals="-3">17494000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q3" unitRef="usd" decimals="-3">56027000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" unitRef="usd" decimals="-3">77680000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="FI2018Q3" unitRef="usd" decimals="-3">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="FI2017Q4" unitRef="usd" decimals="-3">54000</us-gaap:CommonStockValue>
    <SEEL:LicensePayablesLongterm contextRef="FI2018Q3" unitRef="usd" decimals="-3">325000</SEEL:LicensePayablesLongterm>
    <SEEL:LicensePayablesLongterm contextRef="FI2017Q4" unitRef="usd" decimals="-3">200000</SEEL:LicensePayablesLongterm>
    <us-gaap:Liabilities contextRef="FI2018Q3" unitRef="usd" decimals="-3">11103000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="FI2017Q4" unitRef="usd" decimals="-3">14922000</us-gaap:Liabilities>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">963000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">1062000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">10778000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">7429000</us-gaap:LiabilitiesCurrent>
    <SEEL:LicensePayables contextRef="FI2018Q3" unitRef="usd" decimals="-3">7100000</SEEL:LicensePayables>
    <SEEL:LicensePayables contextRef="FI2017Q4" unitRef="usd" decimals="-3">125000</SEEL:LicensePayables>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">1919000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">1924000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">796000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">1887000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:CommonStockSharesIssued contextRef="FI2018Q3" unitRef="shares" decimals="INF">27028533</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" unitRef="shares" decimals="INF">54535891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q3" unitRef="shares" decimals="INF">27028533</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" unitRef="shares" decimals="INF">54535891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">375000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="FD2018Q3YTD">us-gaap:GrantMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="FD2017Q4YTD">us-gaap:GrantMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:OperatingIncomeLoss contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">-18759000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">-29747000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">18759000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">30122000</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">7775000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">7559000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">10984000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">22563000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF">44766640</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF">20308818</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="INF">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="INF">-2.52</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:InterestIncomeDomesticDeposits contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">45000</us-gaap:InterestIncomeDomesticDeposits>
    <us-gaap:InterestIncomeDomesticDeposits contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">151000</us-gaap:InterestIncomeDomesticDeposits>
    <SEEL:ChangeInFairValueOfConvertibleNotesPayable contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:ChangeInFairValueOfConvertibleNotesPayable>
    <SEEL:ChangeInFairValueOfConvertibleNotesPayable contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">-109000</SEEL:ChangeInFairValueOfConvertibleNotesPayable>
    <us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">-342000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">-21508000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">164000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">29000</us-gaap:InterestExpense>
    <us-gaap:ShareBasedCompensation contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">2044000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">459000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">192000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">3000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <SEEL:IncreaseDecreaseInFairValueOfConvertibleNotesPayable contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:IncreaseDecreaseInFairValueOfConvertibleNotesPayable>
    <SEEL:IncreaseDecreaseInFairValueOfConvertibleNotesPayable contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">109000</SEEL:IncreaseDecreaseInFairValueOfConvertibleNotesPayable>
    <us-gaap:RecapitalizationCosts contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:RecapitalizationCosts>
    <us-gaap:RecapitalizationCosts contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">5020000</us-gaap:RecapitalizationCosts>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">791000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">686000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">1091000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">-1424000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">5000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">1533000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">13000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">-4850000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">7425000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">16520000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <SEEL:ProceedsFromIssuanceOfCommonStockInAtthemarketOffering contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:ProceedsFromIssuanceOfCommonStockInAtthemarketOffering>
    <SEEL:ProceedsFromIssuanceOfCommonStockInAtthemarketOffering contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">2567000</SEEL:ProceedsFromIssuanceOfCommonStockInAtthemarketOffering>
    <us-gaap:ProceedsFromWarrantExercises contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">45000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">4517000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">10907000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">26314000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">29524000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">5401000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">10219000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:InterestPaidNet contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">11000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">16000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</us-gaap:IncomeTaxesPaid>
    <SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity>
    <SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">31473000</SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity>
    <SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity>
    <SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">31473000</SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity>
    <SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity>
    <SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">124000</SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash>
    <SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">5600000</SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash>
    <SEEL:EffectOfReverseMerger contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:EffectOfReverseMerger>
    <SEEL:EffectOfReverseMerger contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">299000</SEEL:EffectOfReverseMerger>
    <SEEL:IssuanceOfCommonStockForConversionOfAccruedInterest contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForConversionOfAccruedInterest>
    <SEEL:IssuanceOfCommonStockForConversionOfAccruedInterest contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">164000</SEEL:IssuanceOfCommonStockForConversionOfAccruedInterest>
    <SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">2715000</SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest>
    <SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest>
    <SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">2715000</SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest>
    <SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">9000</SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">2000</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">2441000</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">3000000</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">1000</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">2999000</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockForLicenseAcquired contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForLicenseAcquired>
    <SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">1829407</SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares>
    <SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">2000</SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability>
    <SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">2000</SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability>
    <SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability>
    <SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">947218</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">299000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">300000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <SEEL:IssuanceOfCommonStockForLicenseAcquiredShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">1809845</SEEL:IssuanceOfCommonStockForLicenseAcquiredShares>
    <SEEL:IssuanceOfCommonStockForLicenseAcquiredShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">992782</SEEL:IssuanceOfCommonStockForLicenseAcquiredShares>
    <SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">0</SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares>
    <SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">5600000</SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash>
    <SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash>
    <SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">5600000</SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash>
    <SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash>
    <SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">0</SEEL:ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares>
    <SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">172284</SEEL:IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares>
    <SEEL:IssuanceOfCommonStockForConversionOfDebt contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForConversionOfDebt>
    <SEEL:IssuanceOfCommonStockForConversionOfDebt contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">2551000</SEEL:IssuanceOfCommonStockForConversionOfDebt>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">1112219</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">4475000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares>
    <SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">1197676</SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">1379000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">1000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">1378000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">5920000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">5000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">5915000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">2567000</SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">1000</SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">2566000</SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts>
    <us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;7. Debt&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Convertible Notes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;December 2020 Convertible Note and Private&#13;Placement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On December 11, 2020, the Company entered&#13;into a Securities Purchase Agreement (the &amp;#34;Lind Securities Purchase Agreement&amp;#34;) with Lind Global Asset Management II,&#13;LLC (the &amp;#34;Investor&amp;#34;) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor,&#13;in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note&#13;(the &amp;#34;Note&amp;#34;) in an aggregate principal amount of $12,000,000 (the &amp;#34;Principal Amount&amp;#34;), which will bear no interest&#13;and mature on December 11, 2022 (the &amp;#34;Maturity Date&amp;#34;), and (2) 975,000 shares of the Company's common stock. At any time&#13;following June 11, 2021, and from time to time before the Maturity Date, the Investor shall have the option to convert any portion&#13;of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment&#13;for stock splits, reverse stock splits, stock dividends and similar transactions (the &amp;#34;Conversion Price&amp;#34;). Prior to June&#13;11, 2021, the Company will have the right to prepay up to sixty-six and two-thirds percent (66&lt;sup&gt;2/3&lt;/sup&gt;%) of the then-outstanding&#13;Principal Amount of the Note with no penalty. On or after July 11, 2021, the Company will have the right to prepay up to the then-outstanding&#13;Principal Amount of the Note with no penalty; however, if the Company exercises such prepayment right, the Investor will have&#13;the option to convert up to thirty-three and one-third percent (33&lt;sup&gt;1/3&lt;/sup&gt;%) of the amount that the Company elects to prepay&#13;at the Conversion Price. Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt&#13;financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money&#13;debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the Note, unless&#13;waived by the Investor in advance. Beginning on June 9, 2021, the Note will amortize in eighteen monthly installments equal to&#13;the quotient of (i) the then-outstanding Principal Amount of the Note, divided by (ii) the number of months remaining until the&#13;Maturity Date. All amortization payments shall be payable solely in cash, plus a 2% premium.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On December 17, 2020, the Company entered&#13;into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind&#13;Securities Purchase Agreement (the &amp;#34;December 17 SPAs&amp;#34;), pursuant to which the Company sold, in private placement transactions,&#13;in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1)convertible promissory notes (the &amp;#34;December&#13;17 Notes&amp;#34;) in an aggregate principal amount of $1,365,628, which will bear no interest and mature on December 17, 2022, and&#13;(2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities&#13;purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the&#13;&amp;#34;December 18 SPA&amp;#34;) and, together with the December 17 SPAs, (the &amp;#34;Subsequent Securities Purchase Agreements&amp;#34;),&#13;pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor&#13;of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which will bear no interest and mature&#13;on December 18, 2022 (the &amp;#34;December 18 Note&amp;#34; and, together with the December 17 Notes, the &amp;#34;Subsequent Notes&amp;#34;),&#13;and (2) 26,263 shares of the Company's common stock. The Subsequent Securities Purchase Agreements have substantially the same&#13;terms as the Lind Securities Purchase Agreement, and the Subsequent Notes have substantially the same terms as the Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company received aggregate net proceeds&#13;of $10.9 million from the convertible note offerings, net of $0.5 million of issuance costs. The total gross proceeds were allocated&#13;to the convertible notes and common stock issued under the agreements based on their relative fair values. The Company recognized&#13;a beneficial conversion feature discount on the convertible notes of approximately $0.1 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The discount on the convertible notes is being&#13;amortized to interest expense, using the effective interest method over the term of the convertible notes. As of December 31, 2020,&#13;the principal balance of the convertible notes outstanding and the unamortized discount on the convertible notes is approximately&#13;$13.7 million and $4.1 million, respectively. Interest expense recognized related to the discount was approximately $0.2 million&#13;for the year ended December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;From May 2017 to October 2018, the Company&#13;issued convertible notes (the &amp;#34;Convertible Notes&amp;#34;). The aggregate principal amount of the Convertible Notes was $2.3 million,&#13;and the Convertible Notes were due no later than April 30, 2019 with simple interest at the rate of 8% per annum. The Convertible&#13;Notes provided that they were to convert at a discount of 10% or 20% depending on the terms for each note, or $9.70 to $10.91 per&#13;share, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Convertible Notes were carried at fair&#13;value. The Company recognized an adjustment relating to changes in the Convertible Notes fair value of $0 and $109 thousand during&#13;the year ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;In connection with the closing of the Merger,&#13;the Convertible Notes plus unpaid interest were converted into 172,284 shares of common stock at a price of $9.70 or $10.91 per&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;i&gt;PPP Loan&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;On May 4, 2020, the Company qualified for&#13;and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration&#13;under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the &amp;#34;PPP Lender&amp;#34;), for an aggregate&#13;principal amount of approximately $147,000 (the &amp;#34;PPP Loan&amp;#34;). The PPP Loan bears interest at a fixed rate of 1.0% per annum,&#13;with the first six months of interest deferred, has a term of two years, and is unsecured and guaranteed by the U.S. Small Business&#13;Administration. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program upon the Company's&#13;request to the extent that the PPP Loan proceeds are used to pay expenses permitted by the Paycheck Protection Program, including&#13;payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company intends&#13;to apply for forgiveness of the PPP Loan with respect to these covered expenses. To the extent that all or part of the PPP Loan&#13;is not forgiven, the Company will be required to pay interest on the PPP Loan at a rate of 1.0% per annum, and commencing in the&#13;fourth quarter of 2020, principal and interest payments will be required through the maturity date in May 2022. The terms of the&#13;PPP Loan provide for customary events of default including, among other things, payment defaults, breach of representations and&#13;warranties and insolvency events. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Segment Information&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company operates under one segment which&#13;develops pharmaceutical products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The carrying amounts of financial instruments&#13;such as accounts receivable, accounts payable and accrued expenses approximate their related fair values due to the short-term&#13;nature of these instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Fair Value Option&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;As permitted under ASC Topic 825, Financial&#13;Instruments (&amp;#34;ASC 825&amp;#34;), the Company had elected the fair value option to account for its convertible notes. In accordance&#13;with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Statement of&#13;Operations. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed&#13;as incurred and were not deferred.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">683000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">756000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:Cash contextRef="FI2018Q3" unitRef="usd" decimals="-3">10261000</us-gaap:Cash>
    <us-gaap:Cash contextRef="FI2017Q4" unitRef="usd" decimals="-3">15662000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q3" unitRef="usd" decimals="-3">-56061000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" unitRef="usd" decimals="-3">-75162000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q3" unitRef="shares" decimals="INF">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" unitRef="shares" decimals="INF">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">-20913000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">-19305000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q3" unitRef="usd" decimals="-3">10261000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" unitRef="usd" decimals="-3">15662000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" unitRef="usd" decimals="-3">42000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">15662000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">15662000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">10261000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">10261000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-01-01to2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" unitRef="number" decimals="INF">0.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="number" decimals="INF">0.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">21535000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:RevenueRecognitionLongTermContracts contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company determined that its grant agreement&#13;with Team Sanfilippo Foundation (&amp;#34;TSF&amp;#34;), a nonprofit medical research foundation founded by parents of children with Sanfilippo&#13;syndrome, is within the scope of ASC Topic 606 &amp;#34;Revenue from Contracts with Customers&amp;#34;. Under the TSF agreement, TSF makes&#13;certain milestone payments to the Company as certain milestones related to a specified Phase II/III clinical trial, defined in&#13;the agreement, are met. The Company determined that there is one performance obligation under the TSF agreement. The variable&#13;consideration, in the form of milestone payments, is attributed to the completed portion of the performance obligation that triggers&#13;or results in the payments. During the year ended December 31, 2020 and 2019, the Company recognized $0 and $375,000 of revenue,&#13;respectively, from a milestone payment received as the milestone payment represents the Company's completed portion of its performance&#13;obligation.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionLongTermContracts>
    <us-gaap:SubsequentEventDescription contextRef="From2021-01-01to2021-01-31">On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</us-gaap:SubsequentEventDescription>
    <us-gaap:SubsequentEventDescription contextRef="From2021-02-01to2021-02-28">On February 15, 2021 the Company entered into an amendment to the asset purchase agreement with Vyera. Pursuant to the amendment, the Company agreed to make cash payments to Vyera in the amount of $3.0 million in each of February 2021, June 2021 and September 2021 in exchange for a lower royalty percentage on potential net sales of SLS-002.</us-gaap:SubsequentEventDescription>
    <SEEL:AssumedInMerger contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF">437000</SEEL:AssumedInMerger>
    <SEEL:IssuedInYears contextRef="FD2017Q4YTD">P4Y36D</SEEL:IssuedInYears>
    <SEEL:AssumedInMergerInYears contextRef="FD2018Q3YTD">P3Y180D</SEEL:AssumedInMergerInYears>
    <SEEL:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="FD2018Q3YTD">P9Y108D</SEEL:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="FI2018Q3" unitRef="usd" decimals="-3">348000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="FI2017Q4" unitRef="usd" decimals="-3">66000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2018Q3" unitRef="usd" decimals="-3">84000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" unitRef="usd" decimals="-3">521000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="FI2018Q3" unitRef="usd" decimals="-3">4806000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="FI2017Q4" unitRef="usd" decimals="-3">12320000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <dei:EntityInteractiveDataCurrent contextRef="FD2018Q3YTD">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q4" unitRef="usd" decimals="0">800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_August232019Member">On August 23, 2019, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million, before deducting the placement agents' fees and other estimated offering expenses. The shares were offered by the Company pursuant to the Company's shelf registration statement on Form S-3 filed with the SEC on November 2, 2017, as amended. The Company issued to the investors warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the "August 2019 Warrants"). The August 2019 Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of issuance. The combined purchase price for one share and one warrant to purchase half of a share of common stock in the offerings was $1.50. Roth Capital Partners, LLC ("Roth") served as the placement agent for the issuance and sale of the shares and the warrants, and the Company paid Roth an aggregate fee equal to 7.0% of the gross proceeds received by the Company in the offerings.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_June172019Member">On June 17, 2019, the Company entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Piper Jaffray &amp; Co., as sales agent ("Piper Jaffray"), pursuant to which the Company could offer and sell, from time to time, through Piper Jaffray (the "Offering") up to $50,000,000 in shares. Under the terms of the Equity Distribution Agreement, Piper Jaffray was entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Equity Distribution Agreement. During the year ended December 31, 2019, the Company sold 1,197,676 shares for net proceeds of approximately $2.6 million pursuant to the Equity Distribution Agreement. On August 23, 2019, the Company suspended its continuous offering under the Equity Distribution Agreement and the Equity Distribution Agreement terminated in accordance with its terms on December 7, 2020.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_January242019Member">On January 24, 2019, STI and Apricus closed a private placement transaction with certain accredited investors (the "Investors"), whereby, among other things, STI issued to investors shares of STI's common stock immediately prior to the Merger in a private placement transaction (the "Financing"), pursuant to a Securities Purchase Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors, as amended (the "Purchase Agreement").  Pursuant to the Purchase Agreement, STI (i) issued and sold to the Investors an aggregate of 2,374,672 shares of STIs common stock which converted pursuant to the exchange ratio in the Merger into the right to receive 1,829,407 shares of the Company's common stock and (ii) issued warrants representing the right to acquire 1,463,519 shares of common stock at a price per share of $4.15, subject to adjustment as provided therein (the "Series A Warrants"), most recently adjusted to a price per share of $0.2957 per share, and additional warrants initially representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided therein (the "Series B Warrants" together with the Series A Warrants, the "Investor Warrants"), for aggregate gross proceeds of $18.0 million, or $16.5 million net of financing fees. The terms of the Investor Warrants included certain provisions that could result in adjustments to both the number of warrants issued and the exercise price of each warrant, which resulted in the warrants being classified as a liability upon issuance (see Note 8). The Investor Warrants were recorded at fair value of $21.5 million upon issuance and given the liability exceed the proceeds received, a loss of $5.0 million was recognized.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_March72019Member">On March 7, 2019, the Company entered into Amendment Agreements (collectively, the "Amendment Agreements") with each Investor amending: (i) the Purchase Agreement, (ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate number of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised as of March 7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment Agreements.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_December2020Member">In December 2020, the Company issued an aggregate of 1,112,219 shares of common stock in conjunction with the issuance of convertible notes at a discount for aggregate net proceeds of $10.9 million (see Note 7).</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_September42020Member">On September 4, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors (the "September 2020 Securities Purchase Agreement") pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering, resulting in total net proceeds of $6.4 million, after deducting the placement agent's fees and other offering expenses. The shares were offered by the Company pursuant to the Company's shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (the "SEC") on November 2, 2017, as amended. The Company also issued to the investors warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the "September 2020 Warrants"). The September 2020 Warrants have an exercise price of $0.84 per share of common stock, will be exercisable beginning on March 9, 2021 and will expire on March 9, 2026.  The combined purchase price for one share and one warrant to purchase 0.75 of a share of common stock in the offerings was $0.79. The closing of the offerings occurred on September 9, 2020.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_March162020Member">On March 16, 2020, the Company completed an underwritten public offering pursuant to which it sold 7,500,000 shares of its common stock at a price to the public of $0.60 per share. The net proceeds to the Company from this offering were approximately $4.0 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_February132020Member">On February 13, 2020, the Company completed an underwritten public offering, pursuant to which it sold 6,666,667 shares of its common stock at a price to the public of $0.75 per share. On February 19, 2020, the Company sold an additional 999,999 shares of its common stock at a price to the public of $0.75 per share pursuant to the full exercise of the underwriters' option to cover over-allotments. The net proceeds to the Company from this offering were approximately $4.8 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_January22020Member">On January 2, 2020, the Company entered into a stock purchase agreement (the "Stock Purchase Agreement") with Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG ("Vyera"), pursuant to which the Company issued to Vyera 1,809,845 registered shares of the Company's common stock (the "Shares"). The Company entered into the Stock Purchase Agreement in accordance with an asset purchase agreement with Vyera, as amended by the amendment entered into with Vyera on October 15, 2019 (see Note 5). As partial consideration for the assets of Vyera, the Company agreed to issue the Shares pursuant to the Stock Purchase Agreement.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-01-01to2020-12-31_custom_May112020Member">On May 11, 2020, the Company entered into a consulting agreement (the "Consulting Agreement") with an advisory firm, pursuant to which the advisory firm agreed to provide the Company with certain management consulting, business and advisory services. The Company agreed to issue the advisory firm 300,000 unregistered shares of the Company's common stock, which shares were issued on May 11, 2020, plus $80,000 in cash. On June 9, 2020, the Company and the advisory firm entered into an amendment to the Consulting Agreement (the "Amendment"). Pursuant to the Amendment, the advisory firm agreed to provide the Company with additional services and, in consideration, the Company agreed to issue the advisory firm an additional 200,000 unregistered shares of the Company's common stock (the "Additional Shares"), plus $20,000 in cash. The Additional Shares were issued to the advisory firm on June 9, 2020 and are subject to certain vesting restrictions.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <SEEL:OutstandingAtBalanceSheetDateInYears contextRef="FD2018Q3YTD">P4Y144D</SEEL:OutstandingAtBalanceSheetDateInYears>
    <SEEL:OutstandingAtBalanceSheetDateInYears contextRef="FD2017Q4YTD">P3Y108D</SEEL:OutstandingAtBalanceSheetDateInYears>
    <SEEL:ExercisableAtBalanceSheetDateInYears contextRef="FD2018Q3YTD">P2Y252D</SEEL:ExercisableAtBalanceSheetDateInYears>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2016-09-01to2016-09-30_custom_LicensefromLigandPharmaceuticalsIncorporatedMember">On September 21, 2016, the Company entered into a License Agreement (the "License Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand"), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the "Licensors"), pursuant to which, among other things, the Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors' two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the "Licensed Products"), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the People's Republic of China (each, a "Major Market") or the United States, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.  In connection with the closing of the Merger, the Company issued 801,253 shares of common stock to Ligand and recognized research and development expense totaling approximately $2.2 million during the three months ended March 31, 2019 for the License Agreement.   The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection with Aplindore for the indication of Parkinson's Disease ("PD") or Restless Leg Syndrome, consisting of (i) $750,000 upon submission of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA approval of an application for a particular Licensed Product, (iii) $1.125 million upon regulatory approval in a Major Market for a particular Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major Market for a particular Licensed Product.  The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon submission of an application with the FDA or equivalent foreign body for such a particular Licensed Product, (ii) $350,000 upon FDA approval of an application for such a particular Licensed Product, (iii) $125,000 upon regulatory approval in a Major Market for such a particular Licensed Product, and (iv) $125,000 upon regulatory approval in a second Major Market for such a particular Licensed Product.  The Company agreed to pay to Ligand certain one-time, non-refundable commercial milestone payments in connection with the Licensed Products, consisting of (i) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (ii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), (iv) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists, (v) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (vi) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), and (viii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists.  The Company will also pay to Ligand middle single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty in the upper single digit to lower double digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent and a tiered incremental royalty in the lower single digit to middle single digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent.  The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2018-03-01to2018-03-31_custom_AssetsfromVyeraPharmaceuticalsAGMember">On March 6, 2018, the Company entered into an asset purchase agreement with Vyera, pursuant to which the Company acquired the assets (the "Vyera Assets") and liabilities (the "Vyera Assumed Liabilities") of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The Company is obligated to use commercially reasonable efforts to seek regulatory approval in the United States for and commercialize SLS-002.   As consideration for the Vyera Assets, the Company paid to Vyera a non-refundable cash payment of $150,000 on May 21, 2018. As further consideration for the Vyera Assets, upon public announcement of the entry by Apricus and STI into the Merger Agreement, the Company paid to Vyera a non-refundable cash payment of $150,000. As further consideration for the Vyera Assets, the Company issued to Vyera 191,529 shares of common stock and paid Vyera a non-refundable cash payment of $1,000,000 on January 29, 2019.   Pursuant to the amendment to the asset purchase agreement entered into by the Company and Vyera on October 15, 2019, the Company issued Vyera 1,809,845 registered shares of the Company's common stock on January 2, 2020 and made cash payments to Vyera in the amounts of $750,000, $750,000, $1.0 million and $1.0 million in October 2019, January 2020, April 2020 and July 2020, respectively.  In the event that the Company sells, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company must pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale.  The Company agreed to pay to Vyera certain one-time, non-refundable milestone payments consisting of (i) $10.0 million upon approval by the FDA of a new drug application (an "NDA"), with respect to SLS-002, (ii) $5.0 million upon approval by the European Medicines Agency (the "EMA") of the foreign equivalent to an NDA with respect to SLS-002 in a Major Market, (iii) $2.5 million upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002 in a second Major Market, (iv) $5.0 million upon the achievement of $250.0 million in net sales of SLS-002, (v) $10.0 million upon the achievement of $500.0 million in net sales of SLS-002, (vi) $15.0 million upon the achievement of $1.0 billion in net sales of SLS-002, (vii) $20.0 million upon the achievement of $1.5 billion in net sales of SLS-002, and (viii) $25.0 million upon the achievement of $2.0 billion in net sales of SLS-002. The Company will also pay to Vyera a royalty percentage in the mid-single digits on aggregate annual net sales of SLS-002.  The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2019-02-01to2019-02-28_custom_AssetsfromBioblastPharmaLtdMember">On February 15, 2019, the Company entered into an Asset Purchase Agreement (the "Bioblast Asset Purchase Agreement") with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the "Bioblast Asset Purchase"). The Company paid to Bioblast $1.5 million in cash, and the Company paid to Bioblast an additional $2.0 million in February 2020. Accordingly, the Company recognized a $3.5 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the Bioblast Asset Purchase Agreement, the Company agreed to pay additional consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (i) within 15 days following the completion of the Company's first Phase II(b) clinical trial of Trehalose satisfying certain criteria, the Company will pay to Bioblast $8.5 million; and (ii) within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates, the Company will pay to Bioblast $8.5 million. In addition, the Company agreed to pay Bioblast a cash royalty equal to 1% of the net sales of Trehalose. Under the terms of the Bioblast Asset Purchase, the Company assumed a collaborative agreement with TSF, a nonprofit medical research foundation founded by parents of children with Sanfilippo syndrome. TSF, upon approval by the FDA, planned to begin an open label, Phase II(b) clinical trial in up to 20 patients with Sanfilippo syndrome, which is now known under the study name SLS-005. The Company will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement entitle the Company access to all clinical data from this trial. On July 15, 2019, TSF and the Company amended the agreement whereby the Company agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5 million towards the funding of the trial.</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2019-03-01to2019-03-31_custom_UCRegentsLicenseAgreementMember">On March 7, 2019, the Company entered into an exclusive license agreement (the "UC Regents License Agreement") with The Regents of the University of California ("The UC Regents") pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (&#945;-synuclein). The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the central nervous system ("CNS"). This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the completion of dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market, the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce the Company's license to a nonexclusive license.   The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2019-06-01to2019-06-30_custom_DukeLicenseAgreementMember">On June 27, 2019, the Company entered into an exclusive license agreement (the "Duke License Agreement") with Duke University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression. The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University $0.1 million and recognized $0.1 million charge to research and development expense during the year ended December 31, 2019. The Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, Duke University may terminate the agreement.   The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2019-08-01to2019-08-31_custom_WegLicenseAgreementMember">On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the "Weg License Agreement"), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020 and $0.125 million on January 2, 2021. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company's common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the "Milestone Product"), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval by the EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr. Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <us-gaap:Revenues contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">375000</us-gaap:Revenues>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">-0.906</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">-0.184</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">0.112</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">0.593</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">-0.090</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-12-31_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5">46900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-12-31_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5">90600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" unitRef="usd" xsi:nil="true" />
    <us-gaap:OtherLongTermNotesPayable contextRef="FI2018Q3" unitRef="usd" decimals="-3">0</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:OtherLongTermNotesPayable contextRef="FI2017Q4" unitRef="usd" decimals="-3">147000</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">7146000</us-gaap:ConvertibleDebtNoncurrent>
    <SEEL:IssuanceOfCommonStockForPrepaidServicesShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">400000</SEEL:IssuanceOfCommonStockForPrepaidServicesShares>
    <SEEL:IssuanceOfCommonStockForPrepaidServices contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">330000</SEEL:IssuanceOfCommonStockForPrepaidServices>
    <SEEL:IssuanceOfCommonStockForPrepaidServices contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForPrepaidServices>
    <SEEL:IssuanceOfCommonStockForPrepaidServices contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">330000</SEEL:IssuanceOfCommonStockForPrepaidServices>
    <SEEL:IssuanceOfCommonStockForPrepaidServices contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockForPrepaidServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">15166666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">8850000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">8835000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SEEL:BeneficialConversionFeatureOfConvertibleDebtShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">0</SEEL:BeneficialConversionFeatureOfConvertibleDebtShares>
    <SEEL:BeneficialConversionFeatureOfConvertibleDebt contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">100000</SEEL:BeneficialConversionFeatureOfConvertibleDebt>
    <SEEL:BeneficialConversionFeatureOfConvertibleDebt contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">0</SEEL:BeneficialConversionFeatureOfConvertibleDebt>
    <SEEL:BeneficialConversionFeatureOfConvertibleDebt contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">100000</SEEL:BeneficialConversionFeatureOfConvertibleDebt>
    <SEEL:BeneficialConversionFeatureOfConvertibleDebt contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:BeneficialConversionFeatureOfConvertibleDebt>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">8865000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">6365000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">9000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">6356000</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">0</SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">124000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">150000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ProceedsFromNotesPayable contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">147000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:StockIssued1 contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">2443000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</us-gaap:StockIssued1>
    <SEEL:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3">8850000</SEEL:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <SEEL:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3">0</SEEL:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="FD2018Q3YTD">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;2. Liquidity and Going Concern&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The accompanying consolidated financial statements&#13;have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets&#13;and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future&#13;effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from&#13;uncertainty related to its ability to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company has limited revenues, has incurred&#13;operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and&#13;may never become profitable. As of December 31, 2020, the Company had $15.7 million in cash and an accumulated deficit of $75.2&#13;million. The Company has historically funded its operations through the issuance of convertible notes (see Note 7), the sale of&#13;common stock (see Note 4) and the exercise of warrants (see Note 8).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company evaluated whether there are any&#13;conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern&#13;within one year beyond the release date of this Annual Report on Form 10-K. Based on such evaluation and the Company's current&#13;plans, which are subject to change, management believes that the Company's existing cash and cash equivalents as of December 31,&#13;2020 are not sufficient to satisfy its operating cash needs for at least one year.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company believes it will need to raise&#13;substantial additional funds through one or more of the following: issuance of additional debt or equity and/or the completion&#13;of a licensing or other commercial transaction for one or more of the Company's product candidates. If the Company is unable to&#13;maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely&#13;affected. This could affect future development and business activities and potential future clinical studies and/or other future&#13;ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company's business&#13;operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all.&#13;Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company's existing&#13;stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:ConvertibleDebtCurrent contextRef="FI2018Q3" unitRef="usd" decimals="-3">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="FI2017Q4" unitRef="usd" decimals="-3">2431000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Basis of Presentation and Principles of&#13;Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The consolidated financial statements include&#13;the accounts of the Company and its wholly-owned subsidiaries.&amp;#160;All significant intercompany accounts and transactions have&#13;been eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2018Q3YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company follows the accounting guidance&#13;in the Financial Accounting Standards Board (&amp;#34;FASB&amp;#34;) Accounting Standards Codification (&amp;#34;ASC&amp;#34;) Topic 820, Fair&#13;Value Measurements and Disclosures (&amp;#34;ASC 820&amp;#34;), for its fair value measurements of financial assets and liabilities measured&#13;at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount&#13;that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at&#13;the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market&#13;participants would use in pricing an asset or a liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The accounting guidance requires fair value&#13;measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Level 1: Quoted prices in active markets for&#13;identical assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Level 2: Observable inputs other than Level&#13;1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Level 3: Unobservable inputs which are supported&#13;by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted&#13;cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant&#13;judgment or estimation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The fair value hierarchy also requires an&#13;entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and&#13;liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the&#13;fair value measurement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following tables present information about&#13;the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value&#13;hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during the years&#13;ended December 31, 2020 and 2019 (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 40%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 1) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 2) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 3) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,662&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,662&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liabilities, at fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 40%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 1) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 2) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(Level 3) &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,261&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,261&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liabilities, at fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The common stock warrant liabilities were&#13;recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the fair&#13;value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2020 and 2019:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.18%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.66%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;116.77%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;110.80%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- %&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.07&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted-average fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.06&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The following table is a reconciliation for&#13;the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 75%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 23%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrant liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;- &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant issued in connection with financing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21,535&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liability reclassified to stockholders' equity&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(37,073)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in fair value measurement of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;16,501&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;963&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Warrant liability reclassified to stockholders' equity&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(124)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Change in fair value measurement of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;223&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;Balance as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,062&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Of the inputs used to value the outstanding&#13;common stock warrant liabilities as of December 31, 2020 and 2019, the most subjective input is the Company's estimate of expected&#13;volatility of its common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2018Q3YTD" unitRef="number" decimals="INF">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" unitRef="number" decimals="INF">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q3YTD">P7Y144D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <SEEL:ConsultingExpense contextRef="From2020-01-01to2020-12-31_custom_May112020Member" unitRef="usd" decimals="-3">431000000</SEEL:ConsultingExpense>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q4" unitRef="usd" decimals="-3">42000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="FD2018Q3YTD">The federal and state net operating loss carryforwards, not subject to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset as of December 31, 2020 and 2019 of approximately $15.2 million and $5.6 million, respectively. In consideration of the Company's accumulated losses and the uncertainty</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:OpenTaxYear contextRef="FD2018Q3YTD">2017</us-gaap:OpenTaxYear>
    <us-gaap:LongTermDebtDescription contextRef="FD2018Q3YTD">On December 11, 2020, the Company entered into a Securities Purchase Agreement (the "Lind Securities Purchase Agreement") with Lind Global Asset Management II, LLC (the "Investor") pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the "Note") in an aggregate principal amount of $12,000,000 (the "Principal Amount"), which will bear no interest and mature on December 11, 2022 (the "Maturity Date"), and (2) 975,000 shares of the Company's common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor shall have the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the "Conversion Price"). Prior to June 11, 2021, the Company will have the right to prepay up to sixty-six and two-thirds percent (662/3%) of the then-outstanding Principal Amount of the Note with no penalty. On or after July 11, 2021, the Company will have the right to prepay up to the then-outstanding Principal Amount of the Note with no penalty; however, if the Company exercises such prepayment right, the Investor will have the option to convert up to thirty-three and one-third percent (331/3%) of the amount that the Company elects to prepay at the Conversion Price. Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the Note, unless waived by the Investor in advance. Beginning on June 9, 2021, the Note will amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable solely in cash, plus a 2% premium.  On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the "December 17 SPAs"), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1)convertible promissory notes (the "December 17 Notes") in an aggregate principal amount of $1,365,628, which will bear no interest and mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the "December 18 SPA") and, together with the December 17 SPAs, (the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which will bear no interest and mature on December 18, 2022 (the "December 18 Note" and, together with the December 17 Notes, the "Subsequent Notes"), and (2) 26,263 shares of the Company's common stock. The Subsequent Securities Purchase Agreements have substantially the same terms as the Lind Securities Purchase Agreement, and the Subsequent Notes have substantially the same terms as the Note.   The Company received aggregate net proceeds of $10.9 million from the convertible note offerings, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes and common stock issued under the agreements based on their relative fair values. The Company recognized a beneficial conversion feature discount on the convertible notes of approximately $0.1 million.  The discount on the convertible notes is being amortized to interest expense, using the effective interest method over the term of the convertible notes. As of December 31, 2020, the principal balance of the convertible notes outstanding and the unamortized discount on the convertible notes is approximately $13.7 million and $4.1 million, respectively. Interest expense recognized related to the discount was approximately $0.2 million for the year ended December 31, 2020.   Convertible Notes  From May 2017 to October 2018, the Company issued convertible notes (the "Convertible Notes"). The aggregate principal amount of the Convertible Notes was $2.3 million, and the Convertible Notes were due no later than April 30, 2019 with simple interest at the rate of 8% per annum. The Convertible Notes provided that they were to convert at a discount of 10% or 20% depending on the terms for each note, or $9.70 to $10.91 per share, respectively.  The Convertible Notes were carried at fair value. The Company recognized an adjustment relating to changes in the Convertible Notes fair value of $0 and $109 thousand during the year ended December 31, 2020 and 2019, respectively.  In connection with the closing of the Merger, the Convertible Notes plus unpaid interest were converted into 172,284 shares of common stock at a price of $9.70 or $10.91 per share.  PPP Loan  On May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the "PPP Lender"), for an aggregate principal amount of approximately $147,000 (the "PPP Loan"). The PPP Loan bears interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, has a term of two years, and is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program upon the Company's request to the extent that the PPP Loan proceeds are used to pay expenses permitted by the Paycheck Protection Program, including payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company intends to apply for forgiveness of the PPP Loan with respect to these covered expenses. To the extent that all or part of the PPP Loan is not forgiven, the Company will be required to pay interest on the PPP Loan at a rate of 1.0% per annum, and commencing in the fourth quarter of 2020, principal and interest payments will be required through the maturity date in May 2022. The terms of the PPP Loan provide for customary events of default including, among other things, payment defaults, breach of representations and warranties and insolvency events. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.</us-gaap:LongTermDebtDescription>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>seel-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: SEEL%2D12%2D31%2D2020.xfr; Date: 2021%2D03%2D10T17:52:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +qsps7xRiXgOn8uFZHxMOaSGebOdw5pyKZlBtWZ5bRkavyAo/veRJixTpdY2YQ0O -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:SEEL="http://SEEL/20201231" elementFormDefault="qualified" targetNamespace="http://SEEL/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://SEEL/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited" id="CondensedConsolidatedStatementsOfOperationsUnaudited">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - 1. Organization and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
	  <link:definition>00000008 - Disclosure - 2. Liquidity and Going Concern</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/BusinessCombination" id="BusinessCombination">
	  <link:definition>00000009 - Disclosure - 3. Business Combination</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CommonStockOfferings" id="CommonStockOfferings">
	  <link:definition>00000010 - Disclosure - 4. Common Stock Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/LicenseAgreements" id="LicenseAgreements">
	  <link:definition>00000011 - Disclosure - 5. License Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000012 - Disclosure - 6. Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Debt" id="Debt">
	  <link:definition>00000013 - Disclosure - 7. Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000014 - Disclosure - 8. Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000015 - Disclosure - 9. Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - 10. Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000017 - Disclosure - 11. Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/SubsequentEvent" id="SubsequentEvent">
	  <link:definition>00000018 - Disclosure - 12. Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000021 - Disclosure - Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000022 - Disclosure - Stockholders' Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000023 - Disclosure - Stock-based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000024 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" id="OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails">
	  <link:definition>00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Seelos Merger Agreement (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" id="OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails">
	  <link:definition>00000027 - Disclosure - Organization and Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" id="OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails">
	  <link:definition>00000028 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Assets and Liabilities Recurring Basis (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" id="OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails">
	  <link:definition>00000029 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" id="OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails">
	  <link:definition>00000030 - Disclosure - Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" id="OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails">
	  <link:definition>00000031 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" id="OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails">
	  <link:definition>00000032 - Disclosure - Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" id="OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails">
	  <link:definition>00000033 - Disclosure - Organization and Summary of Significant Accounting Policies - Geographical Information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OtherFinancialInformation-PropertyAndEquipmentDetail" id="OtherFinancialInformation-PropertyAndEquipmentDetail">
	  <link:definition>00000034 - Disclosure - Other Financial Information - Property and Equipment (Detail)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CommonStockOfferingsNarrativeDetails" id="CommonStockOfferingsNarrativeDetails">
	  <link:definition>00000035 - Disclosure - Common Stock Offerings (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/LicenseAgreementsNarrativeDetails" id="LicenseAgreementsNarrativeDetails">
	  <link:definition>00000036 - Disclosure - License Agreements (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/AccruedExpensesDetail" id="AccruedExpensesDetail">
	  <link:definition>00000037 - Disclosure - Accrued Expenses (Detail)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/DebtNarrativeDetails" id="DebtNarrativeDetails">
	  <link:definition>00000038 - Disclosure - Debt (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/OtherFinancialInformation-OtherLong-termLiabilitiesDetails" id="OtherFinancialInformation-OtherLong-termLiabilitiesDetails">
	  <link:definition>00000039 - Disclosure - Other Financial Information - Other Long-term Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails" id="StockholdersEquity-SummaryOfWarrantActivityDetails">
	  <link:definition>00000040 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Stock-basedCompensation-NarrativeDetails" id="Stock-basedCompensation-NarrativeDetails">
	  <link:definition>00000041 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" id="Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails">
	  <link:definition>00000042 - Disclosure - Stock-Based Compensation - Assumptions Of Black-Scholes Option Grant (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails" id="Stock-basedCompensation-SummaryOfStockOptionActivityDetails">
	  <link:definition>00000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" id="Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails">
	  <link:definition>00000044 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails" id="Stock-basedCompensationByExpenseCategoryDetails">
	  <link:definition>00000045 - Disclosure - Stock-Based Compensation by Expense Category (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails" id="IncomeTaxes-DeferredTaxAssetsDetails">
	  <link:definition>00000046 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" id="IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails">
	  <link:definition>00000047 - Disclosure - Income Taxes - Recognition Of Unrecognized Tax Benefits (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails" id="IncomeTaxes-ReconciliationOfIncomeTaxesDetails">
	  <link:definition>00000048 - Disclosure - Income Taxes - Reconciliation Of Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/IncomeTaxes-NarrativeDetails" id="IncomeTaxes-NarrativeDetails">
	  <link:definition>00000049 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails" id="CommitmentsAndContingencies-NarrativeDetails">
	  <link:definition>00000050 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" id="CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails">
	  <link:definition>00000051 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/LitigationNarrativeDetails" id="LitigationNarrativeDetails">
	  <link:definition>00000052 - Disclosure - Litigation - Narrative (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://SEEL/role/SubsequentEventsNarrativeDetails" id="SubsequentEventsNarrativeDetails">
	  <link:definition>00000053 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" name="DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ResearchAndDevelopmentAccruedExpense" name="ResearchAndDevelopmentAccruedExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_LicensePayablesLongterm" name="LicensePayablesLongterm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_LicensePayables" name="LicensePayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ChangeInFairValueOfConvertibleNotesPayable" name="ChangeInFairValueOfConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable" name="IncreaseDecreaseInFairValueOfConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering" name="ProceedsFromIssuanceOfCommonStockInAtthemarketOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" name="ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" name="ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_EffectOfReverseMerger" name="EffectOfReverseMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest" name="IssuanceOfCommonStockForConversionOfAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" name="IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForLicenseAcquired" name="IssuanceOfCommonStockForLicenseAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" name="IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" name="IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForLicenseAcquiredShares" name="IssuanceOfCommonStockForLicenseAcquiredShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" name="ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" name="ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" name="ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" name="IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForConversionOfDebt" name="IssuanceOfCommonStockForConversionOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" name="IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" name="IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" name="IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" name="IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AssumedInMerger" name="AssumedInMerger" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuedInYears" name="IssuedInYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AssumedInMergerInYears" name="AssumedInMergerInYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OutstandingAtBalanceSheetDateInYears" name="OutstandingAtBalanceSheetDateInYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ExercisableAtBalanceSheetDateInYears" name="ExercisableAtBalanceSheetDateInYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForPrepaidServicesShares" name="IssuanceOfCommonStockForPrepaidServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockForPrepaidServices" name="IssuanceOfCommonStockForPrepaidServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_BeneficialConversionFeatureOfConvertibleDebtShares" name="BeneficialConversionFeatureOfConvertibleDebtShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_BeneficialConversionFeatureOfConvertibleDebt" name="BeneficialConversionFeatureOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" name="IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" name="IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ConsultingExpense" name="ConsultingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IRRASSubleaseMember" name="IRRASSubleaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_September2016FinancingMember" name="September2016FinancingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_April2017FinancingMember" name="April2017FinancingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_September2017FinancingMember" name="September2017FinancingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_September2018FinancingMember" name="September2018FinancingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AspireCapitalFundLLCMember" name="AspireCapitalFundLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OtherCountriesMember" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_TwoThousandTwelveIncentivePlanMember" name="TwoThousandTwelveIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_August232019Member" name="August232019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_June172019Member" name="June172019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_January242019Member" name="January242019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_March72019Member" name="March72019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_DirectJanuary2019Member" name="DirectJanuary2019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_PublicDecember2018Member" name="PublicDecember2018Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_PublicJune2018Member" name="PublicJune2018Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember" name="LicensefromLigandPharmaceuticalsIncorporatedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AssetsfromVyeraPharmaceuticalsAGMember" name="AssetsfromVyeraPharmaceuticalsAGMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AssetsfromBioblastPharmaLtdMember" name="AssetsfromBioblastPharmaLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AssetsfromApricusMember" name="AssetsfromApricusMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_UCRegentsLicenseAgreementMember" name="UCRegentsLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_DukeLicenseAgreementMember" name="DukeLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_WegLicenseAgreementMember" name="WegLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_December2020Member" name="December2020Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_September42020Member" name="September42020Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_March162020Member" name="March162020Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_February132020Member" name="February132020Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_January22020Member" name="January22020Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_May112020Member" name="May112020Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsShares" name="IssuanceOfCommonStockAndWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IssuanceOfCommonStockAndWarrantsValue" name="IssuanceOfCommonStockAndWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity" name="WarrantLiabilityReclassifiedToStockholdersEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NoncashRecapitalizationCosts" name="NoncashRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" name="GainLossesonExtinguishmentofDebtNonCashOperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IncreaseDecreaseInLicensesPayableLongterm" name="IncreaseDecreaseInLicensesPayableLongterm" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NoncashDeferredOfferingCosts" name="NoncashDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ReclassOfWarrantLiabilitiesFromStockholdersEquity" name="ReclassOfWarrantLiabilitiesFromStockholdersEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_InLicensingAgreementAbstract" name="InLicensingAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_DebtAbstract" name="DebtAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_EquityCompensationPlansAbstract" name="EquityCompensationPlansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IncomeTaxesAbstract" name="IncomeTaxesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" name="ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_CommonStockIssuanceNarrativeDetailsAbstract" name="CommonStockIssuanceNarrativeDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_WarrantTermInYears" name="WarrantTermInYears" nillable="true" xbrli:periodType="duration" type="us-types:durationStringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_BusinessCombinationsPurchasePriceAllocationAndNarrativeDetailsAbstract" name="BusinessCombinationsPurchasePriceAllocationAndNarrativeDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_CovertibleNotestNarrativeDetailsAbstract" name="CovertibleNotestNarrativeDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AssumedInMergerInUsdPerShare" name="AssumedInMergerInUsdPerShare" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_WeightedAverageRemainingContractualLifeInYears" name="WeightedAverageRemainingContractualLifeInYears" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" name="ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" name="ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OperatingLossAndCapitalLossCarryforwards" name="OperatingLossAndCapitalLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" name="DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="SEEL_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_LeaseAgreementPeriod" name="LeaseAgreementPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OperatingLeaseRenewalOptions" name="OperatingLeaseRenewalOptions" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OperatingLeaseMonthlyRentalPayment" name="OperatingLeaseMonthlyRentalPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation" name="OperatingLeasesRentExpensePercentageOfAnnualEscalation" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_RentAbatementPeriod" name="RentAbatementPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OperatingLeaseRentAbatementRecoveryPeriod" name="OperatingLeaseRentAbatementRecoveryPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_SubleaseTermOfContract" name="SubleaseTermOfContract" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_SubsequentEventNarrativeDetailsAbstract" name="SubsequentEventNarrativeDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>seel-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: SEEL%2D12%2D31%2D2020.xfr; Date: 2021%2D03%2D10T17:52:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://SEEL/role/DocumentAndEntityInformation" xlink:href="seel-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheets" xlink:href="seel-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="seel-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="seel-20201231.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="seel-20201231.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StatementsOfCashFlows" xlink:href="seel-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LiquidityAndGoingConcern" xlink:href="seel-20201231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/BusinessCombination" xlink:href="seel-20201231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommonStockOfferings" xlink:href="seel-20201231.xsd#CommonStockOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LicenseAgreements" xlink:href="seel-20201231.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpenses" xlink:href="seel-20201231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Debt" xlink:href="seel-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquity" xlink:href="seel-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation" xlink:href="seel-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes" xlink:href="seel-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/SubsequentEvent" xlink:href="seel-20201231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpensesTables" xlink:href="seel-20201231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquityTables" xlink:href="seel-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensationTables" xlink:href="seel-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxesTables" xlink:href="seel-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingenciesTables" xlink:href="seel-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:href="seel-20201231.xsd#OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommonStockOfferingsNarrativeDetails" xlink:href="seel-20201231.xsd#CommonStockOfferingsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LicenseAgreementsNarrativeDetails" xlink:href="seel-20201231.xsd#LicenseAgreementsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpensesDetail" xlink:href="seel-20201231.xsd#AccruedExpensesDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/DebtNarrativeDetails" xlink:href="seel-20201231.xsd#DebtNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:href="seel-20201231.xsd#OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:href="seel-20201231.xsd#StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-NarrativeDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensationByExpenseCategoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-DeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-NarrativeDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LitigationNarrativeDetails" xlink:href="seel-20201231.xsd#LitigationNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/SubsequentEventsNarrativeDetails" xlink:href="seel-20201231.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensePayables" xlink:label="loc_SEELLicensePayables" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_SEELLicensePayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensePayablesLongterm" xlink:label="loc_SEELLicensePayablesLongterm" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_SEELLicensePayablesLongterm" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaapOtherLongTermNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="loc_us-gaapInterestIncomeDomesticDeposits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeDomesticDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_SEELChangeInFairValueOfConvertibleNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SEELChangeInFairValueOfConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaapIncomeLossFromContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncomeLossFromContinuingOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable" xlink:label="loc_SEELIncreaseDecreaseInFairValueOfConvertibleNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_SEELIncreaseDecreaseInFairValueOfConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_NoncashRecapitalizationCosts" xlink:label="loc_SEELNoncashRecapitalizationCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_SEELNoncashRecapitalizationCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" xlink:label="loc_SEELGainLossesonExtinguishmentofDebtNonCashOperating" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_SEELGainLossesonExtinguishmentofDebtNonCashOperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="loc_us-gaapAccretionExpenseIncludingAssetRetirementObligations" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapAccretionExpenseIncludingAssetRetirementObligations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncreaseDecreaseInLicensesPayableLongterm" xlink:label="loc_SEELIncreaseDecreaseInLicensesPayableLongterm" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_SEELIncreaseDecreaseInLicensesPayableLongterm" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedSalaries" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedSalaries" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="loc_SEELProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SEELProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering" xlink:label="loc_SEELProceedsFromIssuanceOfCommonStockInAtthemarketOffering" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SEELProceedsFromIssuanceOfCommonStockInAtthemarketOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperations" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperations" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - 2. Liquidity and Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/BusinessCombination" xlink:title="00000009 - Disclosure - 3. Business Combination" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CommonStockOfferings" xlink:title="00000010 - Disclosure - 4. Common Stock Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/LicenseAgreements" xlink:title="00000011 - Disclosure - 5. License Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpenses" xlink:title="00000012 - Disclosure - 6. Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Debt" xlink:title="00000013 - Disclosure - 7. Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquity" xlink:title="00000014 - Disclosure - 8. Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation" xlink:title="00000015 - Disclosure - 9. Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes" xlink:title="00000016 - Disclosure - 10. Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - 11. Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/SubsequentEvent" xlink:title="00000018 - Disclosure - 12. Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpensesTables" xlink:title="00000021 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&apos; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensationTables" xlink:title="00000023 - Disclosure - Stock-based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:title="00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Seelos Merger Agreement (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:title="00000027 - Disclosure - Organization and Summary of Significant Accounting Policies - Property and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:title="00000028 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Assets and Liabilities Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:title="00000029 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:title="00000030 - Disclosure - Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:title="00000031 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:title="00000032 - Disclosure - Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:title="00000033 - Disclosure - Organization and Summary of Significant Accounting Policies - Geographical Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:title="00000034 - Disclosure - Other Financial Information - Property and Equipment (Detail)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaapCapitalLeasedAssetsGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapCapitalLeasedAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CommonStockOfferingsNarrativeDetails" xlink:title="00000035 - Disclosure - Common Stock Offerings (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/LicenseAgreementsNarrativeDetails" xlink:title="00000036 - Disclosure - License Agreements (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpensesDetail" xlink:title="00000037 - Disclosure - Accrued Expenses (Detail)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ResearchAndDevelopmentAccruedExpense" xlink:label="loc_SEELResearchAndDevelopmentAccruedExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_SEELResearchAndDevelopmentAccruedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/DebtNarrativeDetails" xlink:title="00000038 - Disclosure - Debt (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:title="00000039 - Disclosure - Other Financial Information - Other Long-term Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerDepositsNoncurrent" xlink:label="loc_us-gaapCustomerDepositsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:to="loc_us-gaapCustomerDepositsNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:title="00000040 - Disclosure - Stockholders&apos; Equity - Summary of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-NarrativeDetails" xlink:title="00000041 - Disclosure - Stock-Based Compensation - Narrative (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:title="00000042 - Disclosure - Stock-Based Compensation - Assumptions Of Black-Scholes Option Grant (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:title="00000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:title="00000044 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails" xlink:title="00000045 - Disclosure - Stock-Based Compensation by Expense Category (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails" xlink:title="00000046 - Disclosure - Income Taxes - Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" xlink:label="loc_SEELDeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_SEELDeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:title="00000047 - Disclosure - Income Taxes - Recognition Of Unrecognized Tax Benefits (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:title="00000048 - Disclosure - Income Taxes - Reconciliation Of Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-NarrativeDetails" xlink:title="00000049 - Disclosure - Income Taxes - Narrative (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails" xlink:title="00000050 - Disclosure - Commitments and Contingencies - Narrative (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="00000051 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/LitigationNarrativeDetails" xlink:title="00000052 - Disclosure - Litigation - Narrative (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://SEEL/role/SubsequentEventsNarrativeDetails" xlink:title="00000053 - Disclosure - Subsequent Events (Narrative) (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>seel-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: SEEL%2D12%2D31%2D2020.xfr; Date: 2021%2D03%2D10T17:52:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://SEEL/role/DocumentAndEntityInformation" xlink:href="seel-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheets" xlink:href="seel-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="seel-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="seel-20201231.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="seel-20201231.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StatementsOfCashFlows" xlink:href="seel-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LiquidityAndGoingConcern" xlink:href="seel-20201231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/BusinessCombination" xlink:href="seel-20201231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommonStockOfferings" xlink:href="seel-20201231.xsd#CommonStockOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LicenseAgreements" xlink:href="seel-20201231.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpenses" xlink:href="seel-20201231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Debt" xlink:href="seel-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquity" xlink:href="seel-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation" xlink:href="seel-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes" xlink:href="seel-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/SubsequentEvent" xlink:href="seel-20201231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpensesTables" xlink:href="seel-20201231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquityTables" xlink:href="seel-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensationTables" xlink:href="seel-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxesTables" xlink:href="seel-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingenciesTables" xlink:href="seel-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:href="seel-20201231.xsd#OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommonStockOfferingsNarrativeDetails" xlink:href="seel-20201231.xsd#CommonStockOfferingsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LicenseAgreementsNarrativeDetails" xlink:href="seel-20201231.xsd#LicenseAgreementsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpensesDetail" xlink:href="seel-20201231.xsd#AccruedExpensesDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/DebtNarrativeDetails" xlink:href="seel-20201231.xsd#DebtNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:href="seel-20201231.xsd#OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:href="seel-20201231.xsd#StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-NarrativeDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensationByExpenseCategoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-DeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-NarrativeDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LitigationNarrativeDetails" xlink:href="seel-20201231.xsd#LitigationNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/SubsequentEventsNarrativeDetails" xlink:href="seel-20201231.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForPrepaidServicesShares" xlink:label="loc_SEELIssuanceOfCommonStockForPrepaidServicesShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockForPrepaidServicesShares_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForPrepaidServices" xlink:label="loc_SEELIssuanceOfCommonStockForPrepaidServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockForPrepaidServices_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForLicenseAcquiredShares" xlink:label="loc_SEELIssuanceOfCommonStockForLicenseAcquiredShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockForLicenseAcquiredShares_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForLicenseAcquired" xlink:label="loc_SEELIssuanceOfCommonStockForLicenseAcquired_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockForLicenseAcquired_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" xlink:label="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" xlink:label="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" xlink:label="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" xlink:label="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" xlink:label="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" xlink:label="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterest_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_BeneficialConversionFeatureOfConvertibleDebtShares" xlink:label="loc_SEELBeneficialConversionFeatureOfConvertibleDebtShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELBeneficialConversionFeatureOfConvertibleDebtShares_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_BeneficialConversionFeatureOfConvertibleDebt" xlink:label="loc_SEELBeneficialConversionFeatureOfConvertibleDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELBeneficialConversionFeatureOfConvertibleDebt_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" xlink:label="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" xlink:label="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsShares_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsValue" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsValue_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:label="loc_SEELStockIssuedDuringPeriodSharesVestingOfRestrictedStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELStockIssuedDuringPeriodSharesVestingOfRestrictedStock_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WarrantLiabilityReclassifiedToStockholdersEquity" xlink:label="loc_SEELWarrantLiabilityReclassifiedToStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_SEELWarrantLiabilityReclassifiedToStockholdersEquity_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - 2. Liquidity and Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/BusinessCombination" xlink:title="00000009 - Disclosure - 3. Business Combination" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CommonStockOfferings" xlink:title="00000010 - Disclosure - 4. Common Stock Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/LicenseAgreements" xlink:title="00000011 - Disclosure - 5. License Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpenses" xlink:title="00000012 - Disclosure - 6. Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Debt" xlink:title="00000013 - Disclosure - 7. Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquity" xlink:title="00000014 - Disclosure - 8. Stockholders&apos; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation" xlink:title="00000015 - Disclosure - 9. Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes" xlink:title="00000016 - Disclosure - 10. Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - 11. Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/SubsequentEvent" xlink:title="00000018 - Disclosure - 12. Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpensesTables" xlink:title="00000021 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&apos; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensationTables" xlink:title="00000023 - Disclosure - Stock-based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:title="00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Seelos Merger Agreement (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:title="00000027 - Disclosure - Organization and Summary of Significant Accounting Policies - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:title="00000028 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Assets and Liabilities Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_170" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:title="00000029 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:title="00000030 - Disclosure - Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_60" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_60" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_60" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_60" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:title="00000031 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:title="00000032 - Disclosure - Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:title="00000033 - Disclosure - Organization and Summary of Significant Accounting Policies - Geographical Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:label="loc_countryCA_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OtherCountriesMember" xlink:label="loc_SEELOtherCountriesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_SEELOtherCountriesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember" xlink:label="loc_srtAsiaPacificMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaPacificMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenues_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaapNoncurrentAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapNoncurrentAssets_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:title="00000034 - Disclosure - Other Financial Information - Property and Equipment (Detail)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CommonStockOfferingsNarrativeDetails" xlink:title="00000035 - Disclosure - Common Stock Offerings (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_December2020Member" xlink:label="loc_SEELDecember2020Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELDecember2020Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_September42020Member" xlink:label="loc_SEELSeptember42020Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELSeptember42020Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_August232019Member" xlink:label="loc_SEELAugust232019Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELAugust232019Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_March162020Member" xlink:label="loc_SEELMarch162020Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMarch162020Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_February132020Member" xlink:label="loc_SEELFebruary132020Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELFebruary132020Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_January22020Member" xlink:label="loc_SEELJanuary22020Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary22020Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_May112020Member" xlink:label="loc_SEELMay112020Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMay112020Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_June172019Member" xlink:label="loc_SEELJune172019Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJune172019Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_January242019Member" xlink:label="loc_SEELJanuary242019Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary242019Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_March72019Member" xlink:label="loc_SEELMarch72019Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMarch72019Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WarrantTermInYears" xlink:label="loc_SEELWarrantTermInYears_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELWarrantTermInYears_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ConsultingExpense" xlink:label="loc_SEELConsultingExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELConsultingExpense_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_130" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/LicenseAgreementsNarrativeDetails" xlink:title="00000036 - Disclosure - License Agreements (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember" xlink:label="loc_SEELLicensefromLigandPharmaceuticalsIncorporatedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELLicensefromLigandPharmaceuticalsIncorporatedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromVyeraPharmaceuticalsAGMember" xlink:label="loc_SEELAssetsfromVyeraPharmaceuticalsAGMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromVyeraPharmaceuticalsAGMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromBioblastPharmaLtdMember" xlink:label="loc_SEELAssetsfromBioblastPharmaLtdMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromBioblastPharmaLtdMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromApricusMember" xlink:label="loc_SEELAssetsfromApricusMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromApricusMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WegLicenseAgreementMember" xlink:label="loc_SEELWegLicenseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELWegLicenseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_UCRegentsLicenseAgreementMember" xlink:label="loc_SEELUCRegentsLicenseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELUCRegentsLicenseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DukeLicenseAgreementMember" xlink:label="loc_SEELDukeLicenseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELDukeLicenseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpensesDetail" xlink:title="00000037 - Disclosure - Accrued Expenses (Detail)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/DebtNarrativeDetails" xlink:title="00000038 - Disclosure - Debt (Narrative) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:title="00000039 - Disclosure - Other Financial Information - Other Long-term Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:title="00000040 - Disclosure - Stockholders&apos; Equity - Summary of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-NarrativeDetails" xlink:title="00000041 - Disclosure - Stock-Based Compensation - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_TwoThousandTwelveIncentivePlanMember" xlink:label="loc_SEELTwoThousandTwelveIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SEELTwoThousandTwelveIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:title="00000042 - Disclosure - Stock-Based Compensation - Assumptions Of Black-Scholes Option Grant (Details)">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:title="00000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:title="00000044 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails" xlink:title="00000045 - Disclosure - Stock-Based Compensation by Expense Category (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails" xlink:title="00000046 - Disclosure - Income Taxes - Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:title="00000047 - Disclosure - Income Taxes - Recognition Of Unrecognized Tax Benefits (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:title="00000048 - Disclosure - Income Taxes - Reconciliation Of Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-NarrativeDetails" xlink:title="00000049 - Disclosure - Income Taxes - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLossAndCapitalLossCarryforwards" xlink:label="loc_SEELOperatingLossAndCapitalLossCarryforwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SEELOperatingLossAndCapitalLossCarryforwards_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" xlink:label="loc_SEELDeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SEELDeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaapOpenTaxYear_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOpenTaxYear_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails" xlink:title="00000050 - Disclosure - Commitments and Contingencies - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CommitmentsAndContingenciesLineItems" xlink:label="loc_SEELCommitmentsAndContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CommitmentsAndContingenciesTable" xlink:label="loc_SEELCommitmentsAndContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELCommitmentsAndContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaapLitigationStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapLitigationStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IRRASSubleaseMember" xlink:label="loc_SEELIRRASSubleaseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_SEELIRRASSubleaseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LeaseAgreementPeriod" xlink:label="loc_SEELLeaseAgreementPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELLeaseAgreementPeriod_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseRenewalOptions" xlink:label="loc_SEELOperatingLeaseRenewalOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeaseRenewalOptions_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseMonthlyRentalPayment" xlink:label="loc_SEELOperatingLeaseMonthlyRentalPayment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeaseMonthlyRentalPayment_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation" xlink:label="loc_SEELOperatingLeasesRentExpensePercentageOfAnnualEscalation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeasesRentExpensePercentageOfAnnualEscalation_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_RentAbatementPeriod" xlink:label="loc_SEELRentAbatementPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELRentAbatementPeriod_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseRentAbatementRecoveryPeriod" xlink:label="loc_SEELOperatingLeaseRentAbatementRecoveryPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeaseRentAbatementRecoveryPeriod_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_SubleaseTermOfContract" xlink:label="loc_SEELSubleaseTermOfContract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELSubleaseTermOfContract_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_50" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="00000051 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/LitigationNarrativeDetails" xlink:title="00000052 - Disclosure - Litigation - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaapLitigationStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLitigationStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://SEEL/role/SubsequentEventsNarrativeDetails" xlink:title="00000053 - Disclosure - Subsequent Events (Narrative) (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>seel-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: SEEL%2D12%2D31%2D2020.xfr; Date: 2021%2D03%2D10T17:52:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_TwoThousandTwelveIncentivePlanMember" xlink:label="SEEL_TwoThousandTwelveIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_TwoThousandTwelveIncentivePlanMember" xlink:to="SEEL_TwoThousandTwelveIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_TwoThousandTwelveIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Twelve Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_August232019Member" xlink:label="SEEL_August232019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_August232019Member" xlink:to="SEEL_August232019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_August232019Member_lbl" xml:lang="en-US">August 23 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_June172019Member" xlink:label="SEEL_June172019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_June172019Member" xlink:to="SEEL_June172019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_June172019Member_lbl" xml:lang="en-US">June 17 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_January242019Member" xlink:label="SEEL_January242019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_January242019Member" xlink:to="SEEL_January242019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_January242019Member_lbl" xml:lang="en-US">January 24 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_March72019Member" xlink:label="SEEL_March72019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_March72019Member" xlink:to="SEEL_March72019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_March72019Member_lbl" xml:lang="en-US">March 7 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember" xlink:label="SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember" xlink:to="SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember_lbl" xml:lang="en-US">Ligand License</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromVyeraPharmaceuticalsAGMember" xlink:label="SEEL_AssetsfromVyeraPharmaceuticalsAGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AssetsfromVyeraPharmaceuticalsAGMember" xlink:to="SEEL_AssetsfromVyeraPharmaceuticalsAGMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AssetsfromVyeraPharmaceuticalsAGMember_lbl" xml:lang="en-US">Vyera Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromBioblastPharmaLtdMember" xlink:label="SEEL_AssetsfromBioblastPharmaLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AssetsfromBioblastPharmaLtdMember" xlink:to="SEEL_AssetsfromBioblastPharmaLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AssetsfromBioblastPharmaLtdMember_lbl" xml:lang="en-US">Bioblast Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_UCRegentsLicenseAgreementMember" xlink:label="SEEL_UCRegentsLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_UCRegentsLicenseAgreementMember" xlink:to="SEEL_UCRegentsLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_UCRegentsLicenseAgreementMember_lbl" xml:lang="en-US">UC Regents License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DukeLicenseAgreementMember" xlink:label="SEEL_DukeLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DukeLicenseAgreementMember" xlink:to="SEEL_DukeLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_DukeLicenseAgreementMember_lbl" xml:lang="en-US">Duke License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WegLicenseAgreementMember" xlink:label="SEEL_WegLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WegLicenseAgreementMember" xlink:to="SEEL_WegLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_WegLicenseAgreementMember_lbl" xml:lang="en-US">Weg License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_December2020Member" xlink:label="SEEL_December2020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_December2020Member" xlink:to="SEEL_December2020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_December2020Member_lbl" xml:lang="en-US">December 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_September42020Member" xlink:label="SEEL_September42020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_September42020Member" xlink:to="SEEL_September42020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_September42020Member_lbl" xml:lang="en-US">September 4 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_March162020Member" xlink:label="SEEL_March162020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_March162020Member" xlink:to="SEEL_March162020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_March162020Member_lbl" xml:lang="en-US">March 16 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_February132020Member" xlink:label="SEEL_February132020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_February132020Member" xlink:to="SEEL_February132020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_February132020Member_lbl" xml:lang="en-US">February 13 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_January22020Member" xlink:label="SEEL_January22020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_January22020Member" xlink:to="SEEL_January22020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_January22020Member_lbl" xml:lang="en-US">January 2 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_May112020Member" xlink:label="SEEL_May112020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_May112020Member" xlink:to="SEEL_May112020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_May112020Member_lbl" xml:lang="en-US">May 11 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DocumentAndEntityInformationAbstract" xlink:label="SEEL_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DocumentAndEntityInformationAbstract" xlink:to="SEEL_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityListingSecurityTradingCurrency" xlink:label="dei_EntityListingSecurityTradingCurrency" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingSecurityTradingCurrency" xlink:to="dei_EntityListingSecurityTradingCurrency_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingSecurityTradingCurrency_lbl" xml:lang="en-US">Entity Listing, Security Trading Currency</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders' equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensePayables" xlink:label="SEEL_LicensePayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_LicensePayables" xlink:to="SEEL_LicensePayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_LicensePayables_lbl" xml:lang="en-US">License payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liabilities, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensePayablesLongterm" xlink:label="SEEL_LicensePayablesLongterm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_LicensePayablesLongterm" xlink:to="SEEL_LicensePayablesLongterm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_LicensePayablesLongterm_lbl" xml:lang="en-US">License payables, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="us-gaap_OtherLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermNotesPayable" xlink:to="us-gaap_OtherLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermNotesPayable_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible debt, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2020 and 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.001 par value, 120,000,000 shares authorized, 54,535,891 and 27,028,533 issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in-capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Grant revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xml:lang="en-US">Type of Revenue [Extensible List]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="us-gaap_InterestIncomeDomesticDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDomesticDeposits" xlink:to="us-gaap_InterestIncomeDomesticDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDomesticDeposits_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecapitalizationCosts" xlink:to="us-gaap_RecapitalizationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RecapitalizationCosts_lbl" xml:lang="en-US">Loss on warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ChangeInFairValueOfConvertibleNotesPayable" xlink:label="SEEL_ChangeInFairValueOfConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ChangeInFairValueOfConvertibleNotesPayable" xlink:to="SEEL_ChangeInFairValueOfConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ChangeInFairValueOfConvertibleNotesPayable_lbl" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average common shares outstanding basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares_lbl" xml:lang="en-US">Issuance of common stock and warrants in a private offering, net of $16.5 million warrant liability, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability_lbl" xml:lang="en-US">Issuance of common stock and warrants in a private offering, net of $16.5 million warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Effect of reverse merger, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Effect of reverse merger</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForPrepaidServicesShares" xlink:label="SEEL_IssuanceOfCommonStockForPrepaidServicesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForPrepaidServicesShares" xlink:to="SEEL_IssuanceOfCommonStockForPrepaidServicesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForPrepaidServicesShares_lbl" xml:lang="en-US">Issuance of common stock for prepaid services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForPrepaidServices" xlink:label="SEEL_IssuanceOfCommonStockForPrepaidServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForPrepaidServices" xlink:to="SEEL_IssuanceOfCommonStockForPrepaidServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForPrepaidServices_lbl" xml:lang="en-US">Issuance of common stock for prepaid services</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForLicenseAcquiredShares" xlink:label="SEEL_IssuanceOfCommonStockForLicenseAcquiredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForLicenseAcquiredShares" xlink:to="SEEL_IssuanceOfCommonStockForLicenseAcquiredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForLicenseAcquiredShares_lbl" xml:lang="en-US">Issuance of common stock for license acquired, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForLicenseAcquired" xlink:label="SEEL_IssuanceOfCommonStockForLicenseAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForLicenseAcquired" xlink:to="SEEL_IssuanceOfCommonStockForLicenseAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForLicenseAcquired_lbl" xml:lang="en-US">Issuance of common stock for license acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Warrants exercised for cash (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xml:lang="en-US">Warrants exercised for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" xlink:label="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" xlink:to="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares_lbl" xml:lang="en-US">Reclass of warrant liabilites related to Series A warrants exercised for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" xlink:label="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" xlink:to="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash_lbl" xml:lang="en-US">Reclass of warrant liabilites related to Series A warrants exercised for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" xlink:label="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" xlink:to="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares_lbl" xml:lang="en-US">Reclass of Series B warrants from warrant liability to stockholders' equity, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" xlink:label="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" xlink:to="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity_lbl" xml:lang="en-US">Reclass of Series B warrants from warrant liability to stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" xlink:to="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares_lbl" xml:lang="en-US">Issuance of common stock for conversion of debt and accrued interest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" xlink:to="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest_lbl" xml:lang="en-US">Issuance of common stock for conversion of debt and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_BeneficialConversionFeatureOfConvertibleDebtShares" xlink:label="SEEL_BeneficialConversionFeatureOfConvertibleDebtShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_BeneficialConversionFeatureOfConvertibleDebtShares" xlink:to="SEEL_BeneficialConversionFeatureOfConvertibleDebtShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_BeneficialConversionFeatureOfConvertibleDebtShares_lbl" xml:lang="en-US">Beneficial conversion feature of convertible debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_BeneficialConversionFeatureOfConvertibleDebt" xlink:label="SEEL_BeneficialConversionFeatureOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_BeneficialConversionFeatureOfConvertibleDebt" xlink:to="SEEL_BeneficialConversionFeatureOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_BeneficialConversionFeatureOfConvertibleDebt_lbl" xml:lang="en-US">Beneficial conversion feature of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, pursuant to September 2020 Securities Purchase Agreement, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of common stock and warrants, pursuant to September 2020 Securities Purchase Agreement, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" xlink:label="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" xlink:to="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of common stock in at-the-market offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" xlink:label="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" xlink:to="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of common stock in at-the-market offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsShares" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsShares" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsValue" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsValue" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsValue_lbl" xml:lang="en-US">Issuance of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:label="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:to="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_lbl" xml:lang="en-US">Issuance of common stock due to the vesting of restricted stock, net of shares withheld to cover taxes (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs related to common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Amendment of equity classified warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WarrantLiabilityReclassifiedToStockholdersEquity" xlink:label="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity" xlink:to="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity_lbl" xml:lang="en-US">Reclassification of warrant liabilities to equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">Net income (loss) from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss from continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expensed - license acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable" xlink:label="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable" xlink:to="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable_lbl" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_NoncashRecapitalizationCosts" xlink:label="SEEL_NoncashRecapitalizationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NoncashRecapitalizationCosts" xlink:to="SEEL_NoncashRecapitalizationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NoncashRecapitalizationCosts_lbl" xml:lang="en-US">Recapitalization costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecapitalizationCosts" xlink:to="us-gaap_RecapitalizationCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecapitalizationCosts_2_lbl" xml:lang="en-US">Loss on warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" xlink:label="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" xlink:to="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="us-gaap_AccretionExpenseIncludingAssetRetirementObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:to="us-gaap_AccretionExpenseIncludingAssetRetirementObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpenseIncludingAssetRetirementObligations_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities from continuing operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xml:lang="en-US">Licenses payable</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncreaseDecreaseInLicensesPayableLongterm" xlink:label="SEEL_IncreaseDecreaseInLicensesPayableLongterm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IncreaseDecreaseInLicensesPayableLongterm" xlink:to="SEEL_IncreaseDecreaseInLicensesPayableLongterm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IncreaseDecreaseInLicensesPayableLongterm_lbl" xml:lang="en-US">Licenses payable, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants in a private offering</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs related to common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of common stock and convertible notes payable, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering" xlink:label="SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering" xlink:to="SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering_lbl" xml:lang="en-US">Proceeds from issuance of common stock in at-the-market offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Cash flows from discontinued operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by investing activities of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by (used in) discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common stock for license payable</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebt" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForConversionOfDebt" xlink:to="SEEL_IssuanceOfCommonStockForConversionOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfDebt_lbl" xml:lang="en-US">Issuance of common stock for conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest" xlink:to="SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest_lbl" xml:lang="en-US">Issuance of common stock for conversion of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_EffectOfReverseMerger" xlink:label="SEEL_EffectOfReverseMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_EffectOfReverseMerger" xlink:to="SEEL_EffectOfReverseMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_EffectOfReverseMerger_lbl" xml:lang="en-US">Effect of reverse merger</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:label="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:to="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash_lbl" xml:lang="en-US">Reclass of warrant liabilities related to Series A warrants exercised for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_NoncashDeferredOfferingCosts" xlink:label="SEEL_NoncashDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NoncashDeferredOfferingCosts" xlink:to="SEEL_NoncashDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SEEL_NoncashDeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Accrued transaction costs for financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitiesFromStockholdersEquity" xlink:label="SEEL_ReclassOfWarrantLiabilitiesFromStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ReclassOfWarrantLiabilitiesFromStockholdersEquity" xlink:to="SEEL_ReclassOfWarrantLiabilitiesFromStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ReclassOfWarrantLiabilitiesFromStockholdersEquity_lbl" xml:lang="en-US">Reclass of warrant liabilities from stockholders equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business Combinations [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Business Combination</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_InLicensingAgreementAbstract" xlink:label="SEEL_InLicensingAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_InLicensingAgreementAbstract" xlink:to="SEEL_InLicensingAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_InLicensingAgreementAbstract_lbl" xml:lang="en-US">In-Licensing Agreement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DebtAbstract" xlink:label="SEEL_DebtAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DebtAbstract" xlink:to="SEEL_DebtAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_DebtAbstract_lbl" xml:lang="en-US">Warrants Expiring March 2023, Tranche 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_EquityCompensationPlansAbstract" xlink:label="SEEL_EquityCompensationPlansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_EquityCompensationPlansAbstract" xlink:to="SEEL_EquityCompensationPlansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_EquityCompensationPlansAbstract_lbl" xml:lang="en-US">Warrants Expiring March 2023, Tranche 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncomeTaxesAbstract" xlink:label="SEEL_IncomeTaxesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IncomeTaxesAbstract" xlink:to="SEEL_IncomeTaxesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IncomeTaxesAbstract_lbl" xml:lang="en-US">Warrants Expiring March 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:label="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:to="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_lbl" xml:lang="en-US">Merger with Apricus Biosciences, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionLongTermContracts" xlink:label="us-gaap_RevenueRecognitionLongTermContracts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionLongTermContracts" xlink:to="us-gaap_RevenueRecognitionLongTermContracts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionLongTermContracts_lbl" xml:lang="en-US">Grant Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Income (Loss) Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US">Geographic Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy for Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Summary of Fair Value Measurements Valuation Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Level 3 Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Summary of Revenues by Geographic Area</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Long Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Valuation Assumptions for Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Income Tax Effective Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Future Minimum Rental Payments Under Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" xlink:label="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" xlink:to="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired_lbl" xml:lang="en-US">Number of Phase 3 clinical efficacy trials required</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Computer software</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Liabilities, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_lbl" xml:lang="en-US">Warrant issued in connection with financing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US">Warrant liability reclassified to stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Change in fair value measurement of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Number of securities that are antidilutive</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:label="country_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CA_lbl" xml:lang="en-US">Canada</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OtherCountriesMember" xlink:label="SEEL_OtherCountriesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OtherCountriesMember" xlink:to="SEEL_OtherCountriesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OtherCountriesMember_lbl" xml:lang="en-US">Other Countries</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaPacificMember" xlink:to="srt_AsiaPacificMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaPacificMember_lbl" xml:lang="en-US">Asia Pacific</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues by area</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US">Long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Machinery and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="us-gaap_CapitalLeasedAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasedAssetsGross" xlink:to="us-gaap_CapitalLeasedAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasedAssetsGross_lbl" xml:lang="en-US">Capital lease equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Computer software</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares of common stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Cash received from stock sale, before issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Date from which warrants are exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WarrantTermInYears" xlink:label="SEEL_WarrantTermInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WarrantTermInYears" xlink:to="SEEL_WarrantTermInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_WarrantTermInYears_lbl" xml:lang="en-US">Warrant term, in years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Terms and provisions</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ConsultingExpense" xlink:label="SEEL_ConsultingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ConsultingExpense" xlink:to="SEEL_ConsultingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ConsultingExpense_lbl" xml:lang="en-US">Consulting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromApricusMember" xlink:label="SEEL_AssetsfromApricusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AssetsfromApricusMember" xlink:to="SEEL_AssetsfromApricusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AssetsfromApricusMember_lbl" xml:lang="en-US">Apricus Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription_lbl" xml:lang="en-US">License Agreement, Separately Recognized Transactions, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Assets Recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Liabilities Recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Personnel related</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ResearchAndDevelopmentAccruedExpense" xlink:label="SEEL_ResearchAndDevelopmentAccruedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ResearchAndDevelopmentAccruedExpense" xlink:to="SEEL_ResearchAndDevelopmentAccruedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ResearchAndDevelopmentAccruedExpense_lbl" xml:lang="en-US">Outside research and development services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US">Deferred compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CovertibleNotestNarrativeDetailsAbstract" xlink:label="SEEL_CovertibleNotestNarrativeDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_CovertibleNotestNarrativeDetailsAbstract" xlink:to="SEEL_CovertibleNotestNarrativeDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_CovertibleNotestNarrativeDetailsAbstract_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtDescription_lbl" xml:lang="en-US">Debt, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerDepositsNoncurrent" xlink:label="us-gaap_CustomerDepositsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerDepositsNoncurrent" xlink:to="us-gaap_CustomerDepositsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerDepositsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Other long term liabilities, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2_lbl" xml:lang="en-US">Disclosure of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xml:lang="en-US">Common Shares Issuable upon Exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssumedInMerger" xlink:label="SEEL_AssumedInMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AssumedInMerger" xlink:to="SEEL_AssumedInMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AssumedInMerger_lbl" xml:lang="en-US">Assumed in Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Issued (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Cancelled (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Exercisable at balance sheet date (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, beginning balance (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssumedInMergerInUsdPerShare" xlink:label="SEEL_AssumedInMergerInUsdPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AssumedInMergerInUsdPerShare" xlink:to="SEEL_AssumedInMergerInUsdPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AssumedInMergerInUsdPerShare_lbl" xml:lang="en-US">Assumed in Merger (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Issued (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled (in usd per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding, ending balance (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at balance sheet date (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WeightedAverageRemainingContractualLifeInYears" xlink:label="SEEL_WeightedAverageRemainingContractualLifeInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WeightedAverageRemainingContractualLifeInYears" xlink:to="SEEL_WeightedAverageRemainingContractualLifeInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_WeightedAverageRemainingContractualLifeInYears_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssumedInMergerInYears" xlink:label="SEEL_AssumedInMergerInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AssumedInMergerInYears" xlink:to="SEEL_AssumedInMergerInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AssumedInMergerInYears_lbl" xml:lang="en-US">Assumed in Merger (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuedInYears" xlink:label="SEEL_IssuedInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuedInYears" xlink:to="SEEL_IssuedInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IssuedInYears_lbl" xml:lang="en-US">Issued (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OutstandingAtBalanceSheetDateInYears" xlink:label="SEEL_OutstandingAtBalanceSheetDateInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OutstandingAtBalanceSheetDateInYears" xlink:to="SEEL_OutstandingAtBalanceSheetDateInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OutstandingAtBalanceSheetDateInYears_lbl" xml:lang="en-US">Outstanding at balance sheet date (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ExercisableAtBalanceSheetDateInYears" xlink:label="SEEL_ExercisableAtBalanceSheetDateInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ExercisableAtBalanceSheetDateInYears" xlink:to="SEEL_ExercisableAtBalanceSheetDateInYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ExercisableAtBalanceSheetDateInYears_lbl" xml:lang="en-US">Exercisable at balance sheet date (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Options vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Common shares authorized for issuance (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common shares available for future grants (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Stock options exercisable (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair vale of options vested in period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of awards vested in period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options granted (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost related to equity awards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Period of recognition for unrecognized compensation costs (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl" xml:lang="en-US">Share Based Payment Award Stock Options Valuation Assumptions [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl" xml:lang="en-US">Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_lbl" xml:lang="en-US">Forfeiture rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, beginning of period (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Granted in Period (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised in Period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Cancelled (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding, end of period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest, end of period (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Exercisable, end of period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, beginning of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted in Period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised in Period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled (USD per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding, end of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and expected to vest stock, end of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable, end of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Granted, Weighted Average Remaining Contractual Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years) of vested and expected to vest stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years) of exercisable stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Total Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Total aggregate intrinsic value shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Total aggregate intrinsic value of vested or expected to vest stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Total aggregate intrinsic value of exercisable stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Nonvested, beginning of period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Nonvested, end of period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested, beginning of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited (USD per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Nonvested, end of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" xlink:label="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" xlink:to="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards_lbl" xml:lang="en-US">Net operating tax loss and capital loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Start up cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Change in current period positions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Change in prior period positions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Change in prior period positions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xml:lang="en-US">Permanent items</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year true-up</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Deferred rate changes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Revaluation of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLossAndCapitalLossCarryforwards" xlink:label="SEEL_OperatingLossAndCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLossAndCapitalLossCarryforwards" xlink:to="SEEL_OperatingLossAndCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OperatingLossAndCapitalLossCarryforwards_lbl" xml:lang="en-US">Operating loss and capital loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" xlink:label="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" xlink:to="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic_lbl" xml:lang="en-US">Federal operating loss carryforwards and tax credit carryforwards deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Income tax interest and penalties expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Tax Credit Carryforward, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CommitmentsAndContingenciesTable" xlink:label="SEEL_CommitmentsAndContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_CommitmentsAndContingenciesTable" xlink:to="SEEL_CommitmentsAndContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CommitmentsAndContingenciesLineItems" xlink:label="SEEL_CommitmentsAndContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_CommitmentsAndContingenciesLineItems" xlink:to="SEEL_CommitmentsAndContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US">Litigation Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IRRASSubleaseMember" xlink:label="SEEL_IRRASSubleaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IRRASSubleaseMember" xlink:to="SEEL_IRRASSubleaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IRRASSubleaseMember_lbl" xml:lang="en-US">IRRAS Sublease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Related Director</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LeaseAgreementPeriod" xlink:label="SEEL_LeaseAgreementPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_LeaseAgreementPeriod" xlink:to="SEEL_LeaseAgreementPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_LeaseAgreementPeriod_lbl" xml:lang="en-US">Operating lease, agreement period (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseRenewalOptions" xlink:label="SEEL_OperatingLeaseRenewalOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeaseRenewalOptions" xlink:to="SEEL_OperatingLeaseRenewalOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OperatingLeaseRenewalOptions_lbl" xml:lang="en-US">Operating lease, renewal option (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseMonthlyRentalPayment" xlink:label="SEEL_OperatingLeaseMonthlyRentalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeaseMonthlyRentalPayment" xlink:to="SEEL_OperatingLeaseMonthlyRentalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OperatingLeaseMonthlyRentalPayment_lbl" xml:lang="en-US">Operating lease, monthly rent</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation" xlink:label="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation" xlink:to="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation_lbl" xml:lang="en-US">Operating lease, rent expense percentage of annual escalation</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_RentAbatementPeriod" xlink:label="SEEL_RentAbatementPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_RentAbatementPeriod" xlink:to="SEEL_RentAbatementPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_RentAbatementPeriod_lbl" xml:lang="en-US">Operating lease, rent abatement period</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseRentAbatementRecoveryPeriod" xlink:label="SEEL_OperatingLeaseRentAbatementRecoveryPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeaseRentAbatementRecoveryPeriod" xlink:to="SEEL_OperatingLeaseRentAbatementRecoveryPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OperatingLeaseRentAbatementRecoveryPeriod_lbl" xml:lang="en-US">Operating lease, rent abatement recovery period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_lbl" xml:lang="en-US">Future sublease payments receivable from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_SubleaseTermOfContract" xlink:label="SEEL_SubleaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_SubleaseTermOfContract" xlink:to="SEEL_SubleaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_SubleaseTermOfContract_lbl" xml:lang="en-US">Sublease, term of contract</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Loss contingency, damages sought</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">Future Minimum Rental Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_SubsequentEventNarrativeDetailsAbstract" xlink:label="SEEL_SubsequentEventNarrativeDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_SubsequentEventNarrativeDetailsAbstract" xlink:to="SEEL_SubsequentEventNarrativeDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SEEL_SubsequentEventNarrativeDetailsAbstract_lbl" xml:lang="en-US">Warrants Expiring March 2023, Tranche 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsDate" xlink:to="us-gaap_SubsequentEventsDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsDate_lbl" xml:lang="en-US">Subsequent Event, Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent Event, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_April2017FinancingMember" xlink:label="SEEL_April2017FinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_April2017FinancingMember" xlink:to="SEEL_April2017FinancingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_April2017FinancingMember_doc" xml:lang="en-US">April 2017 Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AspireCapitalFundLLCMember" xlink:label="SEEL_AspireCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AspireCapitalFundLLCMember" xlink:to="SEEL_AspireCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_AspireCapitalFundLLCMember_doc" xml:lang="en-US">Aspire Capital Fund, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_CommitmentsAndContingenciesLineItems" xlink:to="SEEL_CommitmentsAndContingenciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_CommitmentsAndContingenciesLineItems_doc" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_CommitmentsAndContingenciesTable" xlink:to="SEEL_CommitmentsAndContingenciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_CommitmentsAndContingenciesTable_doc" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" xlink:to="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards_doc" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards and capital loss carryforwards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" xlink:to="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic_doc" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards, Domestic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_DocumentAndEntityInformationAbstract" xlink:to="SEEL_DocumentAndEntityInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_DocumentAndEntityInformationAbstract_doc" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" xlink:to="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating_doc" xml:lang="en-US">Gain (Losses) on Extinguishment of Debt, Non Cash, Operating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IRRASSubleaseMember" xlink:to="SEEL_IRRASSubleaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_IRRASSubleaseMember_doc" xml:lang="en-US">IRRAS Sublease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_InLicensingAgreementAbstract" xlink:to="SEEL_InLicensingAgreementAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_InLicensingAgreementAbstract_doc" xml:lang="en-US">In-Licensing Agreement [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsShares" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsShares_doc" xml:lang="en-US">Issuance Of Common Stock And Warrants, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IssuanceOfCommonStockAndWarrantsValue" xlink:to="SEEL_IssuanceOfCommonStockAndWarrantsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_IssuanceOfCommonStockAndWarrantsValue_doc" xml:lang="en-US">Value of issuance of common stock and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_LeaseAgreementPeriod" xlink:to="SEEL_LeaseAgreementPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_LeaseAgreementPeriod_doc" xml:lang="en-US">Lease Agreement Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeaseMonthlyRentalPayment" xlink:to="SEEL_OperatingLeaseMonthlyRentalPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_OperatingLeaseMonthlyRentalPayment_doc" xml:lang="en-US">Operating Lease Monthly Rental Payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeaseRenewalOptions" xlink:to="SEEL_OperatingLeaseRenewalOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_OperatingLeaseRenewalOptions_doc" xml:lang="en-US">Operating Lease Renewal Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeaseRentAbatementRecoveryPeriod" xlink:to="SEEL_OperatingLeaseRentAbatementRecoveryPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_OperatingLeaseRentAbatementRecoveryPeriod_doc" xml:lang="en-US">Operating Lease, Rent Abatement Recovery Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation" xlink:to="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation_doc" xml:lang="en-US">Operating Leases Rent Expense Percentage Of Annual Escalation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OperatingLossAndCapitalLossCarryforwards" xlink:to="SEEL_OperatingLossAndCapitalLossCarryforwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_OperatingLossAndCapitalLossCarryforwards_doc" xml:lang="en-US">Amount of operating loss carryforward and deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OtherCountriesMember" xlink:to="SEEL_OtherCountriesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_OtherCountriesMember_doc" xml:lang="en-US">Other Countries [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_RentAbatementPeriod" xlink:to="SEEL_RentAbatementPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_RentAbatementPeriod_doc" xml:lang="en-US">Rent Abatement Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ResearchAndDevelopmentAccruedExpense" xlink:to="SEEL_ResearchAndDevelopmentAccruedExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ResearchAndDevelopmentAccruedExpense_doc" xml:lang="en-US">Research And Development Accrued Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" xlink:to="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired_doc" xml:lang="en-US">Research And Development, Number Of Phase 3 Clinical Efficacy Trials Required</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_September2016FinancingMember" xlink:label="SEEL_September2016FinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_September2016FinancingMember" xlink:to="SEEL_September2016FinancingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_September2016FinancingMember_doc" xml:lang="en-US">September 2016 Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_September2017FinancingMember" xlink:label="SEEL_September2017FinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_September2017FinancingMember" xlink:to="SEEL_September2017FinancingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_September2017FinancingMember_doc" xml:lang="en-US">September 2017 Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_September2018FinancingMember" xlink:label="SEEL_September2018FinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_September2018FinancingMember" xlink:to="SEEL_September2018FinancingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_September2018FinancingMember_doc" xml:lang="en-US">September 2018 Financing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_doc" xml:lang="en-US">Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_doc" xml:lang="en-US">Share Based Payment Award Stock Options Valuation Assumptions [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:to="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_doc" xml:lang="en-US">Stock Issued During Period, Shares, Vesting Of Restricted Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_TwoThousandTwelveIncentivePlanMember" xlink:to="SEEL_TwoThousandTwelveIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_TwoThousandTwelveIncentivePlanMember_doc" xml:lang="en-US">Two Thousand Twelve Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity" xlink:to="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SEEL_WarrantLiabilityReclassifiedToStockholdersEquity_doc" xml:lang="en-US">Warrants Reclassified To Stockholders' Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable" xlink:to="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable_2_lbl" xml:lang="en-US">September 2017 Financing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" xlink:to="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_GainLossesonExtinguishmentofDebtNonCashOperating_3_lbl" xml:lang="en-US">Gain (Losses) on Extinguishment of Debt, Non Cash, Operating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NoncashDeferredOfferingCosts" xlink:to="SEEL_NoncashDeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NoncashDeferredOfferingCosts_2_lbl" xml:lang="en-US">Warrants Expiring March 2020, Tranche 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2_lbl" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_2_lbl" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized_2_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Liabilities Recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>seel-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: SEEL%2D12%2D31%2D2020.xfr; Date: 2021%2D03%2D10T17:52:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://SEEL/role/DocumentAndEntityInformation" xlink:href="seel-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheets" xlink:href="seel-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="seel-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="seel-20201231.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="seel-20201231.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StatementsOfCashFlows" xlink:href="seel-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LiquidityAndGoingConcern" xlink:href="seel-20201231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/BusinessCombination" xlink:href="seel-20201231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommonStockOfferings" xlink:href="seel-20201231.xsd#CommonStockOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LicenseAgreements" xlink:href="seel-20201231.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpenses" xlink:href="seel-20201231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Debt" xlink:href="seel-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquity" xlink:href="seel-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation" xlink:href="seel-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes" xlink:href="seel-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/SubsequentEvent" xlink:href="seel-20201231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpensesTables" xlink:href="seel-20201231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquityTables" xlink:href="seel-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensationTables" xlink:href="seel-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxesTables" xlink:href="seel-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingenciesTables" xlink:href="seel-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:href="seel-20201231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:href="seel-20201231.xsd#OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommonStockOfferingsNarrativeDetails" xlink:href="seel-20201231.xsd#CommonStockOfferingsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LicenseAgreementsNarrativeDetails" xlink:href="seel-20201231.xsd#LicenseAgreementsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/AccruedExpensesDetail" xlink:href="seel-20201231.xsd#AccruedExpensesDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/DebtNarrativeDetails" xlink:href="seel-20201231.xsd#DebtNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:href="seel-20201231.xsd#OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:href="seel-20201231.xsd#StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-NarrativeDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails" xlink:href="seel-20201231.xsd#Stock-basedCompensationByExpenseCategoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-DeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/IncomeTaxes-NarrativeDetails" xlink:href="seel-20201231.xsd#IncomeTaxes-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies-NarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="seel-20201231.xsd#CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/LitigationNarrativeDetails" xlink:href="seel-20201231.xsd#LitigationNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://SEEL/role/SubsequentEventsNarrativeDetails" xlink:href="seel-20201231.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DocumentAndEntityInformationAbstract" xlink:label="loc_SEELDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityListingSecurityTradingCurrency" xlink:label="loc_deiEntityListingSecurityTradingCurrency" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityListingSecurityTradingCurrency" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensePayables" xlink:label="loc_SEELLicensePayables" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SEELLicensePayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensePayablesLongterm" xlink:label="loc_SEELLicensePayablesLongterm" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_SEELLicensePayablesLongterm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaapOtherLongTermNotesPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="loc_us-gaapTypeOfRevenueExtensibleList" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapTypeOfRevenueExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="loc_us-gaapInterestIncomeDomesticDeposits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeDomesticDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_SEELChangeInFairValueOfConvertibleNotesPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SEELChangeInFairValueOfConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForPrepaidServicesShares" xlink:label="loc_SEELIssuanceOfCommonStockForPrepaidServicesShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockForPrepaidServicesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForPrepaidServices" xlink:label="loc_SEELIssuanceOfCommonStockForPrepaidServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockForPrepaidServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForLicenseAcquiredShares" xlink:label="loc_SEELIssuanceOfCommonStockForLicenseAcquiredShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockForLicenseAcquiredShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForLicenseAcquired" xlink:label="loc_SEELIssuanceOfCommonStockForLicenseAcquired" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockForLicenseAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" xlink:label="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" xlink:label="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" xlink:label="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" xlink:label="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" xlink:label="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" xlink:label="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockForConversionOfDebtAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_BeneficialConversionFeatureOfConvertibleDebtShares" xlink:label="loc_SEELBeneficialConversionFeatureOfConvertibleDebtShares" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELBeneficialConversionFeatureOfConvertibleDebtShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_BeneficialConversionFeatureOfConvertibleDebt" xlink:label="loc_SEELBeneficialConversionFeatureOfConvertibleDebt" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELBeneficialConversionFeatureOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" xlink:label="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" xlink:label="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsShares" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsShares" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockAndWarrantsValue" xlink:label="loc_SEELIssuanceOfCommonStockAndWarrantsValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELIssuanceOfCommonStockAndWarrantsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:label="loc_SEELStockIssuedDuringPeriodSharesVestingOfRestrictedStock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELStockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WarrantLiabilityReclassifiedToStockholdersEquity" xlink:label="loc_SEELWarrantLiabilityReclassifiedToStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_SEELWarrantLiabilityReclassifiedToStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaapIncomeLossFromContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable" xlink:label="loc_SEELIncreaseDecreaseInFairValueOfConvertibleNotesPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SEELIncreaseDecreaseInFairValueOfConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_NoncashRecapitalizationCosts" xlink:label="loc_SEELNoncashRecapitalizationCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SEELNoncashRecapitalizationCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_GainLossesonExtinguishmentofDebtNonCashOperating" xlink:label="loc_SEELGainLossesonExtinguishmentofDebtNonCashOperating" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SEELGainLossesonExtinguishmentofDebtNonCashOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="loc_us-gaapAccretionExpenseIncludingAssetRetirementObligations" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAccretionExpenseIncludingAssetRetirementObligations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncreaseDecreaseInLicensesPayableLongterm" xlink:label="loc_SEELIncreaseDecreaseInLicensesPayableLongterm" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SEELIncreaseDecreaseInLicensesPayableLongterm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedSalaries" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedSalaries" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="loc_SEELProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_SEELProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering" xlink:label="loc_SEELProceedsFromIssuanceOfCommonStockInAtthemarketOffering" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_SEELProceedsFromIssuanceOfCommonStockInAtthemarketOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperations" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfDebt" xlink:label="loc_SEELIssuanceOfCommonStockForConversionOfDebt" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELIssuanceOfCommonStockForConversionOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest" xlink:label="loc_SEELIssuanceOfCommonStockForConversionOfAccruedInterest" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELIssuanceOfCommonStockForConversionOfAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuanceOfCommonStockForLicenseAcquired" xlink:label="loc_SEELIssuanceOfCommonStockForLicenseAcquired" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELIssuanceOfCommonStockForLicenseAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_EffectOfReverseMerger" xlink:label="loc_SEELEffectOfReverseMerger" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELEffectOfReverseMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:label="loc_SEELReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" xlink:label="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_NoncashDeferredOfferingCosts" xlink:label="loc_SEELNoncashDeferredOfferingCosts" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELNoncashDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ReclassOfWarrantLiabilitiesFromStockholdersEquity" xlink:label="loc_SEELReclassOfWarrantLiabilitiesFromStockholdersEquity" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SEELReclassOfWarrantLiabilitiesFromStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - 2. Liquidity and Going Concern">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/BusinessCombination" xlink:title="00000009 - Disclosure - 3. Business Combination">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CommonStockOfferings" xlink:title="00000010 - Disclosure - 4. Common Stock Offerings">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/LicenseAgreements" xlink:title="00000011 - Disclosure - 5. License Agreements">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_InLicensingAgreementAbstract" xlink:label="loc_SEELInLicensingAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELInLicensingAgreementAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpenses" xlink:title="00000012 - Disclosure - 6. Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Debt" xlink:title="00000013 - Disclosure - 7. Debt">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DebtAbstract" xlink:label="loc_SEELDebtAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELDebtAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquity" xlink:title="00000014 - Disclosure - 8. Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation" xlink:title="00000015 - Disclosure - 9. Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_EquityCompensationPlansAbstract" xlink:label="loc_SEELEquityCompensationPlansAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELEquityCompensationPlansAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes" xlink:title="00000016 - Disclosure - 10. Income Taxes">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IncomeTaxesAbstract" xlink:label="loc_SEELIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELIncomeTaxesAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - 11. Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/SubsequentEvent" xlink:title="00000018 - Disclosure - 12. Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:label="loc_us-gaapBusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaapStockholdersEquityPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStockholdersEquityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="loc_us-gaapInterestExpensePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInterestExpensePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionLongTermContracts" xlink:label="loc_us-gaapRevenueRecognitionLongTermContracts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionLongTermContracts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpensesTables" xlink:title="00000021 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherNoncurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&apos; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensationTables" xlink:title="00000023 - Disclosure - Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSeelosMergerAgreementDetails" xlink:title="00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Seelos Merger Agreement (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" xlink:label="loc_SEELResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SEELResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetails" xlink:title="00000027 - Disclosure - Organization and Summary of Significant Accounting Policies - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails" xlink:title="00000028 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Assets and Liabilities Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails" xlink:title="00000029 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails" xlink:title="00000030 - Disclosure - Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails" xlink:title="00000031 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails" xlink:title="00000032 - Disclosure - Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails" xlink:title="00000033 - Disclosure - Organization and Summary of Significant Accounting Policies - Geographical Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:label="loc_countryCA" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OtherCountriesMember" xlink:label="loc_SEELOtherCountriesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_SEELOtherCountriesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember" xlink:label="loc_srtAsiaPacificMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaPacificMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaapNoncurrentAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapNoncurrentAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OtherFinancialInformation-PropertyAndEquipmentDetail" xlink:title="00000034 - Disclosure - Other Financial Information - Property and Equipment (Detail)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaapCapitalLeasedAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapCapitalLeasedAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CommonStockOfferingsNarrativeDetails" xlink:title="00000035 - Disclosure - Common Stock Offerings (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CommonStockIssuanceNarrativeDetailsAbstract" xlink:label="loc_SEELCommonStockIssuanceNarrativeDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommonStockIssuanceNarrativeDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_December2020Member" xlink:label="loc_SEELDecember2020Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELDecember2020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_September42020Member" xlink:label="loc_SEELSeptember42020Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELSeptember42020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_August232019Member" xlink:label="loc_SEELAugust232019Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELAugust232019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_March162020Member" xlink:label="loc_SEELMarch162020Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMarch162020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_February132020Member" xlink:label="loc_SEELFebruary132020Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELFebruary132020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_January22020Member" xlink:label="loc_SEELJanuary22020Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary22020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_May112020Member" xlink:label="loc_SEELMay112020Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMay112020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_June172019Member" xlink:label="loc_SEELJune172019Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJune172019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_January242019Member" xlink:label="loc_SEELJanuary242019Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary242019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_March72019Member" xlink:label="loc_SEELMarch72019Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMarch72019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WarrantTermInYears" xlink:label="loc_SEELWarrantTermInYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELWarrantTermInYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ConsultingExpense" xlink:label="loc_SEELConsultingExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELConsultingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/LicenseAgreementsNarrativeDetails" xlink:title="00000036 - Disclosure - License Agreements (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_BusinessCombinationsPurchasePriceAllocationAndNarrativeDetailsAbstract" xlink:label="loc_SEELBusinessCombinationsPurchasePriceAllocationAndNarrativeDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELBusinessCombinationsPurchasePriceAllocationAndNarrativeDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember" xlink:label="loc_SEELLicensefromLigandPharmaceuticalsIncorporatedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELLicensefromLigandPharmaceuticalsIncorporatedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromVyeraPharmaceuticalsAGMember" xlink:label="loc_SEELAssetsfromVyeraPharmaceuticalsAGMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromVyeraPharmaceuticalsAGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromBioblastPharmaLtdMember" xlink:label="loc_SEELAssetsfromBioblastPharmaLtdMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromBioblastPharmaLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssetsfromApricusMember" xlink:label="loc_SEELAssetsfromApricusMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromApricusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WegLicenseAgreementMember" xlink:label="loc_SEELWegLicenseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELWegLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_UCRegentsLicenseAgreementMember" xlink:label="loc_SEELUCRegentsLicenseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELUCRegentsLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DukeLicenseAgreementMember" xlink:label="loc_SEELDukeLicenseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELDukeLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/AccruedExpensesDetail" xlink:title="00000037 - Disclosure - Accrued Expenses (Detail)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPayablesAndAccrualsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ResearchAndDevelopmentAccruedExpense" xlink:label="loc_SEELResearchAndDevelopmentAccruedExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_SEELResearchAndDevelopmentAccruedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/DebtNarrativeDetails" xlink:title="00000038 - Disclosure - Debt (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CovertibleNotestNarrativeDetailsAbstract" xlink:label="loc_SEELCovertibleNotestNarrativeDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="loc_us-gaapLongTermDebtDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCovertibleNotestNarrativeDetailsAbstract" xlink:to="loc_us-gaapLongTermDebtDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/OtherFinancialInformation-OtherLong-termLiabilitiesDetails" xlink:title="00000039 - Disclosure - Other Financial Information - Other Long-term Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerDepositsNoncurrent" xlink:label="loc_us-gaapCustomerDepositsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCustomerDepositsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails" xlink:title="00000040 - Disclosure - Stockholders&apos; Equity - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssumedInMerger" xlink:label="loc_SEELAssumedInMerger" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="loc_SEELAssumedInMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssumedInMergerInUsdPerShare" xlink:label="loc_SEELAssumedInMergerInUsdPerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="loc_SEELAssumedInMergerInUsdPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_WeightedAverageRemainingContractualLifeInYears" xlink:label="loc_SEELWeightedAverageRemainingContractualLifeInYears" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SEELWeightedAverageRemainingContractualLifeInYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_AssumedInMergerInYears" xlink:label="loc_SEELAssumedInMergerInYears" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELWeightedAverageRemainingContractualLifeInYears" xlink:to="loc_SEELAssumedInMergerInYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IssuedInYears" xlink:label="loc_SEELIssuedInYears" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELWeightedAverageRemainingContractualLifeInYears" xlink:to="loc_SEELIssuedInYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OutstandingAtBalanceSheetDateInYears" xlink:label="loc_SEELOutstandingAtBalanceSheetDateInYears" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELWeightedAverageRemainingContractualLifeInYears" xlink:to="loc_SEELOutstandingAtBalanceSheetDateInYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ExercisableAtBalanceSheetDateInYears" xlink:label="loc_SEELExercisableAtBalanceSheetDateInYears" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELWeightedAverageRemainingContractualLifeInYears" xlink:to="loc_SEELExercisableAtBalanceSheetDateInYears" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-NarrativeDetails" xlink:title="00000041 - Disclosure - Stock-Based Compensation - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_TwoThousandTwelveIncentivePlanMember" xlink:label="loc_SEELTwoThousandTwelveIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SEELTwoThousandTwelveIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails" xlink:title="00000042 - Disclosure - Stock-Based Compensation - Assumptions Of Black-Scholes Option Grant (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails" xlink:title="00000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_SEELSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_SEELSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensation-SummaryOfRestrictedStockUnitsActivityDetails" xlink:title="00000044 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails" xlink:title="00000045 - Disclosure - Stock-Based Compensation by Expense Category (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails" xlink:title="00000046 - Disclosure - Income Taxes - Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" xlink:label="loc_SEELDeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SEELDeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails" xlink:title="00000047 - Disclosure - Income Taxes - Recognition Of Unrecognized Tax Benefits (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaapReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails" xlink:title="00000048 - Disclosure - Income Taxes - Reconciliation Of Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/IncomeTaxes-NarrativeDetails" xlink:title="00000049 - Disclosure - Income Taxes - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLossAndCapitalLossCarryforwards" xlink:label="loc_SEELOperatingLossAndCapitalLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SEELOperatingLossAndCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" xlink:label="loc_SEELDeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SEELDeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaapOpenTaxYear" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOpenTaxYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails" xlink:title="00000050 - Disclosure - Commitments and Contingencies - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CommitmentsAndContingenciesTable" xlink:label="loc_SEELCommitmentsAndContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_SEELCommitmentsAndContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_CommitmentsAndContingenciesLineItems" xlink:label="loc_SEELCommitmentsAndContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_SEELCommitmentsAndContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaapLitigationStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapLitigationStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_IRRASSubleaseMember" xlink:label="loc_SEELIRRASSubleaseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_SEELIRRASSubleaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesTable" xlink:to="loc_srtStatementGeographicalAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_LeaseAgreementPeriod" xlink:label="loc_SEELLeaseAgreementPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELLeaseAgreementPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseRenewalOptions" xlink:label="loc_SEELOperatingLeaseRenewalOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeaseRenewalOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseMonthlyRentalPayment" xlink:label="loc_SEELOperatingLeaseMonthlyRentalPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeaseMonthlyRentalPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeasesRentExpensePercentageOfAnnualEscalation" xlink:label="loc_SEELOperatingLeasesRentExpensePercentageOfAnnualEscalation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeasesRentExpensePercentageOfAnnualEscalation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_RentAbatementPeriod" xlink:label="loc_SEELRentAbatementPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELRentAbatementPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_OperatingLeaseRentAbatementRecoveryPeriod" xlink:label="loc_SEELOperatingLeaseRentAbatementRecoveryPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELOperatingLeaseRentAbatementRecoveryPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_SubleaseTermOfContract" xlink:label="loc_SEELSubleaseTermOfContract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_SEELSubleaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="00000051 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/LitigationNarrativeDetails" xlink:title="00000052 - Disclosure - Litigation - Narrative (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaapLitigationStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLitigationStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaapLitigationStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLitigationStatusAxis" xlink:to="loc_us-gaapLitigationStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://SEEL/role/SubsequentEventsNarrativeDetails" xlink:title="00000053 - Disclosure - Subsequent Events (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="seel-20201231.xsd#SEEL_SubsequentEventNarrativeDetailsAbstract" xlink:label="loc_SEELSubsequentEventNarrativeDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsDate" xlink:label="loc_us-gaapSubsequentEventsDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELSubsequentEventNarrativeDetailsAbstract" xlink:to="loc_us-gaapSubsequentEventsDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SEELSubsequentEventNarrativeDetailsAbstract" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744136764808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Seelos Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SEEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001017491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingSecurityTradingCurrency', window );">Entity Listing, Security Trading Currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,249,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingSecurityTradingCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingSecurityTradingCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744136826568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 15,662<span></span>
</td>
<td class="nump">$ 10,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,494<span></span>
</td>
<td class="nump">11,096<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">17,494<span></span>
</td>
<td class="nump">11,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">1,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_LicensePayables', window );">License payables</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debt</a></td>
<td class="nump">2,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,429<span></span>
</td>
<td class="nump">10,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_LicensePayablesLongterm', window );">License payables, long-term</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermNotesPayable', window );">Note payable</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt, long-term</a></td>
<td class="nump">7,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,922<span></span>
</td>
<td class="nump">11,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2020 and 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value, 120,000,000 shares authorized, 54,535,891 and 27,028,533 issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">77,680<span></span>
</td>
<td class="nump">56,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(75,162)<span></span>
</td>
<td class="num">(56,061)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">2,572<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 17,494<span></span>
</td>
<td class="nump">$ 11,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_LicensePayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_LicensePayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_LicensePayablesLongterm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_LicensePayablesLongterm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744136786648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">54,535,891<span></span>
</td>
<td class="nump">27,028,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">54,535,891<span></span>
</td>
<td class="nump">27,028,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744136850696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">us-gaap:GrantMember<span></span>
</td>
<td class="text">us-gaap:GrantMember<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,984<span></span>
</td>
<td class="nump">22,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,775<span></span>
</td>
<td class="nump">7,559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">18,759<span></span>
</td>
<td class="nump">30,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,759)<span></span>
</td>
<td class="num">(29,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeDomesticDeposits', window );">Interest income</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Loss on warrant issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(16,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ChangeInFairValueOfConvertibleNotesPayable', window );">Change in fair value of convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(342)<span></span>
</td>
<td class="num">(21,508)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (19,101)<span></span>
</td>
<td class="num">$ (51,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share basic and diluted</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding basic and diluted</a></td>
<td class="nump">44,766,640<span></span>
</td>
<td class="nump">20,308,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ChangeInFairValueOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ChangeInFairValueOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDomesticDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest earned on deposits in United States money market accounts and other United States interest earning accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDomesticDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138395384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">3,081,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="num">$ (4,806)<span></span>
</td>
<td class="num">$ (4,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares', window );">Issuance of common stock and warrants in a private offering, net of $16.5 million warrant liability, shares</a></td>
<td class="nump">1,829,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability', window );">Issuance of common stock and warrants in a private offering, net of $16.5 million warrant liability</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Effect of reverse merger, shares</a></td>
<td class="nump">947,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Effect of reverse merger</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForLicenseAcquiredShares', window );">Issuance of common stock for license acquired, shares</a></td>
<td class="nump">992,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForLicenseAcquired', window );">Issuance of common stock for license acquired</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Warrants exercised for cash (in shares)</a></td>
<td class="nump">14,332,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Warrants exercised for cash</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares', window );">Reclass of warrant liabilites related to Series A warrants exercised for cash, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash', window );">Reclass of warrant liabilites related to Series A warrants exercised for cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares', window );">Reclass of Series B warrants from warrant liability to stockholders' equity, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity', window );">Reclass of Series B warrants from warrant liability to stockholders' equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,473<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares', window );">Issuance of common stock for conversion of debt and accrued interest, shares</a></td>
<td class="nump">172,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest', window );">Issuance of common stock for conversion of debt and accrued interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,715<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">2,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares', window );">Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs, shares</a></td>
<td class="nump">4,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts', window );">Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">5,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares', window );">Issuance of common stock in at-the-market offering, net of issuance costs, shares</a></td>
<td class="nump">1,197,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts', window );">Issuance of common stock in at-the-market offering, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,566<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51,255)<span></span>
</td>
<td class="num">(51,255)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">27,028,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">56,027<span></span>
</td>
<td class="num">(56,061)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForPrepaidServicesShares', window );">Issuance of common stock for prepaid services, shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForPrepaidServices', window );">Issuance of common stock for prepaid services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForLicenseAcquiredShares', window );">Issuance of common stock for license acquired, shares</a></td>
<td class="nump">1,809,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForLicenseAcquired', window );">Issuance of common stock for license acquired</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">15,166,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">8,835<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Warrants exercised for cash (in shares)</a></td>
<td class="nump">153,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Warrants exercised for cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity', window );">Reclass of Series B warrants from warrant liability to stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares', window );">Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs, shares</a></td>
<td class="nump">1,112,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts', window );">Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_BeneficialConversionFeatureOfConvertibleDebtShares', window );">Beneficial conversion feature of convertible debt, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_BeneficialConversionFeatureOfConvertibleDebt', window );">Beneficial conversion feature of convertible debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares', window );">Issuance of common stock and warrants, pursuant to September 2020 Securities Purchase Agreement, net of issuance costs, shares</a></td>
<td class="nump">8,865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts', window );">Issuance of common stock and warrants, pursuant to September 2020 Securities Purchase Agreement, net of issuance costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">6,356<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,101)<span></span>
</td>
<td class="num">(19,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">54,535,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 77,680<span></span>
</td>
<td class="num">$ (75,162)<span></span>
</td>
<td class="nump">$ 2,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_BeneficialConversionFeatureOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_BeneficialConversionFeatureOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_BeneficialConversionFeatureOfConvertibleDebtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_BeneficialConversionFeatureOfConvertibleDebtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockAndWarrantsInPrivateOfferingNetOf16.5MillionWarrantLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForConversionOfDebtAndAccruedInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForLicenseAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForLicenseAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForLicenseAcquiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForLicenseAcquiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForPrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForPrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForPrepaidServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForPrepaidServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ReclassOfWarrantLiabilitesRelatedToSeriesWarrantsExercisedForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138237048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,101)<span></span>
</td>
<td class="num">$ (51,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Research and development expensed - license acquired</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable', window );">Change in fair value of convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">16,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Loss on warrant issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(791)<span></span>
</td>
<td class="num">(686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Licenses payable</a></td>
<td class="num">(4,850)<span></span>
</td>
<td class="nump">7,425<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(20,913)<span></span>
</td>
<td class="num">(19,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants in a private offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">8,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs</a></td>
<td class="nump">6,365<span></span>
</td>
<td class="nump">5,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of common stock and convertible notes payable, net of issuance costs</a></td>
<td class="nump">10,907<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering', window );">Proceeds from issuance of common stock in at-the-market offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">4,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">26,314<span></span>
</td>
<td class="nump">29,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Cash flows from discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash</a></td>
<td class="nump">5,401<span></span>
</td>
<td class="nump">10,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, beginning of period</a></td>
<td class="nump">10,261<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, end of period</a></td>
<td class="nump">15,662<span></span>
</td>
<td class="nump">10,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for license payable</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForConversionOfDebt', window );">Issuance of common stock for conversion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest', window );">Issuance of common stock for conversion of accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuanceOfCommonStockForLicenseAcquired', window );">Issuance of common stock for license acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_EffectOfReverseMerger', window );">Effect of reverse merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash', window );">Reclass of warrant liabilities related to Series A warrants exercised for cash</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity', window );">Reclass of Series B warrants from warrant liability to stockholders' equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_EffectOfReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_EffectOfReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IncreaseDecreaseInFairValueOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForConversionOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuanceOfCommonStockForLicenseAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuanceOfCommonStockForLicenseAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ProceedsFromIssuanceOfCommonStockInAtthemarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ReclassOfSeriesBWarrantsFromWarrantLiabilityToStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144421544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>1. Organization and Summary of Significant Accounting Policies</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&#160;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>Organization</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Seelos Therapeutics, Inc. and Subsidiaries
(&#34;Seelos&#34; or the &#34;Company&#34;) is a Nevada corporation that was initially formed in 1987. The Company is a clinical-stage
biopharmaceutical company focused on developing novel technologies and therapeutics for the treatment of central nervous system,
respiratory and other disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Merger with Apricus Biosciences, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2019, Apricus Biosciences,
Inc., a Nevada corporation (&#34;Apricus&#34;), completed a business combination with Seelos Therapeutics, Inc., a Delaware corporation
(&#34;STI&#34;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#34;Merger Agreement&#34;)
entered into on July 30, 2018. Pursuant to the Merger Agreement, (i) a subsidiary of Apricus merged with and into STI, with STI
(renamed as &#34;Seelos Corporation&#34;) continuing as a wholly owned subsidiary of Apricus and the surviving corporation of the
merger and (ii) Apricus was renamed as &#34;Seelos Therapeutics, Inc.&#34; (the &#34;Merger&#34;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Merger was accounted for as a reverse
recapitalization under United States generally accepted accounting principles (&#34;U.S. GAAP&#34;) because the primary assets
of Apricus were nominal following the close of the Merger. STI was determined to be the accounting acquirer based upon the terms
of the Merger and other factors, including: (i) STI's stockholders and other persons holding securities convertible, exercisable
or exchangeable directly or indirectly for STI common stock owned the majority of Apricus immediately following the effective time
of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company and (iii) STI's management holds
all key positions in the management of the combined company. Accordingly, the historical financial statements of STI became the
Company's historical financial statements, including the comparative prior periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Basis of Presentation and Principles of
Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiaries.&#160;All significant intercompany accounts and transactions have
been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The preparation of these consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of expenses during the reporting period. The most significant estimates in the Company's financial statements relate to
the valuation of warrants, valuation of convertible notes payable, valuation of common stock and the valuation of stock options.
These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities
and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely
from these estimates. To the extent there are material differences between the estimates and actual results, the Company's future
results of operations will be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value of Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The carrying amounts of financial instruments
such as accounts receivable, accounts payable and accrued expenses approximate their related fair values due to the short-term
nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company records a right-of use (&#34;ROU&#34;)
asset and a lease liability on its balance sheet for all leases with terms of 12 months or longer. Leases are classified as either
finance or operating, with classification affecting the pattern of expense recognition in the income statement. Historically, the
Company recorded rent expense associated with its operating lease on a straight-line basis over the term of the lease. The difference
between rent payments and straight-line rent expense was recorded as deferred rent in accrued liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of December 31, 2020, the Company's leases
had original terms of 12 months or less. The Company does not recognize ROU assets and lease liabilities that arise from leases
with an original term of 12 months or less. Rather the Company recognizes the lease payments on a straight-line basis over the
term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company follows the accounting guidance
in the Financial Accounting Standards Board (&#34;FASB&#34;) Accounting Standards Codification (&#34;ASC&#34;) Topic 820, Fair
Value Measurements and Disclosures (&#34;ASC 820&#34;), for its fair value measurements of financial assets and liabilities measured
at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The accounting guidance requires fair value
measurements be classified and disclosed in one of the following three categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Level 1: Quoted prices in active markets for
identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Level 2: Observable inputs other than Level
1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Level 3: Unobservable inputs which are supported
by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted
cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant
judgment or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The fair value hierarchy also requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and
liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following tables present information about
the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during the years
ended December 31, 2020 and 2019 (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value Measurements as of December 31, 2020</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 1) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 2) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 3) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Total </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Assets</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cash</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,662&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,662&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Liabilities</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liabilities, at fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value Measurements as of December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 1) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 2) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 3) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Total </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Assets</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cash</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,261&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,261&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Liabilities</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liabilities, at fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">963&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">963&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The common stock warrant liabilities were
recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the fair
value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2020 and 2019:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 66%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>December 31, 2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.18%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.66%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Volatility</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">116.77%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">110.80%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Expected term</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.07</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.07</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Weighted-average fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.40</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.06</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table is a reconciliation for
the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="width: 75%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 23%; text-align: center"><font style="font-size: 10pt"><b>Warrant liabilities</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Balance as of December 31, 2018</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant issued in connection with financing</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21,535&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liability reclassified to stockholders' equity</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(37,073)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in fair value measurement of warrant liability</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">16,501&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Balance as of December 31, 2019</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 10pt">963&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liability reclassified to stockholders' equity</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(124)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in fair value measurement of warrant liability</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">223&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Balance as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Of the inputs used to value the outstanding
common stock warrant liabilities as of December 31, 2020 and 2019, the most subjective input is the Company's estimate of expected
volatility of its common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value Option</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As permitted under ASC Topic 825, Financial
Instruments (&#34;ASC 825&#34;), the Company had elected the fair value option to account for its convertible notes. In accordance
with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Statement of
Operations. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed
as incurred and were not deferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Grant Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company determined that its grant agreement
with Team Sanfilippo Foundation (&#34;TSF&#34;), a nonprofit medical research foundation founded by parents of children with Sanfilippo
syndrome, is within the scope of ASC Topic 606 &#34;Revenue from Contracts with Customers&#34;. Under the TSF agreement, TSF makes
certain milestone payments to the Company as certain milestones related to a specified Phase II/III clinical trial, defined in
the agreement, are met. The Company determined that there is one performance obligation under the TSF agreement. The variable consideration,
in the form of milestone payments, is attributed to the completed portion of the performance obligation that triggers or results
in the payments. During the year ended December 31, 2020 and 2019, the Company recognized $0 and $375,000 of revenue, respectively,
from a milestone payment received as the milestone payment represents the Company's completed portion of its performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Research and development costs are expensed
as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related
expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development
and consulting agreements in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Income taxes are accounted for under the asset
and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts
and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect
for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than
not that some or all of the deferred tax assets will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company also follows the provisions of
accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken
or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure
and transition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Income (Loss) Per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Basic loss per share is computed by dividing
net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period.
Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible
debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic
and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both
calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is
anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following potentially dilutive securities
outstanding for the year ended December 31, 2020 and 2019 have been excluded from the computation of diluted weighted average shares
outstanding, as they would be anti-dilutive (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 66%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding stock options</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,120&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">522&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding warrants</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,066&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,584&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Convertible notes</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">8,556&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">23,742&#160;</font></td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,106&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company expenses stock-based compensation
to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of
the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules
are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used
in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and
the application of management's judgment. All stock-based compensation costs are recorded in general and administrative or research
and development costs in the statements of operations based upon the underlying individual's role at the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Segment Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company operates under one segment which
develops pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In August 2018, the FASB issued Accounting
Standards Update (&#34;ASU&#34;) No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure
Requirements for Fair Value Measurement (&#34;ASU 2018-13&#34;). The amendments in this ASU require certain existing disclosure
requirements in Topic 820 to be modified or removed, and certain new disclosure requirements to be added to the Topic. In addition,
this ASU allows entities to exercise more discretion when considering fair value measurement disclosures. The Company adopted ASU
2018-13 effective January 1, 2020. The adoption of ASU 2018-13 did not have a material effect on the Company's financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In December 2019, the FASB issued ASU No.
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#34;ASU 2019-12&#34;), which is intended to simplify
various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic
740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years,
and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is
currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In August 2020, the FASB issued ASU 2020-06:
Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This standard simplifies the
accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature,
as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt
instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest
expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of
ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per
share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable
for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after
December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company is evaluating
the impact of ASU 2020-06 on its consolidated financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140629240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>2. Liquidity and Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The accompanying consolidated financial statements
have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets
and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from
uncertainty related to its ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has limited revenues, has incurred
operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and
may never become profitable. As of December 31, 2020, the Company had $15.7 million in cash and an accumulated deficit of $75.2
million. The Company has historically funded its operations through the issuance of convertible notes (see Note 7), the sale of
common stock (see Note 4) and the exercise of warrants (see Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company evaluated whether there are any
conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year beyond the release date of this Annual Report on Form 10-K. Based on such evaluation and the Company's current
plans, which are subject to change, management believes that the Company's existing cash and cash equivalents as of December 31,
2020 are not sufficient to satisfy its operating cash needs for at least one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company believes it will need to raise
substantial additional funds through one or more of the following: issuance of additional debt or equity and/or the completion
of a licensing or other commercial transaction for one or more of the Company's product candidates. If the Company is unable to
maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely
affected. This could affect future development and business activities and potential future clinical studies and/or other future
ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company's business
operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all.
Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company's existing
stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>



<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140700008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Business Combination</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>3. Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2019, Apricus completed the
business combination with STI in accordance with the terms of the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Merger was accounted for as a reverse
recapitalization under U.S. GAAP because the primary assets of Apricus were nominal at the close of the Merger. STI was determined
to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) STI stockholders and other persons
holding securities convertible, exercisable or exchangeable directly or indirectly for STI common stock owned the majority of the
Company immediately following the effective time of the Merger, (ii) STI holds the majority (four of five) of board seats of the
combined company, and (iii) STI's management holds all key positions in the management of the combined company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">STI acquired no tangible assets and assumed
no employees or operation from Apricus. Additionally, Apricus' intellectual property was considered to have no value. The remaining
Apricus liabilities had a fair value of approximately $300 thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In connection with the Merger, STI entered
into a Contingent Value Rights Agreement (the &#34;CVR Agreement&#34;). Pursuant to the CVR Agreement, Apricus stockholders received
one contingent value right (&#34;CVR&#34;) for each share of Apricus common stock held of record immediately prior to the closing
of the Merger. Each CVR represents the right to receive payments based on Apricus' U.S. assets related to products in development,
intended for the topical treatment of erectile dysfunction, which are known as Vitaros in certain countries outside of the United
States (the &#34;CVR Product Candidate&#34;). In particular, CVR holders will be entitled to receive 90% of any cash payments (or
the fair market value of any non-cash payments) exceeding $500,000 received, during a period of ten years from the closing of the
Merger, based on the sale or out-licensing of Apricus' CVR Product Candidate intangible asset, including any milestone payments
(the &#34;Contingent Payments&#34;), less reasonable transaction expenses. STI is entitled to retain the first $500,000 and 10%
of any Contingent Payments. STI assigned no value to the CVR Product Candidate intangible asset as of December 31, 2020 or the
CVR in the acquisition accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140564440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Common Stock Offerings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Common Stock Offerings</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>4. Common Stock Offerings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Securities Purchase Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>December 2020 Convertible Note and Private
Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In December 2020, the Company issued an aggregate
of 1,112,219 shares of common stock in conjunction with the issuance of convertible notes at a discount for aggregate net proceeds
of $10.9 million (see Note 7).</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>2020 Registered Direct Offering and Concurrent
Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On September 4, 2020, the Company entered
into a Securities Purchase Agreement with certain institutional investors (the &#34;September 2020 Securities Purchase Agreement&#34;)
pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering,
resulting in total net proceeds of $6.4 million, after deducting the placement agent's fees and other offering expenses. The shares
were offered by the Company pursuant to the Company's shelf registration statement on Form S-3 filed with the Securities and Exchange
Commission (the &#34;SEC&#34;) on November 2, 2017, as amended. The Company also issued to the investors warrants to purchase up
to 6,648,750 shares of common stock in a concurrent private placement (the &#34;September 2020 Warrants&#34;). The September 2020
Warrants have an exercise price of $0.84 per share of common stock, will be exercisable beginning on March 9, 2021 and will expire
on March 9, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The combined purchase price for one share
and one warrant to purchase 0.75 of a share of common stock in the offerings was $0.79. The closing of the offerings occurred on
September 9, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>2019 Registered Direct Offering and Concurrent
Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On August 23, 2019, the Company entered into
a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company issued and sold an aggregate
of 4,475,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million,
before deducting the placement agents' fees and other estimated offering expenses. The shares were offered by the Company pursuant
to the Company's shelf registration statement on Form S-3 filed with the SEC on November 2, 2017, as amended. The Company issued
to the investors warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the &#34;August
2019 Warrants&#34;). The August 2019 Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six
months from the date of issuance and will expire four years following the date of issuance. The combined purchase price for one
share and one warrant to purchase half of a share of common stock in the offerings was $1.50. Roth Capital Partners, LLC (&#34;Roth&#34;)
served as the placement agent for the issuance and sale of the shares and the warrants, and the Company paid Roth an aggregate
fee equal to 7.0% of the gross proceeds received by the Company in the offerings.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Public Offerings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On March 16, 2020, the Company completed an
underwritten public offering pursuant to which it sold 7,500,000 shares of its common stock at a price to the public of $0.60 per
share. The net proceeds to the Company from this offering were approximately $4.0 million, after deducting underwriting discounts
and commissions and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On February 13, 2020, the Company completed
an underwritten public offering, pursuant to which it sold 6,666,667 shares of its common stock at a price to the public of $0.75
per share. On February 19, 2020, the Company sold an additional 999,999 shares of its common stock at a price to the public of
$0.75 per share pursuant to the full exercise of the underwriters' option to cover over-allotments. The net proceeds to the Company
from this offering were approximately $4.8 million, after deducting underwriting discounts and commissions and other offering expenses
payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Stock Purchase Agreement with Vyera</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 2, 2020, the Company entered into
a stock purchase agreement (the &#34;Stock Purchase Agreement&#34;) with Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing
Pharmaceuticals AG (&#34;Vyera&#34;), pursuant to which the Company issued to Vyera 1,809,845 registered shares of the Company's
common stock (the &#34;Shares&#34;). The Company entered into the Stock Purchase Agreement in accordance with an asset purchase
agreement with Vyera, as amended by the amendment entered into with Vyera on October 15, 2019 (see Note 5). As partial consideration
for the assets of Vyera, the Company agreed to issue the Shares pursuant to the Stock Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Consulting Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On May 11, 2020, the Company entered
into a consulting agreement (the &#34;Consulting Agreement&#34;) with an advisory firm, pursuant to which the advisory firm
agreed to provide the Company with certain management consulting, business and advisory services. The Company agreed to issue
the advisory firm 300,000 unregistered shares of the Company's common stock, which shares were issued on May 11, 2020, plus
$80,000 in cash. On June 9, 2020, the Company and the advisory firm entered into an amendment to the Consulting Agreement
(the &#34;Amendment&#34;). Pursuant to the Amendment, the advisory firm agreed to provide the Company with additional
services and, in consideration, the Company agreed to issue the advisory firm an additional 200,000 unregistered shares of
the Company's common stock (the &#34;Additional Shares&#34;), plus $20,000 in cash. The Additional Shares were issued to the
advisory firm on June 9, 2020 and are subject to certain vesting restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Through December 31, 2020, the Company has
recognized approximately $431,000 of consulting expense under this Consulting Agreement. On July 9, 2020, the Company cancelled
the Consulting Agreement with an effective date of August 9, 2020. The Company also canceled 100,000 shares that will not vest
due to the cancellation of the Consulting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Equity Distribution Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On June 17, 2019, the Company entered into
an Equity Distribution Agreement (the &#34;Equity Distribution Agreement&#34;) with Piper Jaffray &#38; Co., as sales agent (&#34;Piper
Jaffray&#34;), pursuant to which the Company could offer and sell, from time to time, through Piper Jaffray (the &#34;Offering&#34;)
up to $50,000,000 in shares. Under the terms of the Equity Distribution Agreement, Piper Jaffray was entitled to a commission at
a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Equity Distribution Agreement. During the year ended
December 31, 2019, the Company sold 1,197,676 shares for net proceeds of approximately $2.6 million pursuant to the Equity Distribution
Agreement. On August 23, 2019, the Company suspended its continuous offering under the Equity Distribution Agreement and the Equity
Distribution Agreement terminated in accordance with its terms on December 7, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Pre-Merger Financing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2019, STI and Apricus closed
a private placement transaction with certain accredited investors (the &#34;Investors&#34;), whereby, among other things, STI issued
to investors shares of STI's common stock immediately prior to the Merger in a private placement transaction (the &#34;Financing&#34;),
pursuant to a Securities Purchase Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors,
as amended (the &#34;Purchase Agreement&#34;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Pursuant to the Purchase Agreement, STI (i)
issued and sold to the Investors an aggregate of 2,374,672 shares of STIs common stock which converted pursuant to the exchange
ratio in the Merger into the right to receive 1,829,407 shares of the Company's common stock and (ii) issued warrants representing
the right to acquire 1,463,519 shares of common stock at a price per share of $4.15, subject to adjustment as provided therein
(the &#34;Series A Warrants&#34;), most recently adjusted to a price per share of $0.2957 per share, and additional warrants initially
representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided therein
(the &#34;Series B Warrants&#34; together with the Series A Warrants, the &#34;Investor Warrants&#34;), for aggregate gross proceeds
of $18.0 million, or $16.5 million net of financing fees. The terms of the Investor Warrants included certain provisions that could
result in adjustments to both the number of warrants issued and the exercise price of each warrant, which resulted in the warrants
being classified as a liability upon issuance (see Note 8). The Investor Warrants were recorded at fair value of $21.5 million
upon issuance and given the liability exceed the proceeds received, a loss of $5.0 million was recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On March 7, 2019, the Company entered into
Amendment Agreements (collectively, the &#34;Amendment Agreements&#34;) with each Investor amending: (i) the Purchase Agreement,
(ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate
number of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised
as of March 7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment
to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment
Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">At December 31, 2020, 0.8 million Series A
Warrants remain unexercised. All Series B Warrants were exercised during the year ended December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744154762904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_InLicensingAgreementAbstract', window );"><strong>In-Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>5. License Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Acquisition of License from Ligand Pharmaceuticals
Incorporated</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On September 21, 2016, the Company entered
into a License Agreement (the &#34;License Agreement&#34;) with Ligand Pharmaceuticals Incorporated (&#34;Ligand&#34;), Neurogen
Corporation and CyDex Pharmaceuticals, Inc. (collectively, the &#34;Licensors&#34;), pursuant to which, among other things, the
Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license
under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or
may be modified for use in a product to be administered by any method in any form including, without limitation injection and
intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor
antagonist, which is now known as SLS-010, and either or both of the Licensors' two proprietary CRTh2 antagonists, which are now
known collectively as SLS-008 (collectively, the &#34;Licensed Products&#34;), and (ii) copyrights, trade secrets, moral rights
and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts
to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in
its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union,
the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the
People's Republic of China (each, a &#34;Major Market&#34;) or the United States, and (c) commercialize the Licensed Products
in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making
authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company
believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive
right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In connection with the closing of the Merger,
the Company issued 801,253 shares of common stock to Ligand and recognized research and development expense totaling approximately
$2.2 million during the three months ended March 31, 2019 for the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company also agreed to pay to Ligand certain
one-time, non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection with
Aplindore for the indication of Parkinson's Disease (&#34;PD&#34;) or Restless Leg Syndrome, consisting of (i) $750,000 upon submission
of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA approval
of an application for a particular Licensed Product, (iii) $1.125 million upon regulatory approval in a Major Market for a particular
Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major Market for a particular Licensed Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company also agreed to pay to Ligand certain
one-time, non-refundable regulatory milestone payments in connection with the Licensed Products in connection with Aplindore for
the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon submission of an application with the FDA or equivalent
foreign body for such a particular Licensed Product, (ii) $350,000 upon FDA approval of an application for such a particular Licensed
Product, (iii) $125,000 upon regulatory approval in a Major Market for such a particular Licensed Product, and (iv) $125,000 upon
regulatory approval in a second Major Market for such a particular Licensed Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company agreed to pay to Ligand certain
one-time, non-refundable commercial milestone payments in connection with the Licensed Products, consisting of (i) $10.0 million
upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (ii) $10.0 million
upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist,
(iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen
(as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation
injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), (iv) $10.0 million upon the
achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists, (v) $20.0 million
upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (vi) $20.0 million
upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist,
(vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen
(as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation
injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), and (viii) $20.0 million upon
the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company will also pay to Ligand middle
single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication
of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental
royalty in the upper single digit to lower double digit range on aggregate annual net sales of Licensed Products in connection
with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a
licensed patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed
Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed
Products are not covered under a licensed patent and a tiered incremental royalty in the lower single digit to middle single digit
range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg
Syndrome in a country where such Licensed Products are not covered under a licensed patent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The potential regulatory and commercial milestones
are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Acquisition of Assets from Phoenixus AG
f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (&#34;Vyera&#34;)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On March 6, 2018, the Company entered into
an asset purchase agreement with Vyera, pursuant to which the Company acquired the assets (the &#34;Vyera Assets&#34;) and liabilities
(the &#34;Vyera Assumed Liabilities&#34;) of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The
Company is obligated to use commercially reasonable efforts to seek regulatory approval in the United States for and commercialize
SLS-002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As consideration for the Vyera Assets, the
Company paid to Vyera a non-refundable cash payment of $150,000 on May 21, 2018. As further consideration for the Vyera Assets,
upon public announcement of the entry by Apricus and STI into the Merger Agreement, the Company paid to Vyera a non-refundable
cash payment of $150,000. As further consideration for the Vyera Assets, the Company issued to Vyera 191,529 shares of common stock
and paid Vyera a non-refundable cash payment of $1,000,000 on January 29, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Pursuant to the amendment to the asset purchase
agreement entered into by the Company and Vyera on October 15, 2019, the Company issued Vyera 1,809,845 registered shares of the
Company's common stock on January 2, 2020 and made cash payments to Vyera in the amounts of $750,000, $750,000, $1.0 million and
$1.0 million in October 2019, January 2020, April 2020 and July 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In the event that the Company sells, directly
or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company must pay Vyera an amount equal to
4% of the net proceeds actually received by the Company as an upfront payment in such sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company agreed to pay to Vyera certain
one-time, non-refundable milestone payments consisting of (i) $10.0 million upon approval by the FDA of a new drug application
(an &#34;NDA&#34;), with respect to SLS-002, (ii) $5.0 million upon approval by the European Medicines Agency (the &#34;EMA&#34;)
of the foreign equivalent to an NDA with respect to SLS-002 in a Major Market, (iii) $2.5 million upon approval by the EMA of the
foreign equivalent to an NDA with respect to SLS-002 in a second Major Market, (iv) $5.0 million upon the achievement of $250.0
million in net sales of SLS-002, (v) $10.0 million upon the achievement of $500.0 million in net sales of SLS-002, (vi) $15.0 million
upon the achievement of $1.0 billion in net sales of SLS-002, (vii) $20.0 million upon the achievement of $1.5 billion in net sales
of SLS-002, and (viii) $25.0 million upon the achievement of $2.0 billion in net sales of SLS-002. The Company will also pay to
Vyera a royalty percentage in the mid-single digits on aggregate annual net sales of SLS-002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The potential regulatory and commercial milestones
are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Acquisition of License from Stuart Weg,
MD</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On August 29, 2019, the Company entered into
an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &#34;Weg License Agreement&#34;), pursuant to which
the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002.
Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement.
The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million
on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or
before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020 and $0.125
million on January 2, 2021. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of
(i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company's common stock
upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and
unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that
has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom,
France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the &#34;Milestone
Product&#34;), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval
by the EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however,
that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr.
Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The potential regulatory and commercial milestones
are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Acquisition of Assets from Bioblast Pharma
Ltd. (&#34;Bioblast&#34;)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On February 15, 2019, the Company entered
into an Asset Purchase Agreement (the &#34;Bioblast Asset Purchase Agreement&#34;) with Bioblast. Pursuant to the Bioblast Asset
Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the
&#34;Bioblast Asset Purchase&#34;). The Company paid to Bioblast $1.5 million in cash, and the Company paid to Bioblast an additional
$2.0 million in February 2020. Accordingly, the Company recognized a $3.5 million charge to research and development expense during
the year ended December 31, 2019. Under the terms of the Bioblast Asset Purchase Agreement, the Company agreed to pay additional
consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (i) within 15 days following the
completion of the Company's first Phase II(b) clinical trial of Trehalose satisfying certain criteria, the Company will pay to
Bioblast $8.5 million; and (ii) within 15 days following the approval for commercialization by the FDA or the Health Products and
Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates,
the Company will pay to Bioblast $8.5 million. In addition, the Company agreed to pay Bioblast a cash royalty equal to 1% of the
net sales of Trehalose. Under the terms of the Bioblast Asset Purchase, the Company assumed a collaborative agreement with TSF,
a nonprofit medical research foundation founded by parents of children with Sanfilippo syndrome. TSF, upon approval by the FDA,
planned to begin an open label, Phase II(b) clinical trial in up to 20 patients with Sanfilippo syndrome, which is now known under
the study name SLS-005. The Company will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement
entitle the Company access to all clinical data from this trial. On July 15, 2019, TSF and the Company amended the agreement whereby
the Company agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5
million towards the funding of the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The potential regulatory and commercial milestones
are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Acquisition of License from The Regents
of the University of California</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On March 7, 2019, the Company entered into
an exclusive license agreement (the &#34;UC Regents License Agreement&#34;) with The Regents of the University of California (&#34;The
UC Regents&#34;) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents
pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology
relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (&#945;-synuclein).
The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders
affecting the central nervous system (&#34;CNS&#34;). This program is now known as SLS-007. Upon entry into the UC Regents License
Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense
during the year ended December 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional
consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the completion
of dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing
of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of
the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial
sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market,
the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed
product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product,
if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate
the agreement or reduce the Company's license to a nonexclusive license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The potential regulatory and commercial milestones
are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Acquisition of License from Duke University</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On June 27, 2019, the Company entered into
an exclusive license agreement (the &#34;Duke License Agreement&#34;) with Duke University pursuant to which the Company was granted
an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression.
The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders
affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University
$0.1 million and recognized $0.1 million charge to research and development expense during the year ended December 31, 2019. The
Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as
follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive
validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase
I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical
trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial,
the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company
is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain
milestones within a specified timeframe, Duke University may terminate the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The potential regulatory and commercial milestones
are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_InLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-Licensing Agreement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_InLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140456696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>6. Accrued Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following
(in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Professional fees</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">292&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">151&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Personnel related</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">756&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">683&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outside research and development services</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">764&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">853&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Other</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">112&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">232&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Accrued expenses, net</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,924&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,919&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744154778344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_DebtAbstract', window );"><strong>Warrants Expiring March 2023, Tranche 2 [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>7. Debt</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Convertible Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>December 2020 Convertible Note and Private
Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On December 11, 2020, the Company entered
into a Securities Purchase Agreement (the &#34;Lind Securities Purchase Agreement&#34;) with Lind Global Asset Management II,
LLC (the &#34;Investor&#34;) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor,
in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note
(the &#34;Note&#34;) in an aggregate principal amount of $12,000,000 (the &#34;Principal Amount&#34;), which will bear no interest
and mature on December 11, 2022 (the &#34;Maturity Date&#34;), and (2) 975,000 shares of the Company's common stock. At any time
following June 11, 2021, and from time to time before the Maturity Date, the Investor shall have the option to convert any portion
of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment
for stock splits, reverse stock splits, stock dividends and similar transactions (the &#34;Conversion Price&#34;). Prior to June
11, 2021, the Company will have the right to prepay up to sixty-six and two-thirds percent (66<sup>2/3</sup>%) of the then-outstanding
Principal Amount of the Note with no penalty. On or after July 11, 2021, the Company will have the right to prepay up to the then-outstanding
Principal Amount of the Note with no penalty; however, if the Company exercises such prepayment right, the Investor will have
the option to convert up to thirty-three and one-third percent (33<sup>1/3</sup>%) of the amount that the Company elects to prepay
at the Conversion Price. Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt
financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money
debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the Note, unless
waived by the Investor in advance. Beginning on June 9, 2021, the Note will amortize in eighteen monthly installments equal to
the quotient of (i) the then-outstanding Principal Amount of the Note, divided by (ii) the number of months remaining until the
Maturity Date. All amortization payments shall be payable solely in cash, plus a 2% premium.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On December 17, 2020, the Company entered
into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind
Securities Purchase Agreement (the &#34;December 17 SPAs&#34;), pursuant to which the Company sold, in private placement transactions,
in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1)convertible promissory notes (the &#34;December
17 Notes&#34;) in an aggregate principal amount of $1,365,628, which will bear no interest and mature on December 17, 2022, and
(2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities
purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the
&#34;December 18 SPA&#34;) and, together with the December 17 SPAs, (the &#34;Subsequent Securities Purchase Agreements&#34;),
pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor
of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which will bear no interest and mature
on December 18, 2022 (the &#34;December 18 Note&#34; and, together with the December 17 Notes, the &#34;Subsequent Notes&#34;),
and (2) 26,263 shares of the Company's common stock. The Subsequent Securities Purchase Agreements have substantially the same
terms as the Lind Securities Purchase Agreement, and the Subsequent Notes have substantially the same terms as the Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company received aggregate net proceeds
of $10.9 million from the convertible note offerings, net of $0.5 million of issuance costs. The total gross proceeds were allocated
to the convertible notes and common stock issued under the agreements based on their relative fair values. The Company recognized
a beneficial conversion feature discount on the convertible notes of approximately $0.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The discount on the convertible notes is being
amortized to interest expense, using the effective interest method over the term of the convertible notes. As of December 31, 2020,
the principal balance of the convertible notes outstanding and the unamortized discount on the convertible notes is approximately
$13.7 million and $4.1 million, respectively. Interest expense recognized related to the discount was approximately $0.2 million
for the year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">From May 2017 to October 2018, the Company
issued convertible notes (the &#34;Convertible Notes&#34;). The aggregate principal amount of the Convertible Notes was $2.3 million,
and the Convertible Notes were due no later than April 30, 2019 with simple interest at the rate of 8% per annum. The Convertible
Notes provided that they were to convert at a discount of 10% or 20% depending on the terms for each note, or $9.70 to $10.91 per
share, respectively.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Convertible Notes were carried at fair
value. The Company recognized an adjustment relating to changes in the Convertible Notes fair value of $0 and $109 thousand during
the year ended December 31, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In connection with the closing of the Merger,
the Convertible Notes plus unpaid interest were converted into 172,284 shares of common stock at a price of $9.70 or $10.91 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>PPP Loan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On May 4, 2020, the Company qualified for
and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration
under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the &#34;PPP Lender&#34;), for an aggregate
principal amount of approximately $147,000 (the &#34;PPP Loan&#34;). The PPP Loan bears interest at a fixed rate of 1.0% per annum,
with the first six months of interest deferred, has a term of two years, and is unsecured and guaranteed by the U.S. Small Business
Administration. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program upon the Company's
request to the extent that the PPP Loan proceeds are used to pay expenses permitted by the Paycheck Protection Program, including
payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company intends
to apply for forgiveness of the PPP Loan with respect to these covered expenses. To the extent that all or part of the PPP Loan
is not forgiven, the Company will be required to pay interest on the PPP Loan at a rate of 1.0% per annum, and commencing in the
fourth quarter of 2020, principal and interest payments will be required through the maturity date in May 2022. The terms of the
PPP Loan provide for customary events of default including, among other things, payment defaults, breach of representations and
warranties and insolvency events. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_DebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_DebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140501624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>8. Stockholders' Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company is authorized to issue 10,000,000
shares of preferred stock, par value $0.001. No shares of preferred stock were outstanding as of December 31, 2020 or 2019.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has authorized 120,000,000 shares
of common stock as of December 31, 2020 and 2019. Each share of common stock is entitled to one voting right. Common stock owners
are entitled to dividends when funds are legally available and declared by the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>September 2020 Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The September 2020 Warrants are exercisable
for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants are exercisable
beginning six months after the date of issuance and have a term of five and a half years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of December 31, 2020, 6.6 million September
2020 Warrants remain outstanding at an exercise price of $0.84 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>August 2019 Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The August 2019 Warrants are exercisable for
2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants are exercisable beginning
six months after the date of issuance and have a term of four years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of December 31, 2020, 2.2 million August
2019 Warrants remain outstanding at an exercise price of $1.78 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Series A Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Series A Warrants were initially exercisable
for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to
the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent
adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as
a result of the announcement of the offerings pursuant to the September 2020 Securities Purchase Agreement. The Series A Warrants
were immediately exercisable upon issuance and will expire on January 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the year ended December 31, 2020 and
2019, 0.2 million and 2.7 million Series A Warrants were exercised for approximately $45 thousand and $4.5 million, respectively.
As of December 31, 2020, 0.8 million Series A Warrants remain outstanding at an exercise price of $0.2957 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Series B Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Series B Warrants were initially exercisable
for no shares of common stock, which was adjusted to 7,951,090 shares of common stock on February 27, 2019 and which was further
adjusted to 11,614,483 shares of common stock on March 7, 2019, in each case essentially due to trading at a lower price, pursuant
to the terms thereof. The Series B Warrants had an exercise price of $0.001, were immediately exercisable upon issuance and provided
for an expiration date of the day following the later to occur of (i) the Reservation Date (as defined therein), and (ii) the date
on which the Series B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein)
and no shares remain issuable thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the year ended December 31, 2019, 11.6
million Series B Warrants were exercised for approximately $11,614. As of December 31, 2019, no Series B Warrants remain outstanding
and the Series B Warrants are therefore no longer subject to any further changes in warrants or exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of warrant activity during the
year ended December 31, 2020 is as follows (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Remaining</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Contractual Life</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Warrants</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Price</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><font style="font-size: 10pt"><b>(in years) </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding at December 31, 2018</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Assumed in Merger</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">437&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">20.59&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.5&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Issued</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">17,481&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.42&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.1&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Exercised</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(14,334)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.31&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 2019</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,584&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.86&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.3&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Issued</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6,648&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.84&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Exercised</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(154)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.30&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cancelled</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(12)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">18.00&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,066&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.84&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.4&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Exercisable as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,417&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.79&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.7&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Series A Warrants and the Series B Warrants
were each recognized as a liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value
prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the
period.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144347112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_EquityCompensationPlansAbstract', window );"><strong>Warrants Expiring March 2023, Tranche 3 [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>9. Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has the Amended and Restated
Apricus 2012 Stock Long Term Incentive Plan (the &#34;2012 Plan&#34;), which provides for the issuance of incentive and non-incentive
stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted
stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant.
As of December 31, 2020, an aggregate of 8,038,582 shares of common stock were authorized under the Apricus 2012 Plan, of which
3.2 million shares of common stock were available for future grants. Upon completion of the Merger, the Company assumed the Seelos
Therapeutics, Inc. 2016 Equity Incentive Plan (the &#34;2016 Plan&#34;) and awards outstanding under the 2016 Plan became awards
for common stock. Effective as of the Merger, no further awards may be issued under the 2016 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On May 15, 2020, the Company's stockholders
approved the Company's 2020 Employee Stock Purchase Plan (the &#34;ESPP&#34;), whereby qualified employees are allowed to purchase
limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering
period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The
ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under
the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount
shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately
preceding December 31, and (ii) a number of shares of common stock set by the Company's Board of Directors or the Compensation
Committee of the Board of Directors (the &#34;Compensation Committee&#34;) of the Company on or prior to each such January 1. The
Company did not sell any shares under the ESPP during the year ended December 31, 2020. The compensation costs are calculated as
the fair value of the 15% discount from market price and were approximately $13,000 for the year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On July 28, 2019, the Compensation Committee
adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &#34;2019 Inducement Plan&#34;), which became effective on August
12, 2019. The 2019 Inducement Plan is substantially similar to the 2016 Plan. The 2019 Inducement Plan provides for the grant of
equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units,
including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate
of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual,
as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee
or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number
of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company's common stock. The 2019 Inducement
Plan is administered by the Compensation Committee and expires on August 12, 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Stock options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the year ended December 31, 2020, the
Company granted 4,444,895 stock options to employees with a weighted average exercise price per share of $1.16 and a 10-year term,
subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting requirements. The stock
options granted to employees vest 25% on the first anniversary of the grant and monthly thereafter over the next three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the year ended December 31, 2020, the
Company also granted 179,000 non-qualified stock options to non-employee directors and a consultant with a weighted average exercise
price per share of $1.15 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. 24,000 of the stock options
granted to non-employee directors vest 1/3rd on the first anniversary of the grant and monthly thereafter over the next two years.
80,000 of the stock options granted to non-employee directors vest monthly over the 12 months following the grant. 75,000 of the
stock options granted to a consultant vest 25% on the first anniversary of the grant and monthly thereafter over the next 3 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The fair value of stock option grants are
estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and
lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility
based on the historical volatility of a publicly traded set of peer companies. Additionally, due to an insufficient history with
respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a
permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free
interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the
expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and
does not expect to pay any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the year ended December 31, 2020, no
stock options were exercised and 26,001 options were forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following assumptions were used in determining
the fair value of the stock options granted during the years ended December 31, 2020 and 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 59%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 17%; text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 20%; text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2020</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.3%-1.7%</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.6%-2.6%</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Volatility</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">109%-119%</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">109%-113%</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Dividend yield</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Expected term (years)</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-7</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-7</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Weighted-average fair value</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.97</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.76</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of stock option activity during
the year ended December 31, 2020 is as follows (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average Remaining</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Aggregate</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Stock</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Contractual</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Intrinsic</b></font></td></tr>
<tr>
    <td style="width: 42%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>Options</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>Price</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><font style="font-size: 10pt"><b>Life (in years)</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>Value</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 2019</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">522&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">9.18&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.0&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">21&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,624&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.16&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.3&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Cancelled</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(26)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.96&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,120&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.97&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.2&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,969&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Vested and expected to vest as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">353&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12.45&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.4&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">42&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Exercisable as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">353&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12.45&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.4&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">42&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company recorded $2.0 million and $459,000
in stock-based compensation expense for the years ended December 31, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table summarizes the total stock-based
compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Research and development</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">394&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">118&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">General and administrative</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,650&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">341&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,044&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">459&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_EquityCompensationPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_EquityCompensationPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140501624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IncomeTaxesAbstract', window );"><strong>Warrants Expiring March 2024 [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>10. Income Taxes </b></p>



<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has incurred net operating losses
since inception. At December 31, 2020, the Company has available net operating loss carryforwards of approximately $46.9 million
for federal income tax reporting purposes and approximately $90.6 million for state income tax reporting purposes.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Deferred tax assets consist of the following
(in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Net operating tax loss carryforwards</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">15,223&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5,632&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Accrued expenses</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">66&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">348&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Stock-based compensation</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">521&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Start up cost</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">12,320&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,806&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Total deferred tax asset</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">28,130&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,870&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Less valuation allowance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(28,130)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(10,870)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Net deferred tax asset</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The federal and state net operating loss carryforwards,
not subject to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset as of
December 31, 2020 and 2019 of approximately $15.2 million and $5.6 million, respectively.&#160;In consideration of the Company's
accumulated losses and the uncertainty of its ability to utilize this deferred tax asset in the future, the Company has recorded
a full valuation allowance as of such dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company follows&#160;the provisions of
income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected
to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized
in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.
Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing
the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company's federal
income tax returns for 2017 to 2020 are still open and subject to audit.&#160;In addition, net operating losses arising from prior
years are also subject to examination at the time they are utilized in future years.&#160;Unrecognized tax benefits, if recognized,
would have no effect on the Company's effective tax rate. The Company's policy is to recognize interest and penalties related to
income tax matters in income tax expense. For the years ended December 31, 2020 and 2019, the Company has not recorded any interest
or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within
the next twelve months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A reconciliation of the Company's unrecognized
tax benefits for the years ended December 31, 2020 and 2019, are as follows (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Beginning balance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">718&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in current period positions</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in prior period positions</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(718)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Ending balance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The reconciliation of income taxes computed
using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31,
2020 and 2019, are as follows:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr>
    <td style="width: 73%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Federal statutory tax rate</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21.0&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21.0&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">State and local taxes, net of federal benefit</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">11.2&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.7&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Permanent items</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1.0)</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(9.0)</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Deferred rate changes</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.1&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Other</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">59.3&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(0.3)</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Change in valuation allowance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(90.6)</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(18.4)</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Income tax provision (benefit)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144561720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>11. Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Leases</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In March 2019, the Company entered into a
nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019 the
Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November
2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">For the years ended December 31, 2020 and
2019, rent expense totaled $0.1 million and $0.1 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Future minimum rental payments under operating
lease as of December 31, 2020 are approximately $42,000 for 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Contractual Commitments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has entered into long-term agreements
with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects
to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which
may require up-front payments and long-term commitments of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of December 31, 2020, there was no material
litigation against the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144251240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>12. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Public Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 28, 2021, the Company completed
an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public
of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional
shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting
discounts and commissions and other estimated offering expenses payable by the Company. The Company used $3.8 million of the net
proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Amendment of Asset Purchase Agreement with
Vyera</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On February 15, 2021 the Company entered into
an amendment to the asset purchase agreement with Vyera. Pursuant to the amendment, the Company agreed to make cash payments to
Vyera in the amount of $3.0 million in each of February 2021, June 2021 and September 2021 in exchange for a lower royalty percentage
on potential net sales of SLS-002.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744136804648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock', window );">Merger with Apricus Biosciences, Inc.</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Merger with Apricus Biosciences, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2019, Apricus Biosciences,
Inc., a Nevada corporation (&#34;Apricus&#34;), completed a business combination with Seelos Therapeutics, Inc., a Delaware corporation
(&#34;STI&#34;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#34;Merger Agreement&#34;)
entered into on July 30, 2018. Pursuant to the Merger Agreement, (i) a subsidiary of Apricus merged with and into STI, with STI
(renamed as &#34;Seelos Corporation&#34;) continuing as a wholly owned subsidiary of Apricus and the surviving corporation of
the merger and (ii) Apricus was renamed as &#34;Seelos Therapeutics, Inc.&#34; (the &#34;Merger&#34;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Merger was accounted for as a reverse
recapitalization under United States generally accepted accounting principles (&#34;U.S. GAAP&#34;) because the primary assets
of Apricus were nominal following the close of the Merger. STI was determined to be the accounting acquirer based upon the terms
of the Merger and other factors, including: (i) STI's stockholders and other persons holding securities convertible, exercisable
or exchangeable directly or indirectly for STI common stock owned the majority of Apricus immediately following the effective time
of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company and (iii) STI's management holds
all key positions in the management of the combined company. Accordingly, the historical financial statements of STI became the
Company's historical financial statements, including the comparative prior periods.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Basis of Presentation and Principles of
Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiaries.&#160;All significant intercompany accounts and transactions have
been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The preparation of these consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of expenses during the reporting period. The most significant estimates in the Company's financial statements
relate to the valuation of warrants, valuation of convertible notes payable, valuation of common stock and the valuation of stock
options. These estimates and assumptions are based on current facts, historical experience and various other factors believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ
materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results,
the Company's future results of operations will be affected.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value of Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The carrying amounts of financial instruments
such as accounts receivable, accounts payable and accrued expenses approximate their related fair values due to the short-term
nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value Option</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As permitted under ASC Topic 825, Financial
Instruments (&#34;ASC 825&#34;), the Company had elected the fair value option to account for its convertible notes. In accordance
with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Statement of
Operations. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed
as incurred and were not deferred.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company records a right-of use (&#34;ROU&#34;)
asset and a lease liability on its balance sheet for all leases with terms of 12 months or longer. Leases are classified as either
finance or operating, with classification affecting the pattern of expense recognition in the income statement. Historically,
the Company recorded rent expense associated with its operating lease on a straight-line basis over the term of the lease. The
difference between rent payments and straight-line rent expense was recorded as deferred rent in accrued liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of December 31, 2020, the Company's leases
had original terms of 12 months or less. The Company does not recognize ROU assets and lease liabilities that arise from leases
with an original term of 12 months or less. Rather the Company recognizes the lease payments on a straight-line basis over the
term of the lease.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company follows the accounting guidance
in the Financial Accounting Standards Board (&#34;FASB&#34;) Accounting Standards Codification (&#34;ASC&#34;) Topic 820, Fair
Value Measurements and Disclosures (&#34;ASC 820&#34;), for its fair value measurements of financial assets and liabilities measured
at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The accounting guidance requires fair value
measurements be classified and disclosed in one of the following three categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Level 1: Quoted prices in active markets for
identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Level 2: Observable inputs other than Level
1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Level 3: Unobservable inputs which are supported
by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted
cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant
judgment or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The fair value hierarchy also requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and
liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following tables present information about
the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during the years
ended December 31, 2020 and 2019 (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value Measurements as of December 31, 2020</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 1) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 2) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 3) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Total </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Assets</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cash</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,662&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,662&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Liabilities</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liabilities, at fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value Measurements as of December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 1) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 2) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 3) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Total </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Assets</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cash</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,261&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,261&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Liabilities</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liabilities, at fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">963&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">963&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The common stock warrant liabilities were
recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the fair
value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2020 and 2019:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 66%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>December 31, 2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.18%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.66%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Volatility</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">116.77%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">110.80%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Expected term</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.07</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.07</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Weighted-average fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.40</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.06</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table is a reconciliation for
the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="width: 75%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 23%; text-align: center"><font style="font-size: 10pt"><b>Warrant liabilities</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Balance as of December 31, 2018</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant issued in connection with financing</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21,535&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liability reclassified to stockholders' equity</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(37,073)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in fair value measurement of warrant liability</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">16,501&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Balance as of December 31, 2019</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 10pt">963&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liability reclassified to stockholders' equity</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(124)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in fair value measurement of warrant liability</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">223&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Balance as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Of the inputs used to value the outstanding
common stock warrant liabilities as of December 31, 2020 and 2019, the most subjective input is the Company's estimate of expected
volatility of its common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionLongTermContracts', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Grant Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company determined that its grant agreement
with Team Sanfilippo Foundation (&#34;TSF&#34;), a nonprofit medical research foundation founded by parents of children with Sanfilippo
syndrome, is within the scope of ASC Topic 606 &#34;Revenue from Contracts with Customers&#34;. Under the TSF agreement, TSF makes
certain milestone payments to the Company as certain milestones related to a specified Phase II/III clinical trial, defined in
the agreement, are met. The Company determined that there is one performance obligation under the TSF agreement. The variable
consideration, in the form of milestone payments, is attributed to the completed portion of the performance obligation that triggers
or results in the payments. During the year ended December 31, 2020 and 2019, the Company recognized $0 and $375,000 of revenue,
respectively, from a milestone payment received as the milestone payment represents the Company's completed portion of its performance
obligation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Research and development costs are expensed
as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related
expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development
and consulting agreements in place.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Income taxes are accounted for under the
asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying
amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to
be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more
likely than not that some or all of the deferred tax assets will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company also follows the provisions of
accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken
or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure
and transition.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Income (Loss) Per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Basic loss per share is computed by dividing
net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period.
Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible
debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic
and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both
calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is
anti-dilutive.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company expenses stock-based compensation
to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of
the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules
are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used
in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and
the application of management's judgment. All stock-based compensation costs are recorded in general and administrative or research
and development costs in the statements of operations based upon the underlying individual's role at the Company.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Segment Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company operates under one segment which
develops pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In August 2018, the FASB issued Accounting
Standards Update (&#34;ASU&#34;) No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure
Requirements for Fair Value Measurement (&#34;ASU 2018-13&#34;). The amendments in this ASU require certain existing disclosure
requirements in Topic 820 to be modified or removed, and certain new disclosure requirements to be added to the Topic. In addition,
this ASU allows entities to exercise more discretion when considering fair value measurement disclosures. The Company adopted
ASU 2018-13 effective January 1, 2020. The adoption of ASU 2018-13 did not have a material effect on the Company's financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In December 2019, the FASB issued ASU No.
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#34;ASU 2019-12&#34;), which is intended to simplify
various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic
740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years,
and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is
currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In August 2020, the FASB issued ASU 2020-06:
Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This standard simplifies the
accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature,
as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt
instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest
expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of
ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per
share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable
for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after
December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company is evaluating
the impact of ASU 2020-06 on its consolidated financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116873391&amp;loc=d3e408-128459<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=13988685&amp;loc=d3e8784-128493<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionLongTermContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for long-term construction or production type contracts. This disclosure may include the method or methods used to determine earned revenues and the cost of earned revenue, including the policies relating to combining and segmenting, and accounting for indirect costs, contract incentives and costs included in inventory, if applicable. For contracts accounted for under the percentage-of-completion method the entity also generally discloses its method(s) of measuring the extent of progress towards completion. For contracts accounted for under the completed-contract method, the entity may disclose the specific criteria it uses to determine when a contract is substantially completed. If the entity departs from its basic accounting policy (namely percentage-of-completion or completed-contract method) for a single contract or a group of contracts, such a departure may be disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionLongTermContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744142551928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy for Warrant Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following tables present information
about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the
fair value hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during
the years ended December 31, 2020 and 2019 (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value Measurements as of December 31, 2020</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 1) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 2) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 3) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Total </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Assets</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cash</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,662&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,662&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Liabilities</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liabilities, at fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value Measurements as of December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 1) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 2) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>(Level 3) </b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Total </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Assets</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cash</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,261&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,261&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt"><b>Liabilities</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liabilities, at fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">963&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">963&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Fair Value Measurements Valuation Assumptions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following assumptions were used in determining
the fair value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2020 and 2019:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 55%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 18%; text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td>
    <td style="width: 3%; text-align: right">&#160;</td>
    <td style="width: 3%; text-align: right">&#160;</td>
    <td style="width: 19%; text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2020</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.18%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.66%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Volatility</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">116.77%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">110.80%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Expected term</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.07</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.07</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Weighted-average fair value</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.40</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.06</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value Level 3 Reconciliation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table is a reconciliation for
the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="width: 65%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 33%; text-align: center"><font style="font-size: 10pt"><b>Warrant liabilities</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Balance as of December 31, 2018</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant issued in connection with financing</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21,535&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liability reclassified to stockholders' equity</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(37,073)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in fair value measurement of warrant liability</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">16,501&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Balance as of December 31, 2019</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 10pt">963&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Warrant liability reclassified to stockholders' equity</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(124)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in fair value measurement of warrant liability</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">223&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Balance as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"><font style="font-size: 10pt">1,062&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following potentially dilutive securities
outstanding for the year ended December 31, 2020 and 2019 have been excluded from the computation of diluted weighted average
shares outstanding, as they would be anti-dilutive (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 66%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding stock options</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,120&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">522&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding warrants</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,066&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,584&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Convertible notes</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">8,556&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">23,742&#160;</font></td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,106&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144561720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Accrued Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following
(in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Professional fees</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">292&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">151&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Personnel related</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">756&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">683&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outside research and development services</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">764&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">853&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Other</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">112&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">232&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Accrued expenses, net</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,924&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,919&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140476568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of warrant activity during the
year ended December 31, 2020 is as follows (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Remaining</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Contractual Life</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Warrants</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><font style="font-size: 10pt"><b>Price</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><font style="font-size: 10pt"><b>(in years) </b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding at December 31, 2018</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Assumed in Merger</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">437&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">20.59&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.5&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Issued</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">17,481&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.42&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.1&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Exercised</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(14,334)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.31&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 2019</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,584&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.86&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.3&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Issued</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6,648&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.84&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Exercised</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(154)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.30&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Cancelled</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(12)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">18.00&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,066&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.84&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.4&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Exercisable as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,417&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.79&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.7&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140617240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions for Stock Options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following assumptions were used in determining
the fair value of the stock options granted during the years ended December 31, 2020 and 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 59%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 17%; text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 20%; text-align: center"><font style="font-size: 10pt"><b>Year Ended</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2020</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.3%-1.7%</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.6%-2.6%</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Volatility</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">109%-119%</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">109%-113%</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Dividend yield</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- %</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Expected term (years)</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-7</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-7</font></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: white"><font style="font-size: 10pt">Weighted-average fair value</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.97</font></td>
    <td style="background-color: white; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.76</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of stock option activity during
the year ended December 31, 2020 is as follows (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Average Remaining</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Aggregate</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Stock</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Exercise</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Contractual</b></font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Intrinsic</b></font></td></tr>
<tr>
    <td style="width: 42%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>Options</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>Price</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><font style="font-size: 10pt"><b>Life (in years)</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>Value</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 2019</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">522&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">9.18&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.0&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">21&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,624&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.16&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.3&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Cancelled</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(26)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.96&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Outstanding as of December 31, 20120</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,120&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.97&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.2&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,969&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Vested and expected to vest as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">353&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12.45&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.4&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">42&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Exercisable as of December 31, 2020</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">353&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12.45&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.4&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">42&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table summarizes the total
stock-based compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations
(in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Research and development</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">394&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">118&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">General and administrative</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,650&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">341&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,044&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">459&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140609976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Deferred tax assets consist of the following
(in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Net operating tax loss carryforwards</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">15,223&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5,632&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Accrued expenses</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">66&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">348&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Stock-based compensation</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">521&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Start up cost</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">12,320&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,806&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Total deferred tax asset</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">28,130&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,870&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Less valuation allowance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(28,130)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(10,870)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Net deferred tax asset</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A reconciliation of the Company's unrecognized
tax benefits for the years ended December 31, 2020 and 2019, are as follows (in thousands):</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 74%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Beginning balance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">718&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in current period positions</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Change in prior period positions</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(718)</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Ending balance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-&#160;</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Tax Effective Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The reconciliation of income taxes computed
using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31,
2020 and 2019, are as follows:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr>
    <td style="width: 73%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="width: 1%; text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Federal statutory tax rate</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21.0&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">21.0&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">State and local taxes, net of federal benefit</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">11.2&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.7&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Permanent items</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1.0)</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(9.0)</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Deferred rate changes</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.1&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Other</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">59.3&#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(0.3)</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Change in valuation allowance</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(90.6)</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(18.4)</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#160;&#160;&#160;&#160; Income tax provision (benefit)</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">- &#160;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138460104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Fair Value Assets and Liabilities Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, at fair value</a></td>
<td class="nump">$ 15,662<span></span>
</td>
<td class="nump">$ 10,261<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, at fair value</a></td>
<td class="nump">15,662<span></span>
</td>
<td class="nump">10,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, at fair value</a></td>
<td class="nump">15,662<span></span>
</td>
<td class="nump">10,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liabilities, at fair value</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liabilities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liabilities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liabilities, at fair value</a></td>
<td class="nump">$ 1,062<span></span>
</td>
<td class="nump">$ 963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744142774856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value (USD per share)</a></td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">0.18%<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">116.77%<span></span>
</td>
<td class="nump">110.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years 25 days<span></span>
</td>
<td class="text">4 years 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value (USD per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744136017048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Warrant issued in connection with financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Warrant liability reclassified to stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value measurement of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Warrant liability reclassified to stockholders' equity</a></td>
<td class="num">(124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value measurement of warrant liability</a></td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 1,062<span></span>
</td>
<td class="nump">$ 963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744135506616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of securities that are antidilutive</a></td>
<td class="nump">23,742,000<span></span>
</td>
<td class="nump">4,106,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of securities that are antidilutive</a></td>
<td class="nump">5,120,000<span></span>
</td>
<td class="nump">522,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of securities that are antidilutive</a></td>
<td class="nump">10,066,000<span></span>
</td>
<td class="nump">3,584,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of securities that are antidilutive</a></td>
<td class="nump">8,556,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744185374568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144306792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Geographical Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues by area</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138444968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Offerings (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cash received from stock sale, before issuance costs</a></td>
<td class="nump">$ 8,850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_December2020Member', window );">December 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">In December 2020, the Company issued an aggregate of 1,112,219 shares of common stock in conjunction with the issuance of convertible notes at a discount for aggregate net proceeds of $10.9 million (see Note 7).<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_September42020Member', window );">September 4 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On September 4, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors (the "September 2020 Securities Purchase Agreement") pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering, resulting in total net proceeds of $6.4 million, after deducting the placement agent's fees and other offering expenses. The shares were offered by the Company pursuant to the Company's shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (the "SEC") on November 2, 2017, as amended. The Company also issued to the investors warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the "September 2020 Warrants"). The September 2020 Warrants have an exercise price of $0.84 per share of common stock, will be exercisable beginning on March 9, 2021 and will expire on March 9, 2026.  The combined purchase price for one share and one warrant to purchase 0.75 of a share of common stock in the offerings was $0.79. The closing of the offerings occurred on September 9, 2020.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_August232019Member', window );">August 23 2019</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On August 23, 2019, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million, before deducting the placement agents' fees and other estimated offering expenses. The shares were offered by the Company pursuant to the Company's shelf registration statement on Form S-3 filed with the SEC on November 2, 2017, as amended. The Company issued to the investors warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the "August 2019 Warrants"). The August 2019 Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of issuance. The combined purchase price for one share and one warrant to purchase half of a share of common stock in the offerings was $1.50. Roth Capital Partners, LLC ("Roth") served as the placement agent for the issuance and sale of the shares and the warrants, and the Company paid Roth an aggregate fee equal to 7.0% of the gross proceeds received by the Company in the offerings.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_March162020Member', window );">March 16 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On March 16, 2020, the Company completed an underwritten public offering pursuant to which it sold 7,500,000 shares of its common stock at a price to the public of $0.60 per share. The net proceeds to the Company from this offering were approximately $4.0 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_February132020Member', window );">February 13 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On February 13, 2020, the Company completed an underwritten public offering, pursuant to which it sold 6,666,667 shares of its common stock at a price to the public of $0.75 per share. On February 19, 2020, the Company sold an additional 999,999 shares of its common stock at a price to the public of $0.75 per share pursuant to the full exercise of the underwriters' option to cover over-allotments. The net proceeds to the Company from this offering were approximately $4.8 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_January22020Member', window );">January 2 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On January 2, 2020, the Company entered into a stock purchase agreement (the "Stock Purchase Agreement") with Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG ("Vyera"), pursuant to which the Company issued to Vyera 1,809,845 registered shares of the Company's common stock (the "Shares"). The Company entered into the Stock Purchase Agreement in accordance with an asset purchase agreement with Vyera, as amended by the amendment entered into with Vyera on October 15, 2019 (see Note 5). As partial consideration for the assets of Vyera, the Company agreed to issue the Shares pursuant to the Stock Purchase Agreement.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_May112020Member', window );">May 11 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On May 11, 2020, the Company entered into a consulting agreement (the "Consulting Agreement") with an advisory firm, pursuant to which the advisory firm agreed to provide the Company with certain management consulting, business and advisory services. The Company agreed to issue the advisory firm 300,000 unregistered shares of the Company's common stock, which shares were issued on May 11, 2020, plus $80,000 in cash. On June 9, 2020, the Company and the advisory firm entered into an amendment to the Consulting Agreement (the "Amendment"). Pursuant to the Amendment, the advisory firm agreed to provide the Company with additional services and, in consideration, the Company agreed to issue the advisory firm an additional 200,000 unregistered shares of the Company's common stock (the "Additional Shares"), plus $20,000 in cash. The Additional Shares were issued to the advisory firm on June 9, 2020 and are subject to certain vesting restrictions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ConsultingExpense', window );">Consulting expense</a></td>
<td class="nump">$ 431,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_June172019Member', window );">June 17 2019</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On June 17, 2019, the Company entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Piper Jaffray & Co., as sales agent ("Piper Jaffray"), pursuant to which the Company could offer and sell, from time to time, through Piper Jaffray (the "Offering") up to $50,000,000 in shares. Under the terms of the Equity Distribution Agreement, Piper Jaffray was entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Equity Distribution Agreement. During the year ended December 31, 2019, the Company sold 1,197,676 shares for net proceeds of approximately $2.6 million pursuant to the Equity Distribution Agreement. On August 23, 2019, the Company suspended its continuous offering under the Equity Distribution Agreement and the Equity Distribution Agreement terminated in accordance with its terms on December 7, 2020.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_January242019Member', window );">January 24 2019</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On January 24, 2019, STI and Apricus closed a private placement transaction with certain accredited investors (the "Investors"), whereby, among other things, STI issued to investors shares of STI's common stock immediately prior to the Merger in a private placement transaction (the "Financing"), pursuant to a Securities Purchase Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors, as amended (the "Purchase Agreement").  Pursuant to the Purchase Agreement, STI (i) issued and sold to the Investors an aggregate of 2,374,672 shares of STIs common stock which converted pursuant to the exchange ratio in the Merger into the right to receive 1,829,407 shares of the Company's common stock and (ii) issued warrants representing the right to acquire 1,463,519 shares of common stock at a price per share of $4.15, subject to adjustment as provided therein (the "Series A Warrants"), most recently adjusted to a price per share of $0.2957 per share, and additional warrants initially representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided therein (the "Series B Warrants" together with the Series A Warrants, the "Investor Warrants"), for aggregate gross proceeds of $18.0 million, or $16.5 million net of financing fees. The terms of the Investor Warrants included certain provisions that could result in adjustments to both the number of warrants issued and the exercise price of each warrant, which resulted in the warrants being classified as a liability upon issuance (see Note 8). The Investor Warrants were recorded at fair value of $21.5 million upon issuance and given the liability exceed the proceeds received, a loss of $5.0 million was recognized.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_March72019Member', window );">March 7 2019</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Terms and provisions</a></td>
<td class="text">On March 7, 2019, the Company entered into Amendment Agreements (collectively, the "Amendment Agreements") with each Investor amending: (i) the Purchase Agreement, (ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate number of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised as of March 7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment Agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ConsultingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ConsultingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_December2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_December2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_September42020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_September42020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_August232019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_August232019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_March162020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_March162020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_February132020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_February132020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_January22020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_January22020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_May112020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_May112020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_June172019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_June172019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_January242019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_January242019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_March72019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_March72019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138529528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember', window );">Ligand License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">License Agreement, Separately Recognized Transactions, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On September 21, 2016, the Company entered into a License Agreement (the "License Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand"), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the "Licensors"), pursuant to which, among other things, the Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors' two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the "Licensed Products"), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the People's Republic of China (each, a "Major Market") or the United States, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.  In connection with the closing of the Merger, the Company issued 801,253 shares of common stock to Ligand and recognized research and development expense totaling approximately $2.2 million during the three months ended March 31, 2019 for the License Agreement.   The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection with Aplindore for the indication of Parkinson's Disease ("PD") or Restless Leg Syndrome, consisting of (i) $750,000 upon submission of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA approval of an application for a particular Licensed Product, (iii) $1.125 million upon regulatory approval in a Major Market for a particular Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major Market for a particular Licensed Product.  The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon submission of an application with the FDA or equivalent foreign body for such a particular Licensed Product, (ii) $350,000 upon FDA approval of an application for such a particular Licensed Product, (iii) $125,000 upon regulatory approval in a Major Market for such a particular Licensed Product, and (iv) $125,000 upon regulatory approval in a second Major Market for such a particular Licensed Product.  The Company agreed to pay to Ligand certain one-time, non-refundable commercial milestone payments in connection with the Licensed Products, consisting of (i) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (ii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), (iv) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists, (v) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (vi) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), and (viii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists.  The Company will also pay to Ligand middle single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty in the upper single digit to lower double digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent and a tiered incremental royalty in the lower single digit to middle single digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent.  The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromVyeraPharmaceuticalsAGMember', window );">Vyera Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">License Agreement, Separately Recognized Transactions, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On March 6, 2018, the Company entered into an asset purchase agreement with Vyera, pursuant to which the Company acquired the assets (the "Vyera Assets") and liabilities (the "Vyera Assumed Liabilities") of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The Company is obligated to use commercially reasonable efforts to seek regulatory approval in the United States for and commercialize SLS-002.   As consideration for the Vyera Assets, the Company paid to Vyera a non-refundable cash payment of $150,000 on May 21, 2018. As further consideration for the Vyera Assets, upon public announcement of the entry by Apricus and STI into the Merger Agreement, the Company paid to Vyera a non-refundable cash payment of $150,000. As further consideration for the Vyera Assets, the Company issued to Vyera 191,529 shares of common stock and paid Vyera a non-refundable cash payment of $1,000,000 on January 29, 2019.   Pursuant to the amendment to the asset purchase agreement entered into by the Company and Vyera on October 15, 2019, the Company issued Vyera 1,809,845 registered shares of the Company's common stock on January 2, 2020 and made cash payments to Vyera in the amounts of $750,000, $750,000, $1.0 million and $1.0 million in October 2019, January 2020, April 2020 and July 2020, respectively.  In the event that the Company sells, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company must pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale.  The Company agreed to pay to Vyera certain one-time, non-refundable milestone payments consisting of (i) $10.0 million upon approval by the FDA of a new drug application (an "NDA"), with respect to SLS-002, (ii) $5.0 million upon approval by the European Medicines Agency (the "EMA") of the foreign equivalent to an NDA with respect to SLS-002 in a Major Market, (iii) $2.5 million upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002 in a second Major Market, (iv) $5.0 million upon the achievement of $250.0 million in net sales of SLS-002, (v) $10.0 million upon the achievement of $500.0 million in net sales of SLS-002, (vi) $15.0 million upon the achievement of $1.0 billion in net sales of SLS-002, (vii) $20.0 million upon the achievement of $1.5 billion in net sales of SLS-002, and (viii) $25.0 million upon the achievement of $2.0 billion in net sales of SLS-002. The Company will also pay to Vyera a royalty percentage in the mid-single digits on aggregate annual net sales of SLS-002.  The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromBioblastPharmaLtdMember', window );">Bioblast Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">License Agreement, Separately Recognized Transactions, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February 15, 2019, the Company entered into an Asset Purchase Agreement (the "Bioblast Asset Purchase Agreement") with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the "Bioblast Asset Purchase"). The Company paid to Bioblast $1.5 million in cash, and the Company paid to Bioblast an additional $2.0 million in February 2020. Accordingly, the Company recognized a $3.5 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the Bioblast Asset Purchase Agreement, the Company agreed to pay additional consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (i) within 15 days following the completion of the Company's first Phase II(b) clinical trial of Trehalose satisfying certain criteria, the Company will pay to Bioblast $8.5 million; and (ii) within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates, the Company will pay to Bioblast $8.5 million. In addition, the Company agreed to pay Bioblast a cash royalty equal to 1% of the net sales of Trehalose. Under the terms of the Bioblast Asset Purchase, the Company assumed a collaborative agreement with TSF, a nonprofit medical research foundation founded by parents of children with Sanfilippo syndrome. TSF, upon approval by the FDA, planned to begin an open label, Phase II(b) clinical trial in up to 20 patients with Sanfilippo syndrome, which is now known under the study name SLS-005. The Company will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement entitle the Company access to all clinical data from this trial. On July 15, 2019, TSF and the Company amended the agreement whereby the Company agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5 million towards the funding of the trial.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_WegLicenseAgreementMember', window );">Weg License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">License Agreement, Separately Recognized Transactions, Description</a></td>
<td class="text">On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the "Weg License Agreement"), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020 and $0.125 million on January 2, 2021. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company's common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the "Milestone Product"), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval by the EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr. Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_UCRegentsLicenseAgreementMember', window );">UC Regents License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">License Agreement, Separately Recognized Transactions, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On March 7, 2019, the Company entered into an exclusive license agreement (the "UC Regents License Agreement") with The Regents of the University of California ("The UC Regents") pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (&#945;-synuclein). The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the central nervous system ("CNS"). This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the completion of dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market, the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce the Company's license to a nonexclusive license.   The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_DukeLicenseAgreementMember', window );">Duke License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">License Agreement, Separately Recognized Transactions, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 27, 2019, the Company entered into an exclusive license agreement (the "Duke License Agreement") with Duke University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression. The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University $0.1 million and recognized $0.1 million charge to research and development expense during the year ended December 31, 2019. The Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, Duke University may terminate the agreement.   The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of each transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_LicensefromLigandPharmaceuticalsIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromVyeraPharmaceuticalsAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromVyeraPharmaceuticalsAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromBioblastPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromBioblastPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_WegLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_WegLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_UCRegentsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_UCRegentsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_DukeLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_DukeLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744141775528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Personnel related</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ResearchAndDevelopmentAccruedExpense', window );">Outside research and development services</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses, net</a></td>
<td class="nump">$ 1,924<span></span>
</td>
<td class="nump">$ 1,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ResearchAndDevelopmentAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Accrued Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ResearchAndDevelopmentAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140629240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_CovertibleNotestNarrativeDetailsAbstract', window );"><strong>Issuance Of Common Stock And Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Debt, Description</a></td>
<td class="text">On December 11, 2020, the Company entered into a Securities Purchase Agreement (the "Lind Securities Purchase Agreement") with Lind Global Asset Management II, LLC (the "Investor") pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the "Note") in an aggregate principal amount of $12,000,000 (the "Principal Amount"), which will bear no interest and mature on December 11, 2022 (the "Maturity Date"), and (2) 975,000 shares of the Company's common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor shall have the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the "Conversion Price"). Prior to June 11, 2021, the Company will have the right to prepay up to sixty-six and two-thirds percent (662/3%) of the then-outstanding Principal Amount of the Note with no penalty. On or after July 11, 2021, the Company will have the right to prepay up to the then-outstanding Principal Amount of the Note with no penalty; however, if the Company exercises such prepayment right, the Investor will have the option to convert up to thirty-three and one-third percent (331/3%) of the amount that the Company elects to prepay at the Conversion Price. Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the Note, unless waived by the Investor in advance. Beginning on June 9, 2021, the Note will amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable solely in cash, plus a 2% premium.  On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the "December 17 SPAs"), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1)convertible promissory notes (the "December 17 Notes") in an aggregate principal amount of $1,365,628, which will bear no interest and mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the "December 18 SPA") and, together with the December 17 SPAs, (the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which will bear no interest and mature on December 18, 2022 (the "December 18 Note" and, together with the December 17 Notes, the "Subsequent Notes"), and (2) 26,263 shares of the Company's common stock. The Subsequent Securities Purchase Agreements have substantially the same terms as the Lind Securities Purchase Agreement, and the Subsequent Notes have substantially the same terms as the Note.   The Company received aggregate net proceeds of $10.9 million from the convertible note offerings, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes and common stock issued under the agreements based on their relative fair values. The Company recognized a beneficial conversion feature discount on the convertible notes of approximately $0.1 million.  The discount on the convertible notes is being amortized to interest expense, using the effective interest method over the term of the convertible notes. As of December 31, 2020, the principal balance of the convertible notes outstanding and the unamortized discount on the convertible notes is approximately $13.7 million and $4.1 million, respectively. Interest expense recognized related to the discount was approximately $0.2 million for the year ended December 31, 2020.   Convertible Notes  From May 2017 to October 2018, the Company issued convertible notes (the "Convertible Notes"). The aggregate principal amount of the Convertible Notes was $2.3 million, and the Convertible Notes were due no later than April 30, 2019 with simple interest at the rate of 8% per annum. The Convertible Notes provided that they were to convert at a discount of 10% or 20% depending on the terms for each note, or $9.70 to $10.91 per share, respectively.  The Convertible Notes were carried at fair value. The Company recognized an adjustment relating to changes in the Convertible Notes fair value of $0 and $109 thousand during the year ended December 31, 2020 and 2019, respectively.  In connection with the closing of the Merger, the Convertible Notes plus unpaid interest were converted into 172,284 shares of common stock at a price of $9.70 or $10.91 per share.  PPP Loan  On May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the "PPP Lender"), for an aggregate principal amount of approximately $147,000 (the "PPP Loan"). The PPP Loan bears interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, has a term of two years, and is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program upon the Company's request to the extent that the PPP Loan proceeds are used to pay expenses permitted by the Paycheck Protection Program, including payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company intends to apply for forgiveness of the PPP Loan with respect to these covered expenses. To the extent that all or part of the PPP Loan is not forgiven, the Company will be required to pay interest on the PPP Loan at a rate of 1.0% per annum, and commencing in the fourth quarter of 2020, principal and interest payments will be required through the maturity date in May 2022. The terms of the PPP Loan provide for customary events of default including, among other things, payment defaults, breach of representations and warranties and insolvency events. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_CovertibleNotestNarrativeDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_CovertibleNotestNarrativeDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138529144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Common Shares Issuable upon Exercise</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,584,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_AssumedInMerger', window );">Assumed in Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="nump">6,648,000<span></span>
</td>
<td class="nump">17,481,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(154,000)<span></span>
</td>
<td class="num">(14,334,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Cancelled (in shares)</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">10,066,000<span></span>
</td>
<td class="nump">3,584,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable at balance sheet date (in shares)</a></td>
<td class="nump">3.417000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share)</a></td>
<td class="nump">$ 3.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Issued (in usd per share)</a></td>
<td class="nump">.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice', window );">Cancelled (in usd per share)</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share)</a></td>
<td class="nump">1.84<span></span>
</td>
<td class="nump">$ 3.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Exercisable at balance sheet date (in dollars per share)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_WeightedAverageRemainingContractualLifeInYears', window );"><strong>Weighted Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_AssumedInMergerInYears', window );">Assumed in Merger (in years)</a></td>
<td class="text">3 years 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_IssuedInYears', window );">Issued (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 36 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_OutstandingAtBalanceSheetDateInYears', window );">Outstanding at balance sheet date (in years)</a></td>
<td class="text">4 years 144 days<span></span>
</td>
<td class="text">3 years 108 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ExercisableAtBalanceSheetDateInYears', window );">Exercisable at balance sheet date (in years)</a></td>
<td class="text">2 years 252 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_AssumedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_AssumedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_AssumedInMergerInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_AssumedInMergerInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ExercisableAtBalanceSheetDateInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ExercisableAtBalanceSheetDateInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_IssuedInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_IssuedInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_OutstandingAtBalanceSheetDateInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_OutstandingAtBalanceSheetDateInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_WeightedAverageRemainingContractualLifeInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_WeightedAverageRemainingContractualLifeInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138353320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable (shares)</a></td>
<td class="nump">353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (shares)</a></td>
<td class="nump">4,624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SEEL_TwoThousandTwelveIncentivePlanMember', window );">Two Thousand Twelve Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common shares authorized for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SEEL_TwoThousandTwelveIncentivePlanMember', window );">Two Thousand Twelve Incentive Plan [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SEEL_TwoThousandTwelveIncentivePlanMember', window );">Two Thousand Twelve Incentive Plan [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SEEL_TwoThousandTwelveIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SEEL_TwoThousandTwelveIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744148886872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Of Black-Scholes Option Grant (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">119.00%<span></span>
</td>
<td class="nump">113.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744135478760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (shares)</a></td>
<td class="nump">522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted in Period (shares)</a></td>
<td class="nump">4,624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised in Period (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (shares)</a></td>
<td class="num">(26,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (shares)</a></td>
<td class="nump">5,120,000<span></span>
</td>
<td class="nump">522,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period (shares)</a></td>
<td class="nump">353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, end of period (shares)</a></td>
<td class="nump">353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (USD per share)</a></td>
<td class="nump">$ 84.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted in Period (USD per share)</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised in Period (USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (USD per share)</a></td>
<td class="nump">1.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (USD per share)</a></td>
<td class="nump">1.97<span></span>
</td>
<td class="nump">$ 84.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest stock, end of period (USD per share)</a></td>
<td class="nump">12.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period (USD per share)</a></td>
<td class="nump">$ 12.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">9 years 72 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted, Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">9 years 108 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (in years) of vested and expected to vest stock options</a></td>
<td class="text">7 years 144 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (in years) of exercisable stock options</a></td>
<td class="text">7 years 144 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Total Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total aggregate intrinsic value shares outstanding</a></td>
<td class="nump">$ 196,900<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Total aggregate intrinsic value of vested or expected to vest stock options</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total aggregate intrinsic value of exercisable stock options</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744157132200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation by Expense Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138300904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards', window );">Net operating tax loss and capital loss carryforwards</a></td>
<td class="nump">$ 15,223<span></span>
</td>
<td class="nump">$ 5,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Start up cost</a></td>
<td class="nump">12,320<span></span>
</td>
<td class="nump">4,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">28,130<span></span>
</td>
<td class="nump">10,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(28,130)<span></span>
</td>
<td class="num">(10,870)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards and capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_DeferredTaxAssetsOperatingLossAndCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744140491464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Recognition Of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Change in current period positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Change in prior period positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744148923800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Of Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Permanent items</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Deferred rate changes</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">59.30%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(90.60%)<span></span>
</td>
<td class="num">(18.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision (benefit)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744138548632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax interest and penalties expense</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax Credit Carryforward, Limitations on Use</a></td>
<td class="text">The federal and state net operating loss carryforwards, not subject to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset as of December 31, 2020 and 2019 of approximately $15.2 million and $5.6 million, respectively. In consideration of the Company's accumulated losses and the uncertainty<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 46.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 90.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144307352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744144345144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future Minimum Rental Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139744141918120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_SubsequentEventNarrativeDetailsAbstract', window );"><strong>Subsequent Event Narrative Details Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsDate', window );">Subsequent Event, Date</a></td>
<td class="text">Feb. 15,  2021<span></span>
</td>
<td class="text">Jan. 28,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent Event, Description</a></td>
<td class="text">On February 15, 2021 the Company entered into an amendment to the asset purchase agreement with Vyera. Pursuant to the amendment, the Company agreed to make cash payments to Vyera in the amount of $3.0 million in each of February 2021, June 2021 and September 2021 in exchange for a lower royalty percentage on potential net sales of SLS-002.<span></span>
</td>
<td class="text">On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_SubsequentEventNarrativeDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_SubsequentEventNarrativeDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%JDV4N6*"'/>, -I560B,UB=L$AEY(X=CG[S@)&L!3SHHC"5@M^];MPT</O
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MIM16WM!<?\97R=5;JO3D:LURP5(:8TEB\(13G$<$O&IS DS ]]=G<'MS!VX
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M&M8I<O;"Z9A+(Z\#SR+D0\?IP7=6^^%PV6+Y@7!)%39%?1MIQ0>-I=',A5V
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M>!@[+E7&!?FK5PQ\?>>/4M?&X1Z/Z]2?#^ ] COL0<L>#&,G4I:7N8,#G(_
MYR(ZI).6=#*,5#]<I<(L)6QS"7=R$?=<1 <W;''#L[@+GN?Z<?N?W1SVZN9+
M41WP:0L^'0#>OY6GAQWJ'>_E/I$=]%F+/AN WJ^39P<PP3CP@^GL8[$/ [W0
M\::![Q^'=IU_1XDS 'M 6S>^/>"/1)Z@M_?.1/-"\A.+#6$245AKJ3,*=;N)
M^HRO)XH7U3'YR)4^=*MAIM^+0)@ ?7W-N7J?F).W?=.*WP!02P,$%     @
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M,Y"S%=V5XG/S]"/K PJ5OZPIV^Y_\-3;!C.0[5K15/U@J: JZOU?^K5/Q-$
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M_:IIQ/,;]5CCX4'9JW\ 4$L#!!0    ( /R!:U*1ZO;16P<  +<?   8
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MC'HK++!US(OYR&@<:7&<M$]'PQZ9++DZKOW#4>*#-?/60\@F'1/L\(OC^#W
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M8ZYR&"!Q#$25=X60.CIL"8KWL[PWR0$0Y/G8*G4<(/$-V@O$TQ-VPN3Y4\.
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MP!C _U<"]DO]C7G!X5O]Q;]02P,$%     @ _(%K4@S)7%%U%P  V4(  !@
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M<9$%"Z<=C/#&3>0T23XQ1HX+DN(6L>V8#H-;DQ3(?H/"2)V)>37'5KS"/72
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M1P9:=Z%F,/H\1XQTKQ))T C>'/CI?<%PX0%QDAAXLCD2QG)U.()D;0R^R()
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M<IDGG=?M*QH#H&)/ )'(?3&>S=-A^NKA]^QB>GJM[A#3%';9%2A?#_.7X<2
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MIQ\;GZ1;*YPAFE8PG8Y_?).G,>\7&,-X:5[:@"MX?*SPFX<<;\#WE;6A7W"
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M#ZF]#)J7D'"KQ+-?A=K O1^!2!8C?_52>U**^/'W=\30-;8Y( U.0;&]ZQ@
M&<4SS6MOATH0!N8@I*5EM?ENY%UYC7%V#^V#6!T@)"&G;%P[ 1 *_;YEI!IL
M572J.@)6M#.2W.W@8&M\8!CK16ML)SQ-M<Y+8OGT6@(^&V]H'IFWAE!A)7;
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M'OI)?N5MI]X+5;Y'1L,YW]%<I<TZ^L XG %V#T=C=IGA:Q)T:'),\I;2AY/
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MDT2%.:I-X2.TVJO>-3Q#A/"7P(]<1! TMGO0N[ZPON(3V )KN?R@9_)FF83
MK-A)0#J6%^[8"0 ]^^%TV!\.A[),Z4#+R0*'#A("[\$8#B;V1*N]O+\X(QH:
MZ!CF00<*%I&>)0C/(0,2@C$J X" H+*UO?=MS'QV,AA6Q\SD:6%O=1T,[+<P
MK3P:C,:G[;4['1WAK::C72,AUDG8F'_W2"J  _!<VXFM[>?WI[5= UN:*CHT
M]>)Q&CD:=FJD?(Q&BC6-S$MR1'NI9=,BFBK9P<'VE<6:7HY/ZZ7WU\A]>&^H
M98.(>+1"[J:UHI5/5<@ZA'V=&^W4H-JS")8US07XH<B_<*D,S'<H)\YX*::5
M"Y(4H9HJNY0)I))#H_)& :!A#52O"NUI-G)$JT;_"2;::58C >H+KX'#5:?[
M;^"JF2N*#4FQ_#<GQ:*5%,O?)"EV]M@E<O';BKPC 3X@7L9[*>7X-[.,N^@_
MQ,0VR[B+5KG:;!G?F*O_5LO@:'47=0M>_/:"7[./=E"[!R&+M]I!;1&%8:P%
MY4VQ/@JC&8[+UA\IS22!S;!]*L=@[82J.CM8VIH#R&TY@-B.K*QRM'-]#NT=
MF75&P?B.5<961I6OE(:N0,KGI21V28.@/1D?#%"ZJ[[ZLD^9IIAOY2.M?""]
MV-SC:6C*2?4T4\E,/T5B+3&)G6+: 4"_3DQB14P#>1:&W"^@XEN[TL\JU=8F
MB*4MJB>HDO@&JO2U,A(M&5$Y[*GJ)%?4R2K.JCI9*VP]%M]&GYXJ*_%$?=I#
M5M8QI8;^)JS<!/0$LSM0="[\VDM=6'P<,@G$BHGMG]A261?PKB./"H*,RC^J
MD!>(FUS>] W#P6IS["S/-69S;^QZ;G02/92Y//M93(]OCY7\ZU)G:KV]=/8S
M<_+9UGA6NUAX>]#CF;U#:J;98L_W7.MYT=E'HV!E!.5HQ [UI8(Y%494U4_C
M ^8U.]I6[484;3"SE7>[7NZZ<78S=L?@S':6%)?N8+MB95"YP!H?ZO=4H)DZ
M@33:3I^_?#H:#L? C-R]4E!9>6N#IM[>7QF.64?$5S0%:%BN]>VFG'2M]&QK
M%RW]B_ZE1<7/65[I79THTRI-V=F.H&<[51&S:T>HM711Y7.OI18PNS3=D&(L
M?7_U!=.>EAE[PSUXL #4U>'A,F"Z084ZN&;+I@PL=99FR(AMF?GF\R7K6J-T
M6A<;VZJY?5]BT[X>NX\635>XK:B.7H[ZI^.7&RJXW)5B-O>6/7'HI?^K@I^%
MB,8O;15V(*\;AL76@XDA3_8/6N8I:O-LVC')O-T9]@R"Z%^"PI!#&IU:HIW[
M=YOOOQB^[+]X?DK:[;%Q+8F&#GZ7MRO;S<U9O\=,+*B_UY1)7DO:&8M:4 C@
M]7V%M=_\:]2 O-23;3V(ZNW9K55,@(,^ZV%<<_-K&?LWU$7P;4NN^[/^WK'@
MYZZ1Y464ZY@\< @7%Q3Q4G GSG_JVR8E58,F>:$X\E"+-(Z]531USW;-BWF4
MA5PWLL@G:9%;E'G!\,>I6.)$1#4[ZN 8\?S/?FV*V/ ]@=8A90[4'66O%6CL
M+%Q3"[)( $^$GJ2HM#1*;-RER+^C8&4YVEFOZHB5.TI/+L?S?M3QS;7**1F9
MOI=A5LZ:!47D@(GL?;PXH^XRQRIWIL2H\ZZ^P'2ZBU+5A+Q"1A8@CB"DSG02
M+%T<^^D*9(03NB^8-JKZ=*R)!#.;.%DO5U:5SO'@= =S5V?>^IY.NJ.(Z:LN
M:]+I3"I/<5RB87<ML%C+>V,99VW%T^&P;<F;5F1E.7ULB7#;@OL7,48XG*X5
M17/%5HJ^GS1W,[H]S18^_O@T ,ED0(G!3'O'"NQ_U 3^>Z1*+=*_>R#=NF5V
M ]^7%?)O>M875Q>$@<_*&7E2'VMWH."%[9+:OFQ>,"*LF_<NTUA%QPVB\FIP
M,7#> I_7^ZJ=M[]:/>1[55_U:M[M:I1M/!_4U[9>N'TSAOKT>+YT^ZC[6-B/
M[?PW<+0_;?&%\RGN&^MLX4.][-Q&!V)KQ!3/WU1K%]#K)HY^T$'9O Y0"7,@
M-D<=594)5J =WE]D V92$<B.D0'G/]K0,AR,*AM<1R8^*@R;34FQ-FY475K"
MX*B-$&QLHKL*?*6%';8]-7+$KEOIRHU@FPZ*0I_/4GR%,32YLKFXR<1$DW=?
MTWO\"T['F_>SXBDLB)Y3&]-E93O$P;NTPA ;1XTV@^RV1K1/SY^05]9=R$"L
M'1_?^^B^3>'Q$$^H8V@8W45A#7[\Y0WKY"@QT5X!N[%L'5X(&].]*C]^&F4,
MS;@P8P&@NPA)?#Y$FLLQOOY1JUG-FYH6SM)B4&K<*0E5H2:<?P/BELF$RBK^
M,@>]JS(9<DTDKH"17@XP$$WQ 0S117@J3S-BNN9D_O+RTM[X<?W81L*<*:@9
M\KA*):OJ.."O(,UFA^PN$;E2.C-0MYE='<8J??N: Z7(Q/^^67+GI3*Q<JVM
M+R\+19#[!DH.^=J+8"#,=\;ZC,*WT.4XX0&5OWSWI5_W<KT(K!>_\KKJBW:]
MPPJS;;V/X83M/0'GO97>-_K<W&5:7:B#<=' @=L6M!<M]KMF86_9;5SM%<F"
MS:@OY^8>;H_O.[G$:*$>HD6Y\'F)[:>PWUE).*R"U""!O/,1\<EP!I.>?3_X
MWO.[HZ\ 5R+8V7=!GLH5C ?CTS]+9[]D\G08?)EO;W?\!T$_S3+BN\A,8KH.
M:NN"XD,1 HOT_&-;$WRO)QE[].Y"0/M^?6+7I_J$K0NNWK.O2&X:Y^_=^X'K
MM8[V$F)]B97(XJN,C=S:%1OQJ5J, 0Z[3IMJ(TJE7">5*5YP3Z\J"G[.]%PA
M/FC>E-BTJ=YA5X@U-<V6V5&97.5S>^1=Y:UJ&H6-"MZ(EB^(&N?ECS\P&<6$
MU79)XQJA(L]4<P+FLYG>='NT=;_0WAUD.+K$2'=G<$4+J6"U 2ON5(=M**$A
MA#6,5RV\*9=:@Q;5Q>II69342E^%AZ26& +($*JE?^>"+1A8I+%NPM0:)=CX
M[T,KW?MNWZNE&;5*Y12HITM:V/,89!'C\(W]+E&KU(OZ(%_5M^>W\=Z^<[Y^
M"[=95;%'^(N&(YVW;@Z+]\:$\AT%7O[Z@!MR#M@0JC80<E'_H[Z'<RYG\J9"
M!NWZ6K\MERD.:BU24$V-&)CB;<2 0&P0D>P4$=?PO!YMT[7:^&Q=T@>3*H*,
M?'%-M%+CBO_'FL *,Z[+H?@;%6K"7RRZ6TLL/]^\[PLN+N-$IW33@>I2'(R<
M(4\-5=M<D;M,'.!-$8=<,156$H?XY#)5E9!DT]3(W#7@!DQE8^6M+^ OD\1*
M;J)G'",E?053@F\=][<90D3H@^/QD/!RQ$QM8J2S9</005C$6X9+F2!#=QGK
M:0=2<'#%(7Y_J;U,TWBY<GJ?'^VZ! &!(M8KT2B@CB8%F>;]>HO5+=#$?E@:
M XJ^7'NN(R]$OQ8?? VBE1O;SNAD*;I5VNK3ZJ5XC^L:)W1,N<#**7%#D1BI
M+<2)4=E"!(G(GB-%N"H[+,R]RL+<.5F;J#AAN@W_(1!4JWY$''_2,UK/UWF1
MC0#WYB10^M8)'"GDFD2J;K#^L$]I:5L5R6*I+^>>=%?9R'F$FC^YB[^#'C4Y
MZU6QQO8&[L;*4Z/>U%UG@JE:ST/\U11%:B->C<-T,$],;&9+VU\AB@$RUL+.
M]FX-V_%?(]JTN[[\8')YELPT>>:#+^<?S@#/;BA_JXD(6^9R_98I4+[U Q97
M4.I\%&I*GDG#=%J0SD?)'/93T!<N;:9#X*EPUFBKIOYN=9S.U1'<5QG$&J[N
MX'_^]/+YZ:OZR6&[HD6.U#:.V96Q9X!LV#;8\U)^@G6N+UC)V:'Y4HN&5R[Y
MBS<MDZHLN3G?WFL)HQQ $:(3B*84@QTZH%PIXXIO=F?*'.XW+_0"RG+^\<8B
MW(CJ(P:*L-C0/O\!P8]+>=SHK;JZZ_HK=G1XV]JR7O%I8]KFV_TQK6A\'^9)
MF':;63X)SGYS"/MRV 4#:PA+GBQL?7>I*F%%KO57E8I6@L,&B/K,]F5?M=#H
M.AN6J-A)=%^J#0UXY6HP.VA3,7$'[?V)GS2)W^T0OZ58!SEA,:2O>@UN!IL(
M-3K;K^3!8^G(B@ZM6G4T%[;7UPVGVR1='VL+76H#MA+=G7=+ZUM:(O65JFY6
MQDTTWW2?="F6"D&MJSIL:%UW I=4_:G(L]=T= 5]1S59KJ0*42O+0ZR(8ALV
MK(UV&:<3#\@CQ[$7C:D//H7CA*VN^#:ZDDQN)4K NFAC.\ T((4R:$%+))J-
ML,M)P%I _B,BK(ORMA75&12#R/@;H2A>?R-^6J6^-R#J)LXG@P/6KL*TK"*G
MA0W>2-W!-,H)-Q_/SWBF3WMT$IB0OF6[@BH0QA#B*)W^/:()@(:](,/S;LC0
M?5C=8&'EZ,0VM/!$K"#WQ@J?&_?P'M&I7-&^KT$"H@L)G*RY:LJR;=R' E]^
MO-@($F@(-&WMJ^#UKPW06"30](LU=UI A:*PI=*^L+IO]-["]7YH1>P?NL<;
M<,-323<QB]A!^[0;-GP%Z;5][Q_6MY!WS2I?!-H<H(>= 5I\JP MOR9 B[T#
M]*HQMB+TRLV$WVF<[?J%J./&3V\MZ)XM_<!8;F_8VU_AJIY6OV%V9G^ZJQYN
M?P#M"GXS0I")]113AX,?3GOV]RO\A\*D_$->$U,49L%_SK7"/FD WD\-1.8^
M$('JE]W>_C]02P,$%     @ _(%K4ANU P^F @  D@4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&ULC51+;]LP#+[G5Q#&#AL0Q(\\V@1)@*0/;(>B
M08MMAV$'Q:9MH;+D27+3[M>/DAVO&]J@%TFDR$\?29'+@](/ID2T\%0):59!
M:6V]"$.3EE@Q,U(U2KK)E:Z8)5$7H:DULLP[52),HF@65HS+8+WTNIU>+U5C
M!9>XTV":JF+Z>8M"'59!'!P5=[PHK5.$ZV7-"KQ'^[7>:9+"'B7C%4K#E02-
M^2K8Q(OMQ-E[@V\<#^;%&5PD>Z4>G/ E6P61(X0"4^L0&&V/>(%".""B\:O#
M#/HGG>/+\Q']VL=.L>R9P0LEOO/,EJO@/( ,<]8(>Z<.G[&+9^KP4B6,7^'0
MV48!I(VQJNJ<B4'%9;NSIRX/[W%(.H?$\VX?\BPOF67KI58'T,Z:T-S!A^J]
MB1R7KBCW5M,M)S^[GHU@DZ:ZP0RNGJC2!LTRM 3LKL.T ]FV(,D;('$"-TK:
MTL"5S##[%R D1CVMY$AKFYQ$O,1T!.-X"$F41"?PQGV88X\W?@/O5A=,\M_,
M_80A7"AIE. 9:S^&S&"GT:"TK4+E<,TEDREG NY)B?0+K8$?F[VQFO[1SQ.,
M)CVCB6<T>8/1>[)^$L&UZ\+4+,554#OZ^A&#U^K9*_"H8!HA556MN2$UA6M+
MA%P)ZE NB\%'+DFC&D.9,9\6 RH&5GO4KB #5Q"J2CP?[+3*T;CNI#3E2+@?
M()DGM,;3>+!#;924**AU!:4P@[/I#&;GX\%M8PW/$!QGIM/2%R##1QH0M4LT
MN%!X2GAGLPF<3\F#^&F(Z9LEXV3P?SA#D#2\Z-7A/)FT>SR'UTH4ONB3"G7A
MIX&A5#32MBW3:_N!LVG[[*]Y.ZUNF"ZX-" P)]=H=#8-0+<3H!6LJGW7[96E
M'O;'DH8F:F= ][E2]BBX!_HQO/X#4$L#!!0    ( /R!:U)=FA(<, H  #L<
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*U976_;.!9]UZ\@C!0S
M!53'EO-9) '2=&:WBV;':#H[#XM]H"7:YE0259**D_WU>^ZE),NQXWJ !9K:
MDLG[>>ZYE]+5RMAO;JF4%T]%7KKKP=+[ZOWQL4N7JI!N:"I5XI>YL87TN+2+
M8U=9)3/>5.3'R6AT=EQ(70YNKOC>U-Y<F=KGNE13*UQ=%-(^?U"Y65T/QH/V
MQA>]6'JZ<7QS5<F%>E#^]VIJ<77<2<ETH4JG32FLFE\/;L?O/YS0>E[P+ZU6
MKO==D"<S8[[1Q:?L>C B@U2N4D\2)#X>U9W*<Q($,[XW,@>=2MK8_]Y*_Y5]
MAR\SZ=2=R?_0F5]>#RX&(E-S6>?^BUG]737^G)*\U.2._Q>KL/;D<B#2VGE3
M-)MA0:'+\"F?FCCT-ER,7MF0-!L2MCLH8BL_2B]OKJQ9"4NK(8V^L*N\&\;I
MDI+RX"U^U=CG;\Z'XJ.:^:MC#V%TZSAM-GX(&Y-7-HX3<6]*OW3BES)3V::
M8UC1F9*TIGQ(]DK\J-*AF(QCD8R2T1YYD\ZU"<N;O"+O#VFM+#T,?*JTU>5"
MW$N;+DG\)!9?\1L0+A+Q[WM5S)3]SQZ5)YW*$U9Y\JH+NT.Y=Q?5W7M7R51=
M#U!83ME'-6@3(^Y,^:BLU[-<B7\:KQQNIVPPQVGK=R'+3$RM?I1>1=,<4E%"
M7OQ6KO>-FQC'PB, =Z:H9/DLL$I9E46Z]$9(\:#2VFJOH7!:(VQ OKA=6!7$
M_4P[!Y\U=.U=.'@+//NEX)5_R\U,YN+6.9#-O2Q1]"SLTZ<X^OSYKA'Z"?X
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M:\;^>;<T5B,:_O4*9C9@9@XS.X/YO;9[%842[ZW9\%S<C)!91NBM&)WS#'M
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MUJK:/9:"HSK2 >ROE++]'V(PO,:\_0]02P,$%     @ _(%K4B#/,]']"P
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M-/)BN'H^:[$[6%% 1B@$%31%32OYP<'/S0N9=#Z^9XZGPR7F!PG4ST_,<[&
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M,V@TI^:[,H>= )J8QIV6H:,_:H7PP2&)S&BQCZ'%"VBYA\H#C7-_@L0N"LK
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M$)<G8'QA;=B]L('V3R9W_P502P,$%     @ _(%K4LS*(A_; P  +0D  !D
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MU\;3> U+[EEH^0'=%\;XPX85]%](J[\!4$L#!!0    ( /R!:U*I#84W P0
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M&]/VJZL;6O5BU=+?BF;*TAW+-W.ZU*)V ^C[7!'V^L4Y:*[)D_\ 4$L#!!0
M   ( /R!:U+P-E4?M0(  *$%   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;(U42V_;, R^YU<0Q@XM$-2Q\V@3) &2/K =B@;-'H=A!\6F;:&RY$ER
MT^[7CY(=K^O:8!=+HLE/'_F)G.^5?C %HH6G4DBS" IKJUD8FJ3 DIDS5:&D
M/YG2);-TU'EH*HTL]4&E"./!8!*6C,M@.?>VC5[.56T%E[C18.JR9/IYC4+M
M%T$4' SW/"^L,X3+><5RW*+]4FTTG<(.)>4E2L.5!(W9(EA%L_7(^7N'KQSW
MYL4>7"8[I1[<X5.Z" :.$ I,K$-@M#SB)0KA@(C&SQ8SZ*YT@2_W!_0;GSOE
MLF,&+Y7XQE-;+(*+ %+,6"WLO=I_Q#:?L<-+E##^"_O6=Q! 4ANKRC:8&)1<
M-BM[:NOP/P%Q&Q![WLU%GN45LVPYUVH/VGD3FMOX5'TTD>/2B;*UFOYRBK/+
M59+H&E.X?B*9#1HX^<QV LWI/+0$[YS"I(5:-U#Q.U!1#+=*VL+ M4PQ_1L@
M)%X=N?A ;AT?1;S"Y R&41_B03PX@C?LDAUZO.$[>'<Z9Y+_8NX]].%22:,$
M3UGS/&0*&XT&I6T,*H,;+IE,.!.P)2/26[0&OJ]VQFIZ33^.,!IUC$:>T>@=
M1EMJLK06Z&Y[+<5;"AQ%<PT\,Q5+<!%4+A7]B,&_"A\,># PC9"HLM+<D)F8
MV (A4X(:ELN\=\(E651MJ$3F=-8C5;#<H7;*])PR)$\T[6VTRM"X9J5Z94BX
M'R">QO2-QE%O@]HH*5%0)PNJ90KGXPE,+H:]N]H:GB(XPDPGA5<BQ4>:%Y6K
M.+@\>$)XYY,17(PI@OAIB.B]Q<.X]SJ=/DB:971K?QJ/FC6:PEM:A2_:ID2=
M^^%@J!2UM$T'==9N_JR:MOOCW@RO6Z9S+@T(S"AT<'8^#D W Z$Y6%7Y)MPI
M2RWMMP7-4-3.@?YG2MG#P5W03>7E;U!+ P04    " #\@6M2WG+," D#  "$
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R%5=U/VS 0?\]?<8HF
M#:0NWVT#:BL5QC2DH2'8QL.T!S>Y-A:)W=D.A?]^9R?-8*+LH8T_[O=Q%_LR
MVTEUKRM$ X]-+?3<KXS9GH:A+BILF [D%@7MK*5JF*&IVH1ZJY"5#M3481)%
MD[!A7/B+F5N[5HN9;$W-!5XKT&W3,/5TAK7<S?W8WR_<\$UE[$*XF&W9!F_1
M?-]>*YJ% TO)&Q2:2P$*UW-_&9^>93;>!?S@N-//QF S64EY;R>7Y=R/K"&L
ML3"6@='C <^QKBT1V?C=<_J#I 4^'^_9/[G<*9<5TW@NZSM>FFKNYSZ4N&9M
M;6[D[C/V^8PM7R%K[?YAU\6FD0]%JXUL>C Y:+CHGNRQK\,S0'X(D/2 Q/GN
MA)S+C\RPQ4S)'2@;36QVX%)U:#+'A7TIMT;1+B><6=P:6=Q7LBY1Z?=P\;OE
MY@F.OK%5C?IX%AJ2L(%AT=.==73) ;HX@2LI3*7A0I18OB0(R=M@,-D;/$O>
M9/R(10!I/((D2J(W^-(AX=3QI0?X^A1_+E?:*#H3O][@S ;.S'%FAXK8G6B0
M:[AC2C%A8&E/&PF]5L(WR>PM/-5;5N#<IVNF43V@OUCN;XW5V/4:K-> LE5<
M;,!4Z#TA4X"V]D"5PV:%:J@>< U,PUK6=!4U''%!$-EJ)DI]?.K=N1.,Y3"
MY0,JNIE>_X0;M-><I+R+1U0%UPCG]+9M&5M6PQ>^1J\O@(9KQ0MT(M:3/O:^
MMD8;TK)6F?G77IS#!WA'OP_>4E.R)$_0*U0;"LG2*>TE43 ^@308>Y<400'Q
M=)3E,>U$099 %L2#KQ*.XFR4IMFQVTWCE^K:EO%? T0]&N<9 =(@G]!?NM>9
MC"99[HCR[(7$>,\?>>=,%-1;W')B5^,\B*+_R])KB:-1-)E8"/%3&H.&O84'
M4>DHBZ?.[/0$DF *KQWD\%EG:&PM;?_34,A6F*Y)#*M#BUUVG>5O>->?KYC:
M<*&AQC5!HV Z]D%U/:^;&+EU?68E#74M-ZSH,X'*!M#^6DJSGUB!X<.S^ -0
M2P,$%     @ _(%K4@85#?.5!   P@H  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&ULE59M;^)&$/[N7S&R#C61PHL-.'%$D,A+KR?U=%&2YE15_;#8
M ZQB>^GN&D)_?6?6QN=>"+U^P(S7\S[/S,YDJ_2+62%:>,VSPESY*VO7E_V^
M25:8"]-3:RSHRT+I7%AZU<N^66L4J1/*LWXX&$3]7,C"GT[<V;V>3E1I,UG@
MO093YKG0NVO,U/;*#_S]P8-<KBP?]*>3M5CB(]K?UO>:WOJ-EE3F6!BI"M"X
MN/)GP>5UQ/R.X5GBUK1HX$CF2KWPRZ?TRA^P0YAA8EF#H+\-WF"6L2)RXZ]:
MI]^89,$VO=?^LXN=8ID+@S<J^RI3N[KR+WQ(<2'*S#ZH[2]8QS-F?8G*C'O"
MMN(=ASXDI;$JKX7)@UP6U;]XK?/0$K@8O",0U@*A\[LRY+R\%59,)UIM03,W
M:6/"A>JDR3E9<%$>K::ODN3L]-&JY*7+<:5PHW*JM1$N72=/8IZA.9WT+9EA
MYGY2J[RN5(;OJ Q"^*P*NS)P5Z28_EM!G_QKG SW3EZ'1S7>8M*#87 &X2 <
M'-$W;((>.GW#]X)>"8UUT/=B1QBS,--:%$MT]!^SN;&: //G$6.CQMC(&1N]
M9XSZ*"TS!+6 9Y&557IGAMI@S:0!:BUP=8 OU<FAG!\UPJU[:=8BP2N?>M.@
MWJ _?5HAZ<ZH[V2Q!-&RN$6-4'+XLB ,6]0$+6+R+(L(J6%#GCJ7^<0XYU0M
MO*1$61)-2\UZF6&'0AM +C=0L3"?HVX*!J)(B0CB2^]WXJM0 =]([ZW$=R=!
M[#U(\])=:$3RF-Q%8T$+BS#H#3O=H'?>@: 7=;HA/;QGE5&2,VEW$ QB^AS$
MG3TU['BW<B-3\A5V$K,4NM#AGW?WNJ9)09YQ-N#$A70*X^XY_[ROKKTQ[8H-
M:II6[2Q]("_B<_HC/R(X IEQ YGQ<<A4$Y+3W\8%S'B$45B'\'%4XV%\S/:C
MF VU:US-2LY?56-O7^-W2RP-X:L&FX$30I5=J=)0Y<WI99,\:(@G947FS>I<
M[O\?D*\1!M5LN=2XI )[50+N7E$GTB#-J,)U9BDR^$2DI.LA\>J^@7LM$X1?
MY0*=#W4-N>O0^U):8\FAJA<XY#<H@W$84AGC7G!!CP&18>!]K.$^.HO"$94X
MB.C;T-M[Q #J>C>B2.AFH;>3,#HEKCBBT_\V2:D;G_&3P4,8BGOL0' 61['W
M3" GA=P]V&!3P8:Q?U ;J1F.ARP?]D9C..^-B!Z%>U=YGO\OP6-0CAHH1S\\
M_:J[YOKM7<.M5Q@\!.NCVG]D[%D7=@5T^3<:-Z^L@Y]IW7U)VQ^L_*&EP]#E
MSEH66N5@6M>&V J=&N)(E$ZK.<J*.2Q1['XRI+ P*I.IX+(1"JR[6ESV::/2
MSI#QON^4UH!LU\AS-:H&(84I=+)RN$AQ0VO5VEU:'V 8<]V"X,+[B 69R!R/
M2'FV\WW&^P]A*QI3N4>!1^@^&XQ<J<?QP5KW6WM%CGKIMB<.K2QLM6(TI\V"
M-JOVDF_LU7;W6>@E]2IDN"#10>^<YI6N-J;JQ:JUVU+FRM+.X\@5+9FHF8&^
M+Y2R^Q<VT*RMTW\ 4$L#!!0    ( /R!:U)@A!)O1@0  % *   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;)56VV[C-A!]UU<,A"UJ XZNMN,$M@$[
MV44#=-L@R;8HBC[0TL@F(I$N2<5QO[Y#2E&\&\?;/MCB9>;,[0S)Z4ZJ1[U!
M-/!<E4+/_(TQV\LPU-D&*Z8#N45!.X54%3,T5>M0;Q6RW"E599A$T3BL&!?^
M?.K6;M5\*FM3<H&W"G1=54SMEUC*W<R/_9>%.[[>&+L0SJ=;ML9[-%^VMXIF
M88>2\PJ%YE* PF+F+^++Y=C*.X'?..[TP1AL)"LI'^WD)I_YD74(2\R,16#T
M><(K+$L+1&[\W6+ZG4FK>#A^0?_D8J=85DSCE2Q_Y[G9S/R)#SD6K"[-G=S]
MA&T\(XN7R5*[?]@ULL.A#UFMC:Q:9?*@XJ+YLN<V#P<*D^@=A:152)S?C2'G
MY34S;#Y5<@?*2A.:';A0G38YQX4MRKU1M,M)S\QO1"8KA ?VC!IZ#VQ5HNY/
M0T/05B#,6IAE Y.\ Q,G\%D*L]'P4>28?PT0DD^=8\F+8\OD).(U9@&D\0"2
M*(E.X*5=H*G#2[\;*%QSG952UPKAS\5*&T74^.N$B6%G8NA,#-\Q<4\=D]<E
M@BS@&@M4"G-G<*$U&GTLJR<!;4->ZBW+<.93QVE43^C/.V1#R,PA0R:I2[2Q
MALT&H9 E-1L7:Z_'!:W(6C.1Z_ZE1UG%:H7*9M:SF:7TQA?>+]3]U.>*&5)R
MP)0?@F5*[:GQ=TSE&CY /!HD24J#T6"<)MXBRU1-CN S'1&:^#,>0SJ<>/=&
M9H]GME=R\JRRF\RUX"B)83*D?:8,U%O:))_C9)"2'\/!)!I[#]*PTG;5-R%"
M,AG$:01Q-)B<1][/2-X]L;)N<)D-EXD,H=?(]:'72/9=:$?P/L"9^YTH^Z@K
M^^ADV>^0TI_QDC?.4 V^"$5K:\'_:0FP1($%/TZ!D^#'*;  ]<:FK?L5)9N)
M_8\:Z@,//!OUJO6 N*&<[!Z9TH"V6^&0%:[?@.CBF#$ 1EW"=$LI.B*^(=0?
M!-/T/+S#K26NN1"65RM6NB(UN3^/)][5AHDU F%F-15(&" 2<IG#5FIN(],D
M>G8@MJ5==4RH1W!]CQQY:^ADD<==D<?_L\@'!\K'HD!WN\ =,WBLR"?!CQ?Y
M@8KTMLR\L6K<>6V;JS94X5J[OB4-;9BIC51[(B&G+:!F,R3ZJ@?4Y>@*;.6W
M2CYQ=\/V6HKT'46^LO,]SG@G.?-?2/()<SI]R@/W.T^3.(C@A_;CN7"<J5)F
MI. <'(! =_@5+4P;"L1QD)#N.#@GU5ND6UQ8DE%B*J(R(?9IMW?AOEYWL#JS
MF>.<ABB(2>:,]G^E%"@8702I58J"U"J]4O/H<701!6-G(YX$0RM_\UJ'8ZD_
M:VP=96QX<,M7J-;N+6-)4 O37/C=:O=<6C2OA%?QYJWUF2EJ2@TE%J0:!>=T
M"*GF_=),C-RZ-\-*&GJ!N.&&GGRHK #M%U*:EXDUT#TBY_\"4$L#!!0    (
M /R!:U(]5ZL@E@,  .82   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;,V836_;.!"&_PHA]- ":212\E=A&TAB%"V0=H-XVQX6>V#DL4U4(KTD9;>+
M_?%+2HHH);+B&#[X$HO2O*.9>>Q7"L<[(7^J-8!&O]*$JXFWUGKSP?=5O(:4
MJDNQ 6ZN+(5,J39+N?+51@)=Y*(T\4D0]/V4,NY-Q_FY.SD=BTPGC,.=1"I+
M4RI_7T,B=A,/>X\G[MEJK>T)?SK>T!7,07_;W$FS\JLL"Y8"5TQP)&$Y\:[P
MAQD96$$>\9W!3M6.D6WE08B?=O%Y,?$"6Q$D$&N;@IJ/+=Q DMA,IHY_RJ1>
M=4\KK!\_9O^8-V^:>: *;D3R@RWT>N(-/;2 )<T2?2]VGZ!LJ&?SQ2)1^5^T
M*V,##\69TB(MQ::"E/'BD_XJ!U$3X&B/@)0"<J@@+ 7AH8*H%$3Y9(I6\CG,
MJ*;3L10[)&VTR68/\F'F:M,^XY;[7$MSE1F=GOXA5Y2S?VD!@2_0O/@"(+%$
M<[;B;,EBRC6ZBF.1<<WX"MV)A,4,%'J//E(FT7>:9("NE *M\A2WC#ZPA&D;
M<P]Q)J6575/%%'H[ TU9HMX9];?Y#+U]\PZ]08RC/]<B4T:MQKXV?=GJ_+CL
MX;KH@>SI80;Q)0KQ!2(!"5KD-P?+\:A%/CM</FS*?0.C(D(J(B3/%^[)YV9Z
ML6^H7X"J3,("&69NP#;JJ^#RR<3_NC4W0)\UI.KOCO+"JKPP+R_:4]X-5>L+
M1#5:VCJWMLXV8D6289[$>L]VBGO]/AG[VSJ8EJB ]'$S:O8\*G*)&DU$51-1
M9Q/U&5<#[!A.K\K;.T=V_:J\_BG8%4D&+[!KB6JP:U0XJ"H<=%9X"UM($$;_
MH=<B&E9W&)XCHE%5WN@4B$8'(6J)VH\(!^Z1$1P B1P!"=<>2_@<,6'GTIB<
M E29I<X@>$*I,Z19G3-IW.W2!:+P&$3.0W%TEHB<&>/>21#U7D;4%=*LSGDQ
M[C;C'U1*^V9U!"+GIGAPEHB<&>-A]_?457((J6&+H3USO9:H43_<@\OY,NXV
M9H?K^&<4<19+@G,$1YP_$WQ"<&6RKI]89TBSR-J;=+='/V5VS".+.,\EX5DR
M<X9-NM]Z7\DL>IE95TBS2&?:I-NTGS([YAE&G F3_EDR<PY.7G@A?AVS0<L_
M5,\,LB7JN4'ZM3T%NP/TA<H5XPHEL#2JX')@,,IB4Z58:+')MQD>A-8BS0_7
M0!<@;8"YOA1"/R[LSD6UM37]'U!+ P04    " #\@6M2K%B$#9H#  "H#0
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MA,:9=J>Q6X5N^^<>9O:>Z9I+0P14%AK/KJ\BHL,<! -5YWMOK]!VLE\V]ND
M[1SL>:44'@T78'J,\K]02P,$%     @ _(%K4A/^FXMS @  :@4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S N>&ULC53+;MLP$/R5A9!# C21+#F/!K8
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M* Q8-(R&O]V]8>=G%QUD1UX-(R([/J8&KK?@9+$ B5=LK;(=TZ02S1,1L*4
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M!BLZQ6(M@LAM(TC\R^#[;%:I#0I+H B!F_V7X7TZC!MGU^J.Z'NM5>B@)%4
M:F&=J&$=:J";RVMF=JJK\YO5C6J=%/;H?/DGSERP8''^C6,"-!30-5 GX4'=
MG5<Y6@N[9VL5+W"%1BN$+ YNML:C<-AQN165H[BH>X9&.@AGIV9[4=E,1MW-
MY'-Q\029(N9PG'-JLI>RMU]S:9[8&QP@R27-[0["JG.-KT D%KN_\/5: 3#\
MD^_V_X)#^Y1;<1"@W:3@O%=;>;K,@(HS<=,S.U4021*XVE;N;.D-?Z.8*LLW
M34ZL",45-7!KIU-G$PJ&(B!L@/79;UCNTO&&K.$BKE,#0>-$'*S S](D-H)X
MI5*V/<-:/L(KY29!H^/3#))2<,1@-TMQ2)![/CM9Z[,WML[#E3B-8K;(\3>@
M]DJ\Z234#H5!N)@%T]FT.!.KEN:54J.5B/I3?T79+%).,'IJ)*USO;?,VSX,
M%)SF65[I;9ZI$Y]WNE>A_65*D]N6PA)Y<!Y2N4^>G;X[B,I)4-0]PO'=P_@D
MQ)3CA:A[O/!LB.DF4^UMQH6Q[CZ_(\K7V!&#7?#>!2<!+7-=HWBJ>>6JO,@7
MH&8 )VF57K^.?5<\(V(\0*<IED\ +I#^-J[SA$XWW6C+2)F_2CIE$H45S>0I
M=SLXV+HQ,(P%NG7;]T)M@#@-J[LEL7S^#$Z3Q@0U=60[<8T20#&XLG/3.D83
MQ[[3H'%>. ^P3Z'$2PH @0*O^,*_*Y<OE?[&<MG62?;90<W4QB:J]UQ>'%S9
MN"W>3@=W.%$PFHT!4**Z)1J&L G ?2MA!^(UED1QS4O%5C'7]59RJQ1^585;
MW#P8F]-H$8R'L^?54BC5N2RE]/<<2NQA-\*[0U5_$H\!3Q2>-)Z.@LGQ;T4J
M8Z/:3<39N(^-9*6,XJL_ 1 M:.FB,B7C*B'][3:@'YQR7;D; 5_* $A1]M2
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M2%]!NB_M%@#30=X5I'P-:#<4&?]'0)%-8^S (G\I1'%<>[U>3->UZ<V)F7V
MQ+Z^KORV?#OCA7DGX<;W+^FMC>:U?=4R]I6/-W"H$M$G$@LL.1X]G@WL.TC\
MAUREYB5^<Y7G*C9_K@3']FD ?E\H2-)]( +ENRQ?_#]02P,$%     @ _(%K
M4DW@@.2. @  X 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC55=
M;YLP%/TK%NI#*W4E0("T(DAMLFE[F!:UZ_8P[<&!2[!J;&:;I/WWLPU!:2!1
M7\ ?]YQ[SL6^)#LN7F0)H-!K19F<.Z52]9WKRJR$"LL;7@/3.P47%59Z*C:N
MK 7@W((JZOJ32>16F# G3>S:2J0);Q0E#%8"R::JL'A[ ,IW<\=S]@N/9%,J
ML^"F28TW\ 3JN5X)/7-[EIQ4P"3A# DHYLZ]=[>(3;P-^$5@)P_&R#A9<_YB
M)M_RN3,Q@H!"I@P#UJ\M+(!20Z1E_.LXG3ZE 1Z.]^Q?K'?M98TE+#C]37)5
MSIV9@W(H<$/5(]]]A<Y/:/@R3J5]HET;&^J,62,5KSJPGE>$M6_\VM7A .!-
M3P#\#N!_%!!T@, :;9596TNL<)H(OD/"1&LV,["UL6CMAC#S%9^4T+M$XU1Z
MGV6B@1Q]?M7G0H)$ETM0F- K] D]/RW1Y<45ND"$H9\E;R1FN4Q<I?,:M)MU
M.1[:'/Z)'$O(;E#@72-_XD]&X(L/P[W;]W!7N^TM^[UEW_(%)_A6^ VOJ;:J
MW2#K'U.)_MROI1+Z5/T]DR+H4P0VQ?14"L$+D.:D8XH*@-&BM10S2V$NVS;U
M;_W$W1Y69ACCA5X?\T[;M-<V/:\-A.2, =67D&(%^9BVEB(^R!N'T9&V84PT
M"\:UA;VV\*RV'XV2) >M3 (666D_40Y;W6QJW3H4DB"V)!NO9SC4'$V/- ]C
M9N$)S5&O.3JO694@QO1$@UR>=_Q]AS%^X(_KB7L]\5D]^QL-W8V^1@S4F+YX
M>+9N_>."C0696_A.H7O0?TSO_X[%AC")*!0:-KF)==E%VT_;B>*U;4EKKG2#
ML\-2_X) F "]7W"N]A/3Y?J?6OH?4$L#!!0    ( /R!:U(7N9=//@L  '4@
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;+5:^W/;-A+^5S":9&K/
ML+)$.7[TDLPX3GOGFZ3QQ.WU9XB$)+0DP0*@9=U??]\NP(=D678?-Q/;? "+
MW6^_?0#,V[6QO[F54EX\E$7EWHU6WM??G9RX;*5*Z<:F5A7>+(PMI<>M79ZX
MVBJ9\Z2R.$DGD[.34NIJ]/XM/[NU[]^:QA>Z4K=6N*8LI=U\4(59OQM-1^V#
MKWJY\O3@Y/W;6B[5G?(_U[<6=R>=E%R7JG+:5,*JQ;O1U?2[#Z<TG@?\1ZNU
M&UP+LF1NS&]T<Y._&TU((56HS),$B3_WZEH5!0F"&K]'F:-N29HXO&ZE_\"V
MPY:Y=.K:%+_HW*_>C2Y&(E<+V13^JUG_2T5[WI"\S!2.?XMU&'MZ-A)9X[PI
MXV1H4.HJ_)4/$8?!A(O)$Q/2."%EO<-"K.5'Z>7[M]:LA:71D$87;"K/AG*Z
M(J?<>8NW&O/\^X]J[L71C]):2? <BZ./RDM=N..W)Q[R:=1)%F5]"++2)V1-
M4_'95'[EQ/=5KO)M 2=0K-,N;;7[D!Z4^%%E8S&;)B*=I),#\F:=M3.6-WM"
MWHUSC:PR);XLQ+4I2]#BSIOL-W%5Y>(7 J'R+A%W*VF5.[#>:;?>*:]W>@#=
M1'Q4+K.Z)A;N _6PB"\5YF>JG"LKIA&)1/B5(@-J66V$JKRR*A>Z\D9(<:>R
MQFJOE1.WC<U6H*RX6EJE$$IP-<T<?=*P]^# T3&(Z%>"1_ZS,'-9B"OGD"4^
MRPK1RL)N;A+QZ=-U%'I3W2OPU6)JW5@"V@MHM%[I;)4(";"7PF"DA?:Z6@)G
M\ZQM&@Z#:1)*.%/D)(]>MTLE,!HFUU;?2Z]$7<@L:.;A22<Y\'F,>H!]U5()
MI#&64,L-#YQOM@0*LQ"OII-D,@D_XFAZC 4R@_?6ZWF!F=:44,O8C:@,%@W&
M_XA+&$[JX-\2,"Y9(ZNK3-< #_8W6(_EIZW\./FV&W7%HT;'28 -/B@*,5?2
M8BUR,!SM/,.!A-18M0_"-$K]3".TWP@D!D4B:=I1>BPNS]_PXHYI3BH-(/_&
MP5J.#$>1,197M!Y00BH&>@6R.)PG_MU4JEUP&D0O $P81EZBOW,%N!5+WU(F
MV<8<>L#*E;P/0PU'"@F)L//ZM;'\.&J+G^I;%!GGL30IM(MA.Y <$T*C-W=H
MH) ^, A9H58VC IN&I^! *Z9_XH*0NK(_%<D9*8-T2A,=W6A*6=8!5410=M/
MPUVN[W6NJMP%(NM2%_#H@*,NNNR:#>:"=TL:C8['=$&<-;N0#\.$:=(!:*D2
MT0R4:?!<-#7=./W@-]_B-ROAU^9;A*&%3K ZX]1P=I:>S%X?_SF(.5N I.@6
M9.$W8X'$!;WE IR%ZL7F+ZC^E[7YAUB9-3D(R6"QG3P?8+UVX(5K$&]A678Q
MJ[+#U&UE'Q.U55=;0.U7R*4,MJE4 +O'>C:;#K&.V<&OI-]6C[H7-P"D>[]-
ME+&XZWF:0149DIYB%=T>R.< 6_W>:*H<F)/C K.1W#*E0 H.9AH,_CN,(Z5S
MZA46ND(%I?PMCN" HF%G8)2QN$)PYSPNV<J9/!/XE4!# D@-.F!AE!H94JI:
M*$N:A'B9-[ZK%$BG=5N=$+1JTPG+9*T]W%\H>F?FA4;*Y6"B/,[34;PP6.65
M<@XWJ'>A4 ;WL<)(XYEI*'+ABGGC-(T])D@"X"VE$M%4!8E92_1)^:/"09D_
MOZ?F8BP^J*6N*L(%_N&PO1Q2/S*TX*( A/ZKN$01WY2JR$J_ D"Z M>+@LCH
M!%P 4V,L_-X8E.U ^2-]_,?C(XDIB<TXTE%$U7 9P;@RM'%645M/PC!?%X\3
M.:I#;P6#WQ96%[/ZG$LM>QD%7+%9\)Q#1U 7#1*B2%^3_TO=E&,AMKJ=\V>[
MG1!B#HZR5&U=W]%TG)%M1^-"4FB#0V89Q&C/HH(/';F+^ X(O8;VP<5.4DE3
MMH2VCI\\WS[%?#ZP1=S=7CFJPH]ZHRWSJ,OACN5@3^->U-3L-W&QW:%PI4NF
MLXMDDLZXWSG0[+@]=A&?W(M;GV1V]B8Y2R_^7(,3&)'VK<RN*5/T;I=OS@:U
M'F5XIZ'9XMC%\QTU!390!.RPY2#% L/D7G+]'[EU0=P:$1B@CC=+Q;F/=:&1
MNR1,HH"[/K,?7.^/L/;OZ,7W@@?NI&>7R>Q\]I*>_$5<G('OZ>GYGV/BQ5:K
M/?0%[P1>X@L.G$"\H2]B//4<3\^2]&SVPF[])[Q[L6-#*_/WL#+HZ[>79UM>
MO@H-1Q%@(UIJH2U17'![;U9JT*B$#=OX4J"I+J@ A6T() P)PJPP"W098>=)
M(FCF9/RFFTC)HCT?R(SS+J#I#3492VM0^[M5UV"'@"4FXXXGUN7=%4._O[7;
MB!O:!HU)(/^@/M'I$C6+]%Q;6%[PF8Q82-S=RZ)14:4!-F99H7\ .J!NI18Z
M [Y1#^X.%RJ0-]<N"\ROGE"5"D,- Q\T^$Z%&N!,6W#&P2G/2]$P0U''T+8V
M#$X73NH!';FC9LK1()*AX!4^FNM'E8@: R3N(T9$DI;XCY9$#\+*=Z$UVSI)
MZ$-_+@OV[5."Q+![:LG<5+TA+[)^!\/I;'S>,8R$OCKM4:5=HZN#]06V3#<[
M, T=S&SHJ=;ILI:/UIR,TSX:8H[=4&)3="SW&"@*N>N!+2%JQ0\42)_1 J<3
M9"NL^R7SAN;A_F+O,<UC0(;;VH%PVM?^Q.0_E*'[C<Y0+S+X53J>]2"VOMHS
MEL(T;T@;0?#%#<455BO$;$+F3R]#=L:NO"X&'(P;+1L;BXO7?#H@JXKZU)_V
MK@8GA*:ZW<9M@@+#DPPZ;.AYA(9E\IJV*RG^Y I.S^.NH:6]8P\JF:T8T80&
MO[H<GT](*B>^:7]LL<NG)_1DI3)IK:;$X0?YY>GT4@U//T)FHOB%95S+7;NI
M>KQ:+SUDW! %T\DEQIO&T5W>V#8;'.(ISR2//;+SIB*$JWC2WU7;K#"<9B*7
M/BN[I". _7KR=J2I:JGSG@4!JC"V;0BGYVF27IR^X#R)[&5?D=-V? 6M;V]O
MQ2<#:*DEI4 [W=>,TL9/+\A5Q 2"H"^)HC!A?]SU9C3S5FZRE8(JMQ:6!4QP
MN;2R3%@WOA1,>/)GOYO]>7PW%G<E;=P^Q*VPN,I+[ &=MV%_UU>N:V/1$M]K
M"]RN--J=KZK0:A'B\7N AIXL:YN&C;C*T".$8X6!385B>?$<E #A!]3_!'.?
MR1&[Z1;]W.!<-0+<IIL.<&KSW%:L2['0#Y1FVXW$>#*(^*3GU$);S*!CM+A)
MIK:A%93'<XP$/0_M;;O"M3;,;!? T40TWDG$L^UE(^G3@_HCG@@F/94W.U.U
M&QYA M,EJ,/B>D\>((QH:E,-^?B-XW,CLC;233UX-3R[ZI;NNB4Z46U<*%YT
MIA++&Q\]EMH/"'B0NOUQ$X184Q2A3:.CIGO>KUG2@SMVE.RE7&Z?"H5>+(QL
MO"Z(E-UI17<X%!6)UFXG1/(SG>+2KK"NP3>BZ!#27?"9-3%71;B<ZI1H8< B
MCY$DST-Z+>U>GZ(8="L_?[I'H'<DC?[LI#'[G^)]V\ J/O-KL_S"-!:6(8RM
M#R=&(6\-V%@-LFB'\F/=5M8TRQ!997NRE,NPA0N]1YK&/IRKX2X4L>:R)\+G
M4CK14_>\' ;'#[0]=_9_B6JWH'$XGLPM%UV(L*J&%7@[X-$Z?"O4L<77%7;
M6#-KEPXJ]^S;/D_LM"_Q8,X[7E4HR_U=%V\F8T;&CA6#6?+ IO&^#Y0G@T_!
M)=4[^N!-FT3DAO!5N'O:?5._"I^2^^'A@_QG"7K!WD(M,'4R/G\S"H?B[8TW
M-7]8GAL/W/ERI222"@W ^X5!#,<;6J#[GP;O_P=02P,$%     @ _(%K4H3\
M_T,7!   3A   !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULI5AA;YLZ
M%/TK%IKT5FD+V)! IB12FO9IDU:M:O36SPXX":K!F6V:]M_/-@22$0S3^Q+
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M CZF>56BFVLU*K%#@ZWW_.O"'T>!YZG\O9ZGKCVOF7%!>US3'EMI+U4^,I(
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MN3QM(<6C?R]BW)%6!"8I$^3; V1S4*[]>%-[NSF/ Q(&C18&S@0@C0P)E#N
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M7&&["\HNP/<+*<U^8!W4#?3P7U!+ P04    " #\@6M2N3/'HEP#  !U#
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M5$9<'NJH:G+#Q+)*PVX2?GQ!.O+90*%_>L1T&S%=)Z9[0,P5UW=',P5 >&D
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M\FH$5AO)-F:*K)A4,\DL,_79 %P'J/MKQN1AHQ_0?(A$_P!02P,$%     @
M_(%K4O>ZJ$WG @  7 @  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
MC99M;]HP$,>_BA7U12NMS1,DH0J1*&A:I6VJ2KN]F/;") =8=>+,=H!^^YT3
MB"A):=^ '^[N_[O#9Q-OA7Q1:P!-=CDOU-A::UW>VK9*UY!3=2-**'!G*61.
M-4[ERE:E!)K53CFW/<<)[)RRPDKB>NU!)K&H-&<%/$BBJCRG\O4.N-B.+=<Z
M+#RRU5J;!3N)2[J".>CG\D'BS&ZC9"R'0C%1$ G+L35Q;Z<C8U\;_&*P54=C
M8C)9"/%B)O?9V'(,$'!(M8E \6L#4^#<!$*,?_N85BMI'(_'A^A?Z]PQEP55
M,!7\-\OT>FQ%%LE@22NN'\7V&^SS&9IXJ>"J_B3;QC9T+))62HM\[XP$.2N:
M;[K;U^'(P1V\X^#M';S/.OA[![].M"&KTYI139-8BBV1QAJCF4%=F]H;LV&%
M^17G6N(N0S^=W!>IR($\T1TH<DUFL 0I(3,+9*(4:$4N9Z IX^H*]Y_G,W)Y
M<44N""O(TUI4BA:9BFV-*":@G>YE[QI9[QW9&:0WQ'>_$,_QG![WZ:?=W=%;
M=QL+T%;!:ZO@U?'\#ZM 9DRE7*A* ODS62@M\:#]/2/AMQ)^+3%X1^(G=B3V
MGJ2:%2NB40E5%,'RD9263%/>+*14RE?LSBV5_85M9*):QO3H)G&'GN?']N:X
M?EVK8>![K=&;% 9M"H.S*4S25%9X-F"'=XB"7KHF0GBD&P0G:%T3?Q#UDPU;
MLN%9LKD6Z<NU:6>LIL@-'C6W1!_AL",_]-P3Q*Y--.@G#%K"X -"*C6I2L13
MN@\KZ$BZGF]ZXPU8UVH0.4$_6MBBA6?1GH0Y?-FA\\W1I*;S^RC#CKX7N?XI
M9=?*=:+0Z<>,6LSH+.9WP.[84%[1YO[G^ #1(H4^S*@#<-W'V6-V!G34@HX^
M[/3/57/4:=)3PG,6#9Q]=/>;=_<'E2M6*,)AB3[.38AG639O63/1HJR?@X70
M^+C4PS4^_R"- >XOA="'B7EAVC\4R7]02P,$%     @ _(%K4IA#L428 @
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MSI!_+C&L_7RB#05^?V\,G9+P9L:)+_X"4$L#!!0    ( /R!:U)-4][Q+ 0
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MYI1-55WYNJGZJGFQ/L1='T!__ ]02P,$%     @ _(%K4OTLU:6N 0  P1L
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MDN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(6N"0M8$A:P)"ED3%+(F*&1-4,B:_"=9W[5>_?7_IG:-:U4V1W_6_=2;
M?P)02P$"% ,4    " #\@6M2!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /R!:U*NUK8C[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( /R!:U*97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ _(%K4EE&E5X+!0  @Q,  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( /R!:U).&7:2\P0   \3   8              " @4X-  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #\@6M21K%@\[L"  !U"0
M&               @(%W$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ _(%K4FLR8)F4!   +A   !@              ("!:!4  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( /R!:U+WXD7J[@<
M #0K   8              " @3(:  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #\@6M2D>KVT5L'  "W'P  &               @(%6
M(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ _(%K4@S)
M7%%U%P  V4(  !@              ("!YRD  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( /R!:U(,QHH02P8  &\.   8
M  " @9)!  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #\
M@6M26M5IW/4%  !1#0  &               @($32   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ _(%K4M.(AX#'#   3BD  !D
M         ("!/DX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #\@6M2J4X,30<4  #E30  &0              @($\6P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /R!:U(;M0,/I@(  )(%
M   9              " @7IO  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ _(%K4EV:$APP"@  .QP  !D              ("!5W(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #\@6M2LP1J
MI'\'  #2%   &0              @(&^?   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( /R!:U(@SS/1_0L   P@   9
M  " @72$  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M_(%K4C^YIA,2!P  /A$  !D              ("!J)   'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #\@6M2S,HB']L#   M"0  &0
M            @('QEP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( /R!:U*I#84W P0  *H(   9              " @0.<  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ _(%K4L\M6IZ%%P
M:D<  !D              ("!/:   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #\@6M2EK/OYJ(%   R#P  &0              @('Y
MMP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( /R!:U+P
M-E4?M0(  *$%   9              " @=*]  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ _(%K4MYRS @) P  A 8  !D
M     ("!OL   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /R!:U(WPK_J?@,  *\*   9              "
M@>74  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ _(%K
M4A&;F@T- P  B H  !D              ("!FM@  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #\@6M2SH!'F2D"  "8!   &0
M        @('>VP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( /R!:U(3_IN+<P(  &H%   9              " @3[>  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ _(%K4KN)8Y?,#   02\
M !D              ("!Z.   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #\@6M2!ZC^](,3  #74@  &0              @('K[0
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /R!:U)-X(#D
MC@(  . &   9              " @:4! 0!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ _(%K4A>YET\^"P  =2   !D
M ("!:@0! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #\
M@6M2A/S_0Q<$  !.$   &0              @('?#P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( /R!:U*'ML'OX0,  $P/   9
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M970T,"YX;6Q02P$"% ,4    " #\@6M2F$.Q1)@"   9!P  &0
M    @(&S)@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M /R!:U)3JI,'!@,   ,*   9              " @8(I 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ _(%K4AZKPBRV P  50H  !D
M             ("!ORP! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #\@6M2:@&E%SH"   B!0  &0              @(&L, $ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /R!:U(.D8+#]P$
M /T#   9              " @1TS 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ _(%K4DU3WO$L!   _0D  !D              ("!
M2S4! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #\@6M2
M%[A"P58"  !F#   #0              @ &N.0$ >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( /R!:U*7BKL<P    !,"   +              "  2\\ 0!?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( /R!:U*(Z]1Y(P0   0?   /
M      "  1@] 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #\@6M2_2S5
MI:X!  #!&P  &@              @ %H00$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #\@6M2)OJ'I[4!  #<&P  $P
M    @ %.0P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -@ V +$.   T
%10$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>81</ContextCount>
  <ElementCount>327</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - 1. Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>1. Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 2. Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/LiquidityAndGoingConcern</Role>
      <ShortName>2. Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 3. Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/BusinessCombination</Role>
      <ShortName>3. Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 4. Common Stock Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CommonStockOfferings</Role>
      <ShortName>4. Common Stock Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 5. License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/LicenseAgreements</Role>
      <ShortName>5. License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 6. Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/AccruedExpenses</Role>
      <ShortName>6. Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 7. Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/Debt</Role>
      <ShortName>7. Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 8. Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/StockholdersEquity</Role>
      <ShortName>8. Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 9. Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/Stock-basedCompensation</Role>
      <ShortName>9. Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 10. Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/IncomeTaxes</Role>
      <ShortName>10. Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 11. Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CommitmentsAndContingencies</Role>
      <ShortName>11. Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 12. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/SubsequentEvent</Role>
      <ShortName>12. Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Assets and Liabilities Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueAssetsAndLiabilitiesRecurringBasisDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Fair Value Assets and Liabilities Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-FairValueValuationWarrantAssumptionsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPoliciesChangeInLevel3FairValueDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-SegmentInformationNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Organization and Summary of Significant Accounting Policies - Geographical Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/OrganizationAndSummaryOfSignificantAccountingPolicies-GeographicalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Geographical Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Common Stock Offerings (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CommonStockOfferingsNarrativeDetails</Role>
      <ShortName>Common Stock Offerings (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - License Agreements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/LicenseAgreementsNarrativeDetails</Role>
      <ShortName>License Agreements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/AccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://SEEL/role/AccruedExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/DebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/StockholdersEquity-SummaryOfWarrantActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/Stock-basedCompensation-NarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Stock-Based Compensation - Assumptions Of Black-Scholes Option Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/Stock-basedCompensation-AssumptionsOfBlack-scholesOptionGrantDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Of Black-Scholes Option Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Stock-Based Compensation by Expense Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/Stock-basedCompensationByExpenseCategoryDetails</Role>
      <ShortName>Stock-Based Compensation by Expense Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/IncomeTaxes-DeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Income Taxes - Recognition Of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/IncomeTaxes-RecognitionOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Recognition Of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Income Taxes - Reconciliation Of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/IncomeTaxes-ReconciliationOfIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation Of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/IncomeTaxes-NarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CommitmentsAndContingencies-NarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/CommitmentsAndContingencies-FutureMinimumRentalPaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="seel-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://SEEL/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>seel-20201231.xml</File>
    <File>seel-20201231.xsd</File>
    <File>seel-20201231_cal.xml</File>
    <File>seel-20201231_def.xml</File>
    <File>seel-20201231_lab.xml</File>
    <File>seel-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001136261-21-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001136261-21-000034-xbrl.zip
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MH_OS*SU!6I^4TGK?"T-O_%[KP['W3=,;74 BW9;\I*D3FA3]$=MCB'$5^_4
MZ(US82&;#>5_GCF>L>5PZ/B#6!K]Z;]L\XKC0!!,1]++"OLE:>UU&I/K;?Y&
M!RN\;+W]>C-D\$9HJF^U CM<H;,@.EL5.C>)SG:%SHV@\]$+0?W9D2A?&3JN
M_*Z]T7L]QZL1JA'V/L).N3:!8.%?VI41C,K"R076]<.*L.8*\5:CA5+<\B*P
ME>8>%06@T;NU7J^567F%R-6AJ6L5$BLDE@&)A5EZ+SK8)R6VK%+$JA&J$8Y&
M$1,M3E27=RWMZBX+GQ^<3*\.Q@J)Y4"B7FM6]L(.\9@CZ=_1#5GJJ[6O1.-(
MNS0DU;5<=2W'<^@+*.F;4$:J:[GJ6NX(T%E=RU77<B5$9W4M5XU0C7"T(^R4
M:ZMKN5U8A\U:JZ=79G;E\ZF0>"1(+,S2>]'!JFNY:H1JA*-4Q*IKN>I@K)!X
MY$B\Z+4K+.X(BSE2?I-7<D7*&"J%S9YGQ3OE]1$@26D65=Z+_%Y,W_N "*P_
MF"./"C92&8!TXB\O<I(D1AI*N0#*'XQ$FKQ,-Y1##V2EB2=9C0J_S0.7'K!6
M@FI>%EF<;7BXZ86'JOPL'V%=]_6?S/"U&TPO/1K;9">HV(0ZFKD!Z?5.\]JU
MNZ&;F'727BNLKHC5G44M% 7TW@Z^U0=8,(9J_V*%!-\(2V-W[433:S;T\]<G
MM6*] =*R%/3WN^<8(=5E.JT-T'N-L[,3(SJ]V3AOEH/LKNTGK#IE:5.;.=9)
M;4-=.RVR6[3>79+<S?<)U5^F:IDGM0/M1O/LI!;<6;3@7=+<'PSA9E;=@(&-
M(3L-S_I+]*).LT),+F*:O54H>C^) +LKO\9KFZ(/TS5!>^75UV0]R["((W1.
MQ37N:10QIKDE]$I;JVP!X8FWSKHGZ:)I;2I8-N>^E, LCSOA@ZB.GY^R<5[)
MUG5O&7>YB2O?W]M!$,7=GUQF)NTF1>%)=UB6G=\)[;3T6K?=/?1=3>J%PSF7
ME%G%:N-*-\ ?-4;-K$]J@]^TSVK-L_;;P]K8*VJXB&PZIX9JTM@JV?P#W-?5
MLA575(1[M6YS[5C)!4#/)8H7G[H7.]_"G+5L0N%:9=@"6%L[I&+_G%R)Z.4B
M6F]U*OE<RDW=IGQNM=9FZGT(Y];NW4T;EJ+;")/;,(@'5]!B2WZL+P/1_XW\
M2!0<!R<%%S/X@P=?8_<F--<0E*4^K&61;KR/&>_%&O7_(]IO\\8+=I!I<B:;
M7LKN=:;LYO$47Q%3VX8P2#G7RM#XZ\MDK_VC+P/L?3NV0[Q=XKU9L2N6;*W5
MK27=O0@4I>'F3".M;OSY;:H+G8:-YY@C;K#2_41$%"30DNAS%'?@FNF'V]!N
MJ?$>"(&X QDY"L3LZ3EE!\>X8W*FN6[:=<K[(](9&F0.T3C85#35>9"]#V4C
M\"]QOU1J966(;JO4?78R<:9JY&AJU371R0>@"T1?C0%C0=S)4W3NG(6= E1%
MKT+198QZ?$?4HQ#'$2TPPKASX=Y(_5?B_'OVQ%QQ<;0/,D]U-$PZ O$.+H#[
M(4%I#'U&6YO0UB,SQMJ#X0Y B$PFGO81:-3*MJ5[?/BHDKX!F'<GOC>P0U#!
M+.I.A0U7L)<)D'<\ /V)/<NF&F\K3"+1'-F.!9\X3293$TS!U+5\;\QJ* /Q
M 4&4@>E-2/HES-MK]K08*H%_WH[Q"E#K8V]G/L55!,)P#+I^_'32D8YIL+8$
M+S7ZB$W">7,4$^C2 !#&M@,B&#N*Q;T8!?'&G>6!H;,/IRC=T *0V]P&N1MA
M6\?;VW>WM[>:Z=@NH3#$OL>UN/V=[<87)@I\U".9A9D>EID=Y^V4L2\D0LQ\
M:H)#35/[H"/PS8GR,< 'QL;7_(X$N-ZV!/_7"""Q(]2Y&C9D%C6T=T8(R^E'
M*38?3QQ&3<^P*7G<[WT>@'PE0/5#['#C^;+)LPJ$G+*A7:=[VVC+VMK,"E-J
MNVEI/_!G?FB?=6O-9A.!]#EQ8?]!W$,\J)TI1P;1FS&+A*0!H<'/\KPG1)>B
M[&&?BRADXGQ$[4WRW4N6IP:4>"OG34BX[$L(I@"R$H#D^;/L4($/3F2I>X7?
M1A/89+6W[H#ZUIF\TR\J?D,FZ)Z3>4!'(X--]*:,TST\*YI0N984"@2"['>=
MZK,6-\'&F4 $^A9O-LFH_1ORI!6982)RL\L53;T2BNJSD>$,:MHD\H-(=/%2
M7N#(<"WB=F QRA>1 H'4A;VTV(L)[98W97XTON^Q>[8 (D0@B)2$/H<=R6&;
M$G%J8%V<&*6)%XJWVVLD%LZU;+IL9X>.53(B * DSS?\J=+Y6>GX%7<OBWM6
MSS1KCX&AKM+&=]DT>#"GXUD>C/A:_M, [0!UWWATC)$.8C,%::U/CAM&_;BY
MV/3\I T9_J:T$E06*3E6CH."V,=^QC%\EZ1P"M["* 02CC9V@/,PBA&0B[(3
MOQE[/G9Q_L:PK>M(]/-#%9(W6\4=$ W+Q;EDY:S]V8;?\27J,6M0T[9]=+R+
MU0YL4JBV,J9U!Y3F)=1WI;\J)U2AI_!>MRG:X[N QY()AS>C%K64MB7W2^V8
M3JT-TPXX@U U\0+^1 AZ%$<S=GA,TP/]1GU/.<VP,/(!&SBHV+H@:0?K89J:
M,G<MT^J]E@3HTP#,-1R>,&W%?9$3)L"N>?9>3TXA2]Y\\H+@K78'@N.*6^T/
M(R#YO8FX#R 63 W01:J&%B PR#EX@I$FUT<9!'LCG2 N"_GC: ?"7J#&&'HI
M%X1PL^.KE$<H@NXT&73G1J2? ?'0=-Q"4'TKBN-%-C!D!E(IK O%*<)Q;3L$
M7Q9T?IYSQN#2IX;R !BGQBT%XA@P.8$]0(*R[\PWL:D[D"LW2@.A?078YE'D
MX%-71B-EOQ,0%NO#\,(5Q*6D6(':I9EW8Q86M-!B,42 TSEVWC0Y/Z%$S\4(
MN0GXEDB-%^6Y&1.X); 1[TZ"D:7[5"NX2P CB!".V< 8DSF@];UPQ,TFPS$C
MA_L,8-.8- $&ABG$+?4Z-1(0V7<["(E? 79TA(EY#&'FBZV,G13*#%+#MD$B
MFBCI!2)"NRY'VV]/TIC G*FROIBBN(!4J%P]')?:,=H(]@@$*L-.Z0)',6ES
M*HF;\DK"F-E>CNPL(#6!V6G25CV%U?)&VZUX656F^Y]YH7!%AHBK$W=V7)PX
M26]-46KF(-O676,F@+'*=7W99E;IK1M#9.DR6K\HQTQ*.3G F_+U[SR[-1U(
MO'1U5W:S]E;9>DRI-"FUYY/:$KU9:_9Z)TJ/[5KWO%,RBKS*7D@>X(YL,X[H
MO-;M'C:];A,[ZZ<L+ "X!%&C^Q]VNU7$6NW:66?]'DD5*I4<WYK>+"(@<KC@
MJ(+*8E/@ 77M^@<#P\JNE/O C'FPGSN$^+J1+()ZGZ!4;RUY'((77VG"5*[G
MUN./Y(SJ>X:/%P)H_ >:]\3DC<%_(SNP0_1X^4^VR83C5N/3B*M*&=]F\4"5
MNH6Q;FH\T2")A0 =T1+!1)X_8'88D4/2H BJU-T(O_C@UZCJL]*MY9EFY#>T
M!V798G2*&P%0+&;5GQ XM)?,$;,B1_C)Y#6=B!I -R3@SS<0Z77'=IF\9%N*
M"(2./-H!FQBX#&>JR3DSD1($'2V28(@W4& OF G#&J2L/([<8*6*??Q*1MQK
MQA4$(WF%CFEMTA6;$P8V2-&40&X<^ "$Z1K\\IPNJ8-060J_D'_R'(J*Q( 6
M>"&YO++Y(PE9<,^VQ%9JY/]$UI#'MEPZSEPJ5Z($U)"X(7.9;S@$CV%AH43<
M9O)_\I@4NH-/G.\S80<R@DE>SY)#WXMCZ@0C1!/!"G21S(/J;)=N6R+#@47X
ML$4:C^V1%+ZW^ZL'1OC4;EV*1RF-).-8A1'Y;3Q&< 0"5+K:%/<TM$.!-AD9
M +S)(CI@\=H1PRJ"/<;3H*=)NTSN:^]\S_60YHEN]H;B6U>[C(81L"?F*?,K
MHH^7#Q]D;FL",4'R@-8\<?K7"0ER-8[V:Q)(J'WV&C1B76_7M/P&=]H;&:G;
M?%O3KN/;7.VC;XS9L^=_JU^)J%9QQW2=OO&]1[$KF^6AJ)TWCPJCA"J!E9\L
M,*5KQ4$QX0CD.S[M\SGB $"ZS*+[RC0LO@H+/!<O3=R)@\#E\8$D6,9P=%A<
M_,J!7=C%9$PM-1X?PK"L).*.QN=1Q99E)Q%\,> &CQO VRD2J'C&RSM0"I?
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M 8G-5D).X.^$,$F!!+H&H"ABJ18?]Q1W8H^%+J>$+'O 0JE7@#N!'*C,LC&
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MAI?OOY#QHX>E'69KRQS@'K\@U^*\IK</F\!?E.]W?E9D\;NDWT]X^9132^D
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MPA*)^O*RHR67?A.IRAT(\F8?%&'4_N3E$8BMIM870@LUC&B,^X,:;NRUH#:
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M26A3FJIF_;5IXT7]M;CQ0G H^>9K&2^+V'MMNV7CMLI%,T_/3^P4*9VM5*V
MV!%MBSB0V-F;.>'GV"(_\/"@GU(FQRPHUDP1S/D3%YU9H8B?A+=TR?SR>F#)
M_,4!:*L /"W9"CYCHC_P?!(R%*3_NO'0F#>9$FCUD_9FU;FT>!X<-0XRX<4N
M%]A.Z6E%Z,""N3$*(^7Q6)H=E$2U\W-%^I?SP6FIYILJ=C&]"5VWJ>A98L*\
MO(HI^FIC$$C:BGFY3XS*3F;L0SMEYF.Q4(<?/9Q_\QA7H E  ..6IXYAZ-(
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M@6@@,!Z3EI6PUT"9#82X)TIE+B757H94>=DS3B9JK8\$+_%+6I^9V":-/TW
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MRU71F,1BFU,S^F!.*-IS#"Q.J8X(:"3[F\M"$,T^46"@O,NY0KRO"))DT63
MMU#K=Y7.-*#Q4K\44;0K.0@0>*HWZDQY73)>59@\ *1 LN^A*$M*-GTIB\#E
M40IUM9$8TL\N2 J@'$H,L!G22<048['X"P0U8&.6R,'#>"EA2?]]'G%U\XA+
M>PEAM3JT-O%S:E$$B$(F<Q9(-*._:Z/FO$&J>?8DS2 8Y\VY8&H%0913QO,
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M&"[*3_JEPA@8)+U5>&23V71[3Y))-=W*OP?B+N+8LUQUWBKC4;"W$3;<%:,
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M-X8'9>2'.'T;XJHJ6?U(N-J55X&*<&!<'>\,[LJN %=/I2ALA*O?8BR &2<
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MSA>IP>CFT]CUSUS?NX,3EX1S\RC2#ST^48\C):A'"5EEIR.9'&R$,:E:U8<
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MWF1K!:]9[H&68VX\936QNMF4Z*K\ZGY#A<2K&#!9K<;:XVT\W89L:,ET).[
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MGCBXBPF<#@)F&OI^^(C5'OZ1!D(!T>3AIX!4>I1V&?\[$K!5@F;( %;+[A?
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M'(5W 2AN#(4+QRL04V\,^RIA(35]*E@\3+QXS*<S6 (N"L$Y+/2;!V<2M2-
M4E,AZ1C4L!YD#_ FE-VF%%FR*S2/$5R0&=3G&!5('$=021%$KGYJ!FPC!/0_
MR(VA)K+RE!>F!4V3L*5Y2UMYM[1F;'CBR/6)L)8-YMBZLCJY:6 64PD+F8TC
M*%XWV_6^)G$<^'7';"=Z(N(Y8\$'N_HJARZ+NI@4A?;.:7@>W;A(,"TU@W:
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M\Q*+:%>2N_;*,Z6XBRCT?3:JT"O_0)XBZNI-MC_HN'?N7=9YSE83/YDF7$-
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MC(931T-0%,"NF+EC 3)[#-($./PD'0,[_6%.W4IJK42&>=JU.AO*AAJN?Q6
MAIF2;.:WCTN["*+S3V78:R@="\RCTC)Z.1;D6B7]FY2+J8;2LZ DVQA3== \
MD,WHI.V'*0,U\Z5*(D#UP>4KW$9?MBPAVY6/-J7QY)-'3.KF\3U0Q!FJ2@1"
M(*.Y4ZF!6B >PVC/;_*7^5'9T[EMD#!;.K^] *5\#G;OH-6M&1(D4"PR=-YH
MNQ-?@8=M2]=6R>_="2=!"?9JVLXKG94EJ8$T6-GB.Q\EN**X=AA-, !@3%4Y
M>W9.=+-A2ITR.PJQI,0&@Y,YC-/-^HD',EE&MZ#_<K@XG!(,7[C-,ZC$%,=P
MT>A!59NM>'^AHB2%5==4LA:9<YS4*42<CP\482=7ECP@,EAE67(X#CV!-I*R
MTH_G,7W16(^JL1J)64GXY27F^]G<#Q="R&(K5B.%"[+(<M4HKEA:KNL!F^TF
MN7:./0#5_Y_.FE:-W=YN0!4+XU1"1K/1ZA6;:E4;?.VBFMU>K[5V\/PMHG.P
MMF<I+?N2 N#;;/(9X#.WL/7S[ .RM4@YZW>;.:QL#IEU9TH6A$P3T#LHK+,&
M6<L*2;0:^0[H*R;9"9XLBIX$GB5M[*2LM-O870!T7I#"=T:0;MD)MM48YAK5
M[@;&4R^J6JOG8;O1?<)%E??$.X<I6-%G-75?C&WM3'L";TO6>"CP>NO ZQP%
MMO/XR[2D4(/6'*Z">9K$']%#T>2[IL5G/@D7_4>D4]Q@W >CT)6N(A]K1S98
M=6OOJS[IY;9_@.4^5WHM7 8_T"D]%EO?8-7?SRFMM-SOYY0N7^ZQZ97TW7>8
M4HP.)A'$I$R=8^23;WR_6YA'KCF*>O[H1A.]@O,X3F=\B^_&B__\$ FADD1O
MT+>Y8?&D*H0@B[$4T,3WP8HU1^N-1J8 _E.O^<A(OF1%#%3P(E;?+?3'__9
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MSW78U"KK_&8,!JE)5&$;N^1!I?$3&>GM)=D#B_I%-U8H$RRZ94+).97\./N
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M>X$22^XJ BIYK')R==?-I*.AG[#1 @IVX%,B&*M2..\_G;-(PK^4U]9RY+)
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M\OK9DLP]'2_"%PSL$X];9DB'O;INSA(C4]M]2=Z;5J[LTN(9P8I$P+EB,@2
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M-LM[MN,?A&YD? /X0&P$8\H<@*6?)Q\$R@<?3W>*U)=YN (&N#^)#>/5YP^
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MR C[@XEKQ:DV!V[KM6UWSINV7K')='N"\\FD]TFN98<C?_H;M8M$WWI!I:H
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MS(W #L+<TS.) (;4];^*:-9<WL[NNO][L].YM!J%'AZZ4@2]6P_"NSP(G\.
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M)I+; [6GBXT)\A!MMT;;@&HJ?,^";]HRVP-M2PM[-]&] I&F)>Q9M*ZE//?
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MJFD_.B.'#0TO"&.*X8_QH5-$SY_N2#M@I=,*73B;/IQ-)[V7@+LGH.\IB=;
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M/"L7,%(AW*+0FBXTK)Q9="'6Z;KGDJT$)G,,.=G"M[!8V:*BG5\NW23Y1<B
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M#<Z:W%O6]6*0XA>:5B;J@:H5 1^V-NHKN]$,/^.D!+N2P\:%9J=KS(*.1@*
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MLB!6K=35.>B(C>(;\O98'RW-PY[)6),E&RI#18%!^7[ZJW:K+UZV[.'CF0(
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M%.;ENO>A3B+:39#0]9"HP!L@4SD;\U@\_N\XR*;IX.7BH,%:9_10;,MD'13
M-08(*&>3,/JB,RJR$K\IMX<#=#Z5O$HNDH ]M;=WL*\2" WL>L.'PETN#=HJ
MWMZ6])%?'S5@(3P*&>L!]?)LZ&H^2M97=) B8U:H/@J]OUAHCF!3"4/=02<3
MVDW&B>SINP9C.1Q7N$PS'*V3#L5Y1!CI;E84[%-Y9M'07,*V,H:ZA4GN(8X7
MEC:)A[-WQQ;)K/=+D+%DA(?C, _UD?1]Y@5M(="<0#1P*-QW$@XJ\A?4%HZ
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MB[C_H.N-VYCYX*IR5;]5S\Q=R&]UWG79#MO5O7-?.F@)DGA-D6Z0=%GSZP\
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M)V$>$K:'8'15SK_S%T(G84JF3 :G0;I0VO366O=^2<F"V6A9U%@5PI4JP)4
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M%T>R@HTS!K BJ&M!WY]#@RU$"#C@^L*5[#S-PF60J7)'-\N!GV'# DD[HSA
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MV$I#4;?QA<.!6ID >D/6NY^BKXTNL45QX7&=Q#P4D(@')8G2H;15TK>;V3)
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MER<2IVT37G%FNU7.M]< -GJD#.(8/-7,.8ZGQ=1YDV=I%L131K!\E*AK^?9
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M8XF4N#U@57U;K0:0P)G"-*+.2HN8)\]DU)6F4:%&*^V@@M7V;76:CRL3J>#
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MN")QFSH$R3=1WB]UV_7J8A I3B4&30(J!G<W]X()\O=(,"(]<SM)&RK',/S
ME_&7='I+J! &S"G<J +5//N'"S@U#R+@X<R(PH687L;%6Q<X)D43FJ#::?\
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MSR.SR]@W_Q]02P$"% ,4    " #\@6M2OW/8A!O?   '_@< $0
M    @ $     <V5E;"TR,#(P,3(S,2YX;6Q02P$"% ,4    " #\@6M2,!U7
MEDP3   'U0  $0              @ %*WP  <V5E;"TR,#(P,3(S,2YX<V10
M2P$"% ,4    " #\@6M2SO1]0* 6  ##)P$ %0              @ '%\@
M<V5E;"TR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ _(%K4A_\7F;?)@
MM9P" !4              ( !F D! '-E96PM,C R,#$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( /R!:U(L2B22 &D  &!:!@ 5              "  :HP 0!S
M965L+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #\@6M21*?F1T)'  !+
M! 4 %0              @ '=F0$ <V5E;"TR,#(P,3(S,5]P<F4N>&UL4$L%
3!@     &  8 B@$  %+A 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
